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 Preface 
 This book is a collective project. It was designed and debated in a work-
shop funded largely by the United Nations Industrial Development 
Organization (UNIDO), in London in December 2014. We are grateful 
to UNIDO and to Juergen Reinhardt in particular for his support and 
encouragement. We also would like to thank the Open University 
and the Economic and Social Research Council, UK, for providing the 
funding that allowed this book to be published in open access form. 
 The book draws extensively on original research and on direct experi-
ence of involvement in policy making. Several chapters – and some of 
the broader framing of the book – have their origins in a research project 
on  Industrial Productivity and Health Sector Performance, funded by the 
DFID/ESRC Growth Research Programme. The findings, interpretations, 
conclusions and opinions expressed in the relevant chapters (identified 
in notes) are those of the authors and do not necessarily reflect the views 
or policies of DFID or the UK ESRC. The views expressed throughout are 
the sole responsibility of the authors. 
 When a number of contributors to this book began to work on the 
 Industrial Productivity project in 2012, it is fair to say that the inter-
national policy debates on access to medicines in African countries 
remained focussed on funding procurement of essential medicines 
from Asian manufacturers. The project aimed to explore the scope 
for local developmental synergy between industrial development of 
pharmaceutical production on the Sub-Saharan African subconti-
nent and improvement of the performance of health sectors suffering 
from chronic undersupply of essential medicines. As we have worked 
on the project, we have become part of a much wider movement to 
identify and generate these synergies. This book is an outcome of this 
networking, and we hope it will contribute to strengthening evidence, 
debate and policy making. 
 We have many people to thank. First, our extraordinary authors 
who have given their time and expertise to preparing the chapters 
and participating in the workshop debates. They have brought exper-
tise in pharmaceutical research, manufacturing and policy making, as 
well as social science research. Among our African contributors, the 
editors would particularly like to thank Skhumbuzo Ngozwana and 
Tsige Gebre-Mariam for their commitment and for bringing in other 
OPEN
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xii Preface
expert colleagues also. We are also grateful to Alastair West of UNIDO 
for contributing his breadth of knowledge of this policy field, and to 
our Indian and Brazilian colleagues whose depth of historical under-
standing of interactions between industrial change and health sector 
values helped to shape the book’s themes and objectives. 
 Much more widely, we owe a great deal to all the many manufacturers, 
distributors, health facility staff, pharmacy and drug shop staff, policy 
makers, regulators, researchers and others who have patiently answered 
the questions of authors of these chapters and participated in workshop 
discussions of the findings. 
 At Palgrave Macmillan, we thank our supportive publisher, Christina 
Brian; also Judith Allan, and our enthusiastic series editor Tim Shaw. 
Many thanks also to Radha Ray, who administered the London work-
shop with such welcoming efficiency, and to Jim McGinlay who has 
patiently chased endless manuscript detail. 
 We hope this book can make a real contribution to the search for 
better access to essential medicines alongside industrial development in 
Sub-Saharan Africa. 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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1 This is a book about the industrial development of pharmaceutical 
production in Sub-Saharan Africa. Yet the values that drive this indus-
trial enquiry are rooted in the needs of a subcontinent with the worst 
health status in the world. The central argument of this book is that 
industrial development in pharmaceuticals and the capabilities it gener-
ates are necessary elements in African initiatives to tackle these acute 
health care needs. A successful pharmaceutical industry is no guar-
antor of good health care: India indeed has managed to grow a highly 
successful industry while leaving many of its people without access 
to competent care. However, without the technological, industrial, 
intellectual, organizational and research-related capabilities associated 
with competent pharmaceutical production, the African subcontinent 
cannot generate the resources to tackle the needs and demands of its 
population. 
 The book is a collective endeavour, by a group of editors and authors 
with a strong African and more broadly Southern presence, to find ways 
forward that link technological development, investment and industrial 
growth in pharmaceuticals to improving access to essential good-quality 
medicines, as part of moving towards universal access to competent 
health care. This book presents original research, much of it from 
recent fieldwork in African contexts. The authors include academics, 
researchers and practitioners, including some who have been or are 
currently managing pharmaceutical firms in African contexts, and some 
deeply involved in policy formulation and implementation. We aim to 
 Introduction: African Industrial 
Development, Values and Health 
Care 
 Maureen  Mackintosh,  Geoffrey  Banda,  Paula  Tibandebage 
 and Watu  Wamae 
OPEN
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
2 Mackintosh, Banda, Tibandebage and Wamae
shift the emphasis in international debate towards much more atten-
tion to the scope for sustained Africa-based and African-led initiatives to 
tackle this huge challenge. 
 In this we are contributing to a shift in mind-set that is already under 
way. African governments are increasingly considering medicines supply 
as a national security issue. African Heads of States have adopted the 
African Union’s Pharmaceutical Manufacturing Plan for Africa (African 
Union, 2007), and regional African bodies are taking similar initia-
tives. There has also been a sharp shift in approach amongst UN agen-
cies, including WHO and UNAIDS, from earlier critical stances towards 
support for the development of health sector manufacturing of medi-
cines and supplies in Africa (Sidibé et al., 2014). That shift in turn has 
built on work by UNIDO with African governments and the African 
Union (e.g. African Union 2012a 1 ; UNIDO, 2010; UNIDO/GoT, 2012). 
Bilateral donors, notably German and Japanese, are actively supporting 
upgrading in health-related industries. 
 The book’s roots are in historical political economy. The process of 
building – or failing to build – industrial strengths and industry-health 
system synergies is long term, as the complex 30-year trajectory of 
Brazil’s health-industrial complex illustrates. The book starts by chal-
lenging a highly persistent international myth: that Sub-Saharan Africa 
has no pharmaceutical industry. On the contrary, the industry has a 
long history and is strongly embedded in a number of African countries. 
Operating in a relatively high-skill, high-technology sector, pharmaceu-
tical firms have faced all the well-known challenges of African coun-
tries’ infrastructural weakness, in skills, utilities and transport, but many 
have built successful businesses and are investing in technological and 
product upgrading. Regional inter-country trade is expanding, and new 
investment opportunities are opening up. 
 The big challenges are twofold 
 First, there is the fight to sustain this industrialization effort in the 
current global market context – which is much more constraining to new 
competitors than the market context facing, for example, India in the 
years when it was building its pharmaceutical success story. Multilateral 
and bilateral policies have reinforced the stringent competition faced 
by Africa-based medicines producers. A core concept in our analysis is 
industrial capabilities. In Part I we explore the sources of the organi-
zational, institutional, technical and human capabilities to make good 
products, to compete profitably in globalized markets that constantly 
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Introduction 3
force firms to upgrade, to overcome barriers to market entry and to 
distribute products effectively. 
 The second challenge is to ensure that the skills and competence 
built up by the manufacturers and distributors actually feed into better 
health care access for African populations. The institutional capabili-
ties of the health system need also to be built up, to support, buy and 
use effectively locally manufactured supplies. Only on that basis can 
governments generate policies that bring the interests of the industrial 
and health sectors closer together, to collaborate for mutual benefit. In 
Part II we examine some country experiences of health-industry inter-
actions, comparing East African countries’ experience with Brazil and 
India, arguing that health system structure and initiative are as impor-
tant as industrial policy to successful linkage. The values that underpin 
the importance of the pharmaceutical sector, its claim to policy priority, 
are rooted in the ethical requirement of universal access to competent 
health care. 
 The chapters in Part III therefore tease out experiences of some of 
the key aspects of health-industry interactions in more detail and 
identify some important policy issues to be tackled. All these issues 
are framed by political economy considerations of the ethics, inter-
ests and institutions involved. They include the highly contentious 
matters of price controls and standard setting for pharmaceutical 
products, plus examination of sources and problems of financing, the 
scope for innovative procurement processes that can reflect health 
system values while providing incentives for industrial investment, 
and the contested but important role of industrial manufacturers’ 
associations and political lobbying. 
 This book is a loud challenge to pessimism about African industrial 
development and health care commitment. African governments have 
responsibility for their populations’ health needs, and cannot address 
them without industrial expertise. The book explores the  conditions 
under which industrial improvement can benefit those who need access 
to medicines and health care, pulling together the arguments for access 
and distribution with those for investment and industrial development. 
There are different routes by which improving supply capacities can 
generate local health improvement: this book is about how to generate 
local paths that work. It also identifies ways in which international 
donors and policy makers can shift from impeding to supporting the 
long-term development of local industrial and health system capabili-
ties in African countries. 
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4 Mackintosh, Banda, Tibandebage and Wamae
 Note 
 1 .  See also  http://www.local-pharma-production.net/index.php?id=97 . 
 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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5 Part I 
 The Pharmaceutical Industry in 
Africa 
 Part I of this book aims to strengthen the inadequate evidence base 
on pharmaceutical manufacturing on the Sub-Saharan subcontinent. 
Throughout this book, ‘local manufacturing’ and ‘African manufac-
turing’ refer to manufacture physically located in Sub-Saharan Africa, 
whatever its ownership. The ownership structures are certainly relevant 
to understanding the development of pharmaceutical production, and 
indeed the extent to which the current industry is in African owner-
ship is striking, while most output is produced for local and regional 
consumption. The African industry is, as we show, highly ‘globalized’ 
in the competitive pressures it faces, but also highly ‘localized’ in its 
markets and policy frameworks. 
 Part I therefore starts with an overview of the industry in Africa, tack-
ling the recurrent myth that it barely exists. The four following chap-
ters analyse aspects of the industrial experience of four countries in 
producing medicines: Kenya, Tanzania, Ethiopia and Mozambique. The 
chapters do not aim simply to describe the industrial evolution, though 
that is certainly one objective. They also explore in detail distinct aspects 
of the industrial histories: the evolution of technological capabilities in 
Kenya; the challenges in sustaining a relatively shallow industrial sector 
in Tanzania; the sharp turnaround of the industry in Ethiopia and its 
links to joint ventures and health sector change; and the immense chal-
lenge of starting from scratch in Mozambique, with Brazilian support. 
In each case, the authors are looking for wider lessons for policy and 
practice. 
 The final two chapters in this part are broader, and both also reflect 
some West African experiences. Chapter 6 asks an important ques-
tion: What can help to bring more foreign direct investment to the 
pharmaceutical industry in Africa, with particular reference to Indian 
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6 Mackintosh, Banda, Tibanddebage and Wamae
companies and Ghanaian experience? Finally, Chapter 7 addresses 
directly a question raised in several other chapters: What is the scope in 
African contexts for moving up the technological ladder, into producing 
the ingredients for medicines manufacture, and into more research and 
development activity? 
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7 Introduction 
 This chapter sets out to show that, contrary to widespread mispercep-
tion, pharmaceutical manufacturing in Sub-Saharan Africa is an estab-
lished industry with a long history dating back at least to the 1930s. 
Data for the industry on the subcontinent are fragmented and incom-
plete (Berger et al., 2009; UNIDO, 2010a; 2010b; 2011a; 2011b), and 
this chapter and this book contribute to building a coherent historical 
picture and evidence base. This chapter presents some illustrative histor-
ical evidence, drawn from secondary data, reports and fieldwork by the 
authors and colleagues, as well as academic and non-academic litera-
ture. 1 We show that neither industrial capabilities in pharmaceuticals 
nor policy frameworks to support local pharmaceutical manufacture are 
a new phenomenon on the subcontinent. 
 The chapter takes an historical political economy lens to the develop-
ment of the pharmaceutical industry, providing an overview and then 
examining three countries’ industrial history in more depth. By a ‘polit-
ical economy lens’ we mean a view of the evolution of the industry 
that replaces it within its historical political and economic context. 
Pharmaceuticals share many elements of the broader African experi-
ences of industrialization. The industry also has, however, some very 
specific characteristics concerning technology and markets. 
 This chapter briefly traces the pharmaceutical industry’s genesis and 
development in the context of colonial political history, independence 
and post-independence industrialization. We trace the development of 
the industry during the era of import substitution policies in the 1960s to 
1970s, the economic crises of the 1980s and early 1990s, and the indus-
trial rebuilding from the 1990s onwards. Some key political economy 
 1 
 Making Medicines in Africa: An 
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8 Banda, Wangwe and Mackintosh
themes that are developed throughout the book are introduced here: the 
current context of international market liberalization, initiated in the 
era of economic crisis and structural adjustments policies, and its impli-
cations for manufacturing investment; the varying role of multinational 
corporations’ (MNCs) investment in local manufacturing in Africa; the 
co-evolution and integration of the pharmaceutical industry with other 
manufacturing and industrial sectors; and the insertion of this relatively 
high-technology sector into local and international innovation systems 
and policies. 
 The chapter begins with an initial historical overview, based on firm-
level evidence from nine Sub-Saharan African countries. It then compares 
and contrasts the industrial history of pharmaceuticals in three case 
study countries, Tanzania, Kenya and Zimbabwe, for which we have field 
data. These three countries cannot represent the highly diverse indus-
trial history of Sub-Saharan Africa (henceforth often referred to as just 
Africa). Rather, they provide support and background for some of the 
generalizations suggested by the overview, and identify some illustra-
tive similarities and differences in the pharmaceutical sector’s roots and 
evolutionary trajectories across African countries. The case studies also 
identify a number of themes explored in depth in the rest of the book. 
 Pharmaceutical manufacturing in Africa: an historical 
overview 
 There has been substantial academic and policy questioning of the 
feasibility and desirability of African local pharmaceutical production 
(Kaplan and Laing 2005 is one of the most widely cited sources). We 
begin by countering this perception with evidence that pharmaceutical 
manufacturing companies have been setting up production facilities 
and manufacturing medicines in Africa since the 1930s. 
 A sketch of a pharmaceutical investment timeline 
 Figure 1.1 shows a time line of the pattern of establishment of pharma-
ceutical firms across different political and economic geographies on 
the African continent. It is drawn from a data base of start-up dates 
for manufacturing by larger pharmaceutical firms in a number of the 
major manufacturing countries in Sub-Saharan Africa, including South 
Africa, Nigeria, Kenya and Zimbabwe, and also some countries with 
smaller manufacturing sectors: Tanzania, Botswana, Uganda, Ethiopia 
and Ghana. 
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An Historical Political Economy Overview 9
1920
1930
1940
1950
1960
1970
1980
1990
2000
2010
2020
Julphar:  Ethiopia
Glaxo: Kenya
Abbott: South Africa
May and Baker Nigeria Plc: Nigeria
Kenya Overseas: Kenya
Burroughs Wellcome: Kenya
CAPS Pharmaceuticals: ZimbabweStirling Winthrop: Kenya
Evans Medical Plc: Nigeria;
Datlabs (Pvt) Ltd: Zimbabwe
Neimeth International Pharmaceuticals Plc: Nigeria
Gemini Pharmaceuticals Nigeria:  NigeriaAfrab Chem Limited: Nigeria
Nigerian-German Chemicals Plc: Nigeria
Ayrton: Ghana
Keko: TanzaniaLab and Allied: KenyaMerck South Africa: South Africa
Pharmanova (Pvt) Ltd: Zimbabwe
Genius Pharmaceuical
(Bioclones): RSA
Medipharm Limited: Uganda
SKG Pharma: Nigeria
Infusion Medicare: Kenya
Dawa Pharmaceuticals: Kenya
Emzor Pharmaceuticals: Nigeria
Botswana Vaccine Institute: Botswana;
Cosmos: Kenya
Mopson Pharmaceutical Industries: Nigeria;
Ranbaxy Nigeria: Nigeria
Tanzania Pharmaceuticals: Tanzania
Shelys : Tanzania
Hersol Manufacturing Laboratories: South Africa
Varichem Pharmaceuticals: Zimbabwe
Resmed Healthcare: RSA
Kampala Pharmaceutical Industries: Uganda
Rene Industries: Tanzania
Uganda Pharmaceuticals: Uganda
Universal: Kenya
Plus Five: Zimbabwe
Elys: Kenya
Aspro Nicholas: Kenya
Kinapharma: Ghana
Pan Pharma Pvt Ltd: Botswana
IVEE Aqua: Kenya
Fidson Healthcare Plc: Nigeria
Ferring Pharmaceuticals: South Africa
Gemi Pharmacare: Botswana
Zenufa: Tanzania
Sino-Ethiop Associates: Ethiopia
Archy Pharmaceuticals Limited:
Nigeria
La Gray: Ghana
Herbal-Homeopathic: South Africa 
Danadams: Ghana
Dr Reddys: South Africa
Aurobindo Pharma: South Africa
Quality Chemicals Industries: Uganda
Abacus Parentharals Drugs
Limited: Uganda
Swiss Pharma Nigeria Ltd: Nigeria
 Figure 1.1  A timeline of selected pharmaceutical firm start-ups by country, 
1930–2013 
 Source : drawn by author from created database. 
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10 Banda, Wangwe and Mackintosh
 The genesis of local pharmaceuticals manufacturing in South Africa, 
Nigeria and Kenya appears here as linked to multinational European 
companies setting up subsidiaries in colonies. In South Africa, Abbott 
was set up in 1935; in Nigeria, May and Baker was established in 1944; 
and in Kenya, Glaxo set up shop in 1930 (Figure 1.1). The whole period 
from 1930 to 1960 shows a slow take-off of local manufacturing in 
Kenya, Nigeria, South Africa and Zimbabwe. Historically these are the 
leading industrial countries in Sub-Saharan Africa. Local pharmaceutical 
industry set up did not occur in isolation, but was contemporary with 
the rise of other industrial sectors that supported mining and agricul-
tural processing industries. Some of this industrialization was driven 
by pre-war supply chains with colonies and the disruptions of supplies 
during World War II. 
 Figure 1.1 suggests two major bursts of activity in setting up pharma-
ceutical firms. The first is the 1970s, starting in the 1960s and building 
up. Then there is a gap in the 1980s and early 1990s, when the rate of 
start-ups slows almost to zero. The second major burst of activity is from 
the mid-1990s and continuing into this century. 
 For most of the countries in Figure 1.1, the 1960s and 1970s were 
the early years of independence. Across the subcontinent, this post-
independence era was characterized by efforts to tackle the challenge of 
industrialization and growth. Common approaches to industrial policy, 
promoted also in the development economics and planning literature, 
mixed public sector investment with import substitution policies, as 
briefly described in the case studies below. These were years of active 
developmental states in Africa (Mkandawire, 2001), which were also 
investing in public sector health and education provision to address the 
colonial legacies of inequality and discrimination. Domestic production 
of medicines, by public sector firms and locally owned private compa-
nies, found a market in expanding health sector demand. 
 By the late 1970s, however, this industrial development model was in 
trouble, and the impact of the economic crisis is reflected in Figure 1.1 
by the dearth of new industrial investments in the 1980s. Key events 
included the oil crises of the 1970s, which severely inflated import bills, 
undermined balance of payments and fiscal balances and slowed down 
industrial activity through lack of foreign exchange. The early 1980s 
were years of severe economic crisis in many countries, exacerbated by 
severe drought. 
 The response across much of Africa took the form of structural adjust-
ment programmes, linked to International Monetary Fund fiscal support 
and requiring extensive privatization and liberalization of trade. The 
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An Historical Political Economy Overview 11
timing varied: Ghana, for example, embarked on structural adjustment 
as early as 1983, whereas Zimbabwe only started in 1991. 
 The 1980s and early 1990s were, as a result, a period of deindustri-
alization across much of Africa. Previous industrial gains were eroded 
in many countries, and economic growth turned to decline, while 
health and education also suffered severely (Cornia et al., 1987). This is 
the context for the pause in industrial investment evident in Figure 1.1: 
the case studies that follow add some detail on this period, including the 
fate of existing firms and the distinctive experience of Zimbabwe. 
 From the mid-1990s, Figure 1.1 shows industrial investment in new 
pharmaceutical plants restarting across many countries. Much of this 
investment was by local investors. In some countries after independ-
ence, local entrepreneurs with working experience gained in multina-
tional companies set up their own production facilities, a phenomenon 
not dissimilar to the Indian pharmaceutical industry evolution. 
 Pharmaceutical manufacturing capabilities in Africa: an overview 
 In 2005, a survey found that 37 of 46 African countries possessed some 
pharmaceutical manufacturing capability (Berger et al., 2009). Since 
then, numbers and activity have continued to expand (Figure 1.1). 
Almost all this manufacturing capacity produces generic medicines. 
Generic medicines are copies of originator or innovator branded medi-
cines; generics have the same dosage form, therapeutic effect, delivery 
route, known risks and side effects as the originator drug. Local manu-
facturers in Africa import active pharmaceutical ingredients (APIs) 
and excipients mainly from India and China (UNIDO, 2010a; 2010b; 
2011a; 2011b). Active pharmaceutical ingredients are the therapeutic 
component of the drug, while excipients are pharmacologically inactive 
substances used as a carrier for the active ingredients of a medication 
or as lubricants during the manufacturing process. Local firms import 
plant, equipment and machinery from India and China, while analyt-
ical equipment is sourced mainly from high-income countries such as 
Germany. Only South Africa and Ghana had built some technological 
capabilities to manufacture APIs locally, according to the 2005 survey 
(Berger et al., 2009), though other countries are now seeking to do so as 
well (see Chapter 7). 
 The pharmaceutical technologies in use, and the range of pharmaceu-
tical drugs manufactured in African countries, are extensive. Firms have 
progressed from producing basic tablets and capsules to more complex 
technologies such as layered and sustained-release tablets. Product 
portfolios include suspensions and creams, syrups for children, sprays 
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12 Banda, Wangwe and Mackintosh
for inhalation and a range of sterile products such as injectables and 
ophthalmic preparations. The range of medicines includes anti-pain, 
anti-infectives including the penicillins, anti-worms and anti-virals, 
including anti-retrovirals for HIV/AIDS. There is a concerted effort to 
move into more products for chronic diseases such as hypertension and 
diabetes that are on the rise, implying a growing market. 
 Three indicative country case studies 
 The rest of this chapter briefly compares the industrial evolution of 
the pharmaceutical industry in three contrasting countries: Zimbabwe, 
Kenya and Tanzania. We show that their pharmaceutical sectors did not 
arise in isolation: in each case, the pharmaceutical industry co-evolved 
in important aspects with the broader industrial development. National 
patterns of industrial growth and periods of deindustrialization, along 
with shifts in industrial ownership and financing, are reflected in phar-
maceutical firms’ evolution. Broad industrial, macroeconomic and 
political economy influences are shared across industries in national 
industrial histories. 
 However, pharmaceuticals also display distinctive industrial char-
acteristics that are observable across countries. The most striking are 
the technological challenges embodied in pharmaceutical production; 
the increasing regulatory impact on the African-based industry; and the 
implications of the health sector structure and funding, including the 
rise of donor funding, on the evolution of the local industrial structure. 
These issues are all explored in depth in the rest of the book. Here we 
present a comparative sketch of three pharmaceutical industrial histo-
ries, as an introduction to the analyses to come. 
 These historical sketches also employ some key concepts that will be 
used throughout the book, notably the concept of industrial capabili-
ties. Given the high-skill, technologically demanding requirements of 
pharmaceutical production, as compared to widely produced consumer 
goods in these countries, the technological capabilities of the firms are 
key to their efforts to sustain competitiveness. By ‘technological capabil-
ities’ we mean a set of skills and information the firm requires to operate 
a given technology and its associated organizational system efficiently 
(Wangwe, 1995). Firms’ competitiveness in pharmaceuticals depends on 
their ability to obtain, absorb and use technological knowledge, capa-
bilities which build on past skills and knowledge to cumulative effect. 
Successful firms’ capabilities evolve from simpler to more complex activ-
ities in investment and process and product engineering (Lall, 1992). 
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An Historical Political Economy Overview 13
 Zimbabwe: the loss of early industrial advantage 
 There are elements of triumph and tragedy in the industrial history of 
Zimbabwe. As early as 1990, it was, after South Africa, touted as the 
next newly industrializing country (Pangeti et al., 2000; Phimister, 
2000). The well-established and vibrant manufacturing sector was one 
of the most advanced and diversified in Africa (AfDB, 1994), contrib-
uting 30% to GDP and accounting for 35% of the country’s gross export 
earnings. There were extensive linkages between manufacturing and 
key economic sectors such as mining, finance and agriculture. The 
manufacturing sector evolved to supply mining and agriculture, lever-
aging an extensive infrastructure (Mlambo, 2000; Phimister, 1988; 
2000). Zimbabwe therefore provides a narrative of a pharmaceutical 
sector that arose in integration with other manufacturing and service 
sectors, illustrating the importance of linkages and support structures 
in an economy. 
 Early import substitution 
 The distinctive history of Zimbabwean manufacturing results from its 
political history and the related push towards industrial development 
through import substitution. The legacy begins from the Second World 
War era. Before then, the country was a destination for British and South 
African manufactures. During the war, the blockade of traditional trade 
routes from Britain and the resultant shortages prompted local indus-
trial diversification and accelerated growth of local manufacturing. 
The average annual industrial growth from 1944 to 1948 was 24.4% 
(Pangeti et al., 2000). Later, the unilateral declaration of independence 
(UDI) from Britain in 1965, the trade with South Africa and the resulting 
UN sanctions (Pangeti et al., 2000; Phimister, 2000) reinforced the push 
towards industrial self-supply. 
 Zimbabwe’s industrial history illustrates the potential benefits of 
import-substituting industrialization for countries that later liberalize 
trade. After 1945, imports from overseas recommenced, increasing 
competition. Local industry responded by turning to regional markets as 
an outlet for industrial overcapacity. The expanded markets included the 
1953 Central African Federation (CAF) of Zambia, Zimbabwe and Malawi 
(then Northern and Southern Rhodesia and Nyasaland) (Pangeti et al., 
2000). During this era, foreign direct investment by South African and 
British companies flowed into local manufacturing industry (Phimister, 
2000). Industrial protection and import substitution were then vigor-
ously pursued after UDI. 
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14 Banda, Wangwe and Mackintosh
 During the early expansionary phase, two of the five major pharma-
ceutical companies were established: CAPS Pharmaceuticals and Datlabs. 
The pioneer company, CAPS Pharmaceuticals (then Central African 
Pharmaceuticals [Private] Limited), was founded in 1953, manufacturing 
formulations and wholesaling (UNIDO, 2011b). In 1958, CAPS stopped 
general wholesaling and focussed on manufacturing (CAPS website, 
2012). Datlabs (Pvt) Ltd was set up in 1954 as a subsidiary of Ingrams, 
a South African company (UNIDO, 2007; 2011b). These companies 
focussed on serving the regional market in the Central African Federation 
countries. A third major pharmaceutical company, Pharmanova (Pvt) 
Ltd, was established later, in 1970 in the UDI era (UNIDO, 2007). This 
period created an industrial base second only to South Africa in the 
region, including established pharmaceutical producers, inherited in 
1980 by the independent government. 
 Industry–health care integration 
 A country’s domestic market for pharmaceuticals is dependent on its 
health care spending and health care structure. At independence the 
new Zimbabwean government targeted the narrowing of the inherited 
racial gap in living standards by introducing free health care and educa-
tion for all as key elements of social transformation (Davies and Ratso, 
2000). Zimbabwe became renowned for high growth in education, 
health and public administration to promote social equity in devel-
opment (Helmsing, 1990). The country also continued its inherited 
historically high level of reliance on domestically produced medicines 
(Turshen, 2001). 
 Zimbabwe also made a pragmatic and early shift to cheaper generic 
prescription policies to reduce cost of medicines: in 1981, the Ministry 
of Health produced an essential drugs list (EDLIZ) (WHO, 1995), and this 
formed the basis for local medicines production strategies. Zimbabwean 
entrepreneurs established Varichem Pharmaceuticals (Pvt) Ltd in 1985 
to serve this expanding market (UNIDO, 2007). 
 The government also took industrial policy steps to address some 
of the consequences of 15 years of political unrest, liberation war and 
sanctions. Industrial machinery had become obsolete due to scarcity 
of foreign exchange, which continued into the early years of inde-
pendence (Bond, 1998; Phimister, 1988; Chifamba, 2003). Companies 
struggled to import capital equipment and upgrade their technolo-
gies. The government partially eased foreign-exchange restrictions 
for verified export orders through an Export Revolving Fund (ERF) in 
1983, followed by an Export Retention Scheme (ERS) in 1989 and later 
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An Historical Political Economy Overview 15
an Open General Import Licence (OGIL) in mid-1990s (Chifamba, 
2003). 
 However, Zimbabwe was not spared the economic crises that swept 
across African countries from the mid-1980s. Expansion of social services 
without rising revenues led to budget deficits, forcing the government 
to abandon their initial resistance to economic structural adjustment 
programmes (AfDB, 1998). On the advice of the IMF and technocrats in 
the Ministry of Finance, the country embarked on a structural adjust-
ment programme in 1991. Disastrous economic outcomes included 
deindustrialization, unemployment and deterioration of the health care 
system (AfDB, 1997; Brett, 2005; Richardson, 2005). 
 Despite the deteriorating industrial and economic conditions, 
however, Plus 5 Pharmaceuticals was established in 1996. The start-up 
used venture capital funding (UNIDO, 2007; 2011b), a testament to 
Zimbabwe’s financial system’s capability at the time, despite deindus-
trialization, and also to the continuing vibrancy of the pharmaceutical 
sector. The country continued to rely on locally manufactured medi-
cines (Turshen, 2001), and Zimbabwe appears to have sustained some 
alignment of industrial and health policy goals through this tumultuous 
period. 
 Pharmaceuticals in an era of economic collapse 
 After 1997, however, economic collapse set in. The decade from 1997 to 
2008 saw deindustrialization on a grand scale, as manufacturing decline 
was driven by hyperinflation (MTDP, 2010). Manufacturing real growth 
rates were negative every year from 1997 to 2008 except 2005, signifying 
declining manufacturing capacity as well as loss of skills and techno-
logical capabilities. Manufacturing share of GDP fell from 20% in 1997 
to 11% in 2008 while GDP shrank annually. The manufacturing share of 
exports fell from 20% to slightly over 10%. The private sector declined 
to the point of operating at 10% capacity, faced with shortage of capital, 
foreign currency, and interrupted electricity supplies. Physical infra-
structure crumbled, skilled people emigrated and incentives and institu-
tions were severely debilitated (AfDB, 2009). 
 Yet even in this era, aligned industry, health and social development 
policies did create some positive feedback mechanisms, enhancing local 
manufacturers’ innovative capabilities. This environment was instru-
mental in the country being one of the first in Africa to locally manufac-
ture anti-retroviral medicines (ARVs) to address the HIV/AIDS pandemic 
(Banda, 2013). As Chapter 15 describes, in 2002 Zimbabwe issued a 
compulsory licence allowing its local manufacturers to produce ARVs. 
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16 Banda, Wangwe and Mackintosh
This demonstrated purposive application of political will and policy 
infrastructure, associated with sustained local manufacturing capabili-
ties, to meet a pressing health and social need. 
 However, the economic crisis created a cumulative collapse in the 
public health system’s capacity to procure drugs over the period from 
2003 to 2009. The country shifted to high donor dependence for public 
health care funding and drug procurement (Banda, 2013). In addition 
there was international political isolation, acute shortage of foreign 
currency and dwindling foreign direct investment (FDI) coupled with 
skilled resources flight (AfDB, 1997; Brett, 2005). The greatest challenge 
for local pharmaceutical industry was the loss of public health procure-
ment as an industry policy tool (NECF, 2010). The increased reliance 
on donor funding posed a demand-side constraint for local firms: drugs 
for HIV/AIDS, TB and malaria were procured externally because the 
national procurement agency NATPHARM was incapacitated through 
lack of funds. 
 Current pharmaceutical manufacture in Zimbabwe 
 When the government of national unity was formed in 2009, there 
were various initiatives to resuscitate and rehabilitate the economy. 
Key strategies in the Short Term Economic Recovery Programme 
(STERP, 2009) were social protection, including food and humanitarian 
assistance and education. For health care, the focus was on building 
capacity in human resources, drugs and medical equipment availability, 
and reduction of preventable diseases. The health delivery strategy 
included addressing drug shortages: drug stocks in 2008 were just 36% 
of requirements, and stock-outs of essential drugs, vaccines and medical 
supplies had become common. The strategy also included capacitating 
NATPHARM, the national drug procurement agency, to supply govern-
ment health institutions. There was a gradual improvement in the sector 
in the 2011–14 period. 
 The pharmaceutical industry in Zimbabwe now consists of nine phar-
maceutical manufacturing companies registered with the Medicines 
Control Authority of Zimbabwe (MCAZ). Of these, five are the major 
generic manufacturers accounting for 90% of the formulation busi-
nesses (UNIDO, 2011b). The companies operate in a competition-
intensive, low-margin commodity-type business, where profitability 
and long-term viability depend on economies of scale, assured demand 
and large markets (Berger et al., 2009). Currently the country is capable 
of producing 50% of all drugs on the essential drugs list, and if all 
research and development (R&D) activities in formulations are taken 
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An Historical Political Economy Overview 17
into account, the capability rises to supplying 75% (NECF, 2011). Firms 
used to export quite extensively in the East African region, and also 
to Namibia, Angola and South Africa (UNIDO, 2007; 2011b). In 2014, 
the local industry supplied medicines to the health sector valued at 
US$24 million compared to US$184.7 million of imported medicines 
and US$100.4 million of donated medicines (Zimstats, nd). 
 While Zimbabwe’s experience shows that African countries can manu-
facture drugs for their local health system, and illustrates some ways 
in which health and industrial policies can be aligned, it is also a grim 
history of how economic crisis drives loss of industrial development 
opportunities in pharmaceuticals. 
 Kenya: creating the dominant East African producer 
 Kenya, like Zimbabwe, has a long history of pharmaceutical production. 
Local pharmaceutical manufacture can be traced back to the 1940s. The 
pioneer firm was the Kenya Overseas Company, established in 1947 and 
beginning local manufacturing activities in 1948. The next batch of 
firms included Sterling Winthrop (US), established in 1953; Burroughs 
Wellcome (East Africa) Ltd (UK) in 1955; and Aspro-Nicholas (EA) Ltd 
(Australia) in 1961 (Wamae and Kariuki Kungu, 2014). The early firms 
built up initial skills and experience in pharmaceutical manufacture in 
Kenya before independence in 1963. 
 After independence, Kenya also pursued policies of import-substi-
tuting industrialization (described and explained in Chapter 2). These 
policies supported manufacturing for the domestic market in the face of 
the 1970s balance-of-payments crises and rising oil prices. In this period 
pharmaceutical manufacturing expanded, benefitting from the indus-
trial protection, and also from an active government policy to promote 
investment and technological upgrading. The government established 
the Industrial and Commercial Development Corporation (ICDC) to 
provide development finance, and supported a number of parastatal 
joint ventures, including Dawa and Infusion Medicare. The firms of Lab 
& Allied and Cosmos were also set up in this period. 
 The mid-1980s and 1990s saw in Kenya, as across Sub-Saharan Africa, 
a process of market liberalization, associated with structural adjust-
ment programmes, and a shift to export promotion. In Kenya, export 
promotion included a number of schemes to allow bonded production 
for exports using duty-free inputs, but this had little impact on phar-
maceuticals (Chapter 2). The early 1990s in Kenya also saw a push to 
‘buy local’, using local health section procurement to benefit industrial 
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18 Banda, Wangwe and Mackintosh
development. There was industrial investment in pharmaceuticals 
production in this period, including Universal (Figure 1.1). 
 By the turn of the century, the Kenyan domestic medicines market 
was opening up in familiar ways to more global competition, notably 
from South Asia. Donors moved in to supply medicines for malaria, TB 
and especially HIV/AIDS, but this was later and more patchy in Kenya 
than in some neighbouring countries (Chapter 2). The relative strength 
of the production capabilities of the Kenyan industry by 2001 allowed 
the government to decide to permit compulsory licensing of generic 
production of HIV/AIDS medicines, and the subsequent issuing of 
voluntary licences (UNIDO, 2010a; see also Chapter 2). However import 
liberalization was by this date generating increasing competition from 
imports of finished formulations, and this seems to have been a factor in 
the departure of a number of multinational producers. In 2014, almost 
all pharmaceutical firms in Kenya were locally owned (Chapter 2). 
 A local industry with regional potential 
 In February 2014, Kenya had 39 pharmaceutical manufacturers regis-
tered with the Pharmacy and Poisons Board (PPB). Thirty-four were 
producing pharmaceuticals for human health, while the rest concen-
trated on veterinary products (Wamae and Kariuki Kungu, 2014). There 
were also 20 multinational firms with local representation for marketing 
purposes and /or involved in clinical trials. 
 Like the firms in Zimbabwe, Kenyan pharmaceutical activities are 
mainly production of finished formulations, with some reformulation 
and development activities. The industry mainly produces generic prod-
ucts, importing APIs, excipients and other raw materials from India, 
China and Germany. India dominates both raw materials and finished 
product imports, accounting for 40% of all pharmaceutical-related 
imports in 2008 (UNIDO, 2010a: 49). Few key inputs can be sourced 
locally; exceptions are maize starch, sugar and glucose syrup, rectified 
spirit and ethanol, as well as sodium chloride and quite a wide range of 
packaging materials. 2 
 The Kenyan industry continues to suffer from relative low capacity 
utilization, and Chapter 2 explores the reasons for this in detail. They 
include limitations in the functioning state of machinery, delays in 
sourcing spare parts from abroad and human resource issues, in partic-
ular shortages of highly specialized skills in some critical areas such as 
product development. 
 Despite these constraints, Kenya’s pharmaceutical sector is the 
strongest producer of pharmaceuticals in the East African region, and is 
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upgrading to more demanding technological capabilities. In addition to 
the standard generic products in the dosage forms of tablets, capsules, 
creams and syrups, the industry in Kenya includes three firms producing 
injectable infusions (small and large volume parenteral preparations) 
and ophthalmic formulations. One firm (Universal) has achieved WHO 
prequalification for one of its products, allowing the firm to tender for 
donor contracts and also providing an indicator of the firm’s technical 
capabilities and standards. 
 A further measure of the strength of Kenya-based pharmaceutical 
production is its export success, which accelerated from about 2002. 
Kenyan pharmaceutical producers’ main export destinations are in the 
COMESA region: the Common Market for Eastern and Southern Africa, 
which does not include South Africa or Tanzania. 3 However, the Kenyan 
industry still supplies a tiny fraction of COMESA’s medicines market, 
while provisioning only around a quarter of its own domestic market. 
There is substantial room for expansion. With supportive government 
policies, Kenya should be able to exploit effectively the integration of 
East African and Southern African markets to expand its role as one 
of the medicines production ‘hubs’ in Sub-Saharan Africa. Chapter 2 
discusses the industrial challenges in depth. 
 Tanzania: a latecomer under stress 
 Tanzania has a shorter history of pharmaceutical manufacturing than 
the two countries just discussed. In the colonial period during World 
War II, facilities for manufacturing simple medicines were established to 
counter the risk of blockade. However, after the war, these closed, and 
the country reverted to imports. The mainland, then called Tanganyika, 
did not, unlike Zimbabwe and Kenya, have a large colonial settler popu-
lation in the pre-independence period, and the level of industrialization 
at independence was correspondingly small. 
 Pioneering firms and public sector investment 
 The earliest pharmaceutical manufacturing firm in Tanzania seems to 
have been Mansoor Daya Chemicals Ltd., a privately owned firm. Mr. 
Daya, a pharmacist, began with a retail pharmacy in Dar es Salaam in 
1959. He set up his own firm in 1962, originally in a small godown, later 
moving to his current production site. 4 
 In the 1960s and early 1970s, the Nyerere government in Tanzania 
turned to the promotion of industrial development through public 
investment. In contrast to Kenya, the industrial policies were driven by 
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a more explicitly socialist agenda, although, as the case studies in this 
chapter illustrate, the use of public investment to promote industrial 
development was a broadly implemented approach in these post-inde-
pendence years (Lall and Wangwe, 1998). Manufacturing output rose 
from 4% of GDP at independence to about 8% or 9% in the 1970s. The 
production was mainly oriented to the domestic market, although there 
was a slow growth of manufacturing exports to East Africa, until these 
markets were lost with the break-up of the East African Community in 
1977 (Bagachwa and Mbelle, 1995). 
 This was a period of import-substituting policies, paralleling those 
in Zimbabwe and Kenya, with an overvalued exchange rate, import 
controls, protective tariffs and administrative allocation of foreign 
exchange. It was also a period of state-led industrialization, including 
public sector investments in manufacturing plants. Two public sector 
pharmaceutical firms were established to provide essential medicines 
to a rapidly expanding public health sector. Keko Pharmaceuticals was 
opened as a production unit within the Ministry of Health in 1968 to 
supply tablets, capsules and large-volume parenterals for distribution to 
public sector health care facilities. Tanzania Pharmaceutical Industries 
Ltd (TPI) began as a public enterprise in 1978 with assistance from the 
Finnish government. 
 This was thus a period when the government was placing priority 
on expanding health care to serve a basic need, and the pharmaceu-
tical industry responded to an alignment of industrial and health poli-
cies. The industrial strategy prioritized production to meet basic needs, 
including health care, creating a conducive environment for investment 
in pharmaceuticals. Private clinical practice was banned in 1977, except 
for some religious providers, and the main market for medicines was 
the public sector, plus retail pharmacies. However, the domestic market 
expansion was sufficiently attractive for a second private start-up, Shelys 
Pharmaceuticals, which began production in 1979. In 1984, Shelys was 
bought by the Tanzanian Sumaria Group of companies and built up into 
the largest pharmaceutical firm in the country. 
 Economic crisis and liberalization 
 Like our other other case-study countries in this chapter, Tanzania was 
hit by a major economic crisis in the 1980s. However, the impact in 
Tanzania was particularly severe, a result of a confluence of circum-
stances including a small and particularly internationally uncompeti-
tive manufacturing sector focussing on consumer goods for the domestic 
market, and a liberalization process that was rapid and relatively 
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unconstrained by transitional policy safeguards. The late 1970s and 
early 1980s were marked by severe shortages of goods, as foreign 
exchange constraints reduced inputs to local production and export 
manufacturing declined. Capacity utilization dropped dramatically, 
and manufacturing output fell back to 7% of GDP by 1985 (Bagachwa 
and Mbelle, 1995). Pharmaceutical manufacturers were badly affected 
by foreign exchange shortages that constrained their ability to import 
APIs and other key inputs. 
 The major policy framework reversal was signalled by the adop-
tion of the Economic Recovery Programme (ERP) in 1986. This shifted 
policy sharply away from import substitution, liberalizing imports of 
final goods and providing export incentives for manufacturers. While 
there was some export recovery, production of consumer goods for the 
domestic market suffered badly as cheaper imports flowed in. Given the 
prior levels of industrial protection in Tanzania, the liberalization consti-
tuted a much more severe shock than in Kenya or Zimbabwe, where 
protection had been lower and transition was better managed. Firms in 
Tanzania had little time for adjustment (Lall and Wangwe, 1998: 93). 
The result in Tanzania was a swathe of deindustrialization, and firms 
serving the domestic market failed. 
 Pharmaceuticals faced a second challenge also: the ‘battering’ taken 
by public sector health care funding and other government provided 
social services as the government budget went into severe crisis (Kaijage 
and Tibaijuka, 1996). As a result, the two government firms, Keko and 
TPI, ceased to be able to compete with imported medicines, lost their 
markets, and closed in the early 1990s. However, the two private phar-
maceutical producers, Mansoor Daya Chemicals and Shelys, survived the 
economic crisis years. Shelys in particular was built up into a successful 
business as the largest pharmaceutical firm in Tanzania and expanded 
exports to the region. Another privately owned local firm, Interchem 
Pharmaceuticals was set up in 1989 in Moshi, part-owned by the IPP 
group of companies. 
 The challenges of competitiveness and upgrading 
 Industrial research in the 1990s emphasized the importance of firms’ 
technological capabilities for survival and competitiveness in a more 
open economy (Wangwe, 1995). In the late 1990s and early 2000s, some 
of these technological capabilities were rebuilt in Tanzania, in pharma-
ceuticals as in other industries. The challenge was particularly great in 
pharmaceuticals given its reliance on skills and ability to manage tech-
nological upgrading effectively. 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
22 Banda, Wangwe and Mackintosh
 However, from the late 1990s, the pharmaceutical industry in Tanzania 
was renewed and grew substantially, entirely through the efforts of 
local investors and managers. The government sold 60% of the equity 
in each of the inactive government firms, Keko and TPI, to private 
Tanzanian investors in 1995. Both reopened in the late 1990s. In 2003, 
Shelys bought Beta Healthcare International, a Kenyan pharmaceutical 
company (previously Boots), with private equity funding from Aureos 
Capital. This was the first cross-border merger whereby a Tanzanian 
firm purchased a Kenyan company, and it made Shelys Africa Group the 
largest East African pharmaceutical company at that time. 5 
 By 2009, the high point of Tanzanian pharmaceutical produc-
tion, there were eight firms producing for the local market and also 
exporting regionally. The new firms were started by a mix of local and 
international investment. Tanzansino started production in 2000 as a 
joint venture between the Tanzanian military and a Chinese provin-
cial government body. In 2007, the ownership changed when the 
Chinese provincial government shares were bought by Holley Industrial 
Group Ltd., a Chinese industrial group including a firm producing and 
exporting one of the new artemisinin-based combination therapies for 
malaria. 6 AA Pharmaceuticals, a smaller firm established by a Tanzanian 
private investor who is a pharmacist, began production in 2002. And in 
2007, a new plant, Zenufa Laboratories, was built and opened. Owned 
by a DRC (Congo)-based diversified family firm, Zenufa aimed for 
Good Manufacturing Practice status from the start. These new start-ups 
reflected the changed economic circumstances in Tanzania: faced with 
sharp external competition, they aimed for efficient manufacturing and 
regional export capability from the beginning. 
 Data are not easy to assemble, but Table 1.1 provides a summary over-
view of the pharmaceutical industry in Tanzania just before the start-up 
of Zenufa. Seven firms were then active. Shelys at that time was respon-
sible for about half of local production by value (Table 1.1). Much of 
the rest of the output was supplied by TPI, Interchem and Keko. The 
main suppliers to the public wholesaler (MSD) were Shelys, TPI and 
Keko, while Shelys was also the main exporter. Chapter 3 analyses the 
Tanzanian industry after this date. 
 Conclusion: shifting the debate 
 This chapter aimed to dispel the persistent myth that pharmaceutical 
production is not an African industry, tracing the long industrial history 
of the production of medicines on the Sub-Saharan subcontinent. This 
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book aims to contribute to shifting the whole debate on  making medicines 
in Africa definitively away from ‘Should it be done?’ to ‘How can it be 
done well to the benefit of public health?’ Despite the successes to date, 
local manufacturers serve only a small proportion of African domestic 
demand, let alone population need (Berger et al., 2009; UNCTAD, 2011; 
WHO, 2005; 2011). The bulk of medicines consumed are imported from 
India and China, and there is heavy reliance on disease-specific donor-
funded imports. That situation is not sustainable. African countries need 
to grow their capabilities to address the health needs of their popula-
tions, and pharmaceutical manufacturing and its associated technical 
and scientific bases are needed for that effort. 
 Nationally and across the African subcontinent, efforts to expand 
local manufacturing and innovation are extensive. The business case for 
local drug manufacture – and its potential to enhance security of medi-
cines supply – has gained ground within African Union (AU) and New 
Partnership for Africa’s Economic Development (NEPAD) circles. Not all 
countries have the capacity and capability to embark on the full spectrum 
of pharmaceutical production, innovation and R&D. The  Strengthening 
Pharmaceutical Innovation in Africa strategy report (Berger et al., 2009) and 
the UNIDO-AU-sponsored African Pharmaceutical Manufacturing Plan 
of Action (AU-UNIDO, 2013) propose a phased approach of working 
up the technological ladder (see Chapter 15). Given the current rates of 
investment and industrial development in pharmaceuticals, the debate 
 Table 1.1.  Pharmaceutical production and exports, Tanzania, 2004–05 
Producer
Value of 
production 
(US$ 
million)
Share 
of total 
production 
(%)
Sales 
to the 
public 
sector 
(US$ 
million)
Sales to 
private 
market 
(US$ 
million)
Exports 
(US$ 
million)
Shelys 
Pharmaceuticals
16.0 49.2 5.7 7.4 2.9
Tanzania 
Pharmaceutical 
Industries
6.7 20.4 4.0 2.5 0.2
Other firms 9.9 15.0 1.3 8.5 0.0
Total 32.6 100.0 11.0 18.4 3.1
 Source : Compiled by the authors from data in MoHSW (2006). Data in Tanzanian shillings 
in that source converted to US$ using the average exchange rate of 0.00095 for the year July 
2004–June 2005 obtained from  www.oanda.com . 
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now concerns the policy and business determinants of cost-effective 
manufacture of safe and efficacious medicines, and the conditions for 
aligning industry, finance and public health needs. The mechanics of 
achieving this become a matter of strategic intent at national, regional 
and continental levels. This is the terrain this book explores. 
 Notes 
 1 .  Part of this chapter draws on research undertaken for the project  Industrial 
productivity and  health sector performance . The findings, interpretations, conclu-
sions and opinions expressed here are those of the authors and do not neces-
sarily reflect the views or policies of DFID or the UK ESRC, whose financial 
support is gratefully acknowledged (project ES/J008737/1). Some of the 
evidence is drawn from fieldwork by Watu Wamae and Joan Kariuki Kungu 
for this project. 
 2 .  Source: UNIDO (2010a) and interviews. 
 3 .  Source:  http://about.comesa.int/ , accessed 12 April 2015. 
 4 .  Source: interviews. 
 5 .  Source: Sumaria Group website:  http://www.sumaria.biz/our-businesses/ , 
accessed 6 March 2014. 
 6 .  Source: interview with Tanzansino manager, 2010. 
 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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 Introduction 
 As Chapter 1 briefly outlined, Kenya has a strong and long-standing 
pharmaceutical industry. A 2015 Business Monitor report on pharma-
ceutical manufacturing in Kenya states that the country hosts the largest 
pharmaceutical industrial base in East Africa. The report also sees a bright 
future as a ‘potential base for export across East Africa’ (BMI Research, 
2015). This chapter locates the Kenyan pharmaceutical industry within 
the country’s historical context of industrial development and growth. 
 The features of the local production of medicines are shaped by the 
characteristics of the Kenyan economic and industrial systems, which 
in turn are the product of its economic history. To analyse this shaping, 
this chapter briefly presents and then applies an evolutionary economic 
understanding of industrial capabilities, focusing particularly on techno-
logical capabilities at the firm and industrial system level, their sources 
and evolution. This framework of industrial analysis is also used in a 
number of subsequent chapters in this book. It is particularly illumi-
nating for the analysis of the development of an industry, pharmaceu-
ticals, that is technologically demanding relative to the industrial and 
economic context in a low-income country such as Kenya. 
 Pharmaceutical manufacturers face constant competitive and regula-
tory pressure to upgrade their technological capabilities, and the evolu-
tionary framework of analysis emphasizes the extent to which this 
upgrading relies on both firm-level investment building on existing 
capabilities, and also on the benefits that accrue from its surrounding 
industrial base. Chapter 1 briefly noted that African countries’ broader 
 2 
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industrial base frequently stems in turn from an era of policy-led 
import-substituting industrialization. This chapter explores in more 
detail how the pharmaceutical industry has built on this basis in 
Kenya, and the scope that gives the industry for exploiting the oppor-
tunities opened up by the subsequent more liberalized and competi-
tive markets. It also outlines some of policy decisions that have shaped 
the industry’s development, and some of the challenges for firms and 
policy makers. 
 This chapter draws on a range of sources, including trade and manu-
facturing data, secondary published and grey literature sources and also 
interviews with manufacturers and distributors and other field data 
collected in 2012–14. 1 
 The evolution of Kenya’s pharmaceutical industry in the 
context of post-colonial industrialization 
 The profile of the pharmaceutical industry in Kenya is influenced by the 
country’s broader economic and industrial history. The post-independ-
ence industrial history of Kenya can be split into three periods according 
to the policy regimes adopted: the early years of import substitution 
industrialization (ISI), until the 1970s; the liberalization and gradual 
opening up of the economy in the 1980s and 1990s; and the new millen-
nium (Chege, Ngui and Kimiyu, 2014). 
 Pharmaceutical production was already taking place before the advent 
of independence in 1963, as Chapter 1 described. The early firms were 
mainly foreign direct investments (FDI). The newly independent country 
then continued to implement policies of ISI that had started during the 
colonial period. 
 Import-substituting industrialization is a set of economic and trade 
policies that aim to promote domestic industrialization in order to 
reduce the country’s dependence on manufacturing from abroad. The 
policies seek to promote the accumulation of skills, capital and knowl-
edge for the production of manufacturing goods by limiting imports of 
selected manufacturing goods through a variety of trade restrictions and 
subsidizing domestic manufacturing enterprises. In the Kenyan case, 
local producers were shielded from foreign competition in manufac-
tures in a variety of ways. High tariffs, even reaching 100% of the goods’ 
value, and quotas were imposed on imported manufactures, which were 
also charged higher rail fares, with the result that their prices were high 
for Kenyan consumers. Domestic manufacturing firms were also helped 
with financial subsidies, allocated land for production facilities, and 
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allowed to have import duties refunded on the inputs (raw materials and 
equipment) they had to import for production. 
 The Kenyan government also explicitly welcomed foreign-owned 
firms who set up production facilities in the country, as they contrib-
uted to the domestic industrial development. The large weight of FDI 
in Kenyan industry of the colonial period is also typical of the early 
years of independence, when it even reached half of industrial output 
(Maxon, 1992). Fearing a flight of FDI, a year after independence, in 
1964, the government passed the Foreign Investment Act, which gave 
reassurances to foreign firms in areas such as repatriation of profits and 
protection from nationalization. 
 This policy orientation towards manufacturing for the domestic 
market was reinforced in the 1970s by balance-of-payments crises and 
rising oil prices which led to scarcity of foreign exchange. Manufacturing 
of consumer goods for the local market expanded rapidly in the early 
1970s, and there was diversification into upstream supplier indus-
tries such as plastics. In this period, pharmaceutical manufacturing 
expanded, benefitting from the industrial protection, and also from 
an active government policy to promote investment and technolog-
ical upgrading. Laboratories & Allied was incorporated in 1970. The 
government established the Industrial and Commercial Development 
Corporation (ICDC) to promote the inclusion of local people in industry 
by providing development finance and technical assistance. ICDC helped 
to develop pharmaceutical production in this period through parastatal 
joint ventures. Dawa was established as a 1970s joint venture between 
the ICDC and the Yugoslav government. A firm producing infusions, 
Infusion Medicare, began in the mid-1970s as a joint venture between 
the ICDC and Hoechst E.A. (the latter the East African arm of a German 
pharmaceutical producer now part of Sanofi). 
 ISI policy in this period successfully created an industrial base in Kenya, 
especially in light consumer industries such as textile and foodstuffs, but 
also in others such as metal products. Between independence and 1980, 
industrial output quadrupled, the share of GDP in manufacturing grew 
from 10.1% to 13.3% and the number of industrial establishments more 
than doubled (Ogonda, 1992: 297–98). The increase in local manufac-
turing reduced the multinational companies’ (MNCs) share of industrial 
output, which however still accounted for 20% of industrial output in 
the early 1970s (Maxon, 1992: 385). 
 However, the protection from international competition encouraged 
local firms to focus on the protected local market and neglect exports. 
This created an anti-export bias that, together with external shocks such 
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as the oil crises and a deterioration of terms of trade, led to a shortage 
of foreign exchange. In 1980 Kenya had to take a loan with the World 
Bank, which imposed structural adjustment conditions. This marked 
the beginning of the phase of liberalization and structural adjustment 
policies in the mid-1980s and 1990s, as it happened across Sub-Saharan 
Africa, and the beginning of a shift to export promotion. In Kenya, 
export promotion included a number of measures to allow production 
for exports using duty-free inputs, but the implementation was slow and 
tentative, with little impact on export. 
 The gradual opening up of local markets created competition that 
had an adverse impact on local industrial activity. Shortage in foreign 
currency contributed to the decline of domestic industry as firms found 
it difficult to buy foreign inputs and equipment, with adverse effects 
on capacity utilization and therefore productivity. After an economic 
crisis at the beginning of the 1990s, liberalization and export promo-
tion accelerated with the creation of Export Promotion Zones (EPZs), 
participation in the Common Market for Eastern and Southern Africa 
(COMESA) and the East Africa Community (EAC), and the removal of 
price controls in 1994. Export promotion and international competi-
tion, however, had little impact on pharmaceuticals in that period. More 
important was a push in the 1990s to ‘buy local’, aiming, for example to 
ensure that basic medicines kits should be 50% local products (Wamae 
and Kariuki Kungu, 2014). Local pharmaceutical companies benefitted 
from this policy – an example of active use of health sector procurement 
as an industrial policy. Among the larger Kenyan manufacturers, Regal 
was established in the 1980s and Universal in the 1990s. Parastatal firms 
were privatized. 
 The third phase of industrial development, in the new millennium, 
saw an increase in exports especially in textiles through the United 
States’ African Growth and Opportunity Act (AGOA), which facilitated 
exports to the US and increased activity in EPZs. In spite of this new 
push to promote exports, the pressure of global competition from other 
low-income countries has meant that the share of manufacturing in 
total GDP has not changed significantly, and much of industrial activity 
is still carried out in the informal sector by micro enterprises, whose 
small size makes it difficult to find funds for investment, expansion and 
upgrading. During these years, most of the foreign MNCs also ceased 
to produce in Kenya as they reorganized their supply chains globally in 
the light of competition from China and India to find cheaper locations 
for production. It is possible that local producers may have benefitted 
from the flight of production from MNCs, being able to take their place 
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in some market segments and absorbing employees already trained by 
foreign MNCs. 
 The development of Kenya’s pharmaceutical industry suggests that ISI 
policies were important to build an initial industrial base. Previous anal-
yses of industrialization have argued the ISI policies followed by careful 
liberalization and export promotion might be useful to promote indus-
trialization (see, e.g., Athreye, 2004, for the Indian software industry). 
So it is possible that ISI policies enabled Kenya to start the accumula-
tion of basic technological know-how, perhaps through parastatal joint 
ventures, such as those formed by ICDC, in spite of their problems. The 
opening up of export markets, especially with the creation of COMESA 
and EAC and the policies that promoted exports such as the formation of 
EPZs, also enabled the strongest firms to adapt to international competi-
tion and offered opportunities for the expansion that is observed today, 
as the next section shows. 
 The Kenyan pharmaceutical industry and 
its market position 
 In historical studies of industrialization in Kenya, the pharmaceutical 
sector is rarely mentioned as it traditionally accounted for a very small 
share of industrial output. However, recently its status has been increas-
ingly recognized. For example, pharmaceuticals are mentioned as one 
of the eighteen strategic sectors in the National Industrialization Policy 
2011–15 (Ministry of Industrialization, 2010). Kenyan local manufac-
turers of medicines have shown great resilience during the years of 
economic difficulties and are now embarked on a process of growth 
and technological upgrading that, if successful, can establish them as a 
major player in the East African market for medicines. 
 Kenya’s pharmaceutical production grew continuously from 2007 to 
2013. As Figure 2.1 shows, in that period total production of tablets, 
capsules, liquid preparations for oral use and creams/ointments alone 
increased from US$34.1 million to US$154 million. The figure also 
shows that the composition of products has changed over these years, 
with creams and ointments becoming more popular, although virtually 
all product types have steadily increased with the possible exception of 
capsules. 
 Kenya has also seen strong growth in its pharmaceutical exports in the 
new millennium, especially since 2002. Exports started growing around 
1992–93 thanks to the ‘buy local’ push, which promoted the expan-
sion of local manufacturing. However, during the 1990s and early 2000s, 
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local production was affected by the adverse effects of liberalization 
policies described in the previous section, and exports remained stable. 
These years also saw a wave of divestments of production activities from 
foreign-owned companies that carried on in the new millennium as 
Kenya’s industrial environment deteriorated and MNC producers moved 
out of Kenya to lower cost platforms. By 2014, only one MNC was still 
manufacturing in Kenya – GSK. Otherwise, pharmaceutical firms in 
Kenya are currently mainly locally owned. 
 The great majority of Kenyan’s pharmaceutical exports are destined 
to Sub-Saharan Africa (SSA). COMESA is the main export destination 
for Kenya’s pharmaceutical exports, with Kenya supplying about 50 per 
cent of the region’s production. In relative terms, however, this trans-
lates into a minute share of the COMESA market. 
 With respect to the main importers of Kenya’s pharmaceutical prod-
ucts, Uganda has remained a significant market over a number of 
decades. Somalia and Sudan have also seen significant growth of Kenyan 
products, particularly over the last two decades. 
–
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 Figure 2.1  Local production of non-parenteral medicines in Kenya by type of 
product, 2007–13 (US$ million) 
 Source : Kenya National Bureau of Statistics, Production data for the period 2007 to 2013, 
Government of Kenya, Nairobi, obtained 4 September 2014. 2 
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 In spite of the growth in production and exports, the Kenyan phar-
maceutical industry has to overcome important challenges in order to 
consolidate and expand its influence in the East African region. Kenya’s 
pharmaceutical industry is still mainly oriented towards the home 
market, with an export share of domestic production only ranging 
between 15 and 20 per cent, at least up to 2010. Furthermore, the Kenyan 
producers’ share of their own home market is estimated at around 25% 
of domestic demand (see also Chapter 8), leaving room for expansion 
(Wamae and Kariuki Kungu, 2014). 
 Kenyan manufacturers sell to the Kenyan public procurement agency 
KEMSA, and to the large non-profit wholesaler the Mission for Essential 
Drugs Supply (MEDS) that supplies predominantly the faith-based health 
care sector. They also sell into the large private sector (Chapter 8). Public 
procurement is regulated by the Public Procurement and Disposal Act 
of 2005, and tendering decisions are based mainly on pricing, though a 
15% price preference for local manufacturers is available. Producers and 
distributors are free to set their own prices and mark-ups, and private 
mark-ups are, on average, high. The pricing of medicines in Kenya was 
completely liberalized in 1993. 
 In the new millennium the Kenyan domestic medicines market has 
been hit by more global competition, notably from South Asia. A key 
development for the pharmaceutical industry has been the large-scale 
movement of donors into supplying medicines for malaria, TB and 
especially HIV/AIDS. This has been a strong influence on the domestic 
market and pharmaceutical policies in a number of the countries 
discussed in this book. The arrival of the large donors was, however, 
somewhat later and more patchy in Kenya than in some neighbouring 
countries. PEPFAR, for example, the main US programme for funding 
HIV/AIDS medication, began to operate in Kenya only in 2008, and 
Kenya received no funding under Rounds 8 and 9 of the Global Fund 
financing (UNIDO, 2010: 41). 
 The production capabilities of the Kenyan industry were confirmed 
during this period by the companies’ role in the campaigning that led 
to the 2001 government decision to allow compulsory licensing of 
generic production of HIV/AIDS medicines, and the subsequent issuing 
of voluntary licences (UNIDO, 2010). However, private importers from 
South and East Asia were increasingly generating price-based competi-
tion in the Kenyan medicines market as liberalization took hold. With 
export figures that in absolute terms remain very modest, it is essential 
that Kenyan manufacturers keep upgrading and also control costs in 
order not only to expand its foreign markets but also to keep up with 
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increasingly demanding technological standards and cheap foreign 
competition that creates a serious challenge to local producers. 
 Technological capabilities and sectoral systems of 
innovation 
 The previous sections have shown that Kenyan pharmaceutical manu-
facturers are enjoying a period of growth. However they also face chal-
lenges that arise from cheap imports and the need to constantly upgrade 
their technology in order to keep up with global competition and 
increasingly demanding technical standards and to successfully exploit 
new market opportunities. A key factor in the future prospects of the 
Kenyan pharmaceutical industry is therefore the extent to which the 
local producers will be able to improve their technological capabilities. 
 The notion of technological capabilities, which has now entered the 
mainstream analysis of industrial development, can be traced back to the 
work of evolutionary economists such as Richard Nelson, Sydney Winter, 
Christopher Freeman and Giovanni Dosi (Dosi et al., 1988; Nelson and 
Winter, 1982). Evolutionary economics started as a critique of the domi-
nant theoretical framework in economics, the neoclassical approach. The 
critique arose from the observation that the tools of neoclassical analysis 
were not well suited to the study of technological and industrial change. 
Neoclassical economics focuses on the working of the price mechanism 
in the coordination of economic activity but makes strong and unreal-
istic assumptions about the nature of technological knowledge and the 
way firms (and, in general, other economic agents) operate. Technology 
is seen as information, which has public good features and is therefore 
easily transferred between firms. Technology transfer is simplistically 
seen as the transfer of free information. 
 Evolutionary economists, however, argue that much of technological 
knowledge is tacit and hence difficult to articulate, let alone transfer 
easily. The effective use of technology requires that any publicly available 
technical information be processed using know-how and skills that not 
only are costly to acquire but also differ across firms, industries and coun-
tries. Firms and other organizations, like people, acquire skills, or capa-
bilities, that become embedded in their procedures (also called routines) 
and people through a process of learning that is shaped by the history 
of the firm. Technological capabilities, therefore, are the organizational 
skills that enable firms to make effective use of technologies, including 
the ability to adapt them, improve them and even develop radically 
new products and processes. Because of their tacit nature, capabilities 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
Pharma in Kenya: Technological Capabilities 33
are costly to acquire, are learned over time and change slowly over time. 
An important consequence of this view is that since firms’ histories and 
sources of learning differ, the capabilities that firms accumulate also 
differ. Indeed, industry studies have shown that firms within the same 
industry usually have many differences that are persistent over time: 
each firm is unique (Griliches and Mairesse, 1995). 
 The work on capabilities of early evolutionary economists originally 
focussed on advanced technologies and firms in industrialized coun-
tries. However, other scholars, such as Lall, extended this work into the 
context of developing countries. In an influential paper, Lall (1992) 
distinguished between firm-level and country-level capabilities. Firm 
capabilities include both investment and production capabilities and 
can be classified according to their degree of complexity, from basic, 
which involve experience-based tasks, to intermediate, which involve 
an element of search, to advanced, which are research-based and involve 
the creation of wholly new products and processes. Firm capabilities also 
include ‘linkage capabilities’, the way in which firms learn from and 
transfer knowledge to the external environment, that is, other organiza-
tions and institutions, including customers, suppliers, government agen-
cies and science and technology providers. Countries also have distinctive 
national capabilities, which are more than the sum of the capabilities 
of their firms and other organizations because they also include they 
way economic agents interact and the features of the economic environ-
ment, such as the policies, incentives and institutions. 
 The early work on technological capabilities has been further devel-
oped by many scholars and has now entered mainstream thought in 
the field of science, technology and innovation studies (STI). A useful 
development of this theorizing is the recognition that industrial sectors 
have a set of institutions and organizations that differ across sectors and 
influence the way technological capabilities are accumulated and firms 
compete. In order to understand an industry’s patterns of development 
and change, it is necessary to study the various agents that influence 
the accumulation of knowledge and the nature of competition in the 
industry and the way they interact. 
 The pharmaceutical sector is a typical example of the distinctiveness 
of sectoral institutions that shape technological learning and competi-
tion. Medicines are usually strictly regulated for their efficacy and safety 
by government agencies in a way that is unusual in other industries. 
The structure of demand is also distinctive because of the important role 
played by the state through the public procurement of essential medi-
cines for the health system and, especially in low-income countries, the 
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major role played by international donors in the purchase of key medi-
cines. On the supply side, universities also play an important role as 
providers of skilled labour and scientific knowledge. 
 Technological capabilities in manufacturing of 
medicines in Kenya 
 This section draws on various sources, including firm interview data, in 
order to give an assessment of the Kenyan technological capabilities in 
the local production of pharmaceuticals. The technological capabilities 
of the Kenyan domestic pharmaceutical sector are analysed by looking 
at various dimensions of the production system in which local manufac-
turers of pharmaceutical operate. 
 The analysis starts with the description of the local producers because 
the firms are at the centre of the industrial system. A good starting 
point for the assessment of the manufacturers’ capabilities is the anal-
ysis of the characteristics of their products in terms of quality and tech-
nological sophistication, the extent to which they achieve industry 
standards and their productivity. What firms can achieve, however, 
also depends on the capabilities of the system of suppliers, customers, 
regulations and institutions with which they interact, including the 
educational and financial systems, so these aspects will be included in 
the analysis. 
 Industrial structure 
 Local manufacturing of pharmaceuticals in Kenya is dominated by 
locally owned firms. In 2014 there were 39 local manufacturing firms 
with products registered with the Pharmaceuticals and Poisons Board 
(PPB), the agency that regulates the manufacture and trading of medi-
cines in Kenya. Of these, 34 produced medicines for human consump-
tion, whilst at least five firms produced animal health products. Of the 
34 firms, only one producer is a foreign-owned MNC, GSK East Africa, 
which has not followed the exodus of other MNCs. Although MNCs 
dominated the local production of pharmaceuticals in Kenya in the 
1990s, because of the unattractive economic conditions in Kenya in the 
1990s and changes in global supply chains, most of them have moved 
production facilities to lower cost locations and are only present in 
Kenya for activities such as marketing and clinical studies (Wamae and 
Kariuki Kungu, 2014). 
 However, government policy has provided other incentives for 
local production by removing import duties and taxes from inputs to 
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pharmaceutical products, such as APIs, excipients and packaging mate-
rials. The situation, however, changed in 2013 when the new VAT act 
reintroduced taxation for pharmaceutical inputs and only exempted 
finished products. This decision made locally produced medicines up to 
22% more expensive, and the industry put pressure on the government 
to reverse the decision. This happened in the 2014 Act, but there are still 
some unresolved issues that are worrying local manufacturers (Wamae 
et al., 2014). 
 Studies of the Kenyan supply medicines chain show that Kenya has 
high margins for distributions, which raise the final price of the medi-
cines to users in spite of fairly low manufacturing costs, in comparison 
to countries, such as Brazil, India, Indonesia, Kenya, Netherlands, Russia 
and South Africa. The study shows that the percentage of distribu-
tion costs is clearly highest in Kenya (see IMS Institute for Healthcare 
Informatics, 2014: 11). The high margins are a sign of the market power 
enjoyed by private distributors, who have a global reach and access to 
cheap imports, mainly from India. 
 Products and standards 
 Kenyan manufacturers are mainly engaging in activities that require 
basic to moderate technological capabilities, such as formulation activi-
ties, that is, converting manufactured bulk substances into final usable 
forms, and packaging rather than activities at the high end of the 
technological spectrum, such as R&D aimed at the discovery of new 
molecules and product development or the production of bulk pharma-
ceutical substances (APIs). The tablet is the most common dosage form; 
Kenyan firms also manufacture capsules, topical preparations (creams, 
gels, ointments or pastes), liquid preparations for oral use (including 
syrups), injectable infusions (small and large volume parenteral prepa-
rations) and ophthalmic formulations. Topical preparations have seen 
significant growth between 2007 and 2013 (Figure 2.1) (Wamae and 
Kariuki Kungu, 2014). 
 Formulations, however, can vary substantially in terms of the techno-
logical capabilities required for production. Products such as injectable 
infusions and ophthalmic formulations require sterilization, which is 
achieved through a production process that is technologically complex 
and demanding in terms of meeting standards of safety, efficacy and 
quality – particularly for injectable infusions. There are three local firms 
that manufacture injectable infusions and a few others that produce 
sterile ophthalmic products, including Laboratories & Allied (Wamae 
and Kariuki Kungu, 2014). 
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 There are also important differences in the technological require-
ments within the group of non-sterile formulations. Some of the more 
technologically progressive firms have dedicated laboratories that 
undertake extensive product development activities with regard to 
existing products and are developing the capabilities for the produc-
tion of more technologically sophisticated products. For example, some 
firms are moving from plain tablets to modified-release and sustained-
release tablets. Some firms also engage in active process improve-
ments. Some producers already meet WHO-GMP standards, and are 
also upgrading their production processes to gain WHO recognition, 
which could possibly open the door to funding by international donor 
agencies. One company, Universal Corporation, has already received 
WHO prequalification for its Lamivudine/Zidovudine anti-retroviral 
product in 2011, and other firms, such as Cosmos, are aiming to gain 
pre-qualification in the near future. Other firms are attempting to gain 
GMP standards with the help of PPB and international agencies such as 
UNIDO (UNIDO, 2014). 
 Formal R&D activity (the discovery and product development of new 
active pharmaceutical ingredients) is in its infancy, with only one firm 
engaging in R&D. Another firm, Botanical Extract EPZ (or BEEPZ), is 
the only Kenyan firm developing capabilities for the production of 
artemisinin, which is used in the production of anti-malarials. BEEPZ is 
the development of an industrial concern born in 1996 in Tanzania to 
develop the production of high-quality  artemisia  annua with improved 
yields and artemisinin content. The project expanded its facilities to 
produce the raw materials in Kenya and Uganda, and in 2007 BEEPZ 
commissioned its principal processing facility in the export processing 
zone (EPZ) in Athi River, Kenya, currently producing non-API-grade 
artemisinin for export (Botanical Extracts EPZ, 2015). The expansion of 
production of  artemisia  annua to Kenya and Uganda was possible thanks 
to grants from the UK Department for International Development 
(DFID) and the multinational company Novartis, a leading producer 
of artemisinin-based anti-malarial drugs, which also became a BEEPZ 
customer in 2009, when the EPZ plant started production (IRIN News 
Africa, 2015). 
 There are also three local firms that process some raw materials that 
are used to manufacture bulk pharmaceutical products. These raw mate-
rials are 100% destined for export, as the local capacity for manufac-
turing active pharmaceutical ingredients remains underdeveloped. 
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 Productivity, capacity utilization and cost efficiency 
 Unfortunately, it is too difficult to obtain a direct measure of produc-
tivity for the various manufacturers, but it is well known that capacity 
utilization is an important determinant of productivity. Firms that only 
operate at a low level of capacity utilization are less efficient and can 
only achieve relatively low levels of productivity. 
 Annual capacity utilization for the manufacture of most dosage forms 
averages around 60%. Only injectable infusions experience higher 
capacity utilization ranging between 85 and 100%. A number of reasons 
have been identified from interview data. These include: the functioning 
state of machinery and equipment; delays in sourcing spare parts from 
abroad and specialized maintenance support from machinery and 
equipment suppliers; human resource issues and in particular highly 
specialized skills in some critical areas such as product development; 
perceptions of locally manufactured products by some market segments; 
and lack of policy coherence (Wamae and Kariuki Kungu, 2014). Some of 
these challenges have a direct impact on the competitiveness of locally 
manufactured products. 
 The interesting observation is that these factors seem to apply mainly 
to the supply side of the industry. In other words, limited capacity utili-
zation does not seem to be due to lack of demand. The previous sections 
showed that local producers only supply a quarter of the domestic 
market and a very small fraction, less that 1%, of the COMESA medi-
cines market, so there are plenty of opportunities for expansion. Indeed, 
Kenyan local manufacturers have the twofold challenge of having to 
increase capacity utilization and very importantly considering options 
for expanding their total capacity. 
 On the other hand, once the segments in which local producers 
operate, which are mainly fairly unsophisticated formulations of 
essential medicines, are taken into account, it is possible to see that 
Kenyan manufacturers operate in a very competitive sub-section of 
the market with many competitors, both domestic and importers, and 
where prices and therefore profit margins are low because of the low 
purchasing power of the consumers and the inability to access funding 
from donors because of lack of WHO prequalification (UNIDO, 2012). 
So the technological limitations of the manufacturers also contribute to 
relegating most of them to a narrow and highly competitive segment 
of the industry where demand for each firm’s product might well be 
constrained in some cases. 
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 Human resources and the educational system 
 Successful industrial production requires a range of different skills. 
Local universities, such as Jomo Kenyatta University of Agriculture and 
Technology, Mount Kenya University and the University of Nairobi, 
provide graduates with good-quality basic skills and training in phar-
macy, engineering and chemistry. Top polytechnics such as the Kenya 
Medical Training College are good sources for mid-level training. 
Employees also use foreign universities, for example in the UK, Germany 
and India. All firms also have compulsory training in-house. However, 
the internal education system cannot meet all industry requirements, 
especially as upgrading is needed. 
 Official reviews (UNIDO, 2012) and interviews suggest that there 
is a scarcity of pharmacists specialized in industrial pharmacy. The 
educational system has a high literacy rate and provides people 
well qualified in clinical pharmacy, but newly qualified employees 
need extensive training in the industrial aspects of drug production, 
including specialized training in industrial quality assurance. A key 
issue is that the teachers were originally trained in clinical pharmacy, 
so there is not a long tradition of industrial pharmacy in Kenya. 
University graduates have a good training in basic skills and theory, 
but many firms make use of training programmes run both internally 
and externally by international organizations, such as GIZ, Action 
Medeor and UNIDO. The latter sponsors popular courses such as the 
industrial pharmacy advanced training course run in Tanzania at the 
Kilimanjaro School of Pharmacy with the support of US universities 
(UNIDO, 2015). 
 Firms use some local training institutions, both public, such as the 
Kenya Medical Research Institute (KEMRI) and the PPB, and private. 
For advanced skills, however, they need to bring in experts from 
abroad, usually from India but also from other countries. Expatriates 
are expensive but important for quality because they have rare skills 
and experience in industrial processes. Usually they are offered short-
term contracts (two to three years), possibly renewed once but usually 
not longer because of permit limitations and because new people tend 
to have more up-to-date skills. Foreign experts are identified through 
various channels, such as suppliers, agencies, the Web, competitors and 
international agencies. 
 Finally, in some cases firms also use their informal networks to send 
employees to be trained abroad, with India being a popular destination 
because of the strength of the Indian pharmaceutical industry. So local 
manufacturers seem to be able to rely on solid internal supply of skills, 
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although at a fairly basic level, and to access expertise at a global scale 
even though the latter is subject to intense scrutiny because of its high 
costs. 
 Equipment and inputs 
 The shallow level of the Kenyan industrial sector is an important factor 
when inputs to production and equipment are considered. Kenya’s 
industry is one of the most developed in East Africa, and local producers 
can find local suppliers for basic inputs including packaging, with the 
exception of some more advanced packaging for sterile products, which 
is procured abroad, for example from China. Some more technologi-
cally complex packaging, such as over-pouches for injectables, used to 
be imported but are now produced locally. 
 Raw materials for production are mainly imported, due to the lack 
of producers of APIs and excipients. This dependence on imports is an 
important issue because it generates possible shortages which might 
influence production capacity, and additional costs even though phar-
maceutical inputs are supposed to be exempted from duties. In addition, 
Kenyan firms compete with imports produced by vertically integrated 
companies who also produce APIs, and are likely to price this key ingre-
dient above the competitive level. 
 Kenya does not have a developed industrial machinery sector, so the 
main machinery is imported from international suppliers. A popular 
source of equipment for pharmaceutical production is India followed 
by China, although language can be a barrier. India’s machines have 
the advantage of being significantly cheaper than those from industri-
alized countries and basically do the work well enough for tasks that 
do not require a high level of technological sophistication. Europe 
(especially Germany and Italy) and other high-income countries are 
the sources of more advanced and reliable machinery. The choice of 
suppliers is sometimes dictated by financial considerations: higher-
quality machinery might be not only more efficient but also more 
profitable in the long run. Companies, however, lack the resources 
for a high upfront investment in European machinery, in spite of the 
fact that the financial sector in Kenya is the most developed in East 
Africa. 
 The dependence on imports of machinery creates additional costs for 
local firms. Spare parts attract additional costs because imported prod-
ucts need to be checked and to obtain a quality stamp according to rules 
of the Kenyan Bureau of Standards. Additional inefficiencies are also 
created by the lags that occur in decisions during the process of import. 
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 Machines are operated by local engineers, who also keep records for 
GMP inspections, and are usually installed by suppliers who offer a 
comprehensive package of support including training and maintenance, 
at least for the first few years of life of the machines. 
 Some companies are currently looking to automate their production 
processes. Reduction of labour costs is one of the reasons, but improve-
ment of quality and productivity and reduction of human error and 
exposure in handling are more important factors. 
 Knowledge flows, linkage capabilities and innovation 
 As explained above, capabilities at the industry level depend not only on 
the capabilities of the various economic agents, such as manufacturers, 
but also on how effectively the various components of the industrial 
system interact and promote flows of knowledge. This section, there-
fore, looks in more detail at the flows of knowledge in the system and 
how these influence the accumulation of capabilities within firms. 
 Medicine producers develop their capabilities by acquiring knowledge 
from the external environment and through experience accumulated 
through a process of learning-by-doing over time. An important input 
to the firms’ capabilities comes from the education and training activi-
ties of its workers, as discussed above. Firms, however, can step up their 
accumulation of knowledge by explicitly investing in learning. This can 
happen internally through formal or informal research activities and by 
acquiring knowledge from other firms – suppliers, customers and even 
competitors – or research institutions. Most of the firms interviewed 
mentioned the importance of suppliers as sources of useful knowl-
edge. Suppliers regularly train manufacturers’ employees to use their 
machinery. Furthermore, by coming into contact with many different 
firms, suppliers gain useful knowledge about the industry and can be 
used as sources of technological knowledge or to identify people and 
firms with specific expertise that is useful for a company. Since Kenyan 
firms use foreign suppliers, they have been able to tap into their 
suppliers’ knowledge networks in order to identify foreign experts to 
hire, good training programmes and foreign firms where they can send 
their employees to learn more about advanced industrial technologies: 
some firms, for example, have mentioned examples of employees sent 
to be trained in Indian firms. 
 As mentioned above, firms also gain valuable knowledge by hiring 
international experts from countries such as India, South Africa and 
even European countries. Hiring expatriates and sending employees 
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to train abroad are expensive investments, so firms have schemes 
in which the trained employees relay the knowledge learnt to their 
colleagues. 
 As the innovation literature has pointed out since the work of Von 
Hippel, firms also learn from the users of their products (Von Hippel, 
1982). Some producers have stressed the importance of the feedback 
collected by their marketing teams. A firm selling sterile injectable prod-
ucts stated that important knowledge was learned from nurses who used 
their products, and changes were implemented following the nurses’ 
feedback. 
 Other common channels through which firms learn useful knowl-
edge are exhibitions (also abroad), websites, membership of profes-
sional associations and conferences. Manufacturers also learn from 
each other because employees move between firms or meet and have 
informal exchanges at training events and seminars. Flows of knowledge 
also occur through the industry associations, the Federation of Kenyan 
Pharmaceutical Manufacturers (KFPM) and the Federation of East African 
Pharmaceutical Manufacturers (EAFPM), which organize training events 
and other initiatives. 
 Regulatory agencies also provide firms with valuable knowledge. For 
example, PPB does not only carry out inspections but also helps manu-
facturers with advice, especially on issues relating to the acquisition of 
the GMP standard, including documentation relating to the audits, and 
on Good Laboratory Practice and Good Distribution Practice. Similarly, 
the National Quality Control Laboratory (NQCL) offers training and 
knowledge transfer in the areas of drug testing and medical instrumen-
tation, and Kenya Medical Research Institute (KEMRI) collaborates in 
the areas of research and training (KEMRI, 2015). 
 Licensing and joint ventures: the role of government policy 
 As the previous section has explained, the accumulation of technological 
capabilities occurs over time, and the current capabilities are influenced 
by past events. Because of the cumulative nature of technological knowl-
edge, policy initiatives can have a long-lasting impact on the capabilities 
of firms and industries. In the Kenyan case, there are two examples of 
policy intervention that can be said to have helped the development of 
technological capabilities in the industry: the provisions for compul-
sory licensing in the Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) negotiations, and the policy of forming parastatal joint 
ventures with foreign MNCs in order to develop local capabilities based 
on foreign technology. 
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 In the case of licensing of foreign technology, Kenya campaigned 
vigorously during the trade negotiations that led to the TRIPS agree-
ment in order to be able to carry out compulsory licensing for some 
essential medicines. Compulsory licensing means that governments 
can issue licenses to manufacture medicines that are still protected by 
patents at more affordable prices than those set by foreign pharmaceu-
tical companies that hold the patents, without receiving the latter’s 
consent. Although in practice there has been no compulsory licensing 
in Kenya, it can be argued that the threat of compulsory licensing has 
enabled local firms to reach good licensing agreements with foreign 
MNCs. According to Garwood (2007), ‘Kenya has never issued a compul-
sory license, but came close to in 2004 before the German pharma-
ceutical major Boehringer Ingelheim agreed to enter into a voluntary 
license agreement with Kenyan drug firm Cosmos to produce generic 
versions of its patented anti-AIDS drug nevirapine’. Cosmos went on 
to enter another technology transfer agreement with Roche and is now 
one of the most dynamic Kenyan manufacturers, also aiming to gain 
WHO prequalification for the production of ARVs. The ‘buy local’ drive 
or procurement approach of the 1990s was also significant. It helped to 
lay a strong basis for the mushrooming of private local manufacturers: 
thus Cosmos would probably not have had its advantageous licensing 
position were it not for the ‘buy local’ move that was in effect very much 
steeped in ISI thinking. 
 As the above historical background pointed out, during the import 
substitution period, the government established ICDC to promote 
the development of local capabilities partly through parastatal joint 
ventures with foreign organizations. Joint ventures formed through the 
1970s with the Yugoslav government and a German firm are now the 
precursors of two dynamic Kenyan private firms: Dawa and Infusion 
Medicare, one of the producers of injectables. Cosmos was also origi-
nally formed as a joint venture. Now all three firms are wholly locally 
owned private firms, and critics of import substitution and ICDC inter-
pret the fact that the joint ventures had to be privatized as a failure 
of import substitution and ICDC (see, for instance, Himbara, 1993). 
However, it can be argued that although the parastatal status might 
have hindered the business development of the joint ventures, ICDC 
can still be said to be responsible for the creation of organizations that 
developed local technological capabilities that were later further devel-
oped by private capital. Possibly, without the initial policy of forming 
joint venture, companies like Dawa, Infusion Medicare and Cosmos 
would not exist today. 
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 The ISI policy involving joint ventures, of course, is not the only way 
to build industrial capabilities. In more recent years, Kenyan firms have 
found other ways to draw successfully on foreign capabilities. Two other 
producers of sterile products followed different strategies: one, facilitated 
by the assurance of a large government procurement, bought a South 
African firm outright and transferred the facilities to Kenya, whilst the 
other, which pursued an export-oriented strategy and is located in an 
EPZ, assembled a variety of suppliers and contractors to build a new 
plant with equipment sourced from various countries and drawing on 
international expertise. 
 Conclusions 
 This chapter has provided an outline of the local production of medi-
cines in Kenya, which is the leading manufacturer of pharmaceuticals in 
East Africa, accounting for half of the local production in COMESA and 
boosting rising production and exports. The Kenyan pharmaceutical 
industry is still small in relation to imports into Kenya and the whole 
of COMESA. However it constitutes a story of successful development of 
technological capabilities with examples of firms that are upgrading their 
technology and might be able to become leading players in East Africa, 
such as Universal, which has achieved enough technological capabilities 
to be awarded WHO prequalification. Kenya’s dynamic private sector 
and its access to COMESA and EAC are important strengths that suggest 
good prospects for Kenyan local producers. 
 However, obstacles and limitations remain, and the analysis in this 
chapter has shown that Kenyan firms have to upgrade successfully in 
order to compete effectively against strong imports. Kenyan pharmaceu-
tical producers have not yet been able to access donor funding, with only 
one firm achieving WHO prequalification so far. Most of the firms also 
operate in a highly competitive segment of the industry, the production 
of formulations of essential medicines, which offers low returns and pits 
them against very efficient imports. There are, however, success stories 
of firms that have reached significant technological sophistication, as 
in the case of the producers of injectables, and the analysis paints the 
picture of an industry integrating in global value chains, with access to 
global networks of equipment suppliers, foreign experts and training 
centres. 
 Still, there is work to be done to improve the regulatory environment, 
such as making sure that the VAT regulations do not disadvantage local 
firms, reducing the dependence of local manufacturers on imported raw 
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materials and promoting upgrading throughout the technologically 
weaker firms; the current strategy is to progressively move all firms from 
local to international GMP standards. 
 It is not straightforward to draw general lessons for the promotion of 
local production of pharmaceuticals in low-income countries given the 
messy economic history and diverse patterns of technological accumu-
lation this chapter has presented. It is possible, however, to suggest some 
possible tentative reasons that might have contributed to the observed 
successes of Kenyan pharmaceutical production. The chapter has argued 
that ISI policies, including the use of joint ventures at an early stage of 
industrialization, followed by gradual liberalization, might have been a 
positive factor in the accumulation of technological capabilities. Kenyan 
producers seem also to access global networks that are useful to iden-
tify and tap into rare skills and identify good equipment suppliers. The 
openness of Kenyan manufacturers may also be assisted by India-linked 
networks of some manufacturers with accumulated family experience in 
capitalist production from older merchant enterprises (Himbara, 1993). 
 On the whole, this chapter suggests a positive future for broadening 
and deepening pharmaceuticals production in Kenya. Despite an inter-
national and national context that is often less than helpful, consid-
erable progress has been made in the past few years and capabilities 
have been established that, while often unseen, are laying the basis for 
further growth. With a little extra help at the government level, Kenya 
might soon be a leading African nation in the field. 
 Notes 
 1 .  Research project  Industrial productivity and  health sector performance . The find-
ings, interpretations, conclusions and opinions expressed here are those of 
the authors and do not necessarily reflect the views or policies of DFID or 
the UK ESRC, whose financial support is gratefully acknowledged (project ES/
J008737/1). This chapter draws on fieldwork undertaken by Watu Wamae and 
Joan Kariuki Kungu as part of that research project. 
 2 .  An earlier version of this figure appears in Wamae and Kariuki Kungu (2014), 
reworked with permission. 
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Creative Commons Attribution 4.0 Unported License. To view 
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 Introduction 
 “This sector [pharmaceuticals] is going to die ... A hundred percent 
reliance on imports is dangerous.” (Tanzanian government official) 1 
 As Chapter 1 described, Tanzania has a decades-long history of pharma-
ceutical production, the sector mirroring fluctuations in Tanzania’s post-
independence industrial history. By 2004–05, the sector was estimated to 
be producing pharmaceuticals worth US$32.5 million, supplying around 
30% of the local market and exporting about 10% of local produc-
tion (MoHSW, 2006). The subsequent rise and decline of the sector is 
analysed in this chapter, locating firms’ sources of both market resilience 
and vulnerability in local patterns of ownership, finance and manage-
ment, interacting with the internationalization of firms’ domestic and 
regional markets. Finally, the chapter examines the ‘turnaround’ chal-
lenge facing the local industry. Concerned policy makers are aware, as 
the above quotation shows, of the health sector insecurity inherent in 
complete reliance on medicines imports. 
 Methods and sources 
 The chapter draws on extensive interviewing in 2013–14, some 
earlier interviews, unpublished research findings and feedback from 
 3 
 Pharmaceutical Manufacturing 
Decline in Tanzania: How Possible 
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Phares G.M.  Mujinja 
OPEN
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
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involvement of the authors in policy debates in Tanzania. 2 Senior 
managers in all five pharmaceutical firms producing human medicines 
for the private and public market that were operating at the time of the 
research were interviewed. Interviews were conducted with CEOs and/or 
production managers, using a semi-structured interview schedule that 
focussed on firms’ capabilities to supply the Tanzanian health sector. 
Interview data are not attributed to specific firms except by agreement; 
otherwise, firm-specific information is drawn from the public domain 
and referenced. 
 In addition, informants and stakeholders associated with the industry 
were interviewed, including policy makers, regulators, senior actors in 
business associations and wholesalers in public, non-profit and private 
sectors. Finally, seven firms producing non-pharmaceutical products 
relevant to the health sector were also interviewed. 
 Recent industrial rise and decline in 
pharmaceuticals 
 In 2004–05, seven pharmaceutical firms were producing medicines for 
human consumption in Tanzania (Chapter 1). There were no multina-
tionals, and only one joint venture with an external partner. The years 
up to 2008–09 then saw substantial investment, upgrading and some 
consolidation and new entry in the industry: this was an optimistic 
period in the sector. 
 Investment and consolidation 
 The largest firm is Shelys Pharmaceuticals, a pioneering firm developed 
by the Sumaria group. Sumaria is a successful example of the large, 
diversified, family-owned conglomerates that dominate Tanzania’s large 
industry sector (Sutton and Olomi, 2012). It is a regional multinational, 
producing plastics, cement and consumer goods, and moving into 
renewables. It built up Shelys as a wholly owned firm in Dar es Salaam; 
in 2003, Sumaria bought Beta Healthcare International, a Kenyan phar-
maceutical company, with private equity funding from Aureos Capital, 
making Shelys Africa Group the largest East African pharmaceutical 
company at that time. Shelys built and commissioned a new plant for 
making penicillins in Tanzania in 2008, to international good manufac-
turing practice (GMP) standards, and at the time was planning diversifi-
cation including parenterals and anti-retrovirals (ARVs) (Shelys, 2008). 
In 2008, Sumaria sold 60% of Shelys to Aspen, a South African multina-
tional, allowing private equity to exit. 3 
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 Three other larger firms were developed by Tanzanian African capital. 
Interchem Pharmaceuticals, set up in 1989 in Moshi and part-owned by 
the IPP group of companies that includes large media interests, made 
substantial investments but closed in 2008. In 1995, the government 
sold 60% of the equity in two closed government pharmaceutical firms 
into Tanzanian private family ownership, and each reopened. Keko 
Pharmaceutical Industries then made substantial investments. Tanzania 
Pharmaceutical Industries (TPI) began production in 2008 of three first-
line anti-retrovirals (ARVs) for HIV, the first such production in Tanzania. 
With European Union financial support and technical support from 
Krisana Krasintu of Thailand, TPI was upgrading its production and 
quality assurance and planning a new GMP-compliant plant for ARV 
production (Losse et al., 2007). In 2007, Zenufa, a firm with a family-
owned parent company based in the Democratic Republic of Congo 
(DRC), invested in a new plant in Dar es Salaam, aiming for full GMP 
standards, with initial loan financing from the Belgian Investment 
Company for Developing Countries. 
 Also in this period, Tanzansino, a Chinese government–Tanzanian 
military collaboration, closed for planned major renovation, 4 while 
two family firms owned and run by Tanzanian pharmacists, Mansoor 
Daya and AA Pharmaceuticals, were investing and expanding supplies to 
the local market. Mansoor Daya is the oldest Tanzanian local producer, 
while AA was started in 2003. 
 By 2009, Tanzania-based production was supplying an estimated 35% 
of a local medicines market worth about US$140 million, and rising 
medicines exports had reached almost US$8 million. 5 A particular 
strength of the local firms was supply to the rural areas: rural availability 
relied quite heavily on local manufacturers, and interviews with rural 
medicines buyers in 2006–07 had found evidence of brand recognition 
and trust for locally produced medicines, especially those from Shelys 
(Chaudhuri et al., 2010; Mujinja et al., 2014). In 2009, Tanzanian phar-
maceutical production looked like a relative success story. 
 Recent industrial decline 
 Yet between 2009 and 2013, this success story turned into rapid 
decline (Wangwe et al., 2014a). By 2013, just five pharmaceutical firms 
were operating. The rising trend of medicines exports to 2009 had 
reversed (Figure 3.1). By 2013, imports of pharmaceuticals had risen to 
US$286 million on the back of rising donor spending, while medicines 
exports had fallen to US$1.7 million. Informed local estimates 6 put the 
local producers’ share of the domestic medicines market at under 20%. 
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As the market has expanded, the local firms’ share had fallen. Figure 3.1 
shows the yawning trade gap. 
 Data on availability and sources of medicines in the Tanzanian public 
and private markets confirm this declining trend in local producers’ 
market shares, for a matched sample of medicines and health facilities 
and shops (Table 3.1). 
 As the number of producers dropped, the product range narrowed. 
The only local producer of anti-retrovirals (ARVs) had been closed. All 
but one of the remaining firms had by 2013 largely ceased to produce 
basic antibiotics, and the largest firm was moving out of production of 
many other basic medicines. Local producers’ share of public procure-
ment had been falling, and only one local firm was tendering for public 
sector procurement contracts in 2013–14. A non-profit wholesaler esti-
mated buying locally ‘far less than half’ than four years previously. A 
private wholesaler, who in 2010–11 had bought local medicines worth 
Tshs 1.5–2 billion, was, he said, now buying ‘almost nothing, a few 
syrups’. The resultant decline in the local market share of a number 
of key essential medicines shows up in the survey data (Table 3.2). A 
0
100
200
300
US
$ m
illio
n
1995 2000 2005 2010 2015
Year
Medicines imports Medicines exports
 Figure 3.1  The expanding local supply gap: total imports and exports of medi-
cines and blood products (US$ millions) 
 Source : Drawn from Comtrade data,  http://comtrade.un.org/data/ , downloaded 5 August 
2014. 
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domestic medicines market, worth around US$250 million, had become 
supplied overwhelmingly from imports paid in dollars. 
 Industrial strengths and vulnerabilities: explaining 
sudden decline 
 The predominance of family ownership with diversified business 
activity, described above for the pharmaceutical firms, is characteristic 
of the Tanzanian industrial sector more broadly (Sutton and Olomi, 
2012). Diversified family-run businesses have a number of competitive 
advantages in Tanzania’s challenging business environment. Where 
bank finance is expensive and hard to access, diversified family firms 
can spread risk and provide access to financing which is both ‘patient’ 
(Goodluck, 2014) and also relatively low-cost and flexible. The busi-
ness structure also reduces transparency and helps to weather crises. 
Tanzania has a shallow industrial structure: other than agro-processing, 
manufacturing relies heavily on imported inputs, so firms may integrate 
 Table 3.1  Decline in domestic market share of medicines made in Tanzania, 
2006–12 
 Year 
 Percent of sample medicines available on day of visit, 
by country of origin 
 Tanzania  Kenya  Other  Total 
 2006 33 14 53 100
 2009 21 13 66 100
 2012 12 11 78 100
 Source : Authors’ analysis of WHO/HAI survey data 2006, 2009, 2012. 7 
 Table 3.2  Share of local manufactures among specified tracer medicines avail-
able in sample outlets, 2006–12 
 Year 
 Local share of available: 
 Amoxicillin 
capsules 
 Folic acid 
tablets 
 Albendazole 
tablets 
 Ciprofloxacin 
tablets 
 Diclofenac 
tablets 
2006 79% 79% 81% 40% 45%
2009 74% 27% 33% 32% 26%
2012 13% 51% 43% 24% 4%
 Source : Authors’ analysis of WHO/HAI survey data 2006, 2009, 2012. 
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backwards to produce inputs such as packaging. Large diversified firms 
can gain competitive advantage by addressing in-house some ‘institu-
tional voids’ (Khanna and Palepu, 1997) in their environment, such as 
market information sources, skilled labour pools or institutionalized 
working relations with government. 
 Some of these competitive strengths can be identified in Tanzanian 
family-run pharmaceuticals. Where market information is poor and 
consumers cannot judge quality directly, as in poorly regulated retail 
medicines markets, local brand trust and recognition is a powerful 
marketing tool (Khanna and Palepu, 1997). Where the domestic generics 
market is a firm’s core business, investment in building a reliable generics 
brand benefits both consumers and manufacturer. All the pharmaceu-
tical manufacturers interviewed had relied on capital from other parts 
of diversified family business, including property and trading. One firm 
was producing its own bottles, while two relied on overseas companies 
within a business group for quality assurance of inputs and access to 
technological information. 
 However, the vulnerabilities of family-based industrial organization, 
and of the shallow industrial structure, were also evident in the inter-
views. Reliance on imported inputs lengthens production schedules and 
increases quality risks. All firms had problems sourcing good packaging 
locally, and poor packaging of local products was a common complaint 
by Tanzanian health sector buyers. The financial and reputational risk 
associated with quality problems implied reliance on imported blister 
strips from India. Some firms had found locally bought bottles to be of 
unreliable quality and had switched to imports. While plastic containers 
for bulk tablets (sealed first into clean plastic bags) were made locally, the 
shallow industrial sector constrained improvements in local upstream 
supply. For example, a shift by pharmaceutical firms from glass to plastic 
bottles – desirable for safety and supply reasons – required substantial 
related investments by both pharmaceutical and plastics firms. At root 
of the problem was the small number of firms and a lack of mutual trust 
and coordination, posing a major hurdle to mutually beneficial indus-
trial upgrading. 
 Access to technology and information was also generally constrained. 
Some firms relied on hard-pressed CEO’s visits to trade fairs, and on estab-
lished suppliers, for technical information, for training and upgrading 
support, and sometimes for trade credit. Ensuring quality of inputs 
from Asian suppliers was a constant challenge. Machinery suppliers – 
predominantly Indian or Chinese – installed, trained and provided 
spare parts and advice. Two firms had gained external donor support for 
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technical upgrading and capacity expansion. All trained their own staff 
and complained of the difficulties of finding and retaining pharmacists 
and pharmaceutical technicians. This small cluster of Tanzanian phar-
maceutical firms apparently collaborated rather little, and benefitted 
from few spill-overs or linkages between firms. 
 Changing context and responses 
 The Tanzania-based industry is operating in a very open market context, 
where shifts in the relevant international market segments are imme-
diately experienced within Tanzanian domestic and regional markets. 
Structurally and technologically, several worsening pressures appear to 
be producing a tipping point. The first relates to size and market posi-
tioning. Pharmaceutical firms in Tanzania mainly produce basic essen-
tial generic medicines and over-the-counter items such as cough syrups. 
Economies of scale are limited in basic formulations (Chaudhuri and 
West, 2014) but are large in active pharmaceutical ingredient (API) 
production. While small firms can compete, therefore, in formulations, 
they are at a structural disadvantage to large Indian exporters since they 
buy small API lots from Asian suppliers, some of whom also produce 
formulations. As one manufacturer put it, the ‘key constraint in this 
market is demand’. If firms cannot sell sustainably, they cannot grow, 
and they need their home market as a basis for expansion. 
 The second pressure is technological and regulatory: firms are forced 
into a cycle of constant upgrading, both to meet rising international 
standards that are requirements for different levels of market entry, and 
to meet competitors’ quality standards. Constant upgrading of firms’ 
technological capabilities (Bell and Pavitt, 1993; Lall, 1992) is central to 
firms’ competitive survival in pharmaceuticals, to sustain quality at a 
competitive price and to retain market access. For all the firms, the tech-
nological challenge was framed by Good Manufacturing Practice (GMP) 
standards. 
 GMP constitutes a production  culture to be attained (see also 
Chapter 12). GMP Guidelines 8 emphasize documentation and validation 
of the production flow, including effective quality control (independent 
of production management); high standards of hygiene and preven-
tions of cross-contamination; effective and documented staff training 
and qualifications; and well-maintained equipment and premises. 
Our interviewees noted the extent of professional judgement in GMP 
implementation of, for example, ‘adequate’ ventilation, ‘high’ levels of 
hygiene, risk evaluation drawing on ‘experience’ and ‘well-designed’ 
documentation. 
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 The Tanzania Food and Drug Authority (TFDA) presses for GMP adher-
ence. Tanzanian firms either have attained locally acceptable GMP stand-
ards or are working towards them with TFDA support. Manufacturers 
agreed that TFDA required standards rise over time, just as do the stand-
ards achieved by international competitors and the expectations of 
international buyers. None, when interviewed, had WHO prequalifica-
tion of individual products to allow them to tender for donor-funded 
contracts. 
 All firms reported recent and current substantial investment – relative 
to their capacity – in technological upgrading. Major investments 
included new machinery for expanding capacity or for automating 
processes to improve quality control and lower costs. Other investments 
included expensive improvements in air handling and plant standards 
(e.g. door seals and room separation) and production flow reorganiza-
tion. One firm had just put in a new product line, and another was 
engaged in an expensive upgrade of tablet quality to produce higher 
compression. This last firm was aiming, with donor financial and 
technical support, for WHO product pre-qualification for a combina-
tion therapy. Most firms experienced financial stress in achieving these 
investments, which they saw as essential to stay in business. 
 A third interconnected pressure comes from donors’ tendering proc-
esses. Donors such as the Global Fund 9 procure a large share of medi-
cines used in Tanzania (see also Chapter 8). Their large-scale tenders and 
the market entry requirement of product-by-product WHO prequali-
fication 10 shuts out local firms from markets for HIV, TB and malaria 
drugs. The effect has been most damaging in anti-malarials. In 2006, 
about 90% of the then first-line treatment for malaria (sulphadoxine-
pyrimethamine [SP]) was sourced locally. From 2007, Tanzania shifted 
to the more expensive combination artemisinin-lumefantrine (AL) 
first-line medication. Subsidized supply by the Global Fund and other 
donors shut out local firms. Two firms developed AL formulations but 
concluded that pre-qualification (costing an estimated US$150,000) was 
unlikely to provide market access given the scale and pricing power of 
Asian competitors. One local firm lost an estimated third of turnover; 
others also suffered substantial losses. 11 
 The final major contextual pressure reported by firms was a recent 
sharp increase in price competition from imports. This was particularly 
felt for ‘beta lactam’ antibiotics such as amoxicillin. These are produced 
in a separate plant from other medicines to prevent cross-contamination, 
and all the larger pharmaceutical firms interviewed had such production 
capability. All confirmed they were becoming increasingly unprofitable. 
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One has closed its beta lactams plant; another said it would do so ‘in a 
couple of years, unless policy changes’. International tender prices for 
amoxicillin appear to have flat-lined since 2010 (MSH, 2010, 2013). 12 A 
local NGO wholesaler was buying at a landed import price well below 
a local firm’s factory gate price. One informant stated some importers’ 
landed prices were below his firm’s full materials costs. Since about 78% 
of materials costs were calculated to be APIs in 2012–13, the latter alle-
gation suggests dumping may be occurring. Local producers who up to 
2009 were successfully competing to supply amoxicillin for domestic 
use had by 2012 largely left the market, as Table 3.2 also confirms. 
 At the national level, this move up-market leaves the domestic supply 
of basic essential medicines reliant on imports, which may not be 
sustainable at current low prices, and which may not reach rural areas as 
effectively as local supplies (Mujinja et al., 2014). The government offi-
cial quoted at the beginning of this chapter saw this. Price pressure was 
also transmitted through private market competition. Around half of 
the Tanzanian medicines market is private (Chapter 8), and the number 
of competing wholesalers has been rising. 13 Interviewees contended 
that margins on private sales and public contracts had been severely 
squeezed. The financial risk attached to supplying the public sector had 
also increased, since payment delays by the public procurement agency 
(Medical Stores Department [MSD]) were increasing, driven partly 
by ‘erratic disbursement’ of treasury funding (MSD, 2013: 8; see also 
MoHSW, 2013). These pressures discouraged local firms from tendering, 
and MSD officials confirmed that the local share of their procurement 
was falling. 14 
 The larger manufacturers were responding by moving up-market, 
towards more technologically sophisticated, higher-value products 
with export potential. All continued to supply some over-the-counter 
medicines, and some higher-value items such as ciprofloxacin, an anti-
infective (Table 3.2). Firms were refocusing on the domestic and regional 
private market, narrowing their product range and investing in new 
products for export. Overseas partners could support moves into higher-
value products. 
 This business strategy carries two kinds of risk. At firm level it aban-
dons what one firm called the ‘cash cows’: the cash-generating basic 
commodities; this reduced their turnover and liquidity and hence 
capability to invest. Family firms may find this reduces their survival 
chances in the medium term. The largest firm, Shelys, had been sold 
100% in 2012 to Aspen, the South African multinational firm now 
part-owned by GSK (Aspen Holdings, 2013). The Aspen annual report 
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confirms the subsequent change in Shelys’ business strategy: pursuit of 
higher margins by largely moving out of public sector supply (down to 
5% of turnover in 2013), refocusing on the private market and drop-
ping low-margin products. Shelys’ recent investment has been largely 
in Kenya (ibid). 
 At the national level, this move up-market leaves the domestic supply 
of basic essential medicines reliant on imports, which may not be 
sustainable at current low prices, and which may not reach rural areas as 
effectively as local supplies (Mujinja et al., 2014). The government offi-
cial quoted at the beginning of this chapter saw this trend as a national 
security issue. 
 Turnaround strategies: can the pharmaceutical industrial 
cluster be revived? 
 Government policy is totally unfriendly to pharmaceutical manufac-
turing. (Experienced Tanzanian manufacturer) 
 Where industrial problems vary by activity, policy must vary too: 
selective intervention is an essential element of industrial policy. Lall 
and Wangwe (1997) argued this point nearly 20 years ago; it remains 
true today that distinct sectoral problems require distinctive sectoral 
solutions. Pharmaceuticals share characteristics with Tanzania-based 
industry generally but also face characteristic challenges (see also 
Chapter 1). Furthermore, some of the firms’ problems, as the manu-
facturer quoted above implies, are policy-based and distinctive to the 
pharmaceutical and medical supplies sectors. Furthermore, clusters of 
firms create mutual benefits in terms of knowledge flows and spill-overs 
(Nadvi and Halder, 2007; Page, 2012; see also Chapter 2), and Tanzania 
risks losing these benefits as the number of firms falls. Turnaround for 
this sector needs to be policy-led. 
 However, a shift to active sector-specific support requires change in 
the current policy approach, which, as government officials confirmed, 
currently focuses on policies to influence the general business envi-
ronment and does not address specific sectoral needs (Wangwe et al., 
2014b). The two broad policy challenges are to reverse policies that 
have the largely unintended consequence of incentivizing imports over 
local manufacture, and to generate active policy support for the contin-
uous upgrading of technological capabilities essential for local firms to 
compete in these highly globalized markets. 
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 Sector-specific policy issues 
 Around half of essential medicines used in Tanzania are obtained via 
public and non-profit procurement. MSD’s public sector procurement 
gives local firms a 15% price preference in competition with importers 
when both meet the quality hurdles. The effective preference rate 
is somewhat lower (one interviewee suggested around 9%), because 
importers’ prices are landed prices at the port, while local firms’ price 
includes delivery to MSD’s zonal warehouses. 
 Manufacturers and other interviewees argued, however, that the 
procurement and tax regimes in Tanzania specifically disadvantage local 
firms in pharmaceuticals, as compared to other industrial sectors. The 
key decision that has generated these disadvantages is the removal of 
the import duty on all finished formulations. The decision to remove 
the 10% import duty on pharmaceuticals, applying the East African 
Community (EAC) Common External Tariff (CET) rate of zero per cent, 
was announced in the 2009 budget speech. 15 Since then, manufacturers 
supplying the private domestic market have no protection against 
finished imports. 
 Taxes and duties on imported inputs therefore specifically disadvan-
tage local pharmaceutical manufacturers by raising their materials costs 
of production. The Customs Act 2008, recognizing this disadvantage, 
stated that where finished goods such as essential medicines are zero-
rated for import duties, so are their inputs such as APIs, in order to ensure 
fair competition for local producers. However, as officials acknowledged, 
this commitment has proved ‘complex’ to administer in practice. While 
APIs are zero-rated, problems arise in identifying other inputs such as 
additives and excipients; manufacturers complained that highly refined 
sugar for syrups, for example, paid a high duty but could not be sourced 
locally. Manufacturers stated that efforts to put together a consolidated 
list of imported inputs to be zero-rated had not met with a positive 
response. Requests for zero rating could also be met by harassment and 
accusations of corruption and favour seeking. 
 Manufacturers also complained of uncertainty and instability in the 
tax and duty regime. VAT was payable on many imported inputs, and 
reimbursement was reported to be slow and often incomplete. Tax rules 
changed unpredictably. Proposals to impose duty on packaging were 
reported to have been raised, then withdrawn. ‘Uplift’, whereby customs 
officials increased the taxable value where under-invoicing was suspected, 
was unpredictable and sometimes punitive. Machinery, though exempt 
from duties in principle, required an import licence which could create 
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delay, leaving a choice between paying duty or losing cash flow. One 
interviewee who was considering investing in manufacturing stated that 
in Tanzania the rules are not as clear as in Kenya, ‘where it is clear’ what 
taxes are to be paid. 
 Pharmaceutical manufacturers identified ways in which contracts to 
supply the public sector disadvantaged local suppliers. Trade credit rules 
were an example: an overseas supplier winning a public sector tender 
would be given a letter of credit. This meant the firm was paid as soon 
as the goods were delivered to the port, and it could also be used to raise 
working capital (see Chapter 15). By contrast, local manufacturers were 
paid only 30 days – or more – in arrears once goods were delivered, leaving 
working capital to be raised by the firm. If the order is large relative to a 
firm’s capacity, that imposes a large financial burden. Smaller firms said 
the risk attached to public sector tendering had become unmanageable. 
One now preferred to supply the public sector via private wholesalers. 
A wholesaler who won a tender ordered from the manufacturer, who 
supplied and was paid, thus shifting the tender costs and some other 
financial costs and risks to the wholesaler. 
 This last strategy illustrates a more general trend. There appeared, anec-
dotally, to be a shift in public sector tendering practice towards buying 
from importers who would ‘bundle’ imports with (perhaps) some local 
supplies. Pharmaceutical wholesalers/importers in Tanzania are gener-
ally representatives of external, mainly Indian manufacturers. Tanzanian 
industry, however, has historically strong links to trading capital (Sutton 
and Olomi, 2012), and some local pharmaceutical manufacturers also 
import and distribute, with or without repacking. It follows that a policy 
tilt towards favouring importing over manufacturing may quite rapidly 
result in a shift towards much higher reliance on imported commodi-
ties as traders expand and manufacturers become more ‘hybrid’ in their 
activities, expanding more into importing. 
 Increasing sophistication: the capabilities squeeze 
 Tanzania has a low level of sophistication in manufacturing, that is, a 
low share of medium- and high-technology manufacturing within total 
manufacturing value added (UNIDO/GoT, 2012: 35–36). Its pharma-
ceutical sector produces products that are relatively unsophisticated by 
industry standards. However, within Tanzania, pharmaceuticals never-
theless represent a relatively high-technology, skill-intensive indus-
trial activity as compared to much other Tanzanian manufacturing. 
The recent decline in this sector therefore threatens to reinforce a 
declining share of sophisticated manufacturing in total manufacturing 
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value added. Tanzania may be losing technological capabilities at firm 
level, retreating to a lower level of manufacturing capabilities (Warren-
Rodríguez, 2010). In this sense, the apparent crisis in pharmaceuticals 
identifies a more general problem. 
 Firms’ technological capabilities (Lall, 1992) are core determinants 
of their ability to compete. Many of the challenges described above 
concern product and process capabilities: the ability to manage and 
document the work processes following GMP guidelines, to ensure and 
be able to demonstrate quality and safety of the final product. For phar-
maceutical firms, these capabilities determine their market access, both 
locally (achieving product registration and sustaining quality when 
products are tested) and for access to the regional and international 
markets. All the firms interviewed reflected technological conditions in 
the international industry, in that they were chasing a moving target, 
facing constant pressure to upgrade. They also found it hard to sustain 
technological capabilities over time. 
 Lall (1992) distinguishes between production capabilities, investment 
capabilities and linkage capabilities at the firm level (see also Chapter 2). 
Most pharmaceutical firms interviewed in Tanzania were struggling with 
all three. 
 One of the most serious constraints on firms’ capabilities in Tanzania 
is the low level of general and technical education in the country, 
implying shockingly high levels of innumeracy and illiteracy among 
production line staff (UNIDO/GoT, 2012: 68). Firms argued that they 
have more machine downtime than would be true elsewhere, given 
operators’ limited capabilities. Lack of command of English was also a 
problem as compared, for example, to Kenya, especially when trying to 
promote people internally. The rigorous rule-following, documentation-
centred culture required by GMP is unfamiliar for staff: one CEO wanted 
to send supervisors abroad so they could get a feel for a GMP factory. The 
firms all train internally the laboratory pharmacists and chemists they 
hire, in the equipment and techniques for the factory; they all lose these 
trained staff both to other firms and especially to NGOs and govern-
ment, where work conditions are easier. Training is expensive and there 
is no local pool of skilled labour, constraining a firm, for example, from 
quickly adding an additional shift. Finally, there is a repeatedly reported 
problem in obtaining work permits for essential expatriates. 
 ‘Access to skilled labour is also a problem ... . in Tanzania, which is 
compounded by refusal to grant work permits and where granted, 
they are expensive’. (Manufacturer) 
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 Investment capabilities, including finance, technological information 
and management of investment projects, also become more demanding 
over time, as firms upgrade to meet rising required standards for exports. 
The large jump in production capabilities required to move from local 
market standards to international requirements imposed by donors 
involves investment financing, improvements in internal process opera-
tions, replanning factory layouts, retraining, improving factory infra-
structure and changing marketing capabilities. This kind of investment 
can amount to a substantial proportion of a local firm’s annual turn-
over and generally required funding support from outside the business 
and from non-bank sources. Examples cited in the interviews included 
financial transfers from other family businesses; external grant funding; 
a low-cost loan; and a joint venture partner with ‘financial muscle’, as 
one firm described it. The joint venture and grant routes to improve-
ment can combine finance and access to technology. 
 Development of capabilities in production of combination therapies 
for anti-malarial medication, in the form of two-layer tablets, provides 
an example. One firm 16 was upgrading, with financial and technical 
support from Drugs for Neglected Diseases (DNDi), to produce a fixed 
dose artesunate/amodiaquine combination tablet, primarily for regional 
export through donor-funded procurement. The formulation was 
initially produced by Sanofi, in collaboration with DNDi, which then set 
out to transfer the technology to firms in Africa. 17 To achieve this, the 
firm must meet WHO-prequalification standards at competitive cost, 
requiring changes across the production process. DNDi support includes 
the formulation, technological support and training, new machinery, 
laboratory upgrading, raw materials for the batches and technical and 
training support right through to pre-qualification. The firm itself is also 
investing substantially in quality improvements and cost reductions 
across the plant. The upgrading therefore benefits the entire plant, with 
spin-offs in improved tablet production for the local market also. 
 A second example also relates to combination anti-malarials. Another 
firm was benefitting from a new formulation available from its parent 
company, alongside support from its international network to, for 
example, assure quality of APIs at source. A third firm (currently closed) 
had benefitted from an EU grant to fund a new turnkey plant to produce 
anti-retrovirals plant for HIV/AIDS treatment. Without this type of 
substantial external input, it is hard for the firms in Tanzania to enhance 
their capabilities sufficiently rapidly to regain access to the regional 
market for anti-malarials and other medication widely purchased by 
donors. 
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 External networks and support are thus essential to survival in the 
race to upgrade and retain or regain market access. The Tanzanian phar-
maceutical firms are caught in a capabilities ‘squeeze’: as process and 
product standards rise, and as the standards become more binding as 
requirements for market access, the constraints imposed by the firms’ 
working conditions at home become more severe. Lack of a local skills 
pool, high and rising energy prices, lack of economies of scale for buying 
inputs and marketing output, poor transport and business infrastructure 
and a lack of local linkages – all these constraints have long existed, but 
have become increasingly binding in the new technological and market 
environment. 
 Policy to sustain upgrading and market access in pharmaceuticals: 
Can it be done? 
 It requires a change of mind-set for policy makers in Tanzania to turn to 
prioritizing and actively engaging in selective support of particular indus-
trial sectors. The arguments for prioritizing pharmaceuticals include the 
national security issues raised at the beginning of this chapter. Loss of 
national ability to supply one of its population’s basic needs increases 
reliance on exporters, notably from India, who may not be committed 
to production for this market medium term (Chaudhuri et al., 2010; 
see also Chapter 6). It may reduce availability and reliable supply espe-
cially in rural areas. The decline in the industry is also an element of 
deindustrialization and cumulative industrial decline, losing valuable 
skilled and semi-skilled employment opportunities, both in these firms 
and in upstream suppliers, for example in plastics and packaging firms. 
Tanzania is also losing opportunities to exploit synergies between health 
needs and financing and industrial development benefits, as compared 
to competing countries (see also Chapter 8). 
 Can this sector be turned around? A turnaround requires two key 
changes in mind-set and policy behaviour:
 an acceptance of the need for well-designed industrial protection  ●
mechanisms, and their effective implementation in stable and clearly 
explained rules; 
 an active and sustained engagement with existing firms and their  ●
suppliers, in a determined effort to deepen and strengthen the local 
pharmaceutical production system. 
 There is principled opposition by some Tanzanian officials to protection 
of the market in essential medicines. Duties, argued one official, would 
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raise prices, so ‘people would die’. This echoes emotive WHO and inter-
national NGO characterizations of tariffs on medicines imports as taxes 
that ‘target the sick’ (Olcay and Laing, 2005), or a ‘sick tax’. 18 In practice, 
however, there appear to be no studies of the tax incidence of import 
duties on medicines in comparable contexts, though the most impor-
tant influences on retail prices are likely to be the extent of domestic 
market competition, the purchasing power of out-of-pocket purchasers 
and the extent of competition between public or non-profit and private 
vendors 19 (see also Chapter 6). 
 It is, however, well established that ‘infant industry’ protection, to 
allow local firms to access markets, invest and grow  may support both 
industrial growth and increasing industrial competitiveness, so long it 
is selective and temporary, and associated with incentives for domestic 
competition and export growth (Lall, 1992: 172). In the East African 
Community, of which Tanzania is a member, the common external tariff 
is set at zero for most essential medicines. 20 Tanzania could, without 
challenging the tariff agreement, institute a ‘negative products’ list of 
items that cannot be imported unless local manufacturers are unable to 
supply reliable quality at an acceptable price. 
 The key benefit of this change would be to allow local manufacturers 
to retain and grow their share of the basic essential medicines market. 
Without this market, the firms lose scale, cost efficiency and cash flow. 
The negative list would also be a relatively straightforward policy, in 
contrast to the complex efforts that would be required to identify and 
effectively exempt all essential inputs to local pharmaceutical produc-
tion. Reducing or removing VAT on inputs to pharmaceuticals, or at 
least rapidly reimbursing the tax paid, would also shift the balance of 
incentives back towards manufacturers, as would raising the preference 
level above 15% for local suppliers in public procurement of medicines. 
 Additional practical changes that would shift the balance back towards 
local production include effective implementation by TFDA of their 
formal commitment to fast tracking of tests and registrations for local 
products (which may require additional TFDA resources). Providing 
trade credit for local suppliers to public procurement, as well as to over-
seas importers, would also rebalance the incentive structure, as would 
more timely funding by the Ministry of Finance for procurement by 
MSD of locally contracted supplies. 
 All of these policy changes are feasible, and many are implemented by 
other African countries including Ethiopia and Ghana (see Chapters 4 
and 6). However, they would quite sharply shift incentives against the 
wholesaler/importers who currently manage the bulk of private sector 
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and substantial elements of public sector medicine supply. The changes 
would set manufacturing and importing interests against each other to 
some extent, posing challenges for policy makers. 
 Active engagement with existing firms in supporting upgrading of 
technological capabilities, local input sourcing and market access would 
also assist a shift in policy direction from trading to manufacturing, by 
engaging government officials more closely in manufacturing affairs. 
There are examples in Tanzania, outside pharmaceuticals, of success 
along these lines, such as the sustained consultations with manufacturers 
that led to the successful initiation of production of long-lasting insecti-
cide treated bed nets. Manufacturing associations could strengthen their 
engagement with government. Current Tanzanian initiatives to create 
an active Task Force on Promotion of Local Pharmaceutical Production, 
including manufacturers, to improve policy and implementation in 
support of pharmaceutical manufacturing, could greatly enhance 
government-private sector collaboration. 
 Supporting continuous industrial upgrading requires a combination of 
types of support. Government policy can improve external constraints, 
for example by moderating utility cost increases, and streamlining slow, 
overlapping and expensive industrial licensing. Government can directly 
support areas where firms lack incentives and capability to invest them-
selves, such as industrial and vocation training schemes tailored to the 
needs of specific sectors, and funding for in-house training. Governments 
can work with donors to identify and tackle barriers to international 
market access for local firms. The large government shareholdings in 
pharmaceuticals, at present managed as passive holdings, could be 
actively used to support manufacturing improvement, or otherwise sold 
to support new joint ventures. Government could provide some direct 
financial support for investment. 
 The lack of industrial depth in this sector in Tanzania at present 
implies that government has a role in supplying missing ‘public goods’ 
of the type that larger clusters may generate locally: technological and 
market information; networks and introductions to help to generate 
joint ventures; active support for upgrading that would be available from 
consultants in more developed industrial contexts; and timely facilita-
tion of external expertise when required. At present, in the small cluster 
of pharmaceutical firms, each was creating its own linkages; the mix of 
competition and beneficial externalities and collaboration characteristic 
of successful industrial clusters is missing here. 
 Two government bodies in Tanzania do provide some effective advice 
appreciated by manufacturers interviewed: the Japanese-supported 
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Kaizen unit in the Ministry of Industry and the TFDA. The manufac-
turers interviewed broadly appreciated the TFDA’s practical and informed 
approach. TFDA officials are among the few in government who spend 
substantial time considering the requirements – and the point of view – 
of manufacturers. TFDA expertise could be brought into industrial policy 
implementation, perhaps through secondments, to help in changing 
the policy culture in support for pharmaceuticals. 
 Restructuring public procurement to support local firms’ domestic 
market access can also help to stimulate and fund expansion and 
upgrading. This restructuring may include a policy already under devel-
opment, to allow longer term contracts where procurement supports 
new local investment. This was being considered in relation to new 
investors, but could equally be applied to existing firms requiring longer 
contracts in order to fund upgrading. Manufacturers of medicines with 
longer public contracts could then be encouraged to use that stability 
to support their local suppliers’ investments, for example in packaging. 
Given the shallow industrial structure of pharmaceuticals at present, 
industrial turnaround will need to address the local supply chain for 
pharmaceuticals, including local suppliers. Tanzania currently imports 
large quantities of glass, air, paper and water (bottles, packaging and 
intravenous fluids) in the pharmaceutical sector; even without any 
move into producing APIs, upstream improvement of input suppliers, 
and selective increases in sophistication of technological capabilities 
could cut industrial and import costs. 
 Conclusion: staying in the ‘moving window’ 
 Sutton (2012) argues that as markets integrate internationally, price 
competition intensifies and firms respond by investing in quality, 
producing better quality for a given cost. The net effect is to shift the 
market ‘window’ that firms must access upwards over time, dropping 
out of the window firms that can no longer meet the minimum quality/
price ratio required for market entry. Tanzanian firms, facing a combi-
nation of a shallow industrial structure with few supportive linkages, a 
highly liberalized market, a policy ‘tilt’ towards incentivizing imports, 
and a largely passive industrial policy approach, have been vulnerable 
to these rising barriers to domestic and international market entry. The 
observed industrial fragility – the vulnerability to sudden decline – is 
not a new industrial phenomenon in Tanzania: for example, a number 
of the exporting firms that were the subject of an earlier industrial study 
(Wangwe, 2003) are no longer operating. 
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 This conjuncture urgently requires a more engaged industrial policy. 
However, the industrial policy literature remains thin on how to sustain 
continuous engagement between government and manufacturers 
to support constant upgrading. 21 The small, strategic, but currently 
shrinking pharmaceutical sector offers a good ground for experimen-
tation in policy renewal, given its perceived strategic importance. 
Chapter 4, on Ethiopia, provides a comparative case study of an effective 
set of turnaround policies. 
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data/ , accessed 5 August 2014; NBS (2009) manufacturing survey for phar-
maceutical production data. 
 6 .  There was no available manufacturing survey later than 2009 at the time of 
writing. 
 7 .  Thanks to Mary Justin-Temu for access to these data; Table 3.1 uses the 2006 
sample of facilities and medicines only, for comparability. 
 8 .  East African Community Secretariat (nd)  Guidelines on Good Manufacturing 
Practice for Medicinal Products within the EAC , Arusha: late draft kindly made 
available in near-final form by a TFDA official, in 2014. 
 9 .  The Global Fund to Fight AIDS, Tuberculosis and Malaria,  www.theglobal-
fund.org , henceforth ‘the Global Fund’ in this chapter. 
 10 .  See  http://apps.who.int/prequal/ , also Chapter 12. 
 11 .  Source: interviewing of firms previously supplying anti-malarials, 2010 
 12 .  Median selling prices USD/tablet 0.0171 2010, 0.0173 2013 (MSH 2010, 
2013). 
 13 .  Sources: TFDA figures for wholesaler numbers cited in Mhamba and 
Mbirigenda (2010), and interviews. 
 14 .  An MSD accountant estimated for us that just 11% by value of MSD’s new 
two-year framework contracts had gone to local firms in 2012–13. 
 15 .  Source: URT (2009: 67). 
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 16 .  This example is reported with permission from the company’s CEO. 
 17 .  http://www.dndi.org/diseases-projects/portfolio/asaq.html?highlight=WyJ0
YW56YW5pYSJd , accessed 23 February 2015. 
 18 .  http://www.haiweb.org/medicineprices/29012010/MPM_6.pdf , accessed 23 
February 2015. 
 19 .  See Waning et al. (2010) for an interesting investigation of non-profit supply 
and its impact on competition. We have found no studies of import duties’ 
incidence on medicines prices in low- and middle-income countries. 
 20 .  The currently available EAC tariff schedule, available from  http://www.eac.
int/customs/index.php?option=com_content&id=41:common-external-
tariff-handbook&Itemid=141 , sets antibiotics’ import duties at 10%, but this 
does not appear to be implemented at present in Tanzania. 
 21 .  We owe that observation to Martin Bell. 
 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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 Introduction 
 Manufacturing of medicines in Ethiopia started in 1964 with the estab-
lishment of one joint venture manufacturing company. This company 
remained the sole producer of medicines throughout the military regime 
(1974–91). Following the regime change in 1991, several manufacturing 
plants were established during the period referred to as the ‘boom 
and crash’ period, since, for reasons described below, some of the new 
companies were not successful. To respond to the crisis, the government 
took a mix of initiatives, simultaneously fulfilling its responsibility for 
health care improvement and industrial promotion. As a result of policy 
adjustments and attractive incentives, the environment for investment 
in pharmaceuticals became conducive, prompting private initiative to 
engage in industrial investment. Joint ventures that were realized have 
not only contributed to the pharmaceutical industry; they also effec-
tively transferred skill and technology. 
 This chapter argues for the importance of integrating the health and 
industrial policies to foster local pharmaceutical production. We argue 
that local production of pharmaceuticals is justified from both industrial 
and health polices standpoints. From an industrial policy standpoint, 
local pharmaceutical manufacture is usually justified by its benefits 
for the local economy, such as savings on foreign exchange through 
 4 
 Bringing Industrial and Health 
Policies Closer: Reviving 
Pharmaceutical Production in 
Ethiopia 
 Tsige  Gebre-Mariam,  Kedir  Tahir and  Solomon  Gebre-Amanuel 
OPEN
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
66 Gebre-Mariam, Tahir and Gebre-Amanuel
import substitution, employment creation and the development of 
exports. From a health policy perspective, the rationale for local phar-
maceutical manufacture is largely founded on increasing the access to 
essential medicines. Ethiopia is a country with high disease burden; it 
therefore considers development of the pharmaceutical industry a stra-
tegic endeavour. 
 The chapter is organized to demonstrate the close interconnections 
between industrial and health improvement in recent Ethiopian expe-
rience. After an overview of the stages of pharmaceutical industrial 
development in Ethiopia over the last 50 years, the chapter turns to an 
examination of the context and framework of Ethiopian health policies 
and the supply of medicines, describing the importance of medicines 
demand for the industry and industrial supply for health sector devel-
opment. We describe how the health sector development programme is 
linked to the provision of essential medicines in the primary health care 
(PHC) system of the country, and the government’s social responsibility 
in providing medicines to the population. 
 A key objective of the chapter is to argue, on Ethiopian evidence, 
that joint ventures in the pharmaceutical industry can be designed as 
strategic partnerships. It narrates some success stories in terms of tech-
nology transfer and upgrading manufacturing plants, and localization 
of knowledge within Ethiopia, and their roots in a conducive policy 
environment for private sector investment. A final section examines 
these developmental aspects of Ethiopian industrial policies. In conclu-
sion we acknowledge the headway Ethiopia has made in manufacturing 
medicines and identify some issues to be addressed. 
 In the preparation of this chapter, policy documents, proclamations, 
regulations, guidelines and literature were reviewed. Key informant 
interviews were conducted and plant visits undertaken by the authors. 
 Pharmaceutical industrial development in Ethiopia 
 Phases of industrial development 
 The history of pharmaceutical manufacturing in Ethiopia is only half 
a century old and it may be classified into three periods: the estab-
lishment of the Ethiopian Pharmaceutical Manufacturing company 
(EPHARM), the subsequent boom and crash and the later ‘reform and 
revival’ period. 
 The first pharmaceutical manufacturing plant in Ethiopia, EPHARM 
was founded in 1964 as a joint venture by the Ethiopian government 
and the British company, Smith & Nephew. In 1971, Smith & Nephew 
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was superseded by Teva Jerusalem of Israel. Following the overthrow 
of the monarchial government by the military in December 1975, the 
company was nationalized. Due to the socialistic policy of the military 
regime, private industrial investment generally stagnated and EPHARM 
remained the sole producer of medicines in the country until 1993. In 
February 1994, EPHARM was re-established as a public share holding 
company and recently it was sold to a local investor. 
 The period 1995 to 2004 experienced the boom and crash. Ten new 
pharmaceutical plants were established: Asmi Industry PLC, East African 
Pharmaceuticals (EAP), Addis Pharmaceuticals Factory (APF), ETAB PLC, 
Pharmacure PLC, BioSol PLC, Life-Line PLC, Fews PLC, Sino-Ethiop 
Associate (Africa) PLC (SEAA) and Bethelehem PLC. However, the new 
factories faced daunting challenges, as there were neither policies nor 
regulatory mechanisms to control dumping of cheaper and substandard 
products. The prices of local products were not competitive. In addi-
tion, most of the new factories were poorly organized and managed. 
Consequently, four companies were foreclosed for failure to service their 
loan obligations. 
 According to the secretary of the Ethiopian Pharmaceuticals and 
Medical Supplies Manufacturing Association (PMSMA), the produc-
tion capacities of the majority of the industries at the time was below 
50% of their installed capacity. There was a high tariff on raw mate-
rials and a chronic shortage of experienced human resources, associated 
with high turnover of technical staff, shortage of technical manpower, 
and an absence of any training centre on good manufacturing practices 
(GMP) and pharmaceutical management. In addition there were no 
GMP-certified inspectors at the regulatory authority. It was hard to get 
working capital from banks, there were management problems in the 
industries, an absence of qualified equipment calibration and mainte-
nance centres, and university-industry linkages were weak. 
 Established in 1996, East African Pharmaceuticals (EAP) was one of 
the companies that survived the ‘crash’ period. EAP was an initiative 
of British and Sudanese nationals. It had difficulties at the outset when 
the cost of the investment was driven up due to the decision of Drug 
Administration and Control Authority (DACA) that EAP should recon-
struct its plant to comply with GMP, shortly after it started operation. 
In 2009, the factory was operating at 30% of its capacity. EAP produces 
human and veterinary medicines mainly for the local market, although 
a small portion is exported to Sudan and Somali. Being the only local 
manufacturing company producing veterinary medicines, EAP enjoys 
market monopoly. Hence, it is currently considering increasing its 
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production to meet the market demand. At the time of writing EAP has 
just achieved a GMP Certificate from the Pharmaceutical Inspection 
Convention and Pharmaceutical Inspection Co-operation Scheme 
(PIC/S). 
 Established in 1997, Addis Pharmaceuticals Factory (APF) Sh. Co. is 
the largest pharmaceutical manufacturing plant in Ethiopia. It is located 
in Adigrat, Tigray Regional State, northern Ethiopia. Though the plant 
was constructed and equipped with high-tech production facilities, at 
the start it faced financial and management crisis. In 2009, it acquired a 
second factory located at Akaki at the outskirts of Addis Ababa, which is 
dedicated to the manufacturing of large-volume parenterals. APF manu-
factures about 90 products. It has nine production lines with a capacity 
to produce 1.2 billion tablets, 19 billion ampoules, 10 million vials, 
500,000 capsules, 4 million ointment tubes and 9.6 million bottles of 
syrup. It has fully equipped laboratories. APF is owned and managed by 
the Endowment Fund for the Rehabilitation of Tigray (EFFORT). 1 
 Sino-Ethiop Associate (Africa) PLC (SEAA) was established in 
March 2001 as a joint venture between an Ethiopian company, Zaf 
Pharmaceuticals PLC, and two Chinese companies (China Associate 
Group and Dandong JINWAN Group). SEAA produces empty hard 
gelatin capsules and sells them to pharmaceutical factories in Africa and 
the Middle East. Recently, SEAA completed its expansion project and 
doubled its production capacity, to 2.4 billion capsules annually. SEAA 
has recently acquired Certificate of PIC/S conformity. It will be shown 
later that companies established through joint venture have been gener-
ally successful. 
 The ‘reform and revival’ period began in 2005. The Ethiopian 
Pharmaceutical and Medical Supplies Manufacturers Association 
(EPMSMA) and other key stakeholders appealed to the government for 
appropriate measures to be taken in support of local manufacturing. To 
address the crisis the local manufacturers were facing, the government 
created benefit packages and undertook policy reforms. This improved 
the business environment, resulting in some new joint ventures. 
 In 2007, Cadila Pharmaceuticals Ethiopia PLC (CPEL) was established 
by Cadila Pharmaceuticals Ltd (India) and Almeta Impex PLC (Ethiopia), 
owning 57% and 43% of the company, respectively. The market size, 
including easy access from Ethiopia to other East African countries, moti-
vated the investment. All machines and raw materials were imported 
from India. CEPL has the capacity to manufacture 390 million tablets, 
165 million capsules and 1.44 million litres of liquid per annum. In 
2011, CEPL acquired a GMP certificate. 2 
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 Established in 1998, Pharmacure PLC, a Swedish turnkey plant, is an 
Ethiopian-Saudi investment. It produces large-volume parenterals. Rx 
Africa (Ethiopia) PLC, an Ethiopian-US joint venture was commissioned 
in 2007 through the acquisition of a local company called Sunshine 
Pharmaceuticals. Rx Africa launched 36 products in 2009. Another local 
manufacturer, Fews PLC, produces syrups. 
 In 2013, Julphar (Gulf Pharmaceutical Industries) commissioned its 
pharmaceutical manufacturing facility 3 in Addis Ababa. The facility has 
the capacity to produce 150 million bottles of suspension and syrup, 
500 million tablets and 170 million capsules annually. 
 One unique local manufacturer is the National Veterinary Institute 
located in Bishoftu, 40 km south of Addis Ababa. With its well-equipped 
diagnostic and research laboratories and production plants, the NVI is 
currently producing 19 R&D-based veterinary bacterial and viral vaccines 
for both domestic and international markets to more than 25 countries 
in Africa and the Middle East. 
 The Ethiopian industry today 
 Today, the Ethiopian pharmaceutical industry consists of 15 pharma-
ceutical manufacturers, of which nine produce medicines, one manu-
factures empty gelatin capsules, and the rest are engaged in producing 
medical supplies such as syringes, absorbent cottons, gauzes, bandages 
and sanitary products. Though significant expansion of the industry is 
taking place, as such the base is not yet well developed, and the compa-
nies have relatively low production capacities. 
 The therapeutic categories of local production include antibiotics, 
gastrointestinal drugs, central nervous system drugs, cardiovascular 
drugs, anti-diabetic agents, antihistamines, anthelmintics, analge-
sics and antipyretics, antiprotozoals, respiratory drugs, dermatological 
preparations, minerals and vitamins, large-volume parenterals as well 
as veterinary vaccines. None of the manufacturers produces medicines 
against tuberculosis, HIV/AIDS and malaria. Since the local manufac-
turers were not GMP-compliant, they could not make use of the donor 
funding made available for the procurement of medicines for these 
diseases. Hence these medicines are being imported from abroad, mainly 
from Indian manufacturers. 
 The Ethiopian pharmaceutical industries are small- to medium sized 
industries. Most use labour-intensive, step-by-step manual manufac-
turing, with semi-automated production lines. Manufacturers mainly 
focus on tablets, capsules, powder and liquid preparations. A few produce 
parenteral preparations, creams and ointments. Production is limited 
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to secondary manufacturing that involves combining and processing 
pharmaceutical active ingredients (APIs) and excipients into dosage 
forms. There is no active pharmaceutical ingredient (API) plant in the 
country. Almost all input materials (APIs and excipients), including 
primary packaging materials, are imported, mainly from India and 
China. According to an interview with the procurement department 
manager of EPHARM, input materials are purchased in small quantities, 
at times too small to attract suppliers, and as a result manufactures have 
no power to negotiate better prices. This situation tends to increase the 
cost of input materials. Hence, most of the finished products are not 
competitive as compared to products imported from China and India. 
Just a few inputs such as sugar (for syrup production), empty hard 
gelatin capsules and secondary packing materials are locally produced. 
There are new packaging manufacturers who have begun producing 
PVC and empty bottles for pharmaceutical use replacing some of the 
imports (Sutton and Kellow, 2010). Cardboard boxes for bulk packaging 
are manufactured locally. 
 Although most of the manufacturers operate below their respective 
capacities, the capacity utilization of the manufacturers has shown 
improvement during the 2005–14 period, increasing from a mere 29.3% 
in 2008 to 79.0% in 2013. This is indicative of the growing market for 
locally produced pharmaceuticals – an opportunity lying ahead for the 
sector (CSA, 2014). 
 As regards quality issues, there are three manufacturers that comply 
with basic GMP standards, one of whom is to acquire PIC/S Certification 
soon, while two others are expected to acquire the same in the near 
future. One of the main issues that must be addressed by local manufac-
turers is the need to access updated technology. In terms of personnel, 
however, Ethiopia seems to have sufficient trained pharmacists, though 
there is a dire need for those with industrial and managerial skills. 
 Developing and supplying the health sector 
 This section analyses the interaction of health care development and 
industrial market development, aiming to show how health and medi-
cines policies influenced the development of the local pharmaceutical 
industry. 
 The National Health Policy (NHP) launched in 1993 includes as core 
elements the development of preventive, promotive and curative health 
care; assurance of health care accessibility for all segments of the popu-
lation; and the promotion of private sector and NGO participation 
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in the health sector (TGE, 1993a). In order to achieve these goals, a 
20-year Health Sector Development Programme (HSDP) consisting of 
a series of five-year rolling programmes was established in 1997/98. 
The HSDP has been aligned with the wider frameworks of the Plan for 
Accelerated Development to End Poverty (PASDEP), and a Growth and 
Transformation Plan (GTP) has been formulated and implemented. 
 HSDP implementation takes a sector-wide approach encompassing 
the following components: service delivery and quality of care; health 
facility rehabilitation and expansion; human resource development; 
pharmaceutical services; information, education and communication; 
health sector management and management of information systems; 
monitoring and evaluation and health care financing. 
 Over the last two decades the government has been engaged in health 
facility construction, expansion, rehabilitation, furnishing and equip-
ping. From 2003/04 to 2011, the number of health posts increased from 
4,696 to 17,972 and the number of public health centres from 519 to 
3,871, while the number of hospitals (public and private) rose from 
126 to 194 (FMOH, 2011). Health service coverage increased from 45% 
in 2001 to 95% by 2011. The rise in health service coverage necessi-
tated an increased demand for pharmaceuticals. Hence, the number of 
pharmaceutical manufacturers, importer/distributors and retail outlets 
increased significantly during the same period to serve an expanding 
market. 
 Targets set by HSDP IV with respect to pharmaceutical supply and 
services include increasing the availability of quality pharmaceuti-
cals at an affordable price and in a sustainable manner, and achieving 
improved rational drug use. In the design of HSDP III and IV, the SWOT 
analysis made indicated increasing domestic manufacturing capacity of 
drugs as an opportunity to be explored (FMOH, 2011/12). Recognizing 
the importance of the supply of pharmaceuticals in the overall health 
policy, the government decided to increase the availability of essential 
pharmaceuticals from 75% to 100% and improve the efficiency of regula-
tory activity (MOFED, 2006). Moreover, the Growth and Transformation 
Plan (GTP) anticipated increasing the domestic market share of the local 
pharmaceutical industry from the baseline year 2009/10 share of 15% to 
the target 50% (MOFED, 2012). 
 The market for pharmaceuticals in Ethiopia is met through import 
(purchase and donation) and local production. Local manufacturing still 
represents less than 15% of the total market for pharmaceutical prod-
ucts. Governmental organizations, private importers, non-government 
organizations (NGOs) and international agencies such as the UNICEF 
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and WHO used to participate in the import and distribution of pharma-
ceuticals. In order to streamline the supply and distribution of essential 
medicines to the public health care facilities, the former PHARMID was 
transformed into the Pharmaceutical Fund and Supply Agency (PFSA), as 
established by Proclamation in 2007 (FDRE, 2007). 
 Today, local and international procurement for the public health facil-
ities is mainly provided by the PFSA which operates with a revolving 
fund. PFSA procurement is done through international and local tenders 
as well as through direct purchasing. The PFSA also receives some phar-
maceuticals through donation from sponsors of vertical programmes 
such as those for ARVs, TB and malaria medication and reproductive 
health commodities. From its central hub in Addis Ababa and the 
regional hubs, PFSA distributes medicines and medical supplies directly 
to health care facilities. Private companies import directly from their 
respective suppliers and distribute to wholesalers, and these in turn sell 
to retailers. 
 The PFSA has designed and implemented different strategies to 
support local manufacturers of pharmaceuticals and medical supplies. 
These include the provision of 30% advance payment for the purchase 
of products won through national bidding and 25% price preference 
when local manufacturers participate in international bids. Although 
not yet implemented, a tripartite agreement (PFSA as a collateral, phar-
maceutical companies and the Development Bank) has been signed, 
providing local manufacturers with a loan for 70% of a bid that has 
been won. Furthermore, to increase local production of pharmaceuticals 
and medical supplies and create market linkages with consumers, the 
type and amount of products given priority by the health services have 
been identified. Based on this, a list of 124 pharmaceuticals and medical 
supplies produced in the country has been prepared to serve as a guide 
for the procurement process. 
 With an estimated population of 95 million in 2014, Ethiopia has 
the potential to become a significant market for pharmaceutical 
products in Sub-Saharan Africa. Although the Ethiopian pharmaceu-
tical market grew on average by 20% per annum from 2007 to 2011, 
it is still rather limited, estimated at around US$500 million, due 
mainly to low per capita income. Currently, there is slightly higher 
total health expenditure as a share of GDP, at 4.9% in Ethiopia, as 
compared to other countries in Africa (excluding South Africa), but 
the per capita health expenditure remains among the lowest in the 
region (Wamai, 2009). 
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 Joint ventures and strategic partnerships: fostering 
technology transfer 
 The revival of the pharmaceutical industry of Ethiopia after the boom 
and crash is largely attributed to policy reforms, investment and manu-
facturing incentive packages. One important phenomenon that stands 
out is joint ventures. Through the initiative of joint ventures, a fore-
closed factory revived, an old factory was upgraded, new factories were 
established, and enhanced technology transfer included localization of 
technical knowledge within Ethiopia. 
 One of the shortcomings of the local manufacturers is that they 
are organized at the secondary level and hence dependent on foreign 
companies for raw materials and technology sources. In order to over-
come this problem, some local manufacturers established joint ventures 
as a strategic partnership with foreign companies. These joint venture 
investors gain access to both local and regional markets, and Ethiopia’s 
cheap labour force, as well as a number of investment incentives that 
the country offers in exchange for raw materials, know-how, technology 
transfer and pre-established market networks. This kind of strategic part-
nership can be considered as a key factor for long-term success. The 
joint ventures between the Ethiopian company, Zaf Pharmaceuticals 
PLC, and two Chinese companies, China Associate (group) Co., Ltd and 
Dandong Jinwan (Group) Co., Ltd (Sino-Ethiop Associate Africa PLC), 
and between Medtech (Ethiopia) PLC and Gulf Pharmaceuticals Julphar 
of UAE (Julphar Pharmaceuticals Manufacturing Ethiopia PLC) are based 
on this principle. 
 Sino-Ethiop Associate Africa PLC, the sole empty hard gelatin capsules 
(EHGCs) manufacturer in Africa, was established at the outskirts of 
Addis Ababa in March 2001 and became operational in June 2003. 
China Associate (Group) Co., Ltd. is a 35% shareholder of Sino-Ethiop 
Associate Africa PLC. It is a diversified enterprise engaged in manufac-
turing of bulk pharmaceuticals and finished formulations and has a 
trading business. This company has more than ten years of business 
relationship with the pharmaceutical companies of some African coun-
tries, including Ethiopia. Dandong Jinwan (Group) Co., Ltd. is the other 
partner holding 35% of the shares. It is a diversified enterprise engaged 
in the production of EHGCs itself and manufacturing of equipment for 
capsules production. Zaf Pharmaceuticals PLC, engaged in importing 
of pharmaceuticals, is the Ethiopian counterpart in the joint venture, 
having 30% of the shares. 
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 The company currently has five automatic capsule production lines 
to produce EHGCs, with a total capacity of 2.4 billion EHGCs of size 0, 
size 1 and size 2 per year. The continuous batch system is applied in 
the production process; as a result, production is not interrupted except 
during regular preventive maintenance schedule and size part changes. 
Its capacity utilization is normally more than 95%, operating in three 
shifts. On average, there are more than 300 production days per year. 
The company covers 100% of the local EHGCs demand and exports to 
Sudan, Kenya, Uganda, South Africa, Ghana, Zimbabwe, Democratic 
Republic of Congo, Yemen and Saudi Arabia, among others. 
 The company has recently undergone a major expansion that trans-
formed the overall capacity of the company, doubling the annual 
output. It has also done the civil engineering required to accommodate 
three more production lines. The director of the company revealed that 
the expansion has transformed the company in terms of both quality 
and productivity, including:
 state-of-the-art manufacturing equipment which is automatic and  ●
fully synchronized; 
 Programmable Logic Controller (PLC) systems: advanced from push- ●
button to touch-screen, enabling easy process monitoring and record 
keeping; 
 heating, ventilation and air conditioning (HVAC) system: programmed  ●
based on a one-year study made on the climatic condition of the 
location in order to improve its overall efficiency; 
 water treatment system: use the double-reverse osmosis system along  ●
with electro-deionization system that reduced the use of different 
chemicals and improved the quality of the water; and 
 energy utilization: integrated a solar energy source with the existing  ●
grid supply. 
 After the expansion, the manufacturing lines were moved to the new 
plant, leaving the old facility empty. Although the company is working 
three shifts at full capacity, it is still unable to meet market demand for 
EHGCs. It is therefore planning to increase its capacity from five to eight 
lines at the new plant. Further, the company plans to convert the old 
facility into a formulation plant for contract manufacturing. The other 
plan of the company, which is also of interest to the government, is to 
look into the possibilities of developing gelatin raw materials from cattle 
bone, which is abundant in the country. 
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 Skills and technology transfer has been extensive. Over a period of ten 
years, the Chinese technical and managerial staff have been completely 
replaced by Ethiopian staff (today there is just one Chinese engineer). 
The technology has been totally transferred (by Dandong Jinwan), signi-
fying the critical role that joint ventures can play in the development of 
the pharmaceutical industry. According to the general manager of the 
company, such a smooth transfer was possible due to several comple-
mentary reasons, including the trust developed among the partners, 
the government policy to limit the number of foreign employees in a 
company, training of personnel locally and abroad, and government 
insistence that the transfer of skills and technology by partners should 
take place. 
 Julphar Pharmaceuticals Manufacturing Ethiopia PLC is another 
company established as a joint venture. Its vision is to become one of 
the leading pharmaceutical companies in Africa by the year 2020 with 
a number of product portfolios. The joint venture is formed between 
an Ethiopian company, Medtech Pharmaceuticals PLC, that holds 
45% of the shares, and a United Arab Emirates (UAE) company, Gulf 
Pharmaceuticals (Julphar), that holds 55% of the shares. The UAE partner 
is producer of various pharmaceutical products in the Middle East and in 
its other subsidiaries in Algeria. Julphar maintains a network of 11 manu-
facturing plants based in the UAE, with developments under way to open 
additional facilities in strategic countries such as Saudi Arabia, Ethiopia 
and Algeria. It supplies its generic pharmaceutical products to the global 
pharmaceuticals markets. The Ethiopian partner has been exclusively 
importing and distributing Julphar products and continued to do so for 
products being produced locally by Julphar Ethiopia as well. 4 
 This joint venture transformed a previously bankrupted manufac-
turing facility, Bethelehem Pharmaceuticals, into a viable, state-of-the-art 
facility at a cost of about US$9.17 million. Currently, it is running at full 
capacity and producing and supplying the Ethiopian market with 25 
different products (25 million bottles of syrup/suspension, 500 million 
tablets and 170 million capsules per year). In order to reach the interna-
tional market, the company has already fulfilled GMP requirements and 
is expected to be fully certified with PIC/S. 
 The company has upgraded the facility with new utilities and machin-
eries as per GMP requirements. It has put in place new HVAC system, 
state-of-the-art and fully automated reverse-osmosis water treatment 
system, and boilers for generation of pharmaceutical grade steam. 
Furthermore, to increase its product portfolio and production capacity, 
a new closed and fully automated oral liquid preparation and filling 
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line, tablet compression and blistering machines, and ointment filling 
machines have been installed and made operational. To upgrade the 
quality control system, Julphar has introduced high-performance liquid 
and gas chromatography systems and computerized stability chambers. 
To enhance the quality assurance (QA) system, the company is transfer-
ring QA documentation systems such as product dossiers, procedures 
and validation protocols from the mother company in the Gulf. 
 According to the country director of Julphar UAE, the joint venture 
has been highly encouraged by Ethiopian market access and by the 
investment policy of the government. Accordingly, Julphar has also 
earmarked an additional investment worth US$50 million to establish 
an insulin plant. To facilitate the expansion, the government of Ethiopia 
availed a plot of land for Julphar adjacent to its existing facility. This 
new investment is the first of its kind in Africa and it aims at making 
Ethiopia an insulin hub for the growing African insulin demand. 5 This 
move is heralding the beginning of advanced manufacturing of pharma-
ceuticals of biological origin in Ethiopia. 
 To achieve its vision, Julphar Ethiopia PLC is interested in launching 
new investment in additional plant to produce products like B-lactams 
and small-volume injectable products. The director reiterated the chal-
lenges the company has been facing, including lack of trained and 
skilled engineers to install and maintain pharmaceutical machineries 
and facilities and the unavailability of spare parts and consumable mate-
rials in the local market. To deal with these challenges, the company 
has assigned engineers and technicians from the mother company. This 
arrangement has helped with technology and skill transfer for Ethiopian 
engineers. To overcome the shortage of trained and skilled manpower 
in the pharmaceutical industry, the company has made arrangements 
with local universities for the provision of on-the-job training within 
its facility and abroad in its mother company. Accordingly, a team of 
selected students from different universities were fully funded by the 
company for their stay in Julphar UAE to acquire knowledge and skill 
in the pharmaceuticals manufacturing sector. 6 From the foregoing it is 
apparent that integrating health and industry polices is highly benefi-
cial for industrial development, since it can attract and make good use 
of joint ventures. 
 Socio-economic policies and the investment environment 
 The last section referred to the Ethiopian government’s incentives for 
local industry. This section explores those industrial and socio-economic 
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policies in more depth. The Ethiopian government’s industrial policies 
are developmental in nature, and pharmaceuticals are a key aspect of 
that broader approach. Consequently, the current investment climate 
of the country is considered propitious, since the country has several 
competitive advantages. Ethiopia has sizeable young and educated, 
trainable human resource and a large number of inexpensive labourers; 
rapidly developing green energy, as well as modest transportation infra-
structure and trade logistics; and duty-free, quota-free access to the US 
and EU markets under the African Growth and Opportunities Act (Assefa 
et al., 2013). 
 Both the National Health Policy (NHP) (TGE, 1993a) and the National 
Drug Policy (NDP) (TGE, 1993b) emphasize the importance of local phar-
maceutical production. The NHP states: ‘Availability of drugs, supplies 
and equipment shall be assured by encouraging national production 
capability of drugs, vaccines, supplies and equipment by giving appro-
priate incentives to firms which are engaged in manufacture, research 
and development’ (TGE, 1993a). One of the objectives of the NDP also 
specifies: ‘To develop a domestic drug manufacturing capacity and 
gradual supply to the export market’ (TGE, 1993b). Given the signifi-
cant headway Ethiopia has made in availing access to PHC for its people, 
and given the country’s ambitious local pharmaceutical manufacturing 
plans, the NDP is currently being revised to lead GTP II and GTP III. 
 The regulatory body previously known as DACA was restructured 
(with greater mandates including improved regulation, and setting 
standards in health care facilities as well manufacturing companies) and 
re-established as the Food, Medicine and Healthcare Administration 
Control Authority (FMHACA) by Proclamation, and has set standards 
for manufacturing facilities, among others (FDRE, 2009). Even though 
the primary responsibility of FMHACA is to regulate and control medi-
cines, it has been building the capacity of the local manufacturers in 
GMP in collaboration with the WHO and the United States Agency 
for International Development (USAID) programme ‘Promoting the 
Quality of Medicines’ and United States Pharmacopeial Convention 
(PQM/USP). 
 The other sectoral polices that Ethiopia has put in place that in one 
way or another have contributed to the overall socio-economic develop-
ments (including the local pharmaceutical industry) are trade policies 
(focusing on business transactions such as the pharmaceutical supply 
chain), industrial policies (focusing on fostering manufacturing and 
technology transfer) and investment and labour policies. Since the 
implementation of the 1991 Trade Policy, Ethiopia has made significant 
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progress in opening up its economy and notable improvements have 
been recorded in its international trade. 
 Industry Policies 
 Ethiopia’s Industry Policy dates from August 2001 and is designed within 
the framework of a free market economy. The key principles of the 
strategy include recognition of the role the private sector as an engine 
of industrial development and facilitation by the government towards 
that end; an agricultural development-led industrialization strategy; and 
ultimately export-led industrialization. It focuses on labour-intensive 
industries and aims to coordinate foreign and domestic investment. 
 Local pharmaceutical production in developing countries has always 
been a debatable issue. On one hand, there are opinions that argue 
against local pharmaceutical production for lack of comparative advan-
tage, including absence of GMP and inadequate drug regulatory systems. 
These critics are also concerned with the immediate and long-term 
threats posed by low-quality medicines manufactured by African coun-
tries. People on the other side of the debate consider essential medicines 
as strategic commodities and seek to foster self-reliance and hence local 
production (Bate, 2008). The Ethiopian industry policy fosters the latter 
approach. 
 The investment policy within Ethiopia’s industrial policy frame-
work encourages the private sector to invest in almost all areas of 
economy. The policy does not impose local content, technology 
transfer (although encouraged) or export performance requirements 
on foreign investments. Export-oriented sectors receive long-term 
credit with low interest, export incentives, customs duty privileges 
and provision of land at competitive rents. The Development Bank 
of Ethiopia offers up to 70% of the investment capital for new invest-
ments or expansion projects in the pharmaceutical sector, with a 
7.5% interest rate and a long-term repayment horizon. Investors in 
the manufacturing sector will have customs duty privileges for capital 
goods and construction materials necessary for the investment, spare 
parts whose value is not greater than 15% of the total value of the 
capital goods and tax holiday privileges between two and seven years. 
There are no restrictions on repatriation of earnings, capital, fees or 
royalties (EIC, 2014). 
 Recognizing the role of the private sector in the economy, the govern-
ment of Ethiopia revised its investment law at least three times between 
1992 and 2012. The revisions rendered investment incentives more trans-
parent, attractive and competitive. Major positive changes regarding 
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foreign investments have also been introduced through Investment 
Proclamation No.769/2012 and Regulation No. 270/2012, which detail 
the tax incentives and duty-free privileges for investors. 
 In general, there are a number of reasons for potential investors to 
consider Ethiopia as a desirable location for pharmaceutical invest-
ment, including factors such as investor-friendly policies, conducive 
macroeconomic policies and stable foreign exchange rates, a sizeable 
local market, access to the markets of several African countries through 
COMESA, preferential trade treatment to the EU, ACP-EU, a favourable 
export market under the US Generalized System of Preference, abundant 
and inexpensive skilled and trainable workforce, strategic location with 
proximity to the lucrative markets of the Middle East, Europe and Asia 
and attractive incentive packages for investment. 
 Ethiopia is a member of the World Bank–affiliated Multilateral 
Investment Guarantee Agency, which gives foreign investors guarantees 
against non-commercial risks. Ethiopia is a signatory to several bilat-
eral and multilateral investment promotion and protection treaties. 
Ethiopia has also signed the World Bank Treaty on ‘The Convention 
on Settlement of Investment Disputes between States and Nationals of 
other States’. 
 The country’s current labour policy is based on Labour Proclamation 
No. 377/2003 which calls for workers and employers to comply with 
basic principles of rights and obligations, through co-operative efforts 
(FDRE, 2004) in conformity with international conventions and other 
legal commitments to which Ethiopia is a party. Abundance of inexpen-
sive and disciplined labour together with the introduction of the revised 
labour proclamation is believed to contribute positively towards compe-
tition in the industry and other sectors. 
 Science and technology policies 
 One of the key indicators of the socio-economic development and tech-
nological progress of a country is the contribution of the industrial 
sector to the economy. The Ethiopian government has recognized that 
science and technology are the major driving forces behind industriali-
zation. It is taking steps to foster the growth of science, technology and 
innovation (STI), including the promotion of indigenous knowledge to 
tackle the country’s needs (see also Chapter 7). 
 The Ministry of Science and Technology (MoST) recently published a 
document called the ‘Green Paper on Science, Technology and Innovation 
Policy of Ethiopia-Building Competitiveness through Innovation’ (MoST, 
2012). In this document the pharmaceutical industry has not only been 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
80 Gebre-Mariam, Tahir and Gebre-Amanuel
listed as one of the high-level technology industries but also identified 
as an area in which efforts will be geared to building domestic techno-
logical capability. According to the paper, the pharmaceutical industry 
is among the National Priority Technology Capability Programmes of 
Ethiopia. 
 The national science and technology policy of the country dates from 
1993. Although this policy served to provide general directions to guide 
scientific and technological activities, it was not followed by imple-
mentation strategies and programmes aimed at achieving the envisaged 
policy objectives. It was therefore revised in 2012. The revised policy 
directives and strategies indicate, among other things, that at least 1.5% 
of the country’s gross national product (GNP) will be allocated annu-
ally to support and sustain the different STI activities in all sectors. A 
centralized innovation fund for R&D activities will be created through 
a contribution of 1% of the annual profit of all productive and service 
sectors, and banking and financial institutions will be encouraged 
through various legal and incentive mechanisms to improve their role 
of fostering technological innovation (MoST, 2013). 
 The policy landscape of Ethiopia entered a new phase when the 
Ethiopian government launched the GTP I (2010/11–2014/15). As the 
highest national policy framework, the GTP governs Ethiopia’s devel-
opmental policies, budgets and government organizations, as well as 
actions of development partners and foreign investors. Among other 
things, the GTP is tuned to expand infrastructure significantly and 
increase the role of the manufacturing industry in employment and 
economic development. The GTP identifies the pharmaceutical industry 
as a priority sector. Moreover, government support for the priority 
sectors will focus on, among other things, expanding modern systems 
in the sector by using local and external technical support and ensuring 
foreign technical support and investment, focusing on management 
skills and transformation, technological transfer and capacity building. 
The market share of local pharmaceutical producers is targeted to reach 
50% by 2015 (MoFED, 2010). 
 For this set of objectives, regulatory support is essential. As part of 
the GTP, the FMHACA has been implementing a five-year project which 
states: ‘The main aim of the pharmaceutical industry is substituting 
essential medicines imported to the country and setting the ground 
for export of local products by building the capacity of existing phar-
maceutical and medical device manufacturers and establishing new 
ones’. Notwithstanding the responsibilities vested in the authority by 
Proclamation 661/2009 to ensure the safety, efficacy and quality of 
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products, the FMHACA together with stakeholders has been exerting 
efforts to build the technical capacity of local manufacturers. 
 The FMHACA’s ambitious project envisioned 17 local GMP-certified 
pharmaceutical manufacturers by the end of 2015; at least five phar-
maceutical manufacturers pre-qualified by WHO by 2015; seven newly 
established pharmaceutical manufacturers by the end of 2015; and two 
newly established pharmaceutical raw materials manufacturers and two 
newly established traditional medicines manufacturers (FMHCA, 2011). 
To build the capacities of the local pharmaceutical manufacturers, 
FMHACA also prepared the Medicine Manufacturing Establishment 
Directive, and it has made it mandatory for any person engaging in 
manufacturing medicines to obtain a Certificate of Competence from 
the Authority (FMHCA, 2013a). 
 FMHACA, working together with the WHO and USP/PQM and local 
manufacturers, prepared a five-year GMP Road Map (2013–18). It has 
assessed and mapped the GMP status of the local manufactures and cate-
gorized them into three GMP compliance levels (Level I with up to 50% 
GMP compliance; Level II with 60–80% GMP compliance; and, Level III 
with more than 80% GMP compliance). As per their levels, FMHCA and 
its partners are building the capacity of the local manufacturers for them 
to be GMP compliant by 2018 (FMHACA, 2013b). 
 A major scientific and technological project is the establishment of 
a Regional Bioequivalence Centre (RBEC) in Ethiopia. This presents 
yet another major opportunity for upgrading. To serve as substitutes, 
generic products should be bioequivalent or therapeutically equivalent 
to the originator/comparator products. Consequently, bioequivalence 
becomes even more crucial for generic products such as medicines 
for critical use (e.g. anti-retroviral, anti-tubercular), medicines with 
a narrow margin of safety (e.g. cardiovascular drugs), sustained or 
modified-release products and medicines with inherent solubility and 
permeability problems. 
 To obtain marketing authorization in different countries, manu-
facturers have to get their products approved and registered by the 
national drug registration authorities. Under normal circumstances, 
manufacturers are expected to present product pre-qualification for 
bioequivalence. However, local regulatory authorities could not enforce 
bioequivalence testing thus far, because the service fees charged by inter-
national contract research organizations are not affordable to the local 
manufacturers. Hence, the absence of a local bioequivalence testing 
facility in the subregion has been a big hurdle in the enforcement of the 
bioequivalence testing requirement of the generic medicines. 
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 To assist local manufacturers, the Regional Bioequivalence Centre Sh. 
Co. (RBEC) was recently established in Addis Ababa as a public-private 
partnership. GIZ provided the basic instruments and equipment for 
the bio-analytic laboratory and technical training to key staff. Addis 
Ababa University made available laboratory space and furnished offices. 
Two pharmaceutical manufacturing companies in Kenya (Universal 
Corporation Ltd and Skylight Chemicals Ltd), one local manufacturer 
in Ethiopia (Addis Pharmaceutical Factory PLC) and one generic manu-
facturer in Germany made modest financial contributions to cover the 
running costs of the Centre until it acquires the WHO prequalification 
and thereby begins to generate its own revenue. The Centre has a clinical 
partner, Armauer Hanssen Research Institute, where the clinical studies 
are being conducted. 
 Since RBEC is the first of its kind in the Sub-Saharan region (except 
for South Africa), the centre anticipates an overwhelming demand for 
BE studies. The Centre will also offer services related to assessment of 
quality of medicines. In the long run the RBEC would also play key role 
in clinical trials as well as in pharmaceutical research and development 
activities aiming at product development and drug discoveries. 
 The other important entity that has been recently (2013) established 
by Proclamation is the Food, Beverage and Pharmaceuticals Industry 
Development Institute, which has the objective of transforming the 
food, beverage and pharmaceutical industries through accelerated tech-
nological development and transfer. Currently, the Institute is preparing 
a 10-year strategic plan for the development of the pharmaceutical 
industry. 
 Conclusion: future pathways and challenges 
 Ethiopia is making substantial headway in all areas of socio-economic 
development. It is in the midst of a sustained growth surge that is 
becoming increasingly broad-based, building on major improvements 
in educational attainment, improved health outcomes and improved 
infrastructure capacity (power, transportation and telecommunica-
tions). The GTP sets ambitious targets for further improvements in these 
areas, together with significant reforms aiming to improve local manu-
facturing capacities (including pharmaceuticals) and trade logistics by 
rolling out various export-oriented economic programmes (Assefa et al., 
2013). 
 Despite all these achievements, however, there are still outstanding 
issues to be addressed, such as the low production capacity and 
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overwhelming dependence on importation of medicines; shortage of 
qualified management and technical personnel; and inadequate contin-
uing professional development for practising professionals. 
 Asked about challenges and limitations faced by the local manufac-
turers, the plant technical manager of EAP reiterated the following: 
limited working capital of the factories; conflicts of interest with the 
suppliers of raw materials in India and China (as they are also producers 
of medicines, so they charge higher prices); paying VAT that is not 
reimbursed; shortage of foreign currency and hence longer lead time in 
foreign purchase resulting in price fluctuation and ultimately purchase 
reorders; small bulk orders with no economy of scale; low manufac-
turing capacity and hence high production cost; and limited capacity 
for troubleshooting and management. 
 Finally, based upon the assessment in this chapter, we suggest the 
following ways forward. 
 Strengthen local production: Although some progress has been made 
over the past few years, the development and local production of medi-
cines is still marginal. Consequently, Ethiopia is relying heavily on 
imports for medicines and medical supplies. It is therefore crucial to 
build and strengthen national capacity to manufacture affordable, safe, 
efficacious, high-quality generic essential medicines which can signifi-
cantly contribute to the simultaneous achievement of public health and 
industrial development objectives (MoST, 2012). 
 Competitive and efficient local pharmaceutical production should be 
promoted by strengthening local producers’ capacity to meet WHO-GMP 
and WHO prequalification standards, promoting regional and interna-
tional collaborations and facilitate technology transfer; fostering pooled 
procurement of raw materials and other inputs. 
 Establish raw material manufacturing plants: The fact that most raw 
materials have to be imported has made the local pharmaceutical manu-
facturers less competitive against imported generic products from Asia. 
Therefore, looking for alternative local sources of some of the excipi-
ents and APIs is one important strategy to improve the competitiveness 
of the local manufacturers (Gebre-Mariam and Schmidt, 1996, 1998; 
Gebre-Mariam et al., 1996) (see also Chapter 7). The government should 
foster such an endeavour. 
 Build human capital: The availability of adequate, appropriately trained 
and well-motivated personnel endowed with requisite knowledge, skills 
and attitude to provide effective and efficient services is of paramount 
importance for the development of the pharmaceutical industry. Some 
manufacturers report that local personnel are not adequately trained 
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to carry out pharmaceutical production and business development. 
To rectify this, formal pharmaceutical training should be based on the 
needs of the industry. Strategies should be devised and implemented to 
update professionals who are in service. 
 Enhance research and development: R&D on raw materials (APIs and 
excipients) should be fostered and long-term strategy for their local 
production should be planned and implemented. Research on product 
development to make local products competitive should be enhanced. 
More favourable conditions should be created for the introduction 
of appropriate technology and know-how to vitalize the industry. To 
develop the raw material base for the pharmaceutical industry and to 
enhance the growth of a viable domestic pharmaceutical industry and 
manufacturing capacities, the government should extend its support to 
the private sector engaged in raw materials production. Research collab-
oration between universities, research institutes and local manufacturers 
should be promoted. 
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 Introduction 
 Back in 2003, Brazil’s and Mozambique’s presidents, Luiz Inácio Lula da 
Silva and Joaquim Chissano, agreed to set up the first pharmaceutical 
factory in Mozambique, to be entirely owned by the national govern-
ment. The project – widely known as the Brazil-Mozambican anti-retro-
viral factory because of its commitment to produce AIDS drugs – still 
represents the single most expensive and eye-catching project of Brazil’s 
South-South cooperation programme in the health sector. 
 Part I of this book examines the complexities of African pharmaceu-
tical markets and some practical aspects of setting up and developing 
pharmaceutical industries in the subcontinent. This chapter’s contribu-
tion is to present the experience of establishing a pharmaceutical factory 
in Mozambique through industrial and official development collabora-
tion between two national governments. Uniquely, this is a case study 
of an attempt to kick-start, through an innovative South-South part-
nership, pharmaceutical production in a country that previously had 
none. This chapter therefore discusses an experience sharply distinct 
from most of the countries’ experiences discussed in the book, since 
they have pharmaceutical industries dating back to the 1950s, and with 
substantial numbers of firms in their industries. 
 This chapter draws on multiple sources such as official technical coop-
eration documents and the published literature on the subject, as well 
 5 
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86 Giuliano Russo and Lícia de Oliveira
as on the authors’ direct experience of the Mozambican pharmaceu-
tical markets, of Brazil’s development cooperation programme and of 
the factory’s implementation project. It aims chiefly to discuss whether 
foreign lessons about the development of the pharmaceutical sectors 
can be learned for African countries, and the extent to which similar 
experiences of industrialization and health policy development can be 
exported from Brazil to the complex African environment. Two main 
contributions to the making medicines in Africa debate emerge from the 
analysis of this case study: one is the absolutely key role of the innova-
tive South-South collaboration to the nascent pharmaceutical industry 
in Mozambique in terms of both financial subsidy and technical support. 
The other is that, while the technical collaboration with Brazil remains 
highly positive, the link to the market in Mozambique seems to have 
been a major problem, as the health-industry link so fundamental in the 
Brazilian pharmaceutical development experience seems to have worked 
less well here, at least in the early years of the project. 
 After a description of the evolution of the cooperation project and 
of the collaboration between the two countries to set up a factory in 
Mozambique, this chapter presents details of the technical investment 
needed to start such a complex enterprise in a country with a less-than-
ideal business environment. The crucial link between the factory and 
the local as well as regional pharmaceutical markets is then analysed. 
The chapter ends with a discussion of the issues still hampering the 
development of the factory in Mozambique, and of the insight to be 
gained from such an experience, including insights for those countries 
in the subcontinent with a rather more established pharmaceutical 
industry. 
 The Brazil-supported pharmaceutical factory in 
Mozambique 
 Official reports show that back in 2003, the initiative to set up a phar-
maceutical factory in Mozambique originally had the following stated 
objectives. It aimed to secure the supply of anti-retroviral medicines 
(ARVs) for HIV/AIDS treatment in the country, and to jump-start phar-
maceutical generics’ manufacturing in Mozambique, enabling the fulfil-
ment of the objectives of the national primary care and pharmaceutical 
policies. It also aimed to reduce the country’s dependence on pharma-
ceutical donations and imports and to contribute to the creation of local 
capacity for pharmaceutical production and industrial management (de 
Oliveira, 2013). 
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South-South Collaboration: Mozambique 87
 Following an informal agreement between the two presidents, diplo-
matic and international cooperation efforts were stepped up from both 
the Brazilian and Mozambican governments to iron out the details of 
the project from 2003 onwards. Figure 5.1 summarizes the long timeline 
of the project from its inception to 2014. 
 The Oswaldo Cruz Foundation (Fiocruz) – Brazil’s leading public health 
institution (Roa and Baptista e Silva, 2015) – was appointed in 2004 to 
conduct the factory’s feasibility study. This was completed and approved 
three years later.  Farmanguinhos – Fiocruz’s pharmaceutical arm, and a 
key instrumental actor in Brazil’s national pharmaceutical policy – 
was charged with the pharmaceutical technological transfer, technical 
training and the wider project implementation. These two institutions 
are directly linked to the Brazilian Ministry of Health and have been 
credited with playing a pivotal role in the development of domestic 
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 Figure 5.1  Timelines for the implementation of the factory project 
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88 Giuliano Russo and Lícia de Oliveira
pharmaceutical regulation as well as of the pharmaceutical market in 
Brazil (Flynn, 2008). (Their role is discussed further in Chapter 9). These 
institutions’ early involvement in the factory project in Mozambique 
was considered instrumental in seeking to replicate that experience back 
home. 
 Meanwhile, in the field, a number of cooperation agreements and 
spending authorizations had to be sought by both the Mozambican 
and Brazilian sides, as the project was to be funded through multiple 
sources. The process was lengthy. VALE S.A. – Brazil’s largest mining 
company with ongoing operations in Mozambique – was also recruited 
by President Lula to support the national government in financing the 
factory’s infrastructure works, which were only finalized in 2012. In the 
same year, the majority of the pharmaceutical equipment was procured 
in the international market, donated by  Farmanguinhos , and shipped 
to the future factory venue. The government of Mozambique recruited 
the first 15 local staff in the same year, and  Farmanguinhos donated the 
pharmaceutical production technology files and provided the tech-
nical assistance required to start production of Nevirapine, Lamivudine, 
Captopril and Hydrochlorothiazide in 2013 (Russo et al., 2014). 
 In 2008, the enterprise was officially registered as Mozambique 
Pharmaceuticals Ltd ( Sociedade  Moçambicana de  Medicamentos, SMM), as 
it planned to extend production beyond anti-retroviral drugs. SMM is 
owned by the government of Mozambique’s State Assets Management 
Institute (IGEPE), which appoints the executive director and chair of its 
administrative board from candidates put forward by the Mozambican 
Ministry of Health (MISAU). In addition to the short-term Brazilian 
technical assistance necessary for training and setting up operations, 
four full-time Brazilian consultants in pharmaceutical manufacturing, 
quality assurance, technical engineering and maintenance have been 
appointed for the coming years, with the objective of steering the 
factory towards sustainable production and WHO Quality Certification 
(Russo et al., 2014). 
 According to official documents (de Oliveira, 2012), the government 
of Brazil (GoB) originally agreed to take responsibility for the project’s 
staff training, for procuring equipment and raw materials, for providing 
technical assistance and for designing the factory and managing the 
project. Meanwhile the government of Mozambique (GoM) was to be 
responsible for purchasing the physical infrastructure for the factory, 
for undertaking rehabilitation works, for funding the factory’s recur-
rent expenditures and for buying the bulk of the factory’s pharmaceu-
tical output. The first three-year cooperation agreement was signed in 
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South-South Collaboration: Mozambique 89
2011. Extensions of the original 2011 agreement were to be negotiated 
every three years through official Complementary Agreements ( Ajustes 
 complementares ). 
 In 2014, procurement contracts were signed by MISAU for the 
acquisition of locally produced hospital serum bags and imported but 
locally packaged generic drugs from the factory. Although disruptions 
were experienced in 2014 in the production lines, a fresh cooperation 
agreement was signed the same year to extend Brazil’s support to the 
factory until 2017. Towards the end of the same year, following a visit of 
Mozambican officials to the Brazilian Ministry of Health and Ministry 
of Foreign Trade, Industry and Development, a decision was taken by 
IGEPE – the institution in responsible for the factory – to seek capital 
to finance the factory from the Mozambican banking sector, and at the 
time of writing this seems to be the path identified for the development 
of the project in the near future (Figure 5.1). In the process of devel-
oping the factory, more than ten years and three presidential terms have 
elapsed both in Mozambique and Brazil, and administrative, political 
and foreign affairs details have had to be ironed out across two countries 
and four different political administrations. 
 The new pharmaceutical factory is located in Matola City within 
Mozambique’s capital’s metropolitan outskirts, on a 20,000-square-
metres allotment close to the capital’s commercial port and to the 
South African border. The factory currently engages both in secondary 
and tertiary pharmaceutical production. That is, it produces its own 
formulations from imported active pharmaceutical ingredients (APIs) 
and raw materials, as well as packing imported finished formulations. 
Twenty-one generic drugs are planned to be produced in the next two 
years, including ARVs (Nevirapine, Zidovudine and Lamivudine combi-
nations), hypertension drugs (Captopryl and Propanolol) and a list 
of antibiotics, antimycotics and anti-diabetic compounds specifically 
requested by the MISAU as currently in wide use in the country’s public 
National Health Service (NHS). Such a list can be expanded on demand 
to include generic drugs to meet the WHO requirements for ARV treat-
ment and generic formulation to be sold by third parties. All the formu-
lations (pharmaceutical dossiers) belong to  Farmanguinhos and are 
transferred for free to MISAU. A laboratory for the control of medicine 
quality has been already established, equipped to test drugs for efficacy 
and safety. When fully functional, the laboratory will be capable of 
providing information on the quality of all the drugs imported into the 
country and of contributing to the development of new drug testing 
methodologies. 
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90 Giuliano Russo and Lícia de Oliveira
 The technical investment 
 So far the factory’s overall set-up costs have been estimated at US$ 
39.6 million (de Oliveira, 2013). Capital investment (land, infrastruc-
tures, machinery and implementation of production lines) amounted to 
approximately 46.5% of overall expenditures and pledged funds, while 
technological transfers and technical assistance represented a substan-
tial cost item (13.0%), including the value of compounds dossiers for the 
21 generic drugs, as well as personnel costs for the expatriate staff who 
helped setting up the operations. Running costs for the first year (API 
procurement, training and maintenance) represented 23.7% of present 
and future expenditures (Table 5. 1). 
 Although the Brazilian government funded the majority of the 
project’s set up costs (62.7%), the government of Mozambique contrib-
uted through buying up land and some existing infrastructure for the 
establishment of the factory, while a donation from VALE, a Brazilian 
mining company operating in Mozambique, supported personnel and 
infrastructure expenditures (Table 5.1). 
 As Brazil still lacks a comprehensive legal framework to provide funds 
and procure goods for its international cooperation programme (Cabral, 
Russo and Weinstock, 2014), funds for the project had to be channelled 
through the implementing public institutions linked to the Brazilian 
Ministry of Health – Fiocruz, Fiotec and Farmanguinhos – and through 
the Brazilian Development Cooperation Agency (ABC), linked to the 
Ministry of Foreign Affairs ( Itamaraty ). On the Mozambican side, the 
costly acquisition of the infrastructure from a former hospital serum 
bags factory ( Final  Farmacêutica) was directly managed by the govern-
ment, while IGEPE funded the capital rehabilitation and maintenance 
costs. The donation to the venture by VALE S.A. was expressly solicited 
by the government of Brazil and channelled through the government 
of Mozambique Treasury to set up the factory’s early production lines 
and pay for some Brazilian personnel as part of the running costs. With 
the extension of the cooperation agreement to 2017, both governments 
agreed to further the funding of the project. 
 Although according to the business plan the factory would require 88 
full-time staff to manufacture at full capacity (24 for direct production, 4 
for quality-control-related services, and 18 for management and admin-
istration), at the time of writing only 55 had been recruited, and a team 
of 8 Brazilian technical assistants based in Maputo were still providing 
key management and technical expertise for the factory’s operations. 
Given the limited development of industrial capabilities in Mozambique, 
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 Table 5.1  Estimated cost of setting up the factory (current US$ million) 
 Source of 
funding 
 Implementing 
agencies  Activities 
 Type of 
expenditures 
 Spending 
(to 2013) 
 Pledged 
(2017)  Total 
Government of 
Brazil
Fiotec/Fiocruz/MoH of 
Brazil
Transfer of Technologies; 
Technical assistance
Technology 
transfer
6.3 6.7 13.0
 Farmanguinhos/ 
 Fiocruz/MoH of Brazil 
Equipment Capital 4.0 1.0 5.0
Procurement of raw products Running costs 1.0 2.0 3.0
Brazilian Cooperation 
Agency / Ministry of 
Foreign Relations 
(ABC/Itamaraty)
Capacity building Running costs 0.2 0.5 0.7
Government 
of Mozambique
GoM Purchase of land and 
infrastructure from Final 
Farmacêutica Lda
Capital 8.0 8.0
IGEPE Maintenance of infrastructures Running costs 2.0 2.0 4.0
Development of existing 
infrastructure
Capital 1.4 1.4
VALE S.A. Support to the GoM for 
the project
Setting up production lines Capital 4.0 4.0
Support to the GoM for 
personnel expenses
Payment of Brazilian technical 
director for 4 years
Running costs 0.250* 0.250* 0.5*
 Total  27.2  12.5  39.6 
 Note: *SMM Accounting Report SMM. 
 Sources : Respective implementing agencies, unless otherwise stated. 
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92 Giuliano Russo and Lícia de Oliveira
technical personnel as well as senior managers for the new factory had 
to be either summoned from the Brazilian public sector or recruited in 
the local market and provided for extra training abroad. 
 In terms of technological transfer, until March 2015,  Farmanguinhos 
had donated for free 10 out of 21 technological dossiers for the produc-
tion of specific pharmaceuticals, to include results from pharmaceutical 
equivalence tests, quality control procedures for APIs and other ingredi-
ents, manufacturing process specifications and test failure reports. The 
next steps for technological production are still under way and include:
 adaptation of the Brazilian dossiers to the MISAU’s specifications;  ●
 training local personnel to the local production of the pharmaceu- ●
tical dossier; 
 assisting production for the drugs’ first three pilot batches, following  ●
production as well as commercialization of the products; 
 establishing a pharmacovigilance system.  ●
 In terms of pharmaceutical production equipment, 18 high-tech pieces 
have been procured internationally by  Fiocruz/ Farmanguinhos and 
donated by Brazilian cooperation. This included main production line 
equipment such as compression, coating and blender machines, packing 
equipment – blisters, labelling and capping machines – as well as quality 
and in-process control equipment – tablets’ hardness and dissolution 
testers, chromatography and centrifuges. Given the total absence of 
up-to-date manufacturing machinery in the infrastructures inherited 
from  Final  Farmacêutica , basic non-specific equipment such as water 
purification machines also had to be brought in. 
 The machines presently installed in the factory in Maputo have an 
estimated market value of US$4 million, with an additional list of equip-
ment worth approximately US$1 million to be procured and bought 
by 2017. All the machines were purchased by  Farmanguinhos/ Fiocruz 
through international tenders and donated to the government of 
Mozambique, including installation services and personnel training for 
its use and maintenance. SMM technical personnel were all trained in 
Brazil on the use of the specific machines, and on-site ongoing technical 
assistance is provided for specific manufacturing. 
 The company and the market 
 This section details a key – and often overlooked – aspect of the Brazil-
Mozambique collaboration to produce pharmaceuticals: the link to 
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South-South Collaboration: Mozambique 93
the market. A feasibility study was conducted in 2007 looking at the 
likely costs of setting up the factory in Maputo and its specific produc-
tion capacity for ARVs, but it failed to analyse the market conditions 
in Mozambique and in the wider Sub-Saharan region (Fiotec/Fiocruz, 
2007). 
 Mozambique’s pharmaceutical policy in the 1970s and 1980s focussed 
on procuring and using generic drugs, to extract the best possible value 
from its drugs budget (Barker, 1983). However, as Mozambique became 
after Independence one of the world’s largest recipients of health-
aid funds, international finance for drugs began to be handled, first 
through an externally managed Drugs Common Fund (Pavignani and 
Durão, 1999), and subsequently through an MoH-managed Sector Wide 
Approach common fund agreement (PROSAUDE). Currently, with the 
global push for AIDS fight and the introduction of anti-retroviral treat-
ment (ART) in 2003, the country is enjoying a considerable injection 
of AIDS funds, with anti-retroviral drugs procured in the international 
market by organizations such as the Global Fund, the World Bank and 
USAID. 
 In 2012, the national drugs market in Mozambique was estimated 
to be worth approximately US$140 million in terms of the value of 
drugs imported (COWI, 2012), which represented a drugs expenditure 
of US$5.55 per capita. Eighty-five per cent of the total market value 
was represented by public sector imports, mostly funded by external 
funds and donations, some of them managed by the local Ministry of 
Health through the sector budget support fund, PROSAUDE (CMAM, 
2011). In recent years public drugs expenditures have gone from 
US$78 million in 2004 to US$122 million in 2012 (Table 5.2), the 
increase being driven by in-kind AIDS drugs donations that rose from 
the original US$4 million to the current US$49 million in eight years 
(COWI, 2012). 
 As shown in Table 5.2, AIDS drugs represent the largest single item of 
the national public pharmaceutical expenditures, and enter the country 
exclusively as in-kind donations procured and managed directly by 
foreign organizations. Public funds pay for roughly a quarter of the 
overall public sector drug expenditures, with North-America-based 
organizations (USAID, Supply Management Systems and the Clinton 
Health Access Initiative) contributing to purchase 67% of all the public 
sector drugs procured in the country. In this respect, the local funding 
environment appears still to represent a critical limitation for phar-
maceutical production in Mozambique. Given the typical consumer’s 
limited ability to pay, and the relatively small size of the local private 
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94 Giuliano Russo and Lícia de Oliveira
sector, selling to the public sector is obviously the only way for local 
producers to go to scale and access a local market worth in excess of 
US$140 million. However, the lack of flexibility of the international 
drugs financing environment is pointed to by many as a key limiting 
factor for the development of local production of pharmaceuticals in 
the country; even if locally produced drugs were made available at 
competitive prices, the manner in which external funds for AIDS drugs 
are currently regulated would stand in the way of procuring, or offering 
preferential procurement terms to buy, locally produced drugs. As a side 
effect, free internationally procured ARVs also end up crowding out the 
local private sector, which is traditionally a key customer for locally 
produced goods (Herzer and Grimm, 2012; Rajan and Subramanian, 
2011). 
 Little consolidated data exist about the private pharmaceutical market 
in Mozambique. Some estimates put it at approximately US$20 million, 
calculated on the basis of the drugs value declared on the import 
documents submitted to the pharmaceutical department in 2012 
(COWI, 2012). Although 54 private importers are officially registered 
 Table 5.2  Public sector drug import value, by source and type of health 
programme (2012 US$ ) 
 Health programme 
and associated drugs 
 Internal and 
external funds 
managed by 
MISAU (drug 
pool and state 
budget) 
 In-kind 
donations  Total 
Hospital drugs 11,861,471 1,200,883 13,062,354
Primary care drug kits 8,708,824 0 8,708,824
Community health 3,870,588 7,217,900 11,088,488
STD and HIV-SIDA 0 48,750,977 48,750,977
TB 0 249,550 249,550
Malaria 0 24,124,599 24,124,599
Blood banks 967,647 0 967,647
Oral health 290,294 0 290,294
Surgical supplies 10,111,912 0 10,111,912
Laboratory supplies 2,497,000 0 2,497,000
Imaging devices and 
supplies
1,741,765 0 1,741,765
Total 40,049,500 81,543,908 121,593,408
 Source : CMAM, 2012. 
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South-South Collaboration: Mozambique 95
in Mozambique, a 2010 study found that the private sector is highly 
concentrated, with the four largest firms handling more than 50% of the 
drugs imported (Russo and McPake, 2010). 
 As for the regional market, according to some industry pundits (IMS, 
2012), with its 10.6% yearly growth rate by volume, Africa is the world’s 
fastest-growing pharmaceutical market after Asia, and is estimated to 
reach a value of US$30 billion next year. With specific reference to the 
ARVs market in the Southern African Development Community, the 
SMM business plan estimated in 2012 that a sufficiently homogeneous 
regional demand for ARVs existed for SMM to serve. Previous studies 
of the regional market (COWI, 2012) suggested that across the neigh-
bouring countries of Mozambique, Tanzania, Zambia and Zimbabwe, 
AIDS treatment lines were relatively similar and reliant on standard 
Lamivudine-Zidovudine-Nevirapine combinations. This would have 
implied access to sizeable market for HIV/AIDS drugs of approximately 
6 million treatment doses per year across the four countries. However, 
there is little recognition in SMM’s viability study and subsequent busi-
ness plans of the complexity of those markets, of the possible regional 
and international competition to be faced, as well as of their regulation 
and of the role played by national governments in supporting the local 
industry. 
 Currently, SMM’s business plan expects to sell its products in the 
Mozambican market in the short term, particularly to the NHS. It aims to 
sell into the regional pharmaceutical market only in the medium term, 
once the required certifications are obtained to allow the firm to compete 
in international tenders (COWI, 2012; SMM and Farmanguinhos, 2013). 
SMM unit prices, listed in Table 5.3, reflect the initial production costs 
calculated on the basis of APIs imported from Brazil. As production goes 
to scale and APIs are bought in from the global competitive market, SMM 
is projecting lower selling prices reflecting the lower API costs. SMM also 
enjoys most of the standard preferential policy interventions already 
adopted in the East Africa Community: an ad hoc tax exemption regula-
tion on imported APIs and other manufacturing product and a prefer-
ential buying regime from the government, according to which, when 
procuring drugs for the National Health care Service, the National Drugs 
Acquisition Agency is required to give preference to locally produced 
drugs as long they are no more than 15% more expensive than the prod-
ucts of their international competitors. 
 The prices listed in Table 5.3 represent SMM’s factory gate selling prices 
for public procurement; a comparison with the Management Science 
for Health international median reference prices for procurement is 
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also shown. It is worth noting that although in the same price range, 
SMM prices for ARVs, particularly those involving Lamivudine, appear 
to compare less favourably with international reference prices than do 
those for the other generic drugs (Table 5.3). 
 The factory’s business plan predicted wholesale selling price levels at 
which the factory would break even, on the basis of the cost structure 
model used for the production of ARVs in Brazil’s state pharmaceutical 
factories adapted to the Mozambican context (Pinheiro et al., 2006). 
Although SMM drugs face higher costs because of Mozambique’s burden-
some import duties on non-API production materials, as well as high 
maintenance costs, according to the factory’s business plan these will be 
offset by lower capital costs and smaller operating margins, typical of a 
state-owned company (MacDonald and Yamey, 2001). 
 Table 5.3  Unit price for selected SMM drugs (US$) 
 Product 
 Package 
(Units) 
 SMM’s selling 
price to the 
NHS (US$) 
 MSH* 
median 
price (US$) 
Amoxicillin caps 500 mg cx 
c/500
500 0.0502 0.0313
Glibenclamide tab 5 mg cx 
c/500
500 0.0035 0.0042
Hydrochlorothiazide tab 50 
mg cx c/500
500 0.0047 0.0050
Metronidazole tab 250 mg cx 
c/1000
1000 0.0116 0.0061
Prednisone tab 5 mg cx c/500 500 0.0077 0.0108
Lamivudine 150 mg 60 
tab – 3TC
60 0.1152 0.0508
Lamivudine 150  + Zidovudine 
300 mg 60 tab
60 0.4354 0.1714
Lamivudine 150 mg + 
Zidovudine 300 mg + 
Nevirapine 200 mg
60 0.2754 0.1654
Lamivudine 30 mg + 
Zidovudine 60 mg + 
Nevirapine 50 mg
60 0.1015 0.0726
Nevirapine 200 mg 60 
tab – AD
60 0.0849 0.0611
 Note: *Management Science for Health Drug Price Database. 
 Source : SMM. 
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 According to the factory’s business plan, SMM furthermore will be 
able to sell its products at prices comparable to those from the inter-
national market, thanks to savings in the initial investment in infra-
structures and equipment, donated by the Brazilian cooperation, and in 
national transport charges and taxes, which are particularly favourable 
to business in Mozambique, since the original tax rate on chemical prod-
ucts was scrapped. In comparison to the typical cost structure for ARVs 
(Pinheiro et al., 2006), SMM’s production costs will be largely driven 
by active pharmaceutical ingredients’ (APIs) import prices, and less by 
taxes, profit margins, research and development and local production 
mark-ups (SMM and Farmanguinhos, 2013). 
 The South–South collaboration in context 
 ‘Emerging donors’ and ‘South-South cooperation’ are terms usually refer-
ring to providers of development assistance and forms of cooperation 
that have recently become prominent in the international aid architec-
ture, due to a recent expansion in resources allocated to development 
cooperation with poor countries (Manning, 2006). Thanks to their recent 
economic growth, emerging economies like China, India and Brazil 
are boosting their cooperation programmes (Brautigam, 2009; Cabral, 
2010), and according to one estimate, the volume of aid from emerging 
donors reached between US$9.5 billion and US$12 billion in 2006, 
corresponding approximately to 8–10% of total aid flows. The recent 
literature on the subjects shows that some common features among 
these emerging aid players are discernible. One of the most salient is the 
emphasis on horizontal (South-South) cooperation between developing 
countries and the principle of non-interference in the internal affairs 
of recipient countries. Related to this aspect, emerging donors tend to 
have no policy-related conditionality, such as standards of governance 
and macroeconomic requirements, and fewer procedural conditions, 
such as counterpart funding or separate bank accounts, relative to tradi-
tional donors. More controversially, there is a more evident and openly 
acknowledged association between commercial interests, geo-strategic 
objectives and development cooperation than is the case for traditional 
donors (Kragelund, 2008). 
 Brazil’s overall cooperation programme is still relatively small, esti-
mated to be worth between US$350 million and US$1 billion per year, 
with a substantial component of support to international organizations 
and humanitarian assistance and a smaller proportion directed to tech-
nical cooperation projects (IPEA, 2011). South-South relations play an 
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important part in Brazil’s strategy of diversification of diplomatic and 
economic relations, and technical cooperation provides an expedient 
way of taking forward such an agenda. Brazil’s South-South technical 
cooperation programme has as key features the emphasis on exchange 
of experiences between equal partners (or ‘horizontal cooperation’, as 
it is usually referred to), respect for the partner country’s sovereignty 
and non-conditionality of support, with a dominant but not exclusive 
geographical focus on Latin American and Portuguese-speaking African 
countries and on the agriculture, education and health sectors (Cabral, 
Russo and Weinstock, 2014). 
 Government figures put the value of Brazilian technical health 
cooperation at approximately US$12 million between 2006 and 2009. 
However, recent independent reports estimated that Brazil spent 
between US$12 million and US$14 million in technical health coop-
eration projects in Portuguese-speaking African countries alone for the 
same period (Russo, Cabral and Ferrinho, 2013). Brazil’s health-sector-
specific characteristics and claimed principles suggest some important 
departures from the ways in which development cooperation has been 
traditionally practised. A key feature of Brazil’s cooperation is that it is 
openly driven by foreign policy goals, and development cooperation is 
seen as instrumental in promoting Brazil’s image and interests abroad. 
Brazil openly adopts the notion of ‘health diplomacy’ for its health 
projects (Roa and Baptista e Silva, 2015), implying that health devel-
opment cooperation can be informed by international health objec-
tives, following the recognition that national health problems need to 
be dealt with in the global health arena. Brazilian cooperation officials 
also dispute the use of the term ‘aid’ to define their work, as that would 
impose industrialised countries’ ‘world views, agendas and pre-defined 
objectives’ (Buss, 2011). Instead, ‘horizontal partnership’ is Brazil’s 
preferred terminology to indicate the wish to draw on principles of non-
interference and mutual advantage. Brazilian projects are also claimed to 
promote ‘structural cooperation in health’, a concept defined by some 
as building local capacity for development (Buss, 2011). It begins from 
the premise that health cooperation should focus on integrating human 
resources for health and institutional development, developing local 
capacity to avoid dependency from foreign expertise and promoting 
internal collaboration between local health institutions to elaborate 
their own health system development agenda. 
 As for the relation between national business interests and cooperation 
goals, Brazilian cooperation in health openly claims to be inspired by 
the concept of the ‘health-industrial complex for health development’, 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
South-South Collaboration: Mozambique 99
according to which individual countries need to invest in the national 
health care industry and R&D capacity if they want to develop their 
health systems (see also Chapter 9). Such an emphasis on self-sufficiency 
is also aimed at avoiding costly dependency on foreign health care tech-
nologies (Gadelha, 2006). This approach happens to be particularly rele-
vant for the pharmaceutical and biotechnology business in Brazil, as, 
besides being worth approximately US$24.5 billion in 2012, these two 
sectors are considered to be instrumental in the implementation of the 
Brazilian Unified Healthcare System’s objectives of free and equitable 
access to health care services (Gadelha et al., 2013). Brazil’s position on 
HIV/AIDS drugs appears in line with its support for strong government 
involvement in the provision of health care services, underpinned by 
a constitutional framework that establishes a universal citizen right 
to health and places a duty of health care provision on the state. The 
growing roles of the Brazil’s Ministry of Health research and training 
agency,  Fiocruz , and its pharmaceutical arm,  Farmanguinhos , influential 
government institutions behind the development of the ARV industry 
in Brazil as well as in the factory project in Mozambique, are exemplifi-
cations of the strength of this paradigm of state-led health development 
(see Chapter 9). 
 Local production of pharmaceuticals: issues raised 
by the case study 
 In contrast to the experiences described in other chapters, the Maputo 
factory story provides a case study of an attempt to kick-start, through 
an innovative South-South partnership, pharmaceutical production in 
a country that previously had none. Our narrative of development and 
implementation of the project has shown the key role of the innovative 
South-South collaboration for the nascent pharmaceutical industry in 
Mozambique in terms of both financial subsidy and technical support. 
However, while the technical collaboration with Brazil remains highly 
positive, the link to health markets in Mozambique seems to have been 
a major problem, as the health-industry link so fundamental in the 
Brazilian pharmaceutical development experience seems to have worked 
less well here, at least for these early years. 
 The experience of the Brazil-Mozambique collaboration details the 
challenges of starting up such a complex enterprise from scratch, in an 
environment often lacking the basic infrastructural pillars for industry 
development. Human resources were identified as the single most 
important bottleneck for SMM development. As the majority of the 
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staff recruited locally had to be sent for training abroad, some of those 
employed have been poached by competing businesses in wholesaling 
and retailing, and highly specialized positions in the factory are still 
covered by expatriate staff. Although personnel with middle-manage-
ment skills should be already supplied by the local labour market, expe-
rienced executives with a track record of management in comparable 
industries are acutely lacking in Mozambique, given the country’s rela-
tively recent history of industrial development. 
 Mozambique’s particular industrial environment was recognized 
as another factor hampering the development of the pharmaceutical 
factory. In comparison to other African countries with a more established 
industry, Mozambique seems to be lacking a critical mass of suppliers, 
products and services needed for the development of a competitive 
pharmaceutical business. All the primary products needed for Maputo 
factory’s manufacturing are, up to now, imported from Brazil; all the 
basic maintenance and technical services are contracted to South African 
firms, and resorting to lower cost Indian and Chinese equipment has 
not been an option, given the limited equipment maintenance services 
provided by such suppliers in Mozambique. 
 Strengthening the government’s current quality control of pharma-
ceutical manufacturing processes and final products is needed, as this 
was also reported to be a hurdle for the long-term development of phar-
maceutical manufacturing in Mozambique. A lack of quality regulation 
 de facto allows competitors to employ cheaper substandard machinery 
in pharmaceutical production and produce substandard – and, crucially, 
cheaper – generic products. The factory’s case study shows that lack 
of effective quality regulation ends up benefitting those importers of 
non-branded generics for whom an ability to cut costs and offer wildly 
discounted generics represents the core of their market strategy in 
Mozambique. 
 This experience, however, also identifies a path to local industry 
development based on foreign assistance but also on national govern-
ments’ willingness to support local procurement of drugs (Russo and 
Banda, forthcoming). As is already well known in those African coun-
tries with a more established pharmaceutical industry, this case study 
reaffirms that only through preferential pricing and reduced profit 
margins can local medicine production be competitive in Mozambique, 
but that the spill-over information-related benefits from local produc-
tion can be substantial for epidemiological surveillance as well as 
for governments’ price negotiations (Russo et al., 2014). However, a 
number of points of discussion are raised by this case study on the 
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feasibility, sustainability and opportunity of local pharmaceutical 
production in Africa. 
 At the time of writing, the factory’s sustainability after the likely end 
of Brazil’s support in 2017 remains an issue. Brazil’s original objective 
was to provide MISAU with enough production capacity to carry out its 
medicine policies; however, the GoM’s appointment of IGEPE, together 
with the conspicuous absence of references to the factory in MISAU’s 
policy documents, seem to signal a more pronounced interest in the 
factory’s contribution to the country’s industrial assets rather than to 
its public health goals. To this respect, the GoM will have to decide 
whether it is still in its interest to keep the factory as a public enterprise, 
or to attempt a privatization with a degree of public sector involvement, 
in the way similar experiences developed in Uganda and South Africa 
(Rajagopal, 2013; World News, 2013). 
 Finally, this case study raises questions about the suitability of foreign 
health policy and production models to the African context. If Brazil’s 
original plan was to help Mozambique to replicate its own domestic 
experience in the AIDS fight and in pharmaceutical production, the 
implementation of this factory project exposed Brazil’s limited famili-
arity with the development cooperation conundrum, but also the rele-
vance of the differences between the two contexts (Russo et al., 2014). If 
some of the holdups in the project could be attributed to the relative lack 
of experience of Brazilian civil servants borrowed from their domestic 
duties to implement a cooperation project in the African continent, 
this case study probably shows that solutions that have proved effective 
elsewhere are hard to replicate in Mozambique for more than just one 
reason. 
 First, there is evidence from this experience that MISAU’s engagement 
with the project and enthusiasm for using the factory as an implementa-
tion tool for its own national drug policy has not been the same as that 
which motivated the creation of public pharmaceutical laboratories in 
Brazil in the past decades (Russo et al., 2014; Flynn, 2010). Second, in 
stark contrast to what happens in the Brazilian pharmaceutical market, 
the majority of medicines in Mozambique are imported and paid for by 
the international community, so it is easy to understand why the govern-
ment of Mozambique failed to see short-term gains in acquiring national 
production capacity and paying for something – ARV drugs –already 
provided for free. Finally, the human capital and manufacturing envi-
ronment fundamentals that made possible the development of the 
pharmaceutical industry in Brazil are, in all likelihood, not yet in place 
in Mozambique. As a result, setting up a factory project already tested 
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back home became highly cumbersome in a context where lack of skills, 
funds and services is the norm rather than the exception (Cabral, Russo 
and Weinstock, 2014). 
 Conclusion 
 Contrasting with other chapters in Part I that discuss very different 
experiences in African countries with a more established pharmaceu-
tical industry, the present chapter has presented an original experience 
of developing local manufacturing from scratch through collaboration 
between two national governments. By describing the decade-long 
process through which Brazil and Mozambique cooperated to set up 
 Sociedade  Moçambicana de  Medicamentos in Maputo, we aimed to illustrate 
the complexity of shoring up such an ambitious development coopera-
tion project. Our analysis suggests that national and regional demand 
may justify SMM’s production of ARVs and other generic drugs, but that 
public purchase of drugs remains essential to guarantee the sustaina-
bility of the business. We have also highlighted the differences between 
the two settings, Mozambique and Brazil, and have drawn attention to 
the possible risks involved in putting emphasis on the development of 
an enterprise without linking up adequately with local pharmaceutical 
markets. We believe that such an experience offers an insight into the 
complexities of developing pharmaceutical manufacturing operations in 
Sub-Saharan Africa, and into the options that the international commu-
nity has to support it. The hope is that this will contribute to advancing 
the debate on local pharmaceutical manufacturing and on paths to its 
development. 
 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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 Introduction 
 African countries, particularly the smaller ones, suffer from various 
disadvantages that prevent local producers from serving a substantial 
proportion of their domestic markets for pharmaceuticals. How to take 
care of these disadvantages to promote local production and to reduce 
dependence on imports is an important political and economic issue 
in Africa today. Most of the countries with developed industries have 
used foreign investments and technology in the process of their devel-
opment. Is a similar trend likely in Africa? Are foreign companies likely 
to invest there to undertake manufacturing of pharmaceuticals? Can 
they be induced to do so? The objective of this chapter is to understand 
the prospects for foreign direct investment (FDI) in the pharmaceutical 
industry in Sub-Saharan Africa, particularly in smaller countries such as 
Ghana. 
 The foreign firms which are active in Africa can be broadly classified 
between the multinational corporations (MNCs) and the Indian generic 
companies. These two types of firms are quite different in terms of back-
ground and behaviour, and in the next section some of these differences 
are briefly outlined. The environment for pharmaceutical production 
and manufacturing is changing quite rapidly, both in Africa and abroad, 
and that is having an impact on the behaviour of both the MNCs and 
the Indian companies. The chapter first focuses on the MNCs and 
discusses the implications for the pharmaceutical markets in Africa. It 
then focuses on the Indian companies. We will see in the discussion that 
follows that on their own initiative, Indian companies may not be very 
 6 
 Can Foreign Firms Promote Local 
Production of Pharmaceuticals in 
Africa? 
 Sudip  Chaudhuri 
OPEN
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
104 Sudip Chaudhuri
keen to undertake investments for manufacturing in Africa. But given a 
conducive environment, they may not be averse to initiating manufac-
turing in Africa on a greater scale. The final section of the chapter takes 
up the case of Ghana, a relatively small African country. After a brief 
introduction to the structure of pharmaceutical market and industry in 
Ghana, the chapter analyses some policies which may be undertaken to 
promote local production, particularly in order to induce foreign firms 
to invest in Ghana. 
 MNCs, generics companies and the international 
pharmaceutical industry 
 Traditionally, pharmaceutical companies are classified between a small 
number of big MNCs that do research and development (R&D) for new 
drugs and aim to get these patented, and a large number of smaller 
generics companies that manufacture products that are not patented 
or products for which patents have expired. The MNCs are exception-
ally large in size. The head offices are located in developed countries, 
mainly in the US, the UK, Switzerland, France, and Germany. They 
operate all over the world. The largest pharmaceutical MNC, Novartis 
(headquarters: Basel, Switzerland) reported US$46 billion in pharma-
ceutical sales in 2013. Each of the other top five MNCs – Pfizer (US), 
Roche (Switzerland), Sanofi (France), Merck (US) and GlaxoSmithKline 
(UK) – individually had sales worth more than the entire pharmaceutical 
market of the Middle East and Africa in 2013. 1 
 The patent system and marketing power are at the root of the world-
wide dominance of the MNCs. Naturally, for the products patented by 
the MNCs, they enjoy a monopoly status. They also use an elaborate 
marketing infrastructure to maintain dominant market shares even after 
patents expire. Even when the product is protected through patents, the 
MNCs promote their drugs under brand names, that is, through trade-
marks, rather than under generic names, which are commonly used in 
scientific literature. They continue using these brand names and try to 
take advantage of continuing brand loyalty when generic companies 
enter the market after the expiry of patents. 
 Traditionally MNCs have relied for their growth on patented drugs, 
and have focussed mainly on the large developed country markets. 
The largest pharmaceutical market is in US (US$343 billion), and this 
together with Western Europe (US$241.4 billion) and Japan (US$129.5 
billion) accounted for about two-thirds of the global pharmaceutical 
market of US$1,052.1 billion in 2012 (BMI Espicom, 2013). 
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 Like most other countries in the world, India after independence 
initially recognized product patent protection in pharmaceuticals, and 
the MNCs dominated the Indian market too. However, the abolition of 
product patents in 1972 eliminated the monopoly status that the MNCs 
enjoyed until then. Indian firms started manufacturing and marketing 
the latest drugs and were able to dislodge the MNCs from their posi-
tion of dominance in the domestic market. India became self-reliant in 
drugs. The country furthermore emerged as a major player in the global 
pharmaceutical industry, receiving worldwide recognition as a low-cost 
producer of high-quality drugs. India now supplies medicines not only 
to other developing countries such as those in Africa but also to devel-
oped countries such as the United States. 
 The Indian pharmaceutical industry is highly heterogeneous. Most 
of the firms are small in size and operate only in the domestic market 
or in other developing countries. But some of the companies are large 
and not only compete with these small firms in these markets but also 
are active in regulated markets in developed countries. Two companies 
from India – Sun Pharmaceuticals (rank 48) and Ranbaxy (rank 50) – are 
among the 50 largest pharmaceutical companies in the world. 2 With 
the acquisition of Ranbaxy in 2014, Sun Pharmaceuticals will make 
a significant jump in the rankings. Other major Indian companies 
include Dr Reddys Laboratories, Cipla, Lupin, Glenmark and Cadila 
Healthcare. The larger Indian companies not only manufacture drugs 
in India and export these to different parts of the world. They have also 
started acquiring companies abroad to expand their manufacturing and 
marketing operations. 
 The changing marketing strategy of MNCs in Africa 
 Due to colonial or other links, some of the MNCs, for example 
GlaxoSmithKline (Glaxo as the firm then was known), had offices in 
some African countries. But as the MNCs started focusing more on 
the larger and more lucrative developed country markets, the African 
markets, especially in small countries, became less and less important 
for them and they started closing down their offices. Of course, their 
products were still available, but these imports were managed by their 
agents – local importers/distributors. 
 In recent years, however, the MNCs are returning to Africa and are 
focusing more on the subcontinent. Both push and pull factors are in 
operation. The most important push factor is that developed country 
markets have become less attractive, and the main pull factor is the 
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better growth prospects in Africa (Mckinsey and Company, 2013; 
Tempest, 2011). 
 The cost of developing new drugs has gone up, but the introduc-
tion of new patented drugs in the market has slowed down. Earlier, as 
mentioned above, because of the steady flow of new patented drugs, 
the MNCs focussed mainly on the large markets for patented medicines 
in high-income countries. But in view of the declining productivity of 
R&D, MNCs can no longer afford to ignore the generics markets. Their 
turn to generics markets includes not only the patent-expired markets 
in the high-income countries but also the generics markets in emerging 
economies. The centres of economic activity are changing, with most 
of the growth expected to come from emerging markets (Mckinsey and 
Company, 2013). 
 Among emerging markets, Africa is still relatively small. The combined 
size of the market of the top ten African countries is about US$14 
billion, compared to US$343 billion in the US and US$129 billion in 
Japan (Table 6.1). However, the future growth is expected to take place 
in emerging countries, including in Africa, rather than in the developed 
countries. It has been estimated that between 2012 and 2018, major 
developed country pharmaceutical markets will remain stagnant (as in 
Japan and the UK), increase marginally (as in the US), decline margin-
ally (as in Germany and France) and decline significantly (as in Italy and 
Spain). In contrast, the top ten African countries are expected to grow 
at 11% annually (Table 6.1). Quite understandably, therefore, while 
preparing their strategies for future, the MNCs are focusing more on the 
emerging countries, including in Africa. 
 The major drivers of growth in pharmaceutical markets in Africa have 
included increased disease burdens, particularly HIV/AIDS. The private 
markets have been expanded by developments in health insurance 
schemes, and some countries’ health systems have seen large invest-
ments in public health. Political stability and rapid economic develop-
ment, improving business climate, a maturing regulatory environment 
and increased confidence in generic products have all also contributed 
to market expansion (African Union and UNIDO, 2012; Mckinsey and 
Company, 2013). 
 The changes are having a variety of different impacts on the behav-
iour of the MNCs in Africa. The MNCs are no longer relying only on 
their agents. They have started opening offices and staffing these with 
their own employees. Marketing expenses for brand promotion have 
risen. To push up their sales they have also started offering credit facili-
ties. Another notable development is that the MNCs are toning up their 
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distribution networks. They have started using the services of special-
ized supply chain organizations such as Imperial Health Sciences. The 
latter has operations in South Africa, Kenya, Ghana, Nigeria and Malawi, 
where medicines are received, stored and distributed in countries across 
Africa. 
 Perhaps the most significant development of all is that MNCs have 
started introducing new brands to compete in the generic markets. As 
mentioned above, when MNCs market new patented drugs, they sell 
these in brand names and continue to do so even after the patents 
expire. The patented drugs in monopoly markets are high priced. For 
patent-expired products too, the MNCs participate in the higher end of 
the market that has more limited competition. Even after the patents 
expire, the firms typically continue to use the same brands and continue 
to charge a very high price. 
 This strategy on the part of the MNCs has, in fact, helped the Indian 
generic companies. The large Indian companies typically adopt the 
strategy of charging a price lower than that of the MNCs to enter and 
 Table 6.1  Anticipated trends in global pharmaceutical markets 
Country
 Market size 
 2012 
(US$ billion) 
Estimated 
market size 
2018 
(US$ billion)
Anticipated 
annual growth 
rate*, 
2012–2018 (%)
Emerging markets
China 82 164 12
Russia 22 39 10
India 16 28 10
Brazil 27 39 7
Africa** 14 26 11
Developed markets
US 343 360 1
Japan 129 129 0
Germany 49 47 –1
France 43 41 –1
UK 38 38 0
Canada 26 25 –1
Italy 28 22 –4
Spain 23 16 –6
 Note: * Compound annual rate of growth 
 ** South Africa, Algeria, Egypt, Morocco, Tunisia, Sudan, Nigeria, Libya, Ivory Coast and 
Kenya. 
 Source : Mckinsey and Company, 2013. 
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grow market share in the patent-expired products. Armed with lower 
prices and active brand promotion, Indian companies such as Cipla, 
Ranbaxy, Sun Pharmaceuticals, Cadila and Glenmark have been able to 
dominate the markets in many products. 
 Particularly for Sub-Saharan African countries, India is the predomi-
nant supplier. In Tanzania, for example, the Indian generics company 
Cipla was the second-largest company in the retail market in 2010 with 
a market share of 16%, next only to the local firm, Shelys (21% market 
share), and ahead of MNCs such as Novartis (10%) and GSK (6%). Among 
the other notable Indian participants are companies such as Ranbaxy 
(8%), Sun Pharmaceuticals, Unichem Laboratories, Cadila Glenmark 
and Ajanta Pharma (Frost and Sullivan, 2010: 151; 2012: 81–83). As 
in most African countries, local firms in Tanzania manufacture a rela-
tively simple list of formulations such as simple antibiotics, cough and 
cold preparations, analgesics antipyretics, sedatives, nutraceuticals, 
anthelmintics and anti-malarials (see Chapter 3; Chaudhuri et al., 2010). 
For technologically more sophisticated formulations, the competition is 
mainly between the MNCs and the Indian companies. 
 The MNCs are now increasingly trying to make their presence felt in 
these generic markets. They are reluctant to dilute their innovator brand 
by lowering the price to compete against generic products. There is a 
brand loyalty associated with innovator products and there is a price-
insensitive market segment where MNCs continue to sell despite high 
prices and despite the availability of cheaper generic products. To enlarge 
their market, the MNCs are introducing new brands and selling these at 
prices significantly lower than their innovator brands. The dual-brand 
strategy enables them to be present not only in the price-insensitive 
segment of the market but also in the price-sensitive segment. 
 The most active MNC in this game is GSK. The innovator brand for 
their anthelmintic drug, albendazole, is Zentel. They have introduced 
a new brand for the same product, named Alzental. Another example 
is the antibiotic amoxicillin/clavulanate. The GSK innovator brand is 
Augmentin. They also sell the same product in the brand name Clavulin 
to compete against similar-sounding generic brands such as, for example, 
Clavam of India’s generics company Alkem. These MNC generic brands 
are priced significantly below the innovator price, often 50% or less. 
These are still priced above the brands of generic companies. But with 
the price differential much smaller and their better reputation, the MNCs 
hope to prevent the slide in their sales in the generics markets. 
 Now that they have started competing on prices, the matter of costs 
has become important. Another important trend observed is that the 
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MNCs are trying to get their generic products manufactured in cheaper 
locations. The Ghanaian company LaGray has entered into an agree-
ment with Sandoz, the generic arm of Novartis. The former will manu-
facture products to be marketed in their brand names by the latter. 
India offers an even cheaper location. MNCs such as GSK, AstraZeneca 
and Abbott have entered into supply agreements with Indian compa-
nies such as Dr Reddys, Aurobindo, Cadila Healthcare and Torrent. 
Dr Reddys, for example, will supply about 100 branded formulations to 
GSK for marketing in different emerging markets including in Africa. 
These deals enable the MNCs to get access to low-cost reliable products 
without undergoing the lengthy process of getting regulatory approvals 
in different markets and without incurring any capital expenditure for 
setting up manufacturing plants. The Indian companies gain by having 
access to the formidable marketing resources of the MNCs (Chaudhuri, 
2012). 
 However, what these trends indicate is that although MNCs are 
targeting African markets, they are unlikely to make any significant 
investments to manufacture drugs in Africa, at least not in the near 
future. 
 Indian generic companies in the African market 
 European countries, mainly France, Germany and Switzerland, are 
the most important suppliers for some relatively large North African 
countries such as Algeria, Morocco and Egypt (UNCOMTRADE). But 
for Sub-Saharan Africa, India is the predominant supplier of medi-
cines. As Table 6.2 shows, in 2012 India contributed more than 50% 
of the formulations imports in Uganda and Mozambique and more 
than 40% in Nigeria, Ghana and Rwanda. Its share was also substan-
tial in countries such as Ethiopia, Tanzania and Zimbabwe. If we could 
exclude the imports of high-priced patented medicines and focus only 
on generics, India’s contribution to Africa would be much larger than 
Table 6.2 suggests. Where drugs are purchased from multiple sources, as 
for example for ARVs, India has turned out to be the dominant supplier, 
accounting for more than two-thirds of Africa’s imports (Chaudhuri, 
2008). 
 Indian generic companies exporting medicines to Africa can be clas-
sified into two broad categories: those which are active also in the regu-
lated markets in developed countries such as the United States, and those 
which are not yet present in these markets. The larger and more reputed 
companies belong to the first category. These more dynamic Indian 
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generic companies have been more interested in the patent-expired 
markets in high-income countries such as the US and in Europe because 
of the larger markets and better prices realized. Prices achieved are higher 
in these markets because regulatory requirements to enter these markets 
are stricter and so entry is more difficult. The Indian companies active 
in the African markets also primarily target the markets where entry 
barriers are higher and hence competition is less strong. These compa-
nies promote their products through brands and their main competitors 
are the MNCs (and also generics companies from other countries). As 
mentioned above, these companies often try to enter and grow in these 
markets by charging a price lower than that of the innovator MNC. The 
 Table 6.2  Indian share of pharmaceutical formulations imports into Africa, 
2012 
Country
 Total imports, 
 US$ million 
Imports from 
India (%)
Uganda 204 57.6
Mozambique 50 52.6
Nigeria 263 43.7
Ghana 126 42.7
Rwanda 55 40.4
Ethiopia 154 39.3
United Rep. of Tanzania 161 36.8
Zimbabwe 170 36.6
Mauritius 103 34.7
Burundi 42 33.3
Cameroon 168 25.0
Botswana 124 23.1
Niger 44 21.3
Côte d’Ivoire 259 19.1
Madagascar 49 18.9
South Africa 1,890 15.9
Namibia 142 13.1
Mauritania 15 10.4
Togo 68 6.2
Senegal 167 4.5
Mali 142 4.1
Morocco 360 3.6
Algeria 1,879 2.6
Cabo Verde 8 1.3
Egypt 1,498 0.5
Total (25 countries) 8,139 13.7
 Source : Calculated from UNCOMTRADE database ( http://comtrade.un.org ). 
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smaller Indian companies are more active in over-the-counter medicines 
and in markets for simple products where they compete mainly against 
the local manufacturers and other smaller generic companies. 
 The changing composition of Indian companies 
 The composition of Indian generic companies is however changing in 
Africa. With improvements in the regulatory environment in Africa, 
the not so quality-conscious Indian companies are increasingly finding 
it difficult to operate there. Allegations have been made from time to 
time that some Indian companies have taken advantage of the regula-
tory environment in India and in Africa to export poor-quality drugs. In 
fact, it has been a very common complaint in Africa that India has not 
been taking initiatives to regulate the quality of drugs exported. This is 
now changing. Due to the efforts of the government in India and also 
some steps taken in some African countries, the quality standards have 
improved. Most African countries, for example, do not permit imports 
into their countries from India without a Certificate of Pharmaceutical 
Product (COPP). This is given by the drug control administration in 
India to units that qualify for the WHO-GMP standard. This standard is 
stricter than Schedule M, the Indian version of GMP, and hence exporters 
are required to satisfy higher standards than in the domestic market. 
 Like the MNCs, the more serious Indian players are also getting more 
involved in Africa. Here too both push and pull factors are in operation. 
An important push factor arises from the fact that earlier expectations 
of huge gains in the patent-expired markets in large markets such as 
in the United States have not materialized. Those markets have turned 
out to be very competitive, despite some value-added market segments 
where competition can be limited and where gains are still substantial. 3 
However, with the declining R&D productivity and a reduced flow of 
new patented drugs in the market, the MNCs are aggressively trying to 
make the entry of generic companies more difficult in these markets. 
 The better regulatory environment in Africa has improved the attrac-
tiveness of the market for the larger Indian companies and is acting as 
an important pull factor there. Perhaps more important is the antici-
pated future growth in the pharmaceutical market in Africa. The African 
market is still relatively small for Indian companies. Africa accounts 
for about 15% of India’s exports (Table 6.3). But Africa is an expanding 
market for India. The growth of India’s pharmaceutical exports has been 
quite spectacular, and Africa has been able to increase its share from 
about 10% in 1994–95 to 15% in 2011–12. The growth of the African 
market has in fact been faster than all other regions except America 
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(Table 6.3). In 1994–95, just Nigeria and Kenya accounted for about 
50% of India’s exports to Africa, and the share of top five countries was 
nearly three-quarters of the total. However India’s exports now are more 
diversified. Among the countries which are relatively more important 
are Ghana, Benin, Sudan, Angola, Malawi and Cameroon. 4 
 Are Indian companies likely to invest in manufacturing in Africa? 
 It is clear that Indian companies will continue to play a very active role 
in the African markets. Indeed, because of the factors mentioned above, 
they are likely to expand their operations there. Some Indian companies 
have already been actively involved in foreign direct investments (FDI) 
in Africa. Notable examples are Cadila in Ethiopia, Cipla in Uganda and 
South Africa and Ranbaxy in Nigeria. Other Indian companies too may 
be involved in the future in setting up manufacturing plants in Africa. 
But are Indian companies in general likely to be involved in any signifi-
cant scale in investing in Africa? R Modi, chief of the Indian company 
Cadila, mentioned during his presentation at the African Pharmaceutical 
Summit in Hammamet, Tunisia, on 23–24 September 2013 that profit 
has not been the main motivation for Cadila’s investments in Ethiopia. 
It is possible that beyond narrow financial reasons, some Indian compa-
nies will invest in Africa. But if Africa is to benefit in any significant 
way from Indian companies to further develop the industry there, what 
is required is more systematic investments. Unless Indian companies 
find Africa commercially attractive, it will be difficult to sustain such 
investments. 
 Table 6.3  India’s Pharmaceutical exports 
1994–95 1994–95 2011–12 2011–12
(Rs million) (%) (Rs million) (%)
Europe 10,663 42.4 90,964.35 29.6
America 3,661 14.6 90,147.29 29.3
Asia 7,941 31.6 77,886.87 25.3
Africa 2,676 10.7 45,280.45 14.7
Oceania 182 0.7 2,949.168 1.0
Others 0 0 368.29 0.1
Total 25,123 100 307,596.4 100.0
 Source : India’s Directorate General of Commercial Intelligence and Statistics (DGCI&S) 
trade data, accessed from the ‘India Trades’ database of the Centre for Monitoring Indian 
Economy. 
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 Unless the policy environment changes in Africa, the indications are 
that Indian companies in general will continue to find exporting a better 
option than investing in Africa. The main reasons are the following. 
 Perhaps most importantly, Indian companies essentially face a free 
trade regime in Africa. Some countries impose tariffs on imports of 
finished formulations. Some countries have a restricted list, as in Ghana, 
as discussed below. But in general, imports are not otherwise controlled 
or prohibited. This implies that from the Indian firms’ point of view, it 
is easier to export than to undertake direct investments. Export activity 
does not involve huge investment, nor is it risky. Lately, as just discussed, 
African countries are trying to improve their drug registration and regu-
latory systems, but traditionally it has been very easy to enter most of 
the African markets. 
 The most common model followed by Indian firms is for the Indian 
exporters to tie up with local importers/distributors. In some African 
countries, this trade is dominated by people of Indian origin, so that 
linking up with traders is not a difficult proposition in these countries. 
Again in comparison to China, the main competitor in Africa, India 
has the advantage of more exposure to the English language, which is 
understood and used in many African countries. The main role of the 
Indian company is therefore restricted to getting the product registered 
and manufacturing and supplying to local partners. This hardly requires 
much investment: Indian companies do not create separate plants for 
the African markets. They use their existing capacity – often excess 
capacity – for the purposes. It is also practically riskless. Many exporters 
insist on advance payment. Even where the medicines are supplied on 
credit, at worst the Indian company will lose money for that consign-
ment, and then they can stop supplying medicines in the future. 
 Investments abroad, on the other hand, involve more risks. It is very 
important for foreign investors to be assured of the safety of their invest-
ments. Africa is now politically much more stable. But foreign investors 
seem to expect some proactive steps on the part of the government to 
instill confidence that their money will be safe and that, if necessary, 
they can take money out of the country. There are also risks related to 
volatility of foreign exchange rates. Perhaps most important, the local 
partnerships required for direct investments carry higher risks. Export 
activities of Indian companies are carried out through local partners, as 
mentioned above, and in such cases the roles are clearly defined and risks 
are fewer. In case of joint ventures, however, the success of the company 
will depend much more on the local partners. The question of reliability 
of partners becomes more important in the case of investments abroad, 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
114 Sudip Chaudhuri
since substantial investments would be involved and it is not easy to get 
rid of undesirable partners. 
 It follows that it is still quite a challenge to undertake manufacturing 
activities in Africa. Most of these countries suffer from various disadvan-
tages, discussed in the preceding chapters. They include lack of technical 
know-how and trained manpower in the local African labour markets 
and the low levels of development of support industries including 
suppliers of APIs, other materials and machinery. Production costs may 
be higher than in India because input costs and utility costs are higher, 
and also because productivity may be lower. In some smaller countries, 
the market is considered too small for profitable operations. 5 It is there-
fore much easier for Indian companies to manufacture in India and then 
to serve the African markets through exports. 
 This current status and set of perceptions can however be changed 
through policy interventions. Left to themselves, foreign firms may not 
be keen to invest. But if proper conditions are created, if the above-
mentioned issues and factors are taken care of, then they might be 
induced to do so. If the experience of other countries is any guide, then 
neither the inflows of FDI nor the benefits from FDI result from a passive 
open-door FDI policy (Lall and Narula, 2004; Chang, 2004). What is 
required is an active industrial policy. 
 The last section of this chapter develops this argument for the case 
of Ghana. 6 It discusses how foreign firms can help to develop a local 
pharmaceutical industry, and how they can be induced to contribute to 
promote local production. 
 Ghana, industrial policy and foreign direct investment 
 Ghana is a relatively small African country. The size of its total formu-
lations market was estimated at about US$329 million in 2012 (BMI, 
2013: 16). There are about 38 pharmaceutical manufacturing units 
in Ghana of which about 20 are actively involved in manufacturing 
formulations. Only one company, LaGray, started manufacturing an API 
(erythromycin) for their own use in formulation manufacturing. Local 
production caters to about 30% of the market, with the remaining 70% 
of demand being met from imports. Some of the local firms, for example 
Kama and Ernest Chemists, are involved in both manufacturing and 
importing. 
 India is a major source of Ghanaian imports not only of formulations 
but also of the APIs and other materials required for the local production 
of formulations. Out of the 30% of the market which is supplied by local 
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manufacturers, 25% are over-the-counter (OTC) medications and the 
remaining 5% are simple prescription formulations. About two-thirds 
of drug purchase in Ghana are financed through out-of-pocket expendi-
ture, the remaining being financed through public procurement, donor-
funded purchases and reimbursement by the National Health Insurance 
scheme. Ghana has an elaborate drug distribution system dominated by 
importers/distributors/wholesalers. The branded generics segment of the 
market is large, and both imported products and locally manufactured 
generic products are sold as brands. Local manufacturers are actively 
involved in sales promotion, particularly for OTC items. 
 The Ghanaian government has put in place a number of policies 
that have helped the local industry to grow to attain its present status. 
Among these policies, one of the most important steps taken to promote 
the pharmaceutical industry was to ban the imports of finished formu-
lations of 14 widely used products including ampicillin, tetracycline, 
chlordiazepoxide, indomethacin, paracetamol, aspirin and diazepam. 
Domestic formulations manufacturing has also benefitted substantially 
from the industrial protection provided by combination of zero import 
duties on materials and machinery required for formulations production 
with 10% import duty on imports of finished formulations. Another 
important advantage that domestic formulations manufacturers have 
been enjoying was the refunding of the 15% VAT imposed on all mate-
rials and machinery required for formulations production. However, in 
2013, the government has withdrawn this benefit, as has also happened 
elsewhere (see Chapter 2). 
 Like other countries discussed in this book, Ghana also offers a 15% 
price preference for domestic suppliers in public procurement. This has 
also helped manufacturers, though the system has not always func-
tioned properly. Local manufacturers complain that the procurement 
system is not very transparent, and especially when the government 
buys at regional and local levels there is suspicion that the 15% advan-
tage is often not provided. The government does not reveal the prices at 
which it actually procures. Perhaps if such information is made public 
the situation will improve. 
 Industrial policy in Ghana 
 What can be done to further increase the share of local production 
in the Ghanaian domestic market? What is fundamentally impor-
tant for promoting an industry is to put in place policies to provide 
access to three key aspects of business activity: finance, technology and 
markets. 
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 This section first discusses the problems of finance and technology 
in the context of Ghana. It then explores the ways in which a policy of 
ensuring a larger market for local producers can prompt FDI to assist the 
development of the pharmaceutical industry in Africa. 
 Under the conditions in which they operate, the local firms hardly 
earn adequate profits to plough back into investments. Furthermore, the 
rate of interest charged by banks in Ghana is exorbitant, often exceeding 
30% per annum. As shown below, to set up Good Manufacturing 
Practice (GMP)-compliant manufacturing plants, to develop products 
for getting regulatory approval and for marketing these products, huge 
funds are required. Taking loans at such high interest rates is simply not 
a viable option, so that exploring other funding options is vital. The 
more resourceful foreign firms with access to diverse sources of funding 
offer one of the possible policy options. 
 Technology, furthermore, is a fundamental constraint in Africa today. 
When pharmaceutical manufacturing started in Ghana, technical 
requirements were simpler and technology was often arranged through 
informal channels. The promoters of local companies such as Amponsah 
Efah, LaGray and Pharmanova are themselves technologists, and they 
have used their knowledge and contacts to set up small-scale plants. But 
the technological scenario in recent years has changed fundamentally. 
Current requirements are significantly tougher. If local manufacturing 
in Ghana is to make a significant difference to the industry, then tech-
nical knowledge and expertise need to be available qualitatively and 
quantitatively on a big scale. 
 The first technological requirement is that the manufacturing plants 
need to be GMP compliant. To set up a GMP-compliant plant, signifi-
cant additional costs, particularly investment costs, have to be incurred. 
Moreover, the products manufactured need to be approved for marketing 
by the local drug control administration. The companies are required 
to undertake various types of studies (e.g. bioequivalence studies) and 
to generate data and submit dossiers to the drug control authorities. 
Marketing approval is granted after various types of review by the latter, 
including chemistry review, bioequivalence review and after-plant 
inspection. 
 The technical knowledge required to set up and run GMP-compliant 
plants and to develop products for getting regulatory approvals for 
marketing are not widely available in Ghana and other African coun-
tries. It is vitally important to arrange this if the local industry is to 
develop. 
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 A possible solution is to use the technological resources of foreign 
firms for the purpose. Manufacturing operations by Western MNCs are 
carried out in quite a different environment, while the situation in India 
is much closer to that in Africa. Pharmaceutical technical knowledge is 
furthermore highly diffused in India, so if Indian companies invest in 
Africa, then a major constraint will be lifted. 
 Furthermore, as Chapter 5 has emphasized, market access and serving 
the local market effectively are essential elements of business success. If 
the African governments can initiate policies to substantially limit the 
access of foreign firms to the domestic market, then Indian (or other 
foreign) companies will lose out unless they undertake investments 
in Africa to cater to that market. Where the loss is substantial, as in 
the cases of larger countries or regional markets, chances of FDI will be 
much higher. How can a country manage its domestic market to induce 
foreign firms to invest? 
 Policy makers in developing countries often are reluctant to impose 
import controls on the grounds that such an action may lead to short-
ages and/or lack of import competition may lead to higher prices. But 
this need not necessarily be the case, as Ghana shows. The products 
on its banned list are manufactured adequately in the country, and the 
country did not suffer from shortages after the policy was imposed. Lack 
of import competition has not resulted in higher prices. Importantly, 
import competition has been replaced by domestic competition, leading 
to competitive prices in the domestic market. 
 To explore the question of pricing further, Table 6.4 compares the 
retail prices of selected products in India and Ghana. The products 
include some of those which are manufactured in Ghana, for example 
ciprofloxacin, paracetamol, amlodipine, diazepam, metformin and 
also some of those that are not currently manufactured in Ghana, for 
example anastrazole, granisetron, losartan, rabeprazole and rosuvas-
tatin. As Table 6.4 shows, the extent of price differentials between India 
and Ghana is quite different, depending on whether these products 
are manufactured in Ghana or not. For the products not manufactured 
in Ghana, the price differentials are significantly larger. For the prod-
ucts manufactured in Ghana, not only is the price differential much 
narrower – less than 1.5 times – but it is in fact the case that for three 
products, Ghanaian prices are lower than those in India. These include 
diazepam and paracetamol, which are products reserved for local manu-
facturers. Thus Table 6.4 suggests that local production in Ghana has 
contributed to affordability. 
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 If the number of products on the banned list is increased, and if free 
flow of imports into the economy is controlled, then not only will 
domestic producers find a larger market. Import restrictions may also 
induce foreign firms exporting to the country to undertake manufac-
turing within the country. 
 Table 6.4  Comparison of retail formulations prices in India and Ghana 
India: Median 
price in INR 
(1 tablet) 2013
Ghana: Median 
price in INR 
(1 tablet) 2011
Ghana/India 
price ratio: 
Col(3)/col(2)
 Tablets manufactured in Ghana 
1. Ciprofloxacin, 500 mg 6.18 9.11 1.5
2. Amlodipine, 5 mg 2.36 3.64 1.5
3. Metformin, 500 mg 1.46 1.52 1.0
4. Diazepam, 5 mg 2.90 0.30 0.1
5. Paracetamol, 500 mg 1.14 0.30 0.3
6. Diclofenac, 50 mg 1.43 1.82 1.3
7. Lisinopril, 5 mg 4.58 6.07 1.3
8. Atorvastatin, 10 mg 8.60 9.11 1.1
9. Cetirizine Hcl, 10 mg 3.10 3.04 1.0
10. Metronidazole, 200 mg 0.39 0.61 1.6
 Tablets not yet manufactured in Ghana 
1. Anastrazole, 1 mg 48.50 182.10 3.8
2. Cepacitabine, 500 mg 150.05 267.08 1.8
3. Granisetron, 1 mg 14.05 409.73 29.2
4. Itraconazole, 100 mg 47.50 182.10 3.8
5. Losartan, 50 mg 5.65 12.14 2.1
6. Rabeprazole, 20 mg 2.75 75.88 27.6
7. Risperidone, 2 mg 3.80 75.88 20.0
8. Rosuvastatin, 20 mg 20.36 69.81 3.4
9. Tindazole, 500 mg 5.52 69.81 12.7
10. Sertraline, 100 mg 6.3 98.64 15.7
 Sources : 1. For Indian prices in col (2): median prices of retail brands accounting for 1% 
or more of the market. Market share data have been obtained from the  Sales audit data of 
AIOCD Pharmasofttech AWACS Pvt. Ltd (AIOCD-AWACS), a pharmaceutical market research 
company; Price data have been obtained from CIMS (2013). 
2. For Ghana prices in col (3): ‘Medicines List’, February 2011 of the Ghana National Health 
Insurance Scheme ( http://www.nhis.gov.gh/_Uploads/dbsAttachedFiles/1(3).pdf ). Prices in 
Ghana cedis (GHC) have been converted to Indian rupee (INR) using the annual average 
exchange rates for 2011 from  www.oanda.com . The list specifies the maximum prices at 
which the medicines purchased at the retail level are reimbursable. Pricing data are collected 
from manufacturers, wholesale distributors, private pharmacies, government, mission and 
private health facilities and the median prices are set as the maximum price reimbursable 
under the insurance scheme. 
3. Since the Ghana prices refer to 2011 whereas the Indian prices refer to 2013, depending on 
the extent to which Ghana prices have gone up since 2011, the price differential in fact may 
be larger than the figures show. 
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 Imports can also be controlled in several other ways. Ghana has 
introduced a National Health Insurance Scheme (NHIS), which covers 
about half the population. About 40% of the funds paid out by health 
insurance are for medicines. The NHIS-funded formulations market has 
therefore emerged as a major market segment in Ghana accounting for 
about 23% of the market (Seiter and Gyansa-Lutterodt, 2009: 19). The 
NHIS has expanded since that 2009 study, and the share of insurance-
funded medicine purchase has risen. The substantial bargaining power 
of the NHIS agency can thus be used to enlarge the domestic market. The 
NHIS does not currently differentiate in its procurement between medi-
cines according to whether they are manufactured locally or imported. 
However, after allowing some time for capacities to develop, NHIS reim-
bursement could be restricted to locally manufactured products. Since 
the prices to be reimbursed are being fixed by NHIS in any case, the 
possibility of such actions leading to higher prices will not arise. 
 A further policy option available is to use the instrument of govern-
ment procurement. So far as the institutional market is concerned, the 
only benefit the local manufacturers receive is the 15% price preference, 
and that too, as noted above, does not operate properly. An important 
flexibility that the World Trade Organization (WTO) provides concerns 
public procurement. The WTO Agreement on Government Procurement 
(GPA) is a plurilateral agreement which is applicable only to the member 
countries which have signed the GPA. African countries, including 
Ghana, have not yet joined the GPA. 7 
 Public procurement of drugs (and other goods) in Ghana is currently 
guided by the provisions of the Public Procurement Act. This provides 
for three types of competitive tendering: international, national and 
restricted. ‘International tendering’ means that organizations responding 
need not necessarily be located in Ghana. ‘National tendering’ means 
that the tendering can be restricted to organizations located in Ghana, 
but the organizations need not be manufacturers. They can be importers 
located in Ghana. 
 A simple step that could be initiated in Ghana for the further develop-
ment of the pharmaceutical industry is to introduce tendering restricted 
to local manufacturers. This might be a two-stage tendering process: a 
technical evaluation and then evaluation of the financial bid. At the 
first stage of technical evaluation, tenders may be accepted only from 
those local manufacturers that are GMP-compliant and that have the 
manufacturing capacities to satisfy the procurement requirements. 
The financial bid may be restricted to the companies which qualify 
in the technical evaluation. Based on the widely used International 
Reference Prices, 8 maximum purchase prices may be also specified. This 
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120 Sudip Chaudhuri
will ensure a larger domestic market for local manufacturers, and hence 
a more attractive market for FDI, without compromising on prices. 
 Conclusion 
 This chapter can be appropriately concluded with a quotation from the 
Chairman of an Indian company currently exporting pharmaceuticals to 
Africa. He summarized the prospects of FDI in Africa. He told us during 
an interview that if imported products including those from India are 
freely available in Africa, then it is difficult to induce Indian companies 
to go to Africa and set up plants. But if local production is somewhat 
protected, and if this is supplemented with few steps to take care of the 
disadvantages of local production in Africa including some incentives, 
for example some income tax benefits particularly in initial years and 
infrastructure support (land, water, roads, electricity), then the prospects 
of FDI from India will be brighter. In fact, his company will be willing to 
explore the possibility actively. 
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2014?id=&sk=&date=&&pageID=2 ); BMI Espison, 2013. 
 2 .  See note 1 above. 
 3 .  For example, after the expiry of the basic patent for a chemical, generics 
companies that can successfully challenge some of the secondary patents 
can prevent other generic companies from entering the market for a limited 
period of time, gaining substantial additional value-added. 
 4 .  Source: as in Table 6.3. 
 5 .  See Guimer et al. (2004); Kaplan and Laing (2005); Losse et al. (2007); 
Chaudhuri et al. (2010); Abbott (2011); Moon (2011); UNCTAD (2011); 
African Union and UNIDO (2012); Chaudhuri and West (2014) for further 
insights into local production in Africa. 
 6 .  The case study on Ghana relies to a great extent on the information collected 
through interviews while doing studies for UNIDO, Vienna and UNDP, New 
York. 
 7 .  Mostly developed countries are currently members of GPA; for the list of 
those who have joined, see  https://www.wto.org/english/tratop_e/gproc_e/
memobs_e.htm 
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 Introduction 
 This chapter discusses raising the technological scope for locally manu-
facturing active pharmaceutical ingredients (APIs), excipients and 
biologicals in Africa – a hitherto nascent industry. It also discusses 
African drug development and manufacturing through the standardized 
use of ‘reverse pharmacology’ to bring new treatments for neglected 
diseases to the point of regulatory approvals. Currently there is very 
modest production of APIs on the African continent, although a few 
significant projects exist, 1 (such as LaGray in Ghana and Fine Chemicals 
in South Africa), or are in the planning stages. 2 Generic producers in 
India and China supply nearly all of the APIs used in African phar-
maceutical manufacturing. Most African companies cannot afford the 
heavy investment and research and development activities required for 
API production. 
 Two strategies are suggested to help to address these issues: first, the 
introduction of technology transfer (product development) packages 
at centres of excellence, with each package being transferred to several 
manufacturers; second, the use of ‘leap-frogging’ technologies to reduce 
capital investment, minimize the environmental footprint and enhance 
competitiveness. Leap-frogging technologies have the advantage that 
Africa can skip technology and investment legacy issues. Leap-frogging 
technologies can also narrow the gap between rich and poor economies 
in drug discovery/development and pharmaceutical manufacturing by 
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Raising the Technological Level in Africa 123
taking advantage of the rich diversity of natural products sources and 
indigenous knowledge in disease treatment. 
 In this chapter we tackle API, excipient and biologicals manufacture 
by considering the science, technology and human as well as institu-
tional and organizational capabilities needed to raise Africa’s techno-
logical levels in API, excipient and FPP manufacture. This chapter is 
informed by the laboratory and practice experience in API, excipients 
and biological manufacture. 
 APIs and excipients: important components of 
producing medicines 
 A medicine may be broadly defined as any substance or substances used 
in the treatment, diagnosis, prevention, mitigation or cure of a disease. 
Drug molecules that exert a biological effect are known as active phar-
maceutical ingredients (APIs). APIs alone are unsuitable for human use 
as medicines. Various additional ingredients (excipients) are formu-
lated in combination with APIs to manufacture finished pharmaceu-
tical products (FPPs). An FPP contains one or more APIs and is the form 
in which a medicine is presented to the patient. FPPs can be tablets, 
capsules, oral liquids (suspensions or solutions); creams/ointments for 
topical administration; injectable solutions; or patches, suppositories 
or inhaled-delivery forms. Some delivery forms are inherently easier 
than others to manufacture, but each combination of API and delivery 
form requires an individual development program to assure the iden-
tity, stability, safety, purity, potency and efficacy of the final product. 
The number of APIs used for the treatment of all human diseases is 
relatively small. The various major pharmacopoeial compendia (inter-
national, European, US or British) list fewer than 2,500 different APIs 
that are approved for use as medicines. APIs are formulated in order to 
assure their stability, uniformity and reproducibility, to enhance patient 
compliance and to maximize efficacy by optimizing dissolution, absorp-
tion and bioavailability. 
 APIs alone are unsuitable for direct patient dosing, because FPPs must 
be stable, convenient, palatable and uniform in their dosage and content. 
Since the amount of drug dissolved in stomach fluid after oral dosing is 
a direct measure of how much drug is available for absorption, the use 
of different excipients/formulations may control solubility and whether 
a drug is available for immediate release, extended/sustained release or 
even delayed release. Tablets typically contain 20–60% loading of API 
content by weight. Pre-formulation studies involve the evaluation and 
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establishment of target ranges for the physicochemical properties of an 
API (salt selection, crystal form, particle size distribution [PSD]and level 
of hydration/solvation). 
 Every solid oral dosage form contains at a minimum excipients that 
serve as a binder, filler, lubricant and disintegrant. Excipients that 
serve as surfactants, compression aids, desiccants, glidants, dissolution 
enhancers, taste modifiers, colorants and coatings are also very often 
employed. Many hundreds of excipients of various types are used in 
pharmaceutical formulations. These ingredients are generally regarded 
as safe (GRAS) when present below established permissible daily expo-
sure (PDE) limits. Quality by design (QbD) at this stage involves careful 
evaluation and selection of critical quality attributes (CQAs) of the API, 
and matching of the desired performance characteristics of the FPP with 
selection and grade of excipients used. 
 Table 7.1 shows a range of excipients commonly used in FPPs, typi-
cally used as weight percentages of a tablet, and price ranges (prices 
obtained from import-export data at  www.infodriveindia.com ). If these 
costs are compared with API pricing in Table 7.2, it is readily seen that 
excipients are normally much less expensive than APIs as a contribution 
to the cost of producing FPPs. 
 For solid oral FPP manufacturing the API and excipients are blended 
together, often as powders with unlike properties. Along with blending, 
there is a massing process of bringing these powders together to form 
larger particles of uniform content, known as granules. Wet granulation 
is possibly the most commonly used technique for granulation. Although 
this process is very reliable, a subsequent drying step is required that is 
both process intensive and must be carefully controlled so as not to 
cause risk of degradation. Granules are either filled into hard gelatin 
capsules or compressed into tablets. Tablets may be coated in order to 
improve their appearance, impart distinctive identifying characteristics 
or enhance stability. Compression into tablets does not destroy gran-
ules. The disintegration of tablets in the stomach after ingestion releases 
these granules at an early step in the process of dissolution and absorp-
tion of drugs. Soft gelatin capsules are filled with a solution or suspen-
sion of API(s) in a liquid-fill process, and the technology used for these 
formulations is somewhat specialized. 
 Manufacturing active pharmaceutical ingredients 
 Almost all small-molecule APIs are prepared by chemical synthesis, 
fermentation or extraction and purification of natural products from 
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 Table 7.1  Common excipients used in solid oral dosage formulations, their standard use and weight % content, and pricing on a per-kilogram basis 
 Excipient  Utility in tablet or capsule FPPs* 
 Typical 
weight% in 
FPP  Cost per Kg** 
 Cellulose or Microcrystalline Cellulose Diluent, disintegrant 10–60% $2.00–3.22
 Lactose Binder, diluent, compression aid 5–40% $3.03–3.77
 Calcium phosphate, dibasic Filler, diluent 5–50% $2.46–5.70
 Carboxymethylcellulose Sodium ( Carmellose Sodium, CMC) Binder, disintegrant, coating agent, desiccant 5–25% $3.25–5.99
 Croscarmellose Sodium ( cross-linked CMC) Disintegrant 1–5% $6.56–9.51
 Sodium Starch  Glycolate (SSG) Disintegrant 1–5% $0.96–4.93
 Potassium  Sorbate Anti-oxidant Up to 2% $18–37
 Povidone (poly(vinyl) pyrrolidinone; PVP) Binder, disintegrant, dissolution enhancer 5–20% $8.59–17.11
 Crospovidone ( cross-linked  povidone) Disintegrant 2–5% $3.03
 Magnesium  Stearate Lubricant 0.25–4% $4.30 – 23.50
 Methyl  paraben Antimicrobial 1–2% $11.50
 Sodium  Lauryl  Sulfate Anionic Surfactant, emulsifying agent, lubricant 1–2% 36–51
 Starch,  pregelatinized Binder, diluent, disintegrant 5–35% 2–9
 Talc Glidant, anti-caking agent 0.2–2% $2.00–3.57
 Aluminum Oxide Adsorbent, dispersing agent Less than 5%
 Sodium Benzoate Antimicrobial, lubricant 1–3% $1.62–2.19
 Xanthan Gum Stabilizer, suspending agent, viscosity enhancer; 
often used for extended release products
5–15% $5.02–7.44
 Xylitol Sweetener, diluent, coating agent, antimicrobial 5–10% $2.20–5.75
 Note:  * Summarized from Rowe, Sheskey, Cook and Fenton (2012).  ** Data summarized from  www.infodriveindia.com 
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plant sources. A number of APIs are produced by some combination 
of these techniques. Plant cultivation and extraction of the natural 
product artemisinin, for example, is combined with chemical synthesis 
to produce the anti-malarial APIs artemether and artesunate (USNLM, 
2014), as shown in Figure 7.1. 
 The cost of manufacturing an API depends on the raw material 
pricing, yield, processing time and volume efficiency of each manu-
facturing step. Other cost drivers are the cost of operating the manu-
facturing facility (overheads and labour: OHL) and capital investment 
required to build and equip the manufacturing plant. Overheads and 
labour include costs of personnel, energy, waste disposal, shipping and 
eventual cost of decommissioning the facility. Higher volume demand 
generally decreases the proportionate cost contribution of raw mate-
rials and overheads and labour. Substantial production volumes are 
therefore required to obtain full economy of scale (Jayaraman, 2012). 
Producing 1–5 metric tons per year is more expensive than producing 
100 metric tons of an API in appropriately sized facilities. The effi-
ciency of a synthesis is often quoted in terms of overall yield and as an 
E-factor (Sheldon, 2007) representing the kilograms of waste produced 
per kilogram of product manufactured. Waste management is expen-
sive in chemical manufacturing, and increasing the overall yield or the 
O
O O
O
O
Plant
cultivation
extraction
Artemisinin
2 Synthetic Steps
O
O O
O
OCH3
Artemether
O
O O
O
O
Artesunate Sodium
CO2Na
 Figure 7.1  Chemical synthesis to produce the anti-malarial APIs artemether and 
artesunate 
 Source : Compiled by authors 
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E-factor of an API synthesis reduces costs. With a continued growth of 
volume demand, improved chemistry and competition from multiple 
suppliers, the cost of raw materials and APIs can decrease over time. 
For example, the cost of the API for the HIV/AIDS drug efavirenz at 
launch by the originator company (Dupont Pharmaceuticals) in 1998 
was about $1,600/kg at a first-year demand of about 150 tons (Personal 
recollection from the author, JF). Generic producers in India estimated 
their API costs at about $1,100/kg upon first generic introduction in 
2005 (Personal communication, Mr D.R. Rao, Cipla). Currently, the API 
can be purchased for about $120/kg, a 13-fold decrease in cost of API in 
17 years (import-export data at  www.infodriveIndia.com ). Notably, the 
volume demand of efavirenz in 2015 is also estimated at about 2,000 
tons, since this drug is a standard component of first-line AIDS treat-
ment in low- and middle-income countries. 
 As a rule of thumb, the overall cost of raw materials for an efficient 
process will represent about 50–70% of the total cost of API manufac-
turing, signifying the important role of smart procurement. This rule 
of thumb is applicable to high-volume generic production of synthetic 
APIs. Smaller-volume APIs – those produced by fermentation or natural 
products extraction, or APIs used in sterile products – can have much 
higher proportionate cost contributions for overheads and labour and 
capital investment. The synthetic route of manufacturing the HIV/AIDS 
API tenofovir disoproxil fumarate (TDF) (Figure 7.2) is a typical example. 
The key raw materials – adenine, (R)-propylene carbonate (RPC), diethyl 
p-toluenesulfonyl(oxymethyl)phosphonate (DESMP), chloromethyl 
isopropyl carbonate (CMIC) and fumaric acid – contribute to the molec-
ular structure of the API. Each step uses multiple additional materials as 
solvents or reagents, which are omitted from this simplified synthesis 
scheme. 
 The final crystallization or precipitation step of API manufacturing is 
the stage at which the physicochemical properties of an API are deter-
mined and the last stage at which related substances (impurities) can be 
removed or reduced to acceptable limits. The crystalline form and PSD 
of an API are often critical to the formulation, dissolution, absorption 
and bioavailability of a drug. Bioavailability is the fraction of a drug dose 
that reaches systemic circulation (blood plasma) upon human dosing 
(USFDA). By definition, any drug is 100% bioavailable when adminis-
tered by injection. 
 API cost reductions reflect improvements in production effi-
ciency, procurement and economies of scale. The overall yield of TDF 
(Figure 7.2) from adenine was less than 25% when the generic product 
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was launched in 2006; it is currently in the range of 43–54%, a doubling 
of efficiencies. During this time the API pricing of TDF has decreased by 
65% from more than $600/kg to about $210/kg. Undoubtedly a lot of 
research and development effort went into improving yields, reducing 
use of solvents and reagents and decreasing processing times (Ripin 
et al., 2010). Improved procurement – a critical finance capability (see 
Chapter 13) – greatly reduced the cost of most of the key raw materials; 
this was probably the biggest contributor to cost reductions (Jayaraman, 
2012). Table 7.2 provides a range for the per-kilogram pricing of the key 
raw materials for TDF synthesis. These prices are given for purchasing 
ton-scale amounts of each raw material in the timeframe of January–
December 2014 (import-export data available at  www.infodriveIndia.
com ). When generic versions of TDF were first launched in 2006, the 
pricing for both RPC and DESMP, for example, was more than $20/kg. 
 API costs are often the largest component of the overall cost of a corre-
sponding finished pharmaceutical product (FPP). API producers gener-
ally operate on smaller margins than FPP producers. A well-established, 
competitive market for anti-retroviral (ARV) APIs for the treatment of 
HIV/AIDS in low- and middle-income countries illustrates this. Target 
margins for generic APIs are typically 20–33%. The actual margins on 
N
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TDF
 Figure 7.2  Synthetic route for the manufacture of the API tenofovir disoproxil 
fumarate 
 Source : Compiled by the author 
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ARV drugs with several approved suppliers, however, can be far lower. It 
is generally agreed that margins for the well-established ARV APIs zido-
vudine (AZT) and lamivudine (3TC) do not exceed 10%. 
 Can Africa expand local production of APIs? 
 APIs are sold in bulk, typically as powder in a drum. Global demand for 
very common APIs such as paracetamol, erythromycin or ibuprofen is 
as high as 60,000 tons per year. Volume demand for most APIs is in the 
range of 10 to 500 tons per year. Economies of scale are important for 
both API and FPP production. A manufacturing facility must be oper-
ating at close to its full capacity to maximize operational efficiency. 
Companies that manufacture both APIs and FPPs possess a competi-
tive market advantage because there is one less commercial transaction 
where profit is taken in the value chain. 
 In order to be successful, African API production must be priced simi-
larly to that of Indian and Chinese competitors. The quality must also 
match or exceed the standards of competitor products in the market. 
Procurement information is becoming widely available, and therefore 
African producers potentially have access to knowledge of the best avail-
able pricing for raw materials. African producers are potentially able to 
obtain competitive pricing on APIs and key raw materials, because these 
items are not sold in huge quantities on a single-transaction basis. For 
solvents and reagents that require very large-volume purchases to obtain 
 Table 7.2  Raw Materials that contribute to the structure of the API tenofovir 
disoproxil fumarate (TDF) and their current commercial pricing 
 Raw Material 
 Price per Kg 
( ton scale) 
 Kgs used per Kg 
of TDF produced 
 Raw Material. 
Price Contribution
/kg of TDF 
 Adenine $34.34–38.97 0.64 $21.98–24.94
 R-Propylene 
Carbonate (RPC) 
$7.88–9.75 0.50 $3.94–4.88
 DESMP $6.40–6.98 1.22 $7.81–8.52
 CMIC $8.79–9.24 1.61 $14.15–14.88
 Fumaric Acid $1.53–1.87 0.23 $0.35–0.43
 Total: $48.23–53.65
 Source : Compiled by the author using data from  www.infodriveIndia.com , April 2012–July 
2014. 
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best pricing, however, African producers can be at a disadvantage rela-
tive to Indian and Chinese counterparts. 
 There are many products, however, for which it is realistic that Africa 
production can be price-competitive with India and China. Low-dose 
APIs are one set of medicines. Entecavir, for example, is a very useful 
product for the treatment of hepatitis B virus (HBV). Entecavir is also 
a very important drug for Africa, since the continent bears a very large 
share of the global burden for HBV. Entecavir is delivered at a dose of 
0.5 mg/day. At this extremely low dose, the API contribution to FPP 
pricing is potentially so small that the only important cost contribu-
tion to manufacturing an FPP is the inherent efficiency of formulating 
the tablet FPP. African pharmaceutical manufacturers do not, however, 
presently hold in their organizations the experienced, knowledgeable 
scientific staff to optimize API production processes in the same manner 
as Indian and Chinese producers are able to do. 
 African manufacturing of APIs and FPPs might be successful for a large 
range of moderately priced products that are no longer of high priority 
for Indian generics manufacturers. Many Indian companies target 
exports of more lucrative FPPs (such as gleevec or imatinib for cancer) 
and target high-priced markets in the US and Europe. For well-established 
generic products manufactured in large volumes, it is quite conceivable 
that African companies can purchase APIs at equal pricing to Indian FPP 
producers (Table 7.2). Metformin (diabetes), naproxen sodium (anal-
gesic), amoxicillin (anti-infective), metronidazole (anthelmintic) and 
lumefantrine (malaria) are examples. Under these circumstances, local 
manufacturing may actually be less expensive than importation because 
of differences in added-on pricing due to shipping and import duties. 
This aspect of pharmaceutical pricing is commonly overlooked. The 
associated costs of shipping and tariffs or other duties associated with 
importation of APIs or FPPs can readily amount to a 30% add-on for 
pricing; this can potentially create a pricing advantage for local manu-
facturing. International donor agencies that purchase essential medi-
cines for Africa and African national procurement programmes often do 
not take into account this potential advantage for local manufacturing 
when issuing tender offers for purchase. 
 ‘Leap-frogging’ technologies as opportunities for 
local API manufacture 
 Leap-frogging technologies are advances in manufacturing technology 
that provide large improvements over current techniques and avoid 
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legacies of industrial organic growth. These advances can be related to 
chemistry, formulations or techniques for manufacturing. Global phar-
maceutical companies are traditionally late adopters of new technolo-
gies because manufacturing costs are not closely tied to their product 
pricing or their profit model; furthermore, originator companies have 
huge investments in their current manufacturing facilities. For Indian 
companies, investment in new technologies can be unattractive unless 
it pays for the high cost of decommissioning existing ‘legacy’ manufac-
turing facilities. African companies do not largely suffer from such a high 
degree of captive ‘legacy’ investment in existing facilities. Continuous 
manufacturing of FPPs, for instance, is one area where African produc-
tion can be both environmentally and cost-preferred versus global 
competition. 
 A number of patents and publications (Chava et al., 2014; Datta et al., 
2014; Ripin et al., 2010) have disclosed information about TDF process 
optimizations that have reduced the API pricing by more than 70% since 
initial generic launch, as discussed earlier. New technologies for API 
production for TDF and EFV include biotechnology for the production 
of intermediates and ‘greener’ chemistry that reduces the E-factor of API 
production. In the case of EFV, this reduction is from about 55 to about 
12 (Bolu et al., 2012; Jian, 2008). Green chemistry (GC) includes the 
use of catalytic amounts of amino acids and their derivatives (organoca-
talysis) to reduce the number of steps and the cost of API processing. GC 
also includes continuous or ‘flow’ processing (Hebrault, 2014). Both of 
these technologies are in early stages of implementation and their full 
impact on API pricing is not yet being felt. 
 Flow chemistry is being used in one step of the commercial produc-
tion of an intermediate for the synthesis of the HIV-1 protease inhibitors 
atazanavir and darunavir (Pinho et al., 2014). Flow chemistry can be 
broadly summarized as an engineering approach to improved synthesis. 
Organocatalysis is a more chemistry-based approach to improved 
synthesis. Flow chemistry for commercial manufacturing is a special 
expertise owned by at least one African R&D centre, the Green Center 
for Chemical Manufacturing. Advanced technologies are not mutually 
exclusive and can often be employed together to improve API manufac-
turing efficiencies. 
 Taking advantage of these leap-frogging technology opportunities 
implies adoption of machinery, equipment and processes with higher 
efficiencies and lower environmental impact. This opportunity exists 
for African manufacturing of APIs. However, there is need for integra-
tion of API and FPP production to accommodate the scale needed for 
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API manufacture, requiring in turn financial incentives and supportive 
procurement to leveraging the huge intra-African medicines market. 
 Assuring the quality of APIs: Quality management systems 
and GMP 
 The quality of APIs and FPPs is assured by manufacturing under good 
manufacturing practice (GMP), including process validation, testing 
against previously established specifications and the demonstration 
of clinical bioequivalence (FDA, 2014). The investment and operating 
costs of a quality management system (QMS) for GMP contribute signifi-
cantly to the cost of pharmaceutical production. Producers must desig-
nate and justify to regulatory authorities a starting point or stage in the 
API synthesis from which GMP is applied. 
 Janice Berger, a well-known former USFDA field inspector, often 
remarked: ‘You’re either GMP or you’re NOT’. In a very real sense, this is 
the true. Companies cannot choose to move back and forth from GMP 
to non-GMP activities in the same manufacturing facility. The require-
ments for a QMS and documentation for GMP do not allow switches of 
this type. The general feeling in the industry is that additional invest-
ment in GMP compliance enables companies to gain market share and 
increase sales by differentiating them from their competitors based on 
quality. National drug regulatory agencies (NDRAs) bear the primary 
responsibility of working with companies to evolve their GMP prac-
tices to meet international standards (Chapter 12). The United States 
Pharmacopeia (USP) sponsors training programmes in GMP. Over the 
longer term, African nations must assume full responsibility for their 
own regulatory needs. The emerging Regulatory Sciences Institute 
(RSI) in South Africa is potentially an important player in promoting 
global standards for pharmaceutical manufacturing on the continent. 
It follows that a sustainable African generic pharmaceutical industry 
must be able to:
 develop products and processes meeting SRA standards of quality;  ●
 continuously manufacture under GMP;  ●
 compete with other quality-assured producers on price;  ●
 operate without legal encumbrances (dependent on intellectual  ●
property). 
 Regulatory sciences and rigorous product development are critical for 
obtaining generic drug approvals by SRAs. Originator companies employ 
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a very large number of skilled scientists to develop and launch new medi-
cines. One of us (JF) managed a scientific staff of over 350 chemists and 
engineers to support the filing of, on average, only 1–3 new marketing 
applications per year. Indian and Chinese generic companies also hold 
very substantial staff (60 or more development chemists) to launch 8–12 
new generic FPPs per year. Indian and Chinese generic companies also 
routinely outsource substantial R&D activities to regional centres of 
excellence (universities or technology development centres) to leverage 
their in-house capabilities. It is essential to build a pool of skills with 
capabilities in drug registration and regulation to support research and 
development as well as drug authorizations. 
 The IPAT program at the St. Luke Foundation / Kilimanjaro School 
of Pharmacy in Moshi, Tanzania is a UN ANDI Centre of Excellence 
training pharmaceutical and NDRA experts in GMP drug manufacturing, 
regulatory sciences and leap-frogging technologies since 2008. It was 
awarded a USFDA ‘Honor Award’ in 2013 for Excellence and Innovation 
in Regulatory Sciences training. The IPAT programme is partially funded 
by UNIDO and its approach has also been adopted by the University of 
Ibadan School of Pharmacy. 
 Opportunities for reverse pharmacology and traditional 
medicine for local drug development 
 Reverse pharmacology 
 Reverse pharmacology (RP) integrates traditional knowledge into drug 
discovery, development and production (Patwardan, 2009; Wambebe, 
2001). This approach identifies natural products or mixtures of natural 
products based on traditional knowledge combined with screening in 
biological assays. This green approach to drug discovery takes advan-
tage of cultural and ethno-botanical knowledge of a region to shortcut 
the lengthy, expensive, resource-intense process used in rational drug 
design. 
 The ‘hits’ identified by reverse pharmacology are further developed 
into drug candidates by exploratory studies including safety and activity 
testing, combined with clinical (human) dosing. During clinical devel-
opment, mixtures of compounds obtained as crude extracts are often 
used, but the classical activities of isolating compounds with biological 
activity and elucidating their structure remains a part of reverse pharma-
cology. The correlation of API content with biological activity, safety, the 
development and validation of analytical methods, process validation 
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and the setting of specifications for the active ingredients present are all 
steps in the RP process. 
 Drugs from traditional knowledge 
 Phytomedicines, or herbal medicines, are plants, herbs, extracts and 
purified natural products used for the prevention or treatment of disease, 
most often identified and derived from traditional knowledge. The regu-
latory requirements for approving phytomedicines are lower than for 
new chemical entities (NCEs), although the label claims for efficacy 
are also much more cautious. More than 80% of people in developing 
countries depend on herbal medicines (Iyamu, 2003; Patwardan, 2009; 
Perampaladas, 2010; Wambebe, 2001; Willcox, 2011). The World Health 
Organization has issued guidance on (1) quality assessment (WHO, 
2007), (2) pharmacovigilance (WHO, 2004) and (3) good manufacturing 
practices (WHO, 2007) for herbal medicines. However, processes to regu-
late the registration, approval and standardization of such products are 
only now being made universal (WHO, 2007). 
 Phytomedicines are typically purified by short, simple processes such 
as aqueous or aqueous alcoholic decoction, followed by solvent removal. 
This is very different from pharmaceutical natural product isolation 
from plants, such as the vinca alkaloids, taxol or camptothecins. These 
are typically present as much less than 1% of the dried weight of their 
respective plant sources and are purified by expensive, resource- intensive 
procedures. 
 Nigerian experience with Niprisan™ 
 A major centre for herbal medicines exists at the National Institute for 
Pharmaceutical R&D (NIPRD) in Nigeria. NIPRD utilizes a systematic 
approach to gathering, classifying, extracting, testing and identifying 
the therapeutic elements present in plant sources. A quality management 
system is in place at NIPRD, and standard operating procedures (SOPs) 
are followed by a multi-disciplinary team of scientists. This standardized 
approach has resulted in the launch of several effective medicines for 
treating malaria, sickle-cell anaemia, pain, inflammation and immuno-
logical diseases (Emeje, 2005; Emeje, 2011; Wambebe, 2001a; 2001b). 
The development of the herbal medicine Niprisan™ for treating sickle-
cell anaemia is described below. 
 Niprisan TM is a combined extract of four plants traditionally used in 
Nigeria to prevent sickle-cell disease (SCD) (Iyamu, 2003; Wambebe, 
2001). SCD is caused by a point mutation in the gene encoding for 
the beta globin chain of hemoglobin, distorting red blood cells into an 
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elongated, ‘sickled’ shape. SCD causes impaired circulation, tissue and 
organ damage, severe anaemia and increased mortality.  In vitro studies 
showed that Niprisan™ possesses potent anti-sickling effects. One or 
more of the active ingredients contained in Niprisan™ enhances the 
solubility of deoxy-HbS, retarding polymerization and increasing 
oxygen affinity (Wambebe, 2001). Controlled clinical trials conducted 
in Nigeria showed that Niprisan™ significantly reduces vaso-occlusion 
in SCD patients (Iyamu, 2003; Wambebe, 2001b). 
 Niprisan™ was standardized by extracting various seeds, fruits and 
stems from  Pterocarpus  osun, Sorghum  bicolor, Piper  guineensis and Eugenia 
 caryophyllum. Data from animal testing and using blood from sickle-
cell patients showed that the standard extracts prevent cell sickling. 
The safety of these extracts was demonstrated by animal testing before 
human use to demonstrate the absence of overt toxicities and lack of 
tissue and organ effects (Perampaladas, 2010; Wambebe, 2001a; 2001b). 
An initial human safety study was carried out in twenty patients, with 
the product already being used by thousands of people in Nigeria in an 
unstandardized product presentation (Wambebe 2001a). 
 Clinical phase II/III trials (in sickle-cell patients) using a capsule 
dosage form began about 18 months after the start of the discovery 
program at NIPRD. In that time, the product was identified, extracts 
were standardized, assays were developed, safety assessment was carried 
out, an initial manufacturing process was identified and clinical supplies 
were prepared. The extraction process for Niprisan™ is quite efficient, 
and extraction is not destructive of the cultivated plants. The dried 
extract represents about 20% of the collected biomass. One kilogram of 
Niprisan™ is therefore obtained utilizing about 5 kilograms of biomass 
and 10 litres each of water and ethanol. 
 A randomized, double-blind, placebo-controlled, crossover trial was 
conducted to support the approval of Niprisan™ (Perampaladas, 2010; 
Wambebe, 2001b). Patients with homozygous SCD in one group took the 
test drug (12 mg/kg body weight) daily for six months before crossing over 
to placebo for another six months. Another group took placebo for six 
months before crossing over to active drug for six months. There was a 
one-month washout period between crossovers. Niprisan™ use reduced 
the mean number of crises by 55% from placebo – a highly significant 
improvement (ρ < 0.05). Patients taking Niprisan™ generally rated their 
health as better and reported less sickness and absenteeism versus placebo. 
Apart from headache (12%), patients reported no significant adverse 
effects (Perampaladas, 2010; Wambebe, 2001a; 2001b). It was concluded 
that Niprisan™ was efficacious for the prophylactic management of SCD. 
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 SCD patients can, to a substantial degree, recognize the symptoms of 
impending SCD attacks. The occasional prophylactic use of Niprisan™ 
with chronic, intermittent dosing by approximately 90,000 people in 
Nigeria has resulted in the reduction of SCD attacks by 98% in this 
population. 
 Herbal extracts almost always contain several compounds, so the 
attribution of biological activity to a single particular compound can 
be difficult. Experience at NIPRD has shown that some phytomedi-
cines are more active as crude extracts than as purified entities. As in 
the case of Niprisan™, some extracts contain multiple closely related 
molecules with similar biological activity. Niprisan™ was approved by 
the Nigerian National Agency for Food and Drug Administration and 
Control (NAFDAC) in 2006 (see  http://nafdac.org.ng/ ). The estimated 
total discovery and development costs of Niprisan™ were approxi-
mately US$28 million (out-of-pocket), including US$8 million to build 
a manufacturing facility (Pandey, 2009). This figure is much lower than 
the figures for rational drug discovery and development. 
 The following conclusions can be offered when comparing reverse 
pharmacology with rational drug discovery and manufacturing:
 Medicines from traditional knowledge/reverse pharmacology can be  ●
standardized in production and demonstrated to be safe by current 
standards. 
 It is possible to prove that phytomedicines are effective in clinical  ●
trials. 
 Phytomedicines production can be much less expensive than  ●
common means of pharmaceutical production. 
 Reverse pharmacology can be highly effective and much less expen- ●
sive than rational drug design for discovery and development. 
 Not all emerging economies, especially those in Sub-Saharan Africa, 
can afford to extensively adopt rational drug design to discovering and 
developing new medicines for their unique health needs, whereas global 
pharmaceutical originator companies cannot invest heavily in neglected 
tropical diseases (NTDs). Reverse pharmacology is a much less expensive 
approach to drug discovery and pharmaceutical manufacturing. Failure 
rates in RP development are reduced by evidence of human safety from 
traditional use. Clinical trials using an RP approach are not as rigorous as 
those for rational drug discovery. Yet it is possible to design and success-
fully execute placebo-controlled, crossover studies to demonstrate clin-
ical efficacy for herbal medicines. Ultimately, drugs derived from RP are 
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more accessible and affordable than those from pharmaceutical origi-
nator companies, and some compromises must be made to provide new 
medicines for these significant, unmet medical needs. This only empha-
sizes the need for green chemistry in drug discovery, to make all valid 
forms of drug discovery much more efficient. 
 African capacity for API pharmaceutical manufacturing 
 South Africa has invested heavily in research of medical significance, 
with a large number of research units funded by the Medical Research 
Council. The country has worked to build the capacity for national 
pharmaceutical manufacturing of APIs and FPPs, as small-molecule 
biological therapeutics, largely through the Department of Trade and 
Industry (DTI). The national government has sustained, for example, 
an investment in BIOVAC for several years in an attempt both to 
minimize reliance on imported vaccines and to generate foreign 
exchange by export of vaccine products. BIOVAC is presently manu-
facturing the final stages of vaccine production for local and external 
use under license from at least one global, originator pharmaceutical 
company. 
 The only South African-based API manufacturer, Fine Chemicals 
Corporation (FCC) was founded in 1962 in Cape Town. At incep-
tion, FCC produced codeine phosphate, morphine sulphate and para-
cetamol exclusively for the South African market. The product range was 
expanded in the 1980s with the development of a number of generic 
APIs, primarily for the US market. In the 1990s, FCC invested heavily 
to meet emerging international standards of GMP production. Since 
then, the company has been successfully inspected by various regula-
tory authorities including the USFDA in 1996, 1999, 2002 and 2006. 
 The company currently has 79 installed reactors with a capacity of 
125,000 litres, with individual reactor capacities ranging from 100 
litres to 6,000 litres for glass-lined and stainless steel. The company 
has significant expertise internally and supplements this with partner-
ships with local and international contract research organizations and 
organizations with expertise in chiral separations and catalysis. The use 
of APIs is typically regulated by the filing of a drug master file (DMF) 
that fully describes the route of synthesis, controls, CQAs, testing and 
specifications. FCC has in excess of 150 DMF submission in more than 
16 countries around the world. Therapeutic uses for locally manufac-
tured APIs are as immunosuppressants, anticancer, muscle relaxants, 
anti-psychotics, anticholinergic, bronchodilators, carbonic anhydrase 
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inhibitors, analgesics, antihypertensive, antianginals and anaesthetics, 
among others. 
 Bioclones was founded in 1982 with the aim of developing mono-
clonal antibodies and manufacturing biotechnology-derived products 
for human use. The company became one of the first in the world to 
develop recombinant human erythropoietin, which was registered by 
the MCC in 1997 and marketed in South Africa in 1998. 
 LaGray Pharmaceuticals in Nsawam, Ghana, is unique among African 
pharmaceutical manufacturers. LaGray was founded in 2002 by Alexandra 
Graham and Paul Lartey, a wife-husband team with extensive experi-
ence in drug discovery, development and manufacturing of both APIs 
and FPPs in the global pharmaceutical industry. Dr. Lartey is the former 
director of anti-infective drug discovery at Pfizer Corp. Dr. Graham held 
several management positions at Abbott Labs. LaGray aims to differ-
entiate the company from its competitors by meeting international 
standards of GMP. LaGray products for topical use include a number of 
anti-infectives. The company’s early approach focussed on new prod-
ucts whose quality could be assured without the added investment of 
human bioequivalence trials. LaGray has implemented advanced proc-
esses for waste management and wastewater remediation, an area which 
is often ignored in African pharmaceutical manufacturing. LaGray is 
presently cooperating with the USP (United States Pharmacopeia) to 
train operators – the skilled workers who do the actual pharmaceutical 
manufacturing, a critical training need in West Africa. LaGray also has a 
small-scale manufacturing facility for APIs and is producing commercial 
amounts of the macrolide antibiotic azithromycin in Ghana. 
 Leap-frogging technologies and training in new 
technologies for competitive advantage 
 Manufacturing processes for APIs typically reflect the standard of chem-
istry available at the time the corresponding FPPs were first registered 
and approved for use. Although API processes evolve over time to give 
improved yields, reduce solvent use and reduce manufacturing time, 
the routes of synthesis generally are those as registered by originator 
companies. Malaria drugs are one therapeutic area for which this is 
true. Artemisinin combination therapies (ACTs) for malaria treatment 
consist of older drugs that were combined in fixed-dose combination 
or co-packaged FPPs for use. The Global Fund and other non-govern-
mental organizations sourced approximately 389 million ACT treat-
ments in 2013 (UNITAID, 2013). Artesunate: amodiaquine (ASAQ) and 
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dihydroartemisinin: piperaquine (DHAP) are two standard ACTs. ASAQ 
is the second-most used ACT behind artemether: lumefantrine (ALU). 
 The Kilimanjaro School of Pharmacy has trained participants in the 
IPAT program to synthesize these APIs during laboratory exercises in 
API manufacturing. Trainees have also used the API they synthesized 
to manufacture DHAP and ASAP FPPs in the Kilimanjaro School of 
Pharmacy pilot plant. One of us (JF) has created new chemistry for 
the synthesis of these two APIs that is used by participants in the IPAT 
training. One of these exercises has been published (Fortunak et al., 
2013). The new chemistry utilized for this purpose has simplified the 
manufacturing process for amodiaquine from five steps to two steps 
with no intermediate isolations; this synthesis is also readily adapted for 
continuous-flow chemical reactors (Fortunak, 2014). The overall yield 
of this synthesis is about 93% as compared with 65% for the previous 
route. New chemistry discovered for synthesizing piperaquine has the 
same number of steps as the commercial synthesis, but completely elim-
inates the presence of a genotoxic impurity previously present at a level 
of more than 2% in an intermediate stage of the synthesis. This has 
allowed an overall improvement in the E-factor of the synthesis from 
more than 45-plus kilograms of waste to approximately 8 kg of waste 
generated per kilogram of API produced. The overall yield of this process 
again has improved, from approximately 55% to 93% on a five-kilogram 
demonstration scale (Fortunak, 2014). 
 To address the challenge of cost-competitive production of APIs 
in South Africa, one of us, PW, and researchers at Nelson Mandela 
Metropolitan University (NMMU) are working to provide a step-change 
in pharmaceutical manufacturing technology that will increase the 
availability and affordability of APIs. This step-change will result from 
the continuous production of APIs in small, modular units known as 
flow reactors. Flow reactors operate continuously on a small scale, for 
extended periods of time. Production carried out on a 24/7 basis reduces 
the size of reactors needed for production and thereby reduces the capital 
investment needed for production start-ups. Although flow chemistry is 
engineering-intensive and the individual reactors are more expensive 
than traditional, chemical stirred tank reactors, this upfront investment 
in advanced science can create substantial efficiencies in manufacturing 
footprint and production costs as well as capital investment. Waste 
generation during flow processing can often be significantly less than 
for traditional ‘batch’ processing of APIs. 
 Compared to stirred batch reactor methodology, the benefits of MRT/
flow chemistry are:
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 increased reaction control and reproducibility by:  ●
 efficient mixing  ●
 accurate control of time, temperature and pressure  ●
 increased catalyst lifetime and activity  ●
 enhanced safety due to:  ●
 rapid dissipation of heat  ●
 low reactant volumes at any given time  ●
 real-time analytical evaluation  ●
 lower cost due to  ●
 higher chemical yield  ●
 reduced material use and waste generation  ●
 reduced investment  ●
 This system’s flexibility has the potential to reduce the time and risk 
associated with transferring technology from research into production. 
This methodology is being exploited profitably by fine chemical compa-
nies in Europe. The aim of this project is to exploit this technology to 
reduce cost of drugs of importance to South Africa making the country 
more self-reliant. In the first instance NMMU are focusing on three anti-
HIV drugs, but the technology could readily be applied to other drugs of 
relevance to African needs. 
 Ethiopia: Research on local sources of starch 
as an excipient 
 Excipients used in FPPs may originate from natural sources, chemical 
synthesis or biotechnology. Since excipients are ingested every time a 
patient takes an FPP, safety, quality and price are important. Most excipi-
ents are generally regarded as safe (GRAS) for humans because of a long 
history of use in the food, flavourings and cosmetics industries. One of 
us (TGM) is researching the development of inexpensive local sources of 
excipients in Ethiopia for pharmaceutical production, with a focus on 
starch and starch derivatives, gums and resins. 
 There is a huge potential for the development of new and alternative 
local sources of excipients in Africa. Starch is used as a component in 
the manufacture of pharmaceuticals, food, textiles, paper and adhesives. 
The use of native starch or its modified forms is based on its adhesive, 
thickening, gelling and film-forming properties. Starches are readily 
available, low cost and can be processed to provide high-quality mate-
rials of varying grades for a variety of uses. Although starch is a major 
component in most plants, the main commercial sources are the seeds 
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of cereal grains (maize, wheat and rice), tubers (potato) and certain roots 
(sweet potato, cassava and arrow roots). Over the last ten years, native 
( enset ) starch has been produced on commercial scale in Ethiopia for the 
food and beverage industries. 
 The worldwide market for industrial starches is expanding, and the 
industrial trend is towards the use of commercially viable raw mate-
rials other than maize, wheat and potato, which have competing food 
uses. Some tropical plants including  enset ,  dioscorea , cassava and  godare 
have been investigated.  Enset starch extracted from  boulla provided a 
99% yield (recovery) of available starch on dry weight basis. Scanning 
electron microscopy (SEM) of  enset starch granules showed characteristic 
morphology that was somewhat angular and elliptical. Laser diffraction 
studies revealed normal granule size distribution with a mean particle 
size of 46 μm (Gebre-Mariam and Schmidt, 1996a). Evaluated as a 
binder and disintegrant for compressed tablets,  enset starch was found 
to compare favourably with potato and maize starches (Gebre-Mariam 
and Nikolayev, 1993; Gebre-Mariam and Schmidt, 1996b). 
 Super-disintegrants are modified polymers that rapidly absorb water 
and swell in the aqueous environment of the stomach. Sodium starch 
glycolate (SSG) is the sodium salt of the carboxymethyl ether of native 
starch. SSG rapidly absorbs water and swells, causing tablets and capsules 
containing these excipients to break apart rapidly, enhancing their 
release properties for improved drug absorption.  Enset starch was modi-
fied into sodium starch glycolate and evaluated as a super-disintegrant 
in compressed tablets. SSG of  enset starch was found to be at least as effi-
cient as commercial grades of SGG, Primojel ® or Croscarmellose sodium. 
In soluble tablet formulations, sodium starch glycolate of  enset was more 
efficient than Primojel ® or Ac-Di-Sol ® . Tablets prepared with sodium 
starch glycolate of  enset exhibited shorter disintegration times and faster 
rates of swelling and water uptake. Similarly, the sodium starch glyco-
late of  dioscorea starch was found to be more efficient than EXPT ® (the 
‘Explo-tab’ brand of SSG) in soluble and insoluble tablet formulations 
(Gebre-Mariam et al., 1996b). 
 Comparative studies of the starch in tablet formulations indicated 
 dioscorea starch has practically identical binding and disintegrating 
ability to that of potato starch (Gebre-Mariam and Schmidt, 1998). 
Drug release studies from matrix tablets revealed that the rate of release 
changed from rapid release to sustained release as the degree of substitu-
tion increased. Dissolution studies showed that  enset starch acetates with 
high degree of substitution could act as matrix-forming agents in tablets, 
where the release of a drug can be significantly sustained (Nigussu et al., 
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2013). Efforts are under way to progress the work for adoption in local 
pharmaceutical production. 
 Conclusion: building skills for API manufacture and 
drug discovery 
 African pharmaceutical companies largely employ excellent scien-
tists – their staff are often the equal of scientists anywhere. A major 
gap, however, is one of experience. The USFDA commonly notes that 
an appropriate combination of ‘education, training, and experience’ is 
needed to operate under GMP. Another challenge for pharmaceutical 
production is that African companies rarely are able to apply substan-
tial resources to developing new products. It is common for compa-
nies to purchase technical development packages from Indian generics 
producers as the source of their process descriptions. These packages 
are not nearly as detailed as needed for the full process understanding 
and control needed for SRA approvals. It is also difficult for African 
companies to expend equivalent resources on laboratory and pilot scale 
equipment and on preparing pilot- and commercial-scale development 
batches to optimize their manufacturing processes. 
 This chapter pinpoints two important strategies by which existing 
capabilities can be leveraged to support the emergence of a sustainable 
API, excipients and generic pharmaceutical industry on the African 
continent. Both of these approaches are suitable for implementation by 
regional centres of excellence (CoEs) in drug development and regula-
tory sciences. Regional CoEs are recognized by the PMPA and by the 
United Nations African Initiative for New Drugs and Diagnostics (ANDI) 
Program as important for developing African capabilities in pharmaceu-
tical innovation. 
 The first of these strategies is to develop education and training 
curricula at universities and academic Institutions. These programs must 
initially borrow from the experience of external experts to reduce the 
gap in hands-on experience in manufacturing technologies API, excipi-
ents and FPP as well as regulatory science. There are substantial numbers 
of African nationals working in important positions in global pharma-
ceutical companies today. Active recruitment of some of these experi-
enced scientists to ‘return home’ – a process known as braingain – could 
be an important point of leverage for promulgating, implementing 
and improving international standards for product development and 
SRA approvals. A number of African countries have courses in phar-
macy, industrial chemistry, fermentation technologies, microbiology, 
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biochemistry (including immunology) and process engineering, among 
others. As alluded to earlier, what is missing is hands-on industrial expe-
rience and learning-by-doing (DUI) mode of innovation. 
 A second strategy to promote African API, excipient and FPP devel-
opment is to fund regional CoEs to develop Technology Transfer 
Packages (TTPs) that enable pharmaceutical companies to implement 
quality-assured manufacturing of a specific API, excipient or FPP. If 
adequately funded, equipped and staffed with competent people, the 
CoEs could develop pharmaceutical manufacturing processes, analyt-
ical test methods and specifications for essential medicines. They can 
serve as clinical trial coordinators and knowledge brokers. With such 
an approach it should be feasible to sustainably raise the technological 
scope for locally manufacturing APIs, excipients and biologicals and to 
support a broader value chain of local pharmaceutical production on 
the continent. 
 Notes 
 1 .  See, for example, Bioclones (South Africa), manufacturing erythropoietin, 
 http://www.bioclones.co.za/ , and LaGray Chemical Company (Ghana), manu-
facturing azithromycin,  http://www.lagraychem.com/ . 
 2 .  See, for example, South Africa: Ketlaphela – South Africa Government’s ARV 
Manufacturing Project Enters Next Phase, all Africa, 16 May 2013,http://alla-
frica.com/stories/201305211581.html; Sarah Wild, ‘ARV plan bounces back’, 
 Mail & Guardian , 24 May 2013,  http://mg.co.za/article/2013–05–24–00-arv-
plan-bounces-back . 
 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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 Part II 
 Industrialization for Health 
 In Part II of this book we turn from the challenges of industrialization 
to the theme at the heart of this book: how to industrialize for health. 
Chapter 4 already explored the interactions between health and indus-
trial policies within one African country. The next three chapters ask 
how the aim of universal access to health care, and the needs of popu-
lations frequently denied competent care, can become the values that 
shape the industrialization drive. 
 Chapter 8 returns to two East African countries whose pharmaceutical 
industries have already been analysed, Kenya and Tanzania. Drawing on 
the framework of capabilities analysis developed and applied in Part I, 
this chapter asks: How can two sectors, health and industry, develop 
collaborative capabilities – the ability to work together? Industrial 
and health managers, like industrial and health policy makers, live in 
different silos across the world. Just bringing officials from the relevant 
ministries into the same room can feel like a major innovation. This 
chapter argues that while dialogue across these boundaries is essential, 
what has to follow is institutional change in both sectors to progres-
sively generate capabilities to work together. 
 In addressing the challenge of linking industry and health, in Part II 
we turn explicitly to learning from other continents. Chapters 9 and 
10 present a historical perspective on the experiences of, respectively, 
Brazil and India. The experiences are very different. Brazil can track a 
progressive coming-together of industrial policy and industrial devel-
opment with the needs of health care, rooted in the development of a 
universalist health care system. India, in contrast, has developed a major 
export industry in pharmaceuticals, but has been much less successful 
in meeting its population’s health needs. A common theme of these two 
chapters is the necessity of an historical understanding of cumulative 
change, economic incentives and key policy interventions in explaining 
outcomes in both health and industrial development. 
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 Introduction: health sector organization as implicit 
industrial policy 
 A recognition that the demand patterns and investment incentives gener-
ated by health care and health policies constitute an ‘implicit’ industrial 
policy for manufacturers of medicines and medical supplies is not new. 
In a European context, Thomas (1994) argued that post-1945 UK health 
care pricing and regulation policies drove a shift to global competitive-
ness in the locally based pharmaceutical industry, while French post-war 
health policy did not. Reich (1990) has argued that Japanese success in 
pharmaceuticals was nurtured, not by the MITI’s industrial policy, but 
mainly by government regulation and funding of the health sector and 
manipulation of pharmaceutical pricing. 
 The most sophisticated analyses of the health-industry relationships 
are by Indian and Brazilian scholars. Srinivas (2012) has analysed 
in depth the changing institutional relationships in India among 
the ‘triad’ of industrial production, health care provision/delivery 
and consumption of health care (Chapter 10) through three histori-
cally distinct ‘market environments’. Brazilian scholars and policy 
makers have been addressing for three decades the development of a 
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 ‘health-industrial complex’ (Chapter 9) consisting of a health sector 
aiming at universalization of access and framed by the constitutional 
right to health, the development of pharmaceutical, biotech and 
other medical supplies industries, and the supporting governmental 
institutions (D’Ávila Viana and Elias, 2007, citing pioneering analysis 
by Cordeiro, 1985; see also Gadelha et al., 2012; Shadlen and Massard 
da Fonseca, 2013). 
 This chapter examines health-industry interactions in two East African 
countries. The chapter traces the ways in which the health sector’s insti-
tutional organization in each country influences the domestic markets 
for industrial supplies. We argue that the recent institutional evolution 
in the health sector has tended to undermine local manufacturers’ link-
ages with their domestic health sectors in both countries, with a progres-
sive disconnection in particular between public and non-profit health 
care procurement of medicines and supplies and local manufacturers 
seeking market access. Coupled with rising external competition in the 
private medicines markets in each country (Chapters 2 and 3), these 
institutional changes have driven a process of partial disconnection of 
domestic industrial-health market linkages in the two countries. The 
effect is most striking in Tanzania, where the industrial structure is less 
robust (Chapter 3). 
 We argue that to achieve better developmental synergies between 
industrial development in manufacturing medicines and health system 
performance, both health and industrial sectors have to strengthen what 
we call ‘collaborative capabilities’: the capability to respond effectively to 
the opportunities offered by the other sector. We identify key elements 
of these collaborative capabilities in each sector and trace some ways in 
which institutional evolution and changing market structures can move 
health and industrial supplier sectors towards or away from mutually 
beneficial trading and working relations with each other. 
 We then go on to explore the mediation of these interactions via 
the under-researched institutions of procurement and local marketing. 
Procurement and marketing, we argue, are culturally and politically 
rooted institutions, not mere policy instruments. We aim to demon-
strate that policy coherence, which is essential to incentivizing health-
industry collaboration, is not only a matter of political will: it is itself a 
social construct that has to be built through institutional generation of 
collaborative capabilities and compatible incentive structures between 
health and industry at national level. 
 These conceptual arguments are developed through engagement 
with the findings from research undertaken in 2012–13 in Kenya and 
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Tanzania, which investigated supply chains from local producers and 
importers into the health sector. 1 Qualitative interviews and quantitative 
data collection on availability, source and price of a checklist of ‘tracer’ 
medicines 2 and other essential supplies were conducted in both coun-
tries. In Tanzania, 42 health facilities (public, faith-based and private), 
pharmacies and drug shops across four very diverse districts were visited 
(Tibandebage et al., 2014), while in Kenya, 55 health facilities, pharma-
cies and shops were interviewed in a comparative study (Kariuki et al., 
2015). Following these supply chain studies, wholesalers, manufacturers 
and policy and regulatory stakeholders were interviewed in both coun-
tries in 2013–14. This chapter draws also on some of these interviews, 
alongside secondary data sources. 
 Health sector market structure 
 In political economy terms, health sectors are  not best understood as 
‘delivery systems’ – the linear and top-down framing favoured in much 
of the global health literature. 3 Rather, they represent complex and 
culturally embedded social institutions and important sectors of the 
economy whose evolution can be analysed using the tools of industrial 
economics. In almost all low- and middle-income countries, health 
sector institutions include widespread markets in services as well as 
commodities. 
 A key determinant of a health sector’s capacity to procure and use 
medicines and other medical supplies effectively, and to develop good 
local suppliers, is therefore its market structures. These determine how 
the population’s demand for and need for medicines feeds through (or 
fails to feed through) into wholesale purchasing; who are the resultant 
wholesale buyers of essential supplies; what market power those buyers 
exercise; and how they select and distribute supplies. 
 Market and supply chain segmentation 
 The Tanzanian and Kenyan health sectors, like many others in Africa, 
rely heavily on private individual expenditure for financing; hence, 
fees and charges operate as barriers to access to adequate health care 
for much of the population (Chuma and Okungu, 2011; Maluka, 2013). 
WHO data for 2012 estimate that private out-of-pocket (OOP) spending 
funded 48% of Kenyan health care, with another 6% from private insur-
ance. The figures for Tanzania were 32% OOP, with negligible private 
insurance. 4 Charges are applied quite widely in the public as well as 
private sectors in both countries. 
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 Private health care facilities, including for-profit, and faith-based and 
non-governmental non-profit facilities play a quite substantial role in 
each country. Private for-profit providers in Kenya run 27% of the hospi-
tals and virtually all the nursing homes and clinics. Over half of Kenyan 
hospitals and over 75% of the health centres and dispensaries, however, 
are government-owned and run, with the rest (around 17% of each cate-
gory) in the faith-based sector. 5 Tanzanian data are not strictly compa-
rable, but the for-profit sector in Tanzania appears relatively smaller, 
owning 16% of dispensaries, 3% of health centres and 15% of hospitals 
(but only 4% of hospital beds). The faith-based sector is relatively larger 
in Tanzania, including 42% of hospitals, some funded and run as part of 
the government system (MoHSW, 2009). 
 These differentiated health care sectors buy medicines through quite 
segmented supply chains in each country. In the 2012–13 study outlined 
above, the public sector sourced supplies overwhelmingly from one 
large public wholesaler in each country. 6 Public facilities in Kenya had 
sourced 91% of the set of ‘tracer’ essential medicines from the public 
sector wholesaler, KEMSA. In Tanzania the comparable figure for public 
sector sourcing from the Medical Supplies Department (MSD) was 97%. 
In Kenya, private facilities sourced 99% of these essential medicines 
from private wholesalers, in Tanzania 94% (the main exception in each 
case was anti-retrovirals (ARVs) for HIV/AIDS sourced through the public 
sector). Only the non-profit facilities in Kenya had diverse wholesale 
sources, buying 44% from a faith-based, non-profit wholesaler (MEDS), 
about one-third from private wholesalers, and sourcing the rest from the 
public sector. In Tanzania there is no large non-profit wholesaler; the 
faith-based facilities’ medicines came largely (83%) from private whole-
salers, and the rest from the public sector. 
 However, a substantial proportion of essential medicines used by the 
population in these two countries, as across Sub-Saharan Africa (Wafula 
et al., 2013), is not accessed as part of treatment at a facility: rather, the 
medicines are bought in retail drug shops and pharmacies. Availability 
of essential medicines is limited and variable in the public sector in 
both countries, and public sector patients are often sent to shops to 
buy medicines out of pocket. 7 There are no reliable estimates of the 
percentage of essential medicines accessed through the private shops 
in either country, in part because of gaps in household budget survey 
data (MoHSW, 2012). National Health Accounts do not separate medi-
cines purchase from other facility spending (MoMS and MPHS, nd). The 
private shops were found to be entirely reliant on private wholesalers to 
source medicines. 
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 Market power and local purchasing 
 The implication of these market structures is that, with exceptions 
noted below, the final users and consumers of essential medicines 
exercise little influence over the sourcing and pricing of their medi-
cines. That market power lies with the wholesalers and with some large 
funding bodies. The different sectors in the two countries exercise 
that market power to different effect in terms of local procurement of 
medicines. 
 Our supply chain data (Table 8.1) show that the public sector whole-
saler in each country had bought a higher proportion of the tracer essen-
tial medicines from local manufacturers than had the private wholesalers. 
The faith-based wholesaler in Kenya (MEDS) was the most likely of all 
to source these medicines locally. All Kenyan wholesale sectors, further-
more, were more likely than their Tanzanian counterparts to buy these 
essential medicines from their local manufacturers (Table 8.1). Finally, 
while Tanzania buyers sourced medicines from Kenya (‘other African’ 
for Tanzania in Table 8.1 is largely Kenyan), the Kenyan buyers bought 
little from non-Kenyan African suppliers. 
 To what extent are these different patterns of local purchasing summa-
rized in Table 8.1 generated from the health sector side, from the manu-
facturing capabilities side, and from effective institutional cross-sector 
interaction? We begin by examining in turn the public, donor, non-
profit and private purchasing practices and their implications for health 
system capability and willingness to purchase effectively and economi-
cally from local suppliers. 
 Table 8.1  Country of origin of tracer essential medicines, by procurement sector, 
Tanzania and Kenya, 2012–13 (% by sector) 
 Country 
 Tanzania  Kenya 
Wholesale sector Wholesale sector
 Source  Public  Private  Public  Faith-based  Private 
Domestic manufacturers 22 11 53 76 33
Other African 10 21 0 0 6
India and Pakistan 49 50 30 11 31
China 6 6 8 1 4
EU and Switzerland 7 11 1 4 19
Other 6 0 7 8 7
 Total  100  100  100  100  100 
 Note : Numbers may not add to 100 because of rounding. 
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 Public sector procurement capabilities 
 The view from ‘below’ 
 Interviews with clinical and administrative staff in public sector facili-
ties in both countries about their experiences of procurement belie 
the image in the aggregated data above, of clearly segmented supply 
chains. The view from ‘below’ was not of a single linear public sector 
ordering process, but was more like navigating an interactive maze while 
constantly distracted by clinical demands. 
 In all the lower-level health facilities (dispensaries, health centres, 
smaller clinics), most people doing procurement were nurses and clin-
ical officers doing it as part of the day job 8 :
 Like me now, who is a clinician, I do almost everything, I am the 
procurement person, I am seeing the patients. (Clinical officer, 
Kenyan public health centre) 
 The only institutions that might have procurement officers with 
specialist training were larger hospitals: there, pharmacists, laboratory 
in-charges, nurses and medical directors would be involved, and team-
work was emphasized. A high-end private hospital in Nairobi felt they 
were coping:
 I can tell you in a hospital like this you will really need team work. 
We have trained everybody on inventory management. What they 
need to keep in terms of safety stock versus ensuring they have re 
order levels. (Hospital pharmacist, Kenyan private hospital) 
 Procurement staff in a stressed Tanzania urban district hospital by 
contrast felt they lacked the capabilities needed to do this well:
 This is a big hospital that has different departments. ... Some are slow 
while some are sharp. This delays the process ... departments that 
were quick in submitting their items ... keep knocking at our doors 
asking for their order. We have to tell them, procurement process is 
under way, while waiting for other department to submit theirs. They 
get angry because patients are waiting at their doors. (Procurement 
officer, Tanzanian public hospital) 
 Procurement, like all aspects of health care, is social and relational. 
Though form-filling is required, the ordering and control systems work 
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well only where institutional relationships stitch them into responding 
to health care needs on the one hand, and into effective and timely 
supply systems on the other hand. 
 In both countries, there were almost universal complaints about long 
delays and incompletely or inaccurately filled orders from the public 
wholesaler. Availability of our tracer medicines in public hospitals was 
61% in Kenya and 86% in Tanzania; these were all items hospitals should 
have held. The corresponding figures for the lower-level public facilities 
were 48% in Kenya and 58% in Tanzania. The prevalence of ‘stock-outs’ 
at the public wholesaler was thus a fact of life in both countries, forcing 
a search for alternative sources of supply. Patients were sent to shops 
to buy missing medicines, and in both countries many found it unaf-
fordable. Among many examples, a health centre interviewee serving 
low-income patients in Kenya commented that in cases of antibiotic 
resistance, ‘sometimes you are forced to write a prescription to that 
patient [for another type of antibiotic] but you see the patients we deal 
with are the less privileged people’, so some just went untreated. 
 Keeping essential items on the shelves was a constant struggle. The 
alternatives public sector staff turned to when stocks failed included 
spending user fees to fill gaps, using other pockets of public and donor-
supported funds, borrowing between public sector facilities, soliciting 
personal and institutional donations and even spending their own 
money. 
 How these pressures feel can be illustrated from interviews in two 
public dispensaries and a public hospital in a single rural district of 
Tanzania. In the two dispensaries, procurement was done by a clinical 
officer in-charge. They had no procurement training. They ordered most 
of their medicines from the public wholesaler every three months, via 
the district medical officer (DMO), and struggled with missing essen-
tial items and resultant accusations from patients of mismanagement or 
corruption. Opening the consignments was overseen by a local village 
health committee. 
 All collected fees from patients, but only the hospital retained them; 
the dispensaries deposited them with the DMO. The DMO had access 
to a donor-supported ‘basket’ fund; like the budgets for the district 
at the public wholesaler, these were sometimes deposited with a delay. 
The dispensaries applied to the DMO for gap-filling from the ‘basket’; 
the hospital also used its fees for this purpose. The hospital pharmacist 
would cycle off directly to buy urgent essentials at district-designated 
pharmacies. In the hospital, most essential medicines on our list were 
there, but barely, with little backup stock. 
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 An exception was items provided by ‘vertical programmes’ via the 
DMO, such as test kits for HIV, malaria and pregnancy. These were 
generally available but had to be collected from the district centre – a 
challenge for rural dispensaries with no petty cash and no means of 
transport. Staff paid for their own transport if no lifts could be found: 
one remarked, ‘this is not correct’. Medical equipment was the most 
problematic item: ‘even if you order them, you do not get them, so we do 
not order them ... we ask donors to help’. One clinical officer displayed 
thermometers obtained from a Dutch personal donor, a blood pressure 
machine sent to him by a friend in the United States and a stethoscope 
he had bought himself: individual networks of local rural sourcing were 
thus quite globalized. 
 Kenyan local-level experience echoes this complexity. There, public 
sector lower-level facilities obtained their KEMSA supplies through the 
local district hospital. The parallels to the ‘basket funds’ were the Health 
Sector Services Fund (HSSF) and Facility Improvement Funds (FIF), and 
they also used fees and charges. In addition, there was in Kenya a wide-
spread local culture of borrowing between public facilities, especially 
when patients could not afford to buy medicines in the shops, and espe-
cially in the rural districts: in these circumstances, 
 We usually borrow from other facilities, and they also borrow from 
us. (Nurse in-charge, Kenyan rural public dispensary) 
 Donor influence and government leverage 
 Local-level public sector procurement staff had little influence over deci-
sions on wholesale procurement of medicines from different manufac-
turing sources. Some, when asked, had views and preferences on where 
medicines should be bought, commenting for example on problems 
of packaging of locally manufactured items, or positively on patients’ 
acceptance of local brands. But decisions on manufacturing source of 
medicines in both countries were taken at wholesale level with little or 
no reference to facility-level views. 
 The public sector procurement bodies, KEMSA and MSD, sourced 
their medicines largely through international open tenders. 9 MSD is 
an autonomous government department working on a commercial 
basis 10 ; KEMSA was, until 2013, a government agency, and is now an 
authority. Tendering by both authorities is strongly price-focussed, and 
most tenders are very large. The emphasis on open tendering has effec-
tively liberalized the public sector medicines market in both countries. 
Both bodies can give 15% price preference to local manufacturers in 
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competition with imported products. In Tanzania, local manufacturers 
argue, this equates to around 9% effective preference, since they deliver 
to MSD, while overseas suppliers deliver to the port of entry. 11 In Kenya, 
some local manufacturers complain the preference is not reliably applied 
(UNIDO, 2010: 9). 
 In both countries, public procurement practices for medicines are 
strongly influenced by tendering rules promoted by the multilaterals 
and other donors; they are also shaped by requirements of the large 
donors providing medicines funding. The very large international 
tenders have helped to control tendering costs and improve confidence 
in the public procurement process. 12 The biggest institutional evolution 
in both countries’ medicines markets in the last decade has been the 
growth of large-scale donor-funded procurement of medicines for TB, 
HIV/AIDS and malaria. Around 63% of MSD’s income from medicines 
and medical supplies came from these ‘vertical programmes’ in 2011–12, 
and this percentage varies sharply year on year (MSD, 2013). In Kenya, 
the latest estimate we have found is for 2005–06, when the government 
budget share of total public expenditure on medicines was estimated 
at 21.6%, the bulk of the expenditure being donor-financed (MMs and 
MPHS, 2010: 53). 
 For donor-funded medicines, there is substantial international partici-
pation and control of pooled procurement processes by organizations 
such John Snow International and Management Sciences for Health 
within the Partnership for Supply Chain Management. 13 The donors’ 
emphasis has been on generating a global supply management chain 
for very high volumes of imports into East Africa, from ‘pre-qualified’, 
generally Asian suppliers to regional level in Africa. The pre-qualifica-
tion process, run by the World Health Organization (WHO) 14 to approve 
specified products of individual suppliers, has in practice largely excluded 
local manufacturers in both countries from the domestic markets for 
these products (see also Chapters 2, 3 and 5). 
 International donors also fund other essential medicines, including 
other public medicines’ procurement. The ‘basket’ fund in Tanzania, 
mentioned above, is donor-funded. The flows of support are complex, 
erratic, poorly documented, generally unconsolidated and uncoordi-
nated, and sometimes provided in-kind, as shown by ‘spaghetti’ diagrams 
of hugely complex financing and in-kind flows for medicines supply in 
each country (KEMSA Task Force, 2008: 28; MoHSW, 2008: 23). 
 In these circumstances, how much leverage do national governments 
exert over their domestic medicines markets and procurement? Leverage 
over procurement patterns can be exerted through national regulatory 
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policies – for example, by setting tendering rules and coordinating 
funding flows. However, the extent to which the national governments 
contribute funds to the medicines procurement ‘pot’ remains an impor-
tant element of policy leverage. Data are poor, but estimates drawn from 
national health accounts and policy documents suggest that in each 
county, only around 5% of the domestic medicines consumption is 
currently funded by the government taxes. 
 For Tanzania, the domestic market size for medicines was estimated at 
around US$250 million in 2011–12. 15 Of this market, public wholesaler 
(MSD) sales were around 50% (US$125 million), of which 70% in turn 
were donor-funded vertical programme sales (MSD, 2013). That leaves 
just US$37.2 million as government-funded MSD procurement, or 15% 
of the total market. However, the Ministry of Health and Social Welfare 
has estimated that only around 30% of the pooled public funds held by 
public health facilities in accounts at MSD for medicines and medical 
supplies were locally tax funded, equating to around US$11.3 million, 
the rest coming from donor basket funds (MoHSW, 2013: 4–5). The 
implication is that just 5% of Tanzanian medicines were tax-funded in 
2011–12. 
 A parallel calculation for Kenya could only be drawn from the most 
recent Kenyan National Health Accounts (MMS and MPHS, nd). They 
show total health spending (THE) for 2009–10 as US$1.62 billion. The 
Kenyan National Pharmaceutical Policy (NPP) (MoMS and MPHS, 2010: 
53–54) estimates total pharmaceutical expenditure (TPE) at around 
20% of THE, or US$324 million; of that ‘about 15–20%’ was public 
expenditure, or around US$64.8 million. Finally, the same document 
states (p. 53) that government spending was estimated in 2005–06 at 
21.6% of public spending on medicines, the rest being donor funded. 
If that percentage were stable over time, it would imply a government 
tax-funded share of the Kenyan domestic medicines market in 2009–10 
of under 5%. 
 None of these calculations is at all secure. But they are sufficiently 
similar and striking to indicate a strategic policy constraint for both 
governments. The market size estimates are likely to be low rather 
than high: UNIDO’s Kenyan review (2010: 36) concluded of their own 
calculations that ‘not all, if any, of the donor-funded supply of medi-
cines is included in such [market size] estimates’. Policy documents in 
both countries indicate very high reliance on donor funding of medi-
cines (MoMS, 2010). The robust conclusion for both countries is that 
the governments exercise very little tax-funded leverage over their 
domestic medicines markets in relation to both need and demand. Both 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
Health Systems as Industrial Policy 157
governments’ leverage at present depends almost solely on regulatory 
interventions. These data also suggest that, over time, it will be impor-
tant to shift tax resources into the medicines funding stream. 
 Non-profit wholesaling: a case study of local procurement 
 Non-profit wholesalers and distributors can have a beneficial impact 
on essential medicines markets, providing low-priced competition in 
the supply of quality-assured medicines (Mackintosh et al., 2011). Both 
Tanzania and Kenya have non-profit medicines wholesalers supplying 
the faith-based and NGO sectors. Those in Tanzania, Action Medeor 
and MEMS, are small, while MEDS in Kenya is a large wholesaler with a 
turnover of about US$15 million in 2012 16 and therefore with substan-
tial market impact. Action Medeor was supplying both faith-based and 
government facilities, and also selling to the Accredited Drug Dispensing 
Outlets (ADDOs), the regulated drug shops in Tanzania. It was, however, 
too small a supplier to appear in our Tanzania facility survey data. MEDS, 
on the other hand, supplied most of the faith-based and NGO facilities 
interviewed in Kenya. 
 The interviews showed that MEDS had a good reputation among 
those procuring medicines for faith-based and non-profit facilities. The 
two main reasons given for reliance on MEDS were price first and also 
reliance on their quality assurance. There was general agreement that 
they were cheap: not always the cheapest, but a combination of cheap-
ness and reliability of quality and supply. 
 MEDS was also regarded as responsive to its clients on quality, 
responding to queries and complaints, taking back problematic 
supplies, and consulting on its stock lists. MEDS is working in a market 
context, where facilities have a choice of supplier, and it also responded 
to requests concerning the brands and origins of specific medicines, 
and to consider suggestions for new items. They would also order items 
not held in their stocks, and they maintained short delivery times 
(1–3 days) for stocked items. They were serving a differentiated faith-
based health sector, with facilities serving higher-income groups and 
those serving the very disadvantaged, and they might stock more than 
one brand of the same item if preferences of customers require. They 
warned in advance when phasing out items from their stock lists, or 
when a shortage arose. They gave some credit: ‘we pay at the end of the 
month and they do not push us’ (Kenya, faith-based clinic). ‘They are 
very reliable’, one interviewee remarked. This was a remarkably positive 
set of assessments. 
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 Both Action Medeor and MEDS had a strong orientation towards 
buying locally, subject to quality and price considerations. Action 
Medeor stated on its website: ‘Most of our products are purchased locally 
in line with Action Medeor’s policy to support local manufacturers – 
however, without compromising on quality’. 17 Given the limitations of 
Tanzanian suppliers (Chapter 3), Action Medeor was in practice buying 
from manufacturers in the East African region, notably Kenya and 
Uganda, as well as Tanzania. 18 Both Action Medeor and MEDS organized 
their procurement by ‘pre-qualifying’ local suppliers, using their own 
technical staff for inspections, site visits and questionnaires. MEDS kept 
suppliers ‘on their toes’ through batch testing of supplies on-site in their 
WHO-prequalified laboratory. 
 As Table 8.1 showed, MEDS was buying a high proportion of their 
basic essential medicines from local manufacturers. This success in local 
purchasing reflected a strong capability for local procurement built up 
over a number of years. 19 In contrast to the Kenyan public wholesaler, 
MEDS issues only local tenders for medicines and supplies, with no 
direct importing. Two local tenders a year go only to MEDS’s pre-quali-
fied supplier pool of local manufacturers and distributors. 
 Price is a very important component of MEDS’s tender acceptance, but 
as private businesses, non-profit wholesalers such as MEDS can make 
their own supplier decisions, and price may not be the only consid-
eration. 20 Both quality and supplier performance, including lead times 
and meeting delivery deadlines, influence MEDS’s supply decisions. 
Local manufacturers can provide short lead times and reliable quality if 
working relationships are good. Furthermore, MEDS sustains its working 
relationships with suppliers through an annual invitation-only suppliers’ 
conference during which issues are discussed and tender documents are 
generally available so that suppliers can plan ahead. 
 In our 2012–13 data, two local manufacturers had supplied nearly 70% 
of the tracer items sourced from MEDS: local firms producing a broad 
range of basic formulations can generally compete on the required mix of 
price and performance, though they can be beaten on price by imports. 
While MEDS leans towards regularly inspected local suppliers for basic 
essential medicines, donors’ subsidized procurement arrangements, for 
example of the first-line anti-malarial medication, has meant a lack of 
local supply, and local distributors import those items for MEDS. 
 This case study of MEDS suggests some lessons about effective local 
procurement and supply, working with local suppliers and faith-based 
facilities. That capability is now being tested, as the decentralization 
reforms allow counties to switch suppliers, causing demand for MEDS’ 
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services to rise sharply from new buyers who lack experience in quan-
tifying demand, and may delay payment. 21 The market segmentation 
identified from our data is now breaking down, as MEDS and KEMSA are 
effectively in competition (PSP4H, 2014; Yadav, 2014). 
 Private sector procurement and local products 
 The public, donor and non-profit procurement of medicines is impor-
tant for medicines access. However, in both countries, half of medicines 
access or more relies on private sector wholesaling and importing. The 
interviews with private facilities and shops demonstrate that, in both 
countries, private retailers and clinicians rely almost wholly on private 
wholesalers. While most smaller buyers had little influence over the 
sources of the medicines they bought, many had opinions on the best 
sources of medicines, as did their patients. Asked systematically about 
the comparison between locally produced and imported medicines, the 
respondents’ views varied according to their clientele. Some high-end 
private hospitals in Kenya, when procuring medicines, specified brands 
preferred by their patients, notably from European suppliers. Some phar-
macies in better-off areas also said there was resistance to locally made 
branded generics. 
 Generally, however, the facilities and shops with lower-income clien-
tele, who were buying from private wholesalers, would focus on price. 
Where the local items were price competitive, their clients would gener-
ally accept local brands, especially some, such as Shelys in Tanzania, 
which had built up a strong brand image (Mujinja et al., 2014). While 
in Tanzania opinions varied as to whether locally made medicines were 
cheaper or more expensive than imports, the consensus in Kenya was 
that local items tended to be cheaper:
 By the way the locally manufactured drugs are cheap and the people 
who go for them are the health facilities in upcountry. ... mission 
hospitals, clinics, district hospitals and local pharmacists in upcountry, 
they really support local manufacturers. (Private hospital, Kenya) 
 Most private retailers and facilities in both countries had built up long-
term relationships with one or a few private wholesalers/importers, 
from whom they bought most of their supplies. The determinants of 
choice of supplier were predominantly price and credit terms, followed 
by issues such as transport arrangements and variety of items available. 
None could judge quality except through expiry dates and experience 
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of clinical effectiveness, and only one interviewee had changed supplier 
for quality reasons: they found near-expiry drugs repackaged, more than 
once, as longer-dated on the external packaging, and changed supplier 
as a response. 
 The interrelated issues of price and credit terms were key: private 
shops and facilities are often struggling to maintain cash flow them-
selves, so they are looking for credit from suppliers. This was quite a 
typical comment:
 The main reasons why I chose those wholesale pharmacies are the 
prices of the drugs, quality and the convenience each of them offers. 
[Pharmacy X] is my number one priority because for most medicines 
they have the lowest prices. (Tanzanian rural private dispensary) 
 This was the type of credit relationship that sustained many small drug 
shops:
 [Pharmacy Y] can give medicines on a loan basis without any collat-
eral provided what you take from the pharmacy does not exceed 
400,000/= [Tanzanian] Shillings, and you pay after selling, in one or 
two months’ time. (Rural drug shop, 22 Tanzania) 
 The main criticisms of locally manufactured medicines raised by private 
sector respondents in both countries concerned packaging, which was 
said to compare poorly with imported competing items, putting off 
users. In Tanzania, there was repeated criticism that some locally manu-
factured tablets tended to disintegrate too easily, and some unfavourable 
comparisons with the quality of Kenyan manufactured tablets. 
 The decisions of private wholesalers were therefore important to 
the local manufacturers’ domestic market demand. Kenyan manu-
factured medicines were quite widely imported into Tanzania by the 
private wholesalers (Table 8.1; see also Chapter 2), while there were few 
Tanzanian items found in the Kenyan market. The Tanzanian private 
market was more heavily reliant on India (Table 8.1). 
 In both countries, many private wholesalers are also importers, who 
act as representative agents for Indian and European manufacturers. If 
margins are better on imported items, then importers will lack incentives 
to source and distribute local manufactures. Some large wholesalers/
importers supply only imported products, while others also deal in local 
products. Some importers, such as Phillips, have worked closely with 
a number of donor-funded projects, for example distributing imported 
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subsidized anti-malarials and importing items for PEFAR-funded gap-
filling supplies for donors’ projects. 
 There are also wholesalers who have retail chains, and supply other 
retailers, and in both countries they buy locally as well as from importers. 
One such pharmaceutical wholesaler in Tanzania explained that there 
was demand for both Tanzanian and Kenyan medicines; however, there 
were constant shortages of Tanzanian items, whereas ‘Kenyan products 
are always available in the market’. Kenyan suppliers such as Elys have 
representatives in Tanzania, and their products are widely distributed 
there. 
 Local manufacturers’ collaborative capabilities 
 An important difference between the two countries is in the scale of 
the local pharmaceutical industry and the range of products the firms 
have the capability to supply (Chapters 2 and 3). While Tanzania had 
just five operating firms when the 2013 research was done, Kenya had 
about 40 producers, including firms capable of supplying parenterals 
manufactured in sterile conditions. The density in itself meant that 
Kenyan firms were more able than Tanzanian firms to supply their local 
market. However, they still currently (2013) supply only around 25% of 
the domestic demand (Chapter 2). There is clearly room for expansion 
of local supply in both countries. 
 In both countries, local manufacturers are strongly oriented to 
supplying the private market. Despite sharp price competition from 
imports and a lack of trade protection in the private market, Kenyan 
producers are continuing to compete successfully. One contribution to 
this price competitiveness appears to be export success: Kenyan manufac-
turers have expanded exports to the region (Chapter 2), allowing them 
to build up economies of scale and keep prices down. In addition to sales 
through local wholesalers, at least one large manufacturer in Tanzania 
had developed its own marketing teams to ensure wide product availa-
bility and brand recognition across the very large geographical distances 
in that country. 
 However, in both countries, there were problems concerning supply to 
the public wholesaler, and also problems of policy directions that were 
undermining the competitiveness of the local industry. The problem 
was sharper in Tanzania (Chapter 3). Even in Kenya, however, at least 
one large manufacturer had moved away from public sector tendering, 
citing KEMSA’s focus on the lowest possible price, in order to build up 
higher-margin exports. Some larger Kenyan firms, with an expanding 
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product range, continued to tender successfully. In Tanzania, some local 
manufacturers had shifted to supplying the public sector through local 
private wholesalers, who could carry the costs of bundling local and 
imported items and also carry some of the tendering costs and associ-
ated risks. 
 Furthermore, in both countries, there had been tax and tariff deci-
sions that had undermined local manufacturers’ competitiveness. In 
Kenya, manufacturers and distributors noted that the 2013 decision to 
impose VAT on inputs for pharmaceutical production was forcing up 
prices and undermining market access. In Tanzania, as Chapter 3 docu-
ments, the removal of tariffs on final goods, associated with VAT and 
tariffs on some inputs, was a substantial problem for the sustainability 
of the whole industry. In Kenya, however, the manufacturers’ associa-
tions had made strong representations, and in 2014 this was amended 
to exempt inputs or raw materials for pharmaceutical manufacturing in 
Kenya. 23 However, the amendment was silent on packaging: the Kenyan 
manufacturers had previously fought successfully to remove taxes from 
packaging inputs, and had then seen those gains reversed. It appears 
that Kenyan manufacturers’ associations are able to exert more influ-
ence over relevant policies than their equivalents in Tanzania. 
 However, local manufacturers in the two countries have historically 
struggled to exert influence over policies of donors. Many donor poli-
cies have excluded local firms from domestic market segments, the most 
damaging having been the loss of most of the regional anti-malarials 
markets to donor-subsidized, WHO-prequalified external suppliers. The 
extent of local firms’ collaboration with external donors and multilat-
erals has, however, been increasing recently. Examples include working 
with WHO and UNIDO projects to support technological upgrading; 
working with charities such as Drugs for Neglected Diseases (DNDi) 
to implement new formulations and achieve pre-qualification; and 
working with PEPFAR to supply gap-filling medicines to donor projects. 
This process of learning to exert influence and benefit from collabora-
tive projects is an important element of firms’ learning and upgrading 
in the strongly donor-influenced regulatory and policy environments 
within which these firms work. 
 Conclusion: building collaborative capabilities 
 The sharp process of institutional change in the health systems and medi-
cines financing in Kenya and Tanzania has faced the largely locally owned 
manufacturers of medicines currently working in the two countries with 
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major shifts in market structure, regulation, demand patterns and the 
political economy of policy influence. The big changes have included 
increasing liberalization and ‘globalization’ of the domestic markets for 
medicines, associated with a growing private health and retail pharmacy 
sector, especially strong in Kenya, and a sharp rise in the variety and 
volume of imports on the market. 
 The public sector market has also been globalized, with increasing 
donor pressure for large-scale open international tenders, pooled 
procurement and a ruthless focus on price. Donors have been able to 
exert leverage for this evolution because of the huge increase in external 
funding provided for medicines and the need for reform because of 
earlier problems with public tendering processes. One outcome has been 
a dominant international ‘framing’ of the supply chains and procure-
ment issues as a challenge in linking ‘pre-qualified’ external suppliers 
to local patients. Barriers to domestic market entry for local firms were 
raised by these institutional changes, and domestic market linkages 
disaggregated. 
 Now, these disaggregated linkages need to be substantially and collab-
oratively rebuilt, and then sustained in a very open market environ-
ment. For this purpose, there is a highly important role for government. 
Key policy objectives should be to institute and enforce measures to 
enhance medicines access through public and faith-based facilities in 
the health sectors within both countries, and to shift procurement 
incentives towards encouraging purchasing from local suppliers. 
 At the same time, these policies can only be effective if they are 
designed in collaboration with the market actors who must build and 
manage the market linkages that allow effective domestic market supply. 
The MEDS example, though operating in a specific niche, suggests some 
of the key elements for the rebuilding of market linkages between health 
and industrial sectors. They include active consultation and working 
relationships between procurement agents and supplier firms; pre-quali-
fication of local suppliers, with a strong element of quality control; and 
a necessary level of business autonomy in procurement decisions on 
price/quality trade-offs. 
 Some of these elements are observable also within public sector 
procurement and can be built upon to create cumulative improve-
ment. Some medical and other supplies (such as furniture items) are 
bought by the public wholesalers from local suppliers under more flex-
ible purchasing arrangements. Local firms actively produce and supply 
emergency items (and resent being called upon in this way after they 
have lost earlier tenders). Furthermore, the public wholesalers have the 
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financial capability to offer more active collaboration, in the form of 
longer contract to incentivize suppliers’ investments, and better credit 
terms, if they wish to do so. In Kenya, the decentralization reforms have 
given KEMSA more autonomy while shifting some demand to MEDS 
(PSP4H, 2014). 
 This (re)building of domestic linkages has to be done in the context, 
not only of high levels of external competition but also in the face of the 
very high level in each country of ‘fragmentation’ (Chuma and Okungu, 
2011; McIntyre et al., 2008) in health financing, procurement, service 
supply and management, and in a context where government expendi-
ture exerts little domestic market leverage, as documented above. Policy 
coherence between health and industrial policies, an essential objective 
for governments seeking developmental synergies, is not merely a set 
of government decisions, but a social construction that has to be built 
over time through institutional generation of collaborative capabilities 
in both sectors, and associated incentives for extracting mutual benefit. 
The Ethiopian governments’ effort to combine health-sector improve-
ment with industrial-sector support (Chapter 4) identifies the relevance 
of health-sector restructuring for strengthening local health-industry 
collaboration. The Brazilian experience explored in the next chapter 
reinforces this point. 
 Notes 
 1 .  This chapter is based on the research project  Industrial productivity and  health 
sector performance . The findings, interpretations, conclusions and opinions 
expressed are those of the authors and do not necessarily reflect the views 
or policies of DFID or the UK ESRC, whose financial support is gratefully 
acknowledged (project ES/J008737/1). Particular thanks to all our interviewees, 
who gave time within very pressured lives to talk to us, often at considerable 
length. Thanks also to participants in a Policy Dialogue workshop in REPOA, 
Dar es Salaam, June 2013, at which early findings from these surveys were 
presented and discussed, and to Watu Wamae for research collaboration and 
for comments on an earlier draft. The same disclaimer applies. 
 2 .  In Kenya, a set of 29 essential medicines, including ARVs, were used for the 
quantitative data collection (Kariuki et al., 2015); in Tanzania, a comparable 
set of 24 medicines was used (Tibandebage et al., 2014); the differences were 
largely the result of differing treatment regimes between the two countries. 
 3 .  For example, the WHO Health Systems Framework and its ‘building blocks’ 
are a framework for service delivery;  http://www.wpro.who.int/health_serv-
ices/health_systems_framework/en/ . See also Kim et al. (2013) for the rise of 
‘health care delivery science’ in the global health field. 
 4 .  WHO Global Health Observatory,  http://apps.who.int/gho/data/node.
main.78?lang=en (accessed 3 March 2015) (Kenya);  http://apps.who.int/gho/
data/node.main.75?lang=en (accessed 20 November 2014) (Tanzania). 
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 5 .  Calculated by the authors from Ministry of Health, Health Management 
Information Systems data for 2010. 
 6 .  These data were collected in Kenya before the decentralization reforms that 
have allowed counties to diversify procurement sources for public health 
sector supplies. 
 7 .  Source: quantitative data and interviews, 2012–13. 
 8 .  All quotations are from fieldwork unless otherwise stated. 
 9 .  Source: interviews, KEMSA website,  http://www.kemsa.co.ke/ , UNIDO (2010). 
 10 .  http://www.msd.or.tz/index.php/aboutus/msd-organizationconsulted 
(accessed 27 March 2015). 
 11 .  Source: interviews. 
 12 .  Source interviews, see also Yadav (2014) and MSD (2013). 
 13 .  http://pfscm.org/pfscm consulted 6/3/15. 
 14 .  See  http://apps.who.int/prequal/ consulted 27/3/15. 
 15 .  Source, interviews. 
 16 .  Calculated from MEDS (2013: 38), from sales of KShs 1.413 billion. 
 17 .  http://medeor.de/en/medeor-tanzania/purchasing-information.html 
(accessed 1 April 2015). 
 18 .  Source: interviews. 
 19 .  Source: interviews. 
 20 .  An HAI/WHO assessment of medicines procurement prices in 2004 confirmed 
this perception independently: MEDS procurement prices were somewhat 
higher than KEMSA procurement prices, though both were paying low prices 
by international standards;  http://www.who.int/medicines/areas/technical_
cooperation/MedicinepricesKenya.pdf (accessed 29 March 2015). 
 21 .  MEDS (2013) confirms a problem of rising debt that has to be addressed. 
 22 .  This shop was an Accredited Drug Dispensing Outlet (ADDO). 
 23 .  By the Value Added Tax (Amendment) Act, No. 7 of 2014, Kenya. Inputs or 
raw materials (either procured locally or imported) supplied to pharmaceu-
tical manufacturers in Kenya for manufacturing of medicaments, as approved 
from time to time by the Cabinet Secretary for National Treasury in consulta-
tion with the Cabinet Secretary responsible for health, were added to list of 
exempts. 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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 Introduction 
 In a book exploring the scope for mutually supportive integration 
between addressing health care needs and promoting industrializa-
tion, Brazil’s experience offers an important case study. 1 This chapter 
presents Brazil’s main strategies to ensure access to medicines to tackle 
the population’s principal health problems. It particularly aims to show 
how the principle of the universality of care has influenced industrial 
policies and production in the pharmaceutical sector. Although more 
than 25 years have passed since Unified Health System ( Sistema  Único de 
 Saúde : SUS) was established, and much progress has been made, a great 
many challenges remain. This chapter focuses particularly on those 
related to access to health technologies. 
 The underlying premise of the Brazilian approach is that health is a 
social right and improving the health of individuals has a positive impact 
on society as a whole. Yet the sustainability of the health system depends 
on a domestic production system capable of producing the needed tech-
nologies for health care. That production system in turn constitutes an 
important economic sector, generating employment and income and 
capable of reducing external dependence in strategic areas. This chapter 
explores how this relationship is configured within Brazilian society, the 
progress made and challenges faced by attempts to guarantee a reduc-
tion in health inequalities, with the aim of increasing policy dialogue 
between Brazilian, African and other policy makers and researchers. 
Brazilian experience in the dissemination of local innovations to meet 
health needs could be learned from and drawn upon by other countries, 
including recognition of the huge challenges that remain. 
 9 
 The Dissemination of Local Health 
Innovations: Political Economy 
Issues in Brazil 
 Erika  Aragão,  Jane Mary  Guimarães and  Sebastião  Loureiro 
OPEN
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 New medical technologies hold great promise for improvements to the 
population’s health, but they accentuate concerns about the amplifica-
tion of already significant health inequalities, since their consumption 
is determined by a range of factors, including the socio-economic status 
of the patient and the existence of public systems that guarantee patient 
access (Goldman and Smith, 2005). The impact of new technologies on 
health disparities depends on how hard they are to adopt and who effec-
tively receives treatment. They are not uniformly absorbed into health 
systems, nor is there a guarantee of access for all, even in systems with 
universal coverage (Loureiro et al., 2007). 
 In high-income countries, research and development (R&D) efforts 
may result in innovations driven by technology, despite a high degree 
of uncertainty. However, in developing countries, demand constitutes 
the principal stimulus for innovation. From this perspective, the legal 
framework and the organization of health systems may either direct the 
diffusion of technologies towards social interests or allow the process to 
occur in a manner more closely aligned with market interests. 
 For its part, health care is increasingly expensive and dependent on 
a series of technologies such as diagnostic and surgical equipment and 
pharmaceutical products. The factors responsible for significant increases 
in health spending as a proportion of a country’s domestic income and 
which may compromise the sustainability of its health system, include: 
the cumulative nature of the use of medical technologies; the oligopo-
listic structure of the sector, which often includes temporary monopo-
lies obtained via intellectual protection; increases in per capita income 
and life expectancy; and changes to the epidemiological profile. 
 The sustainability of health systems is therefore one of the greatest 
challenges for public administrations at a global level, particularly 
for countries with universal systems such as Brazil, a middle-income 
country. Since 1988, the Brazilian state has considered health as a right 
and its provision as a duty that must be guaranteed to all its citizens; this 
includes pharmaceutical health care, which is considered necessary for 
the guarantee of comprehensive services. 
 Given significant pressure for the systematic incorporation of new 
medicines into the Brazilian health system, the country has sought to 
incentivize the growth of domestic technological capability, reflecting 
the demands of its Unified Health System. From this perspective, inno-
vation within this industry has significant relevance for Brazil’s social 
and economic development and presents huge challenges, given the 
complexity of scientific and technological development activities, 
the political and institutional coordination required, the scarcity of 
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resources and the nature of mechanisms for knowledge production and 
appropriation. 
 This is, therefore, a field that allies economic dimensions with a strong 
social dimension, requiring the mobilization of a broad regulatory and 
institutional apparatus. In this way, despite the crisis in the both the 
Keynesian and the welfare state, health continues to be one of the most 
significant areas of state intervention, both in the service sector and in 
scientific and technological activities (Aragão et al., 2014; Gadelha and 
Costa, 2012). 
 Pharmaceutical health care in Brazil: seeking to link 
economic and social logic 
 The logic of social rights 
 The Unified Health System (SUS) was instituted by the 1988 Federal 
Constitution, as a result of a widespread movement for the democ-
ratization of society and another within the health sector, known as 
Sanitary Reform, which sought to create a public health system for all 
the country’s citizens (Paim, 2009). Since 1988, health has been consid-
ered an inalienable right, and the state is responsible for guaranteeing 
universal, comprehensive and equitable access to activities and services 
that include the prevention of diseases and the promotion and restora-
tion of health. 
 Through the 1988 Federal Constitution, the health system was inte-
grated into the social security system and the social care and welfare 
systems (Federal Constitution 1988, art. 194), becoming a sector without 
restrictions on beneficiaries, where access did not require users’ contri-
bution (Brasil, 1998, art. 196). 
 The interpretation of the concept of social justice in the Brazilian 
Federal Constitution is innovative, since it views social security as ‘an 
integrated series of activities initiated by the public authorities and by 
society, aimed at security rights related to health, welfare and social 
care’, 2 introducing the notion of universal social rights as a condition 
of citizenship. It recognizes social rights and asserts that it is the duty of 
the state to guarantee such rights. 
 In the case of the SUS, universality represents the opportunity for 
all citizens to use public health activities or services without barriers 
to access of an economic, physical or cultural nature; comprehensive-
ness is understood in relation to a series of coordinated and continuous 
preventative and curative, individual and collective activities and serv-
ices, at all levels of system complexity; and equity contains within it a 
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certain notion of justice. It recognizes that individuals are different from 
each other, and therefore deserve differentiated treatment. In this sense, 
access to medicines begins to constitute a right, in that it is a health care 
component at all levels of complexity. 
 The 1990 Organic Health Law ( Lei  Orgânica  da  Saúde : LOS) asserts that 
the execution of comprehensive therapeutic care activities falls to SUS, 
and this includes pharmaceutical health care, given that medicine is 
a strategic ingredient to support health activities and its absence may 
compromise treatment, affecting both the patient’s quality of life and 
the problem-solving capacity of health activities. 
 To secure this, it is envisaged that the SUS, amongst other bodies, 
formulates public policies; develops programmes that enable the popu-
lation’s access to medicines, equipment, vaccines and other supplies to 
meet its health needs; and participates in their production, either directly 
through public laboratories, or indirectly, acting jointly with those 
economic and science and technology bodies aimed at guiding research, 
development and production in the public interest. Furthermore, it 
operates through agreements and partnerships with private pharma-
cies, enlarging distribution channels. This is regarded as a tense arena 
of negotiation between collective and private interests, highlighting the 
need for state action to ensure that the institutional framework func-
tions adequately (Gadelha, 2006; Gadelha et al., 2012; Oliveira et al., 
2006). 
 Brazilian pharmaceutical health care policy 
 The integration of pharmaceutical management with production 
policy is distinctive of the Brazilian approach. To secure its guarantee 
to supply medicines to the Brazilian population, the Ministry of Health 
needed to work with, amongst others, the economic and science and 
technology spheres as core elements in the conduct of policies that 
guarantee the production of pharmaceutical products designed to 
meet SUS needs. 
 Although the right to pharmaceutical health care has been enshrined 
in the SUS since its creation, a specific policy – the National Medicine 
Policy ( Política  Nacional de  Medicamentos : PNM) – was only created 
in 1998. In 2004, this was superseded by the National Policy of 
Pharmaceutical Care ( Política  Nacional de  Assistência  Farmacêutica : PNAF) 
(Brasil, 2004a). Overall, this strategy extends the Brazilian population’s 
access to medicines and is therefore based on the same principles that 
guide SUS. This policy is based on the promotion of the rational use of 
medicines. It includes a range of adjustments to pharmacy practices and 
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regulation, the production of essential medicines and scientific and tech-
nological development. Thus several initiatives were taken to enhance 
the national production of pharmaceutical drugs such as qualifying the 
public laboratories, and incentives to private groups to produce priority 
drugs to meet the SUS demand with financial support from distinct 
governmental agencies and offices other than the health sector. 
 The financing of public pharmaceutical health care programmes is the 
responsibility of the three spheres of SUS management: the federal, state 
and municipal governments. The allocation of resources to finance the 
acquisition of medicines and supplies is organized into three pharma-
ceutical health care components: basic, strategic and specialized. Each 
component includes resources for financing one or more programmes or 
activities, and each has its own features related to planning and admin-
istration. Medicines for HIV/AIDS, cancer and coagulopathy are not 
included within any of these components, but are funded exclusively by 
the federal government. 
 The federal government also bears the cost of supplying medicines 
through the Brazilian Popular Pharmacy ( Programa  Farmácia Popular do 
 Brasil : PFPB) and the  Here There Is a Popular Pharmacy ( Aqui Tem  Farmácia 
Popular ) programmes (described below), which provide certain medi-
cines either free of charge or at low cost, making them more accessible 
to the population (Brasil, 2004b). 
 Links to technological development in medicines 
 With the implementation of the PNM, Brazil expanded a strategic project 
for the technological development of medicines, initially through public 
production of essential medicines by laboratories belonging to the SUS 
(currently 19 SUS public laboratories). Two notable health policies in this 
initial period were investments by the Ministry of Health to allow public 
laboratories to produce less-expensive versions of anti-retroviral drugs, 
beginning in 1996, and the implementation of the Generic Medicines 
Law in 1999. 
 Brazil’s policy of universal access to free anti-retroviral treatment 
supplied directly to the public sector has been in force since 1996, and has 
been an exemplary model for global efforts to reduce the HIV epidemic. 
However, it has also involved a significant increase in Ministry of Health 
spending on medicines, which rose from approximately US$35 million 
in 1997 to a landmark US$305 million in 1999 (Loyola, 2008). The vast 
majority of these medicines were imported, implying that fluctuations 
in the dollar led to interruptions in supply. The response was investment 
in the domestic production of medicines. 
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 This initiative inaugurated the systematic establishment of agree-
ments between the public and private sectors for the transfer of tech-
nology to public laboratories that manufacture medicines. Currently, 
the country is capable of producing 10 of the 23 medicines that 
constitute the HIV/AIDS treatment cocktail. Farmanguinhos alone, 
the Oswaldo Cruz Foundation (FIOCRUZ) Laboratory and part of the 
Ministry of Health, produces and distributes seven of the ten anti-
retroviral drugs produced in the country (Fiocruz, 2014). FIOCRUZ is 
the largest public health institution in the country, for research, educa-
tion, health care, development and pharmaceutical drugs production. 
Farmanguinhos is the unit for the production of pharmaceutical chem-
icals, and Biomanguinhos for the production of biologicals. These 
units, like others public laboratories, supply the specific programmes 
of the Ministry of Health. 
 The Generic Medicines Law enabled competition on the part of the 
public and private domestic industry in the market for drugs with 
expired patents. On the other hand, from 1996 onwards, the Patent 
Law (1996) recognized pharmaceutical patents in Brazil by adhering 
to the Trade-Related Aspects of Intellectual Property Rights (TRIPS). 
This had a negative impact on the domestic industry, one of whose 
competitive pillars was the commercialization of similar medicines 
(copies of the branded drugs) and which could not compete with 
the large international oligopolies in the production of innovative 
medicines. The domestic market configuration changed as a result. 
National companies focussed on the production of generic versions 
and multinationals increased their share in reference products that are 
more expensive that generic versions (Capanema and Palmeira, 2004; 
Gomes et al., 2014) 
 Strengthening industrial policy for pharmaceuticals 
 However, the right to pharmaceutical assistance within the SUS and 
the need to provide essential products to the Brazilian population at 
accessible prices required a series of measures to strengthen the phar-
maceutical industry in Brazil, particularly in sectors serving the prin-
cipal public health requirements. In the face of these challenges, the 
strengthening of the pharmaceutical chain became a strategic objective 
of Brazil’s industrial and development policies. 
 Several public bodies, including the National Development Bank 
( Banco  Nacional de  Desenvolvimento: BNDES), started to support the devel-
opment of the country’s pharmaceutical chain. The Support Program for 
the Development of the Pharmaceutical Productive Chain ( Programa de 
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 Apoio à  Cadeia  Farmacêutica : ROFARMA), launched in 2004, provided 
specific BNDES credit support to contribute to growth in the domestic 
pharmaceutical industry. 
 Between 2004 and 2013, BNDES invested almost 5 billion Brazilian 
Reals in approximately 110 operations, spread across lines of support 
aimed at production, innovation, restructuring and biotechnology, and 
focusing on domestically owned companies and public laboratories. In 
its first phase, PROFARMA constituted an important source of funds to 
ensure that the national pharmaceutical complex complied with the 
new regulatory demands, which had become much more rigorous after 
the 1999 creation of the National Health Surveillance Agency ( Agência 
 Nacional de  Vigilância  Sanitária : ANVISA). However, throughout its exist-
ence, the programme adapted to industry needs, focusing on the produc-
tion of generic medicines, on innovation and on the development of 
biotechnology, due to the increasing application of biopharmaceuticals 
in the treatment strategies for a range of diseases, particularly chronic 
non-communicable illnesses (Palmeira Filho et al., 2012). 
 These and other initiatives resulted in increased investment in 
research and development (R&D) within the Brazilian pharmaceutical 
industry. According to the Survey of Technological Innovation ( Pesquisa 
de  Inovação : PINTEC), in 2003, R&D investment by the pharmaceutical 
industry corresponded to 0.5% of net revenue, slightly lower than indus-
trial sector average. In 2011, this had risen to 2.4% of net revenue, while 
the average for the industrial sector remained at around 0.7% (PINTEC/
IBGE, 2011). 
 Local production for domestic requirements 
 The combination of the legal framework and the SUS organizational 
system has sought to direct the diffusion of technologies towards social 
interests, rather than allowing the process to occur in a manner aligned 
only with market interests. The data show that the investments in the 
pharmaceutical supply chain have been reflected in the consolidation 
of the local generic medicine sector. Since 2004, the total pharmaceu-
tical market in Brazil has grown exponentially, both in number of units 
sold (9% per annum) and in real value (10% per annum), reaching 
almost R$ 40 billion in 2013 (Gomes et al., 2014; Interfarma, 2014). 
The market for generic medicines has provided a significant element 
of this growth, since in terms of unit sales, generic drugs’ share of total 
sales leapt from 9% in 2004 to 27% in 2013 (Figure 9.1), while sales 
of both brand-name drugs and similar drugs fell (Gomes et al., 2014; 
Kaplan et al., 2013). 
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 As the Gomes et al. (2014) study points out, the opportunities gener-
ated by the dynamism of the internal market, increasing improvements 
to sanitary regulation in Brazil and public policies have all been exploited 
by domestically owned companies, whose domestic market share rose 
from 30% at the beginning of the 2000s to over 50% in 2012. 
 In 2013, five Brazilian pharmaceutical companies were among the ten 
biggest companies in the Brazilian national market, measured by total 
sales. Generic drugs had almost 30% of the Brazilian market, measured 
in units sold, 15% by total sales. Furthermore, 85% of the drugs available 
in the Popular Pharmacy Program are generic drugs. As regards the origin 
and ownership of the capital invested, about 90% of the companies 
producing generic drugs are Brazilian, 6.3% are from India, 0.8% from 
Germany, 0.6% are Canadian and 0.5% Spanish (Progenericos, 2014). 
 The share of household income spent on medicines is higher in Brazil 
for those on lower incomes. Medicines account for 4.2% of spending 
in households with a monthly income of up to US$452.20. This corre-
sponds to 76.4% of health expenditure for households within this 
income bracket. For those with a monthly income over US$5,655.20, 
spending on medicines is only 1.9% of income (IBGE-POF, 2008–09). 
Therefore, the SUS is a decisive instrument for the reduction of inequali-
ties, in coordination with the economic and science and technology 
fields, and for the promotion of health as a priority for the sustainable 
development of the country (Gadelha et al, 2014). 
0
500
1000
1500
2000
2500
3000
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
m
illi
on
 u
ni
ts
 
No Generic Medicines Generic Medicines
9%
15%
21%
27%
5% 12% 13%
16% 19%
24%
26%
 Figure 9.1  The Brazilian pharmaceutical market (unit sales), 1997–2013 
 Source : Drawn by the authors from data sourced from Progenericos (2014) and Gomes et al. 
(2014). 
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 Public demand and domestic medicines production 
 The enlargement of the state’s purchasing power has been a funda-
mental strategy for extending access to medicines and strengthening 
the production base to address SUS interests, both public and private. 
Out of a range of important inter-sectoral initiatives (Aragão et al., 2014; 
Gadelha and Costa, 2012), two programmes particularly help to under-
stand how current initiatives to strengthen the health sector in Brazil 
have had an impact on the domestic production of medicines. 
 The first, the Brazilian Popular Pharmacy Programme ( Programa 
 Farmácia Popular do  Brasil : PFPB), was established in 2004 within the 
Ministry of Health in order to extend the population’s access to essen-
tial medicines. It was hugely important in the growth of the generic 
medicines sector in Brazil, since its establishment relied heavily on the 
extension of the domestic production base. The second, the Partnerships 
for Productive Development ( Parcerias  para o  Desenvolvimento  Produtivo : 
PDPs), begun in 2012, aimed to strengthen the domestic pharmo-chem-
ical and medicine industries, particularly in more innovative areas such 
as biotechnology, in order to reduce external dependence in key stra-
tegic areas. 
 Industrial policy in Brazil generally recognizes the potential of public 
procurement to promote competition in markets where government 
demand is significant, such as health. Rules have been defined for the 
use of public purchasing power, which allow a price preference of up to 
25% for purchases from domestic producers, using a method of calcu-
lation that takes into account employment and income generation, 
impact on tax revenues, national development and other factors. 3 
 The Brazilian Popular Pharmacy Programme (PFPB) 
 The PFPB expanded access to medication for the most common diseases, 
benefitting people on low incomes and enabling access to low-cost 
medicines for users of the private health network. Federal government 
initiatives included centralization of the medicines procurement and 
administrative improvements. Medicines were acquired, distributed and 
managed centrally by FIOCRUZ, a unit of the Ministry of Health. This 
procurement strategy was underpinned by a guarantee of state funding. 
 In order to meet the pharmaco-therapeutic needs of PFPB users, 
the Ministry of Health established a list of medicines based on the 
National Essential Medicines List, which was defined using epidemio-
logical criteria, taking into account the principal diseases that affect the 
Brazilian population and the treatments that have the greatest impact 
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on household budgets. The list also considers the medicines contained 
within the Ministry of Health’s Welfare Programmes, the production 
capacity of the Official Pharmaceutical Laboratories and registration as a 
generic medicine (Brasil, 2005; 2010). 
 Initially restricted to the SUS network, from 2006 the Programme was 
extended to the private sector through partnerships with pharmacies. 
In 2011, with the launch of the Brazil Without Extreme Poverty Plan 
( Plano  Brasil  Sem  Miséria ), the municipalities included in this plan to 
eradicate extreme poverty were prioritized by the PFPB, in line with 
criteria adopted by the Ministry of Social Development and Combating 
Hunger. 
 Given the country’s epidemiological profile, one programme priority 
is to extend access to hypertension and diabetes medication. About 
33 million Brazilians have been diagnosed with hypertension and 
80% (or approximately 22.6 million hypertension sufferers) are treated 
within the public health network. According to 2011 data, more than 
7.5 million Brazilians have a diabetes diagnosis and about 6 million of 
these patients are treated within the public system. These diseases are 
included in the risk factors for cardiovascular problems, the greatest 
cause of mortality in Brazil (WHO, 2012). Through the activities of the 
PFPB aimed at non-communicable diseases (NCDs), medicines for the 
treatment of hypertension, diabetes and, latterly, asthma began to be 
dispensed to patients free of charge. In 2011, respiratory diseases were 
the third cause of death in the country (MS/PFPB, 2014; WHO, 2012). 
 Currently, the PFPB provides access to essential medicines for a wide 
range of patients with a private medical prescription, complementary to 
SUS, at low cost or free of charge. The initial list of medicines included 84 
pharmaceuticals, dispensed to the population using their generic names, 
representing more than 1,200 commercial medicine brands registered in 
the pharmaceutical market. The PFPB provides for the inclusion of new 
products and takes into account regional variations, given its territo-
rial coverage and the diversity of the epidemiological profiles across the 
different regions of the country. The first additions to the PFPB list of 
medicines occurred in 2004, when seven new items were added. Since 
then, new updates to the list have been made in order to increase its 
coverage. By 2013, more than 550 medicines had been made available 
(Brasil, 2004b; MS/PFPB, 2014). 
 It is worth noting that the products distributed through the PFPB are 
acquired through specific procurement processes, not to be confused 
with public procurement by federal, state, federal district and munic-
ipal governments. The programme prioritizes purchase of medicines 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
176 Aragão, Guimarães and Loureiro
produced by official government laboratories (public industrial units) 
and generic medicines (acquired through a bidding process); a pharma-
ceutical’s availability as a generic medicine is therefore a factor for inclu-
sion into the PFPB medicine selection process. 
 The expansion of the PFPB budget, of the accredited network and of 
the number of municipalities served has both reflected demand and 
coincided with growth in the generics market in Brazil (Figure 9.2). 
 By March 2015, more than 33,000 establishments had been accredited 
by the PFPB, distributed across 4,351 of the 5,570 Brazilian municipali-
ties and providing almost 80% coverage in municipalities with Popular 
Pharmacy establishments. This is in contrast to 2006, when 2,955 
establishments were accredited in 594 municipalities, with coverage of 
only 11% of municipalities. To this end, the programme’s budget has 
increased significantly over the years. 
 Federal spending on the PFPB, in real terms in 2013 prices, has jumped 
from a little over R$35.7 million in 2006 to R$879.5 million in 2011, 
R$1.4 billion in 2012 and R$1.9 billion in 2013. In 2013, total spending 
on medicines rose to slightly over R$10 billion (Sala de Situacão em Saude, 
2015). These data demonstrate the programme’s importance and the 
need to coordinate it with production development policies, since rising 
demand has driven the increased production of generic medicines. 
 In turn, the Ministry of Health budget grew from R$59 billion in 2006 
to R$100.5 billion in 2013, also in real terms. By 2013, the amount 
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
10.7%
18.5% 22.0%
34.9%
44.3%
58.3%
67.0%
73.9%
78.0% 78.1%
 Figure 9.2  Percentage of municipalities covered by the PFPB, 2006–15 
 Source : Drawn by the authors from data from Sala de Situacão em Saude (2015), accessed 8 
March 2015. 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
Dissemination of Local Health Innovations: Brazil 177
spent on medicines represented more than 10% of the total Ministry of 
Health budget. Public purchasing is responsible for 30% of the country’s 
demand for medicine (Interfarma, 2014). 
 Strengthening public industrial production units has been a strategy 
to secure production in less intensive knowledge areas, such as generic 
products, in several Ministry of Health programmes. This approach also 
applies in more intensive knowledge areas, such as biological products, 
where the proportion of total Ministry of Health medicines expenditure 
has grown significantly, due to high prices, and contributed to the health 
sector’s trade deficit. The Partnerships for Productive Developments 
(PDPs) were launched as a response to this. 
 Inter-sector coordination has enabled the creation of significant regu-
latory frameworks, which have tended to have a positive impact on the 
strategic sectors for the country’s development. Significant features of 
these regulatory frameworks of support for innovation are Law 10973 
of 2004 (Brasil, 2004c), known as the Innovation Law, 4 and the Goods 
Law of 2005 (Brasil, 2005), which were important for the development 
of Brazil’s health-related goods industry. Furthermore, the PDPs have 
been the object of inter- and cross-sector policies aimed at reducing 
external dependency, in favour of innovation and the extension of 
domestic capacity to produce strategic technologies, including biologi-
cals, for SUS. 
 Partnerships for productive development ( Parcerias  para o 
 Desenvolvimento  Produtivo : PDPs) 
 The PDPs form part of the policies in the Greater Brazil Plan, which 
contains guidelines that focus on innovation and productivity growth in 
the Brazilian industrial complex. They are one of the components of the 
Programme for Investment in the Health Industrial Complex ( Programa 
de  Investimento no  Complexo Industrial  da  Saúde: PROCIS). The latter was 
launched in 2012 to coordinate the national strategy for development 
and innovation in health through investment in public producers and 
in public infrastructure for production and innovation. It is thus aimed 
at strengthening Brazilian industry, providing the country with greater 
autonomy for the production of strategic SUS technologies. 
 There are currently 19 SUS public laboratories involved in PDPs. They 
are responsible for the production of medicines, serum and vaccines to 
meet the country’s public health needs. However, many products are 
still imported from other countries, and gaps in domestic production as 
well as the high cost of medicines may hinder access. Through PROCIS, 
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the Ministry of Health has invested in public companies’ infrastructure 
and workforce training (MS/DECIIS, 2015). 
 The partnerships are established between public drug production 
companies and the private production sector, aiming to absorb the tech-
nology to make new formulations. Thus, foreign companies with tech-
nological dominance commit to transferring to domestic companies 
the technology required to produce the medicine, as well as to produce 
within the country, to some degree, the active pharmaceutical ingredi-
ents (APIs) (the substance responsible for the treatment), over a five-year 
period. In return, the government guarantees exclusivity in procuring 
these products – at values below those quoted in the global market – 
over the same period. Until this point, since 1985, when the self-suffi-
ciency programme in immunobiologicals was launched, there had been 
no other stimulus or public production investment programmes (Brasil, 
2012 – Portaria nº 837/2012). 
 At the end of the technology transfer period, the domestic public labo-
ratory will initiate autonomous production of the medicine in order to 
meet domestic demand. With production conducted inside the country, 
public laboratories will begin reducing dependence on imports (as illus-
trated by Figure 9.3), extending their competitive advantage and tech-
nological capacity. 
–8.00
–6.00
–4.00
–2.00
0.00
2.00
4.00
6.00
8.00
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Imports Exports Deficit
 Figure 9.3  Pharmaceutical products: Balance of trade, Brazilian exports and 
imports (US$ billion FoB) 
 Source : Drawn by the author from data from MDIC/Secex/Sistema Alice apud, INTERFARMA, 
2014. 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
Dissemination of Local Health Innovations: Brazil 179
 As well as generating significant savings for the Ministry (estimated at 
approximately R$4 billion a year) and reducing the country’s dependence 
on importing products (Figure 9.3), the partnerships signed thus far have 
also benefitted the population, since they guarantee the supply of essen-
tial medicines to the SUS network. In 2012, more than R$250 million 
was invested in public pharmaceutical companies’ infrastructure and 
workforce training – more than five times the average investment for 
the previous twelve years (R$42 million). Between 2000 and 2011, total 
government investment was R$ 512 million. 
 At the end of 2014, the Ministry of Health was involved in 104 product 
development partnerships, involving 19 public and 57 private laborato-
ries. These agreements provide for the development of 101 products (66 
medicines, 7 vaccines and 28 other health products). 
 Partnerships are focussed on the production of biological medicines, 
which have an average value significantly higher than traditional medi-
cines and are principally used for the treatment of non-communicable 
diseases, such as various types of cancer and rheumatic problems. 
Although biological medicines represent approximately 5% of the medi-
cines purchased by the Ministry of Health (measured by unit sales), they 
represent 49% of spending. Importing these products has been one of the 
main reasons for the increase in the health trade deficit, which leapt from 
approximately US$1 billion in 1997 to more than US$5 billion in 2013. 
 Reducing dependence on imported biopharmaceuticals by taking 
advantage of the predicted expiry of a series of product patents over 
the next few years may extend the population’s access to treatments for 
those diseases for which the technology is demonstrably more effective 
than traditional medicine. In 2015, more than 25 biopharmaceutical 
products are available in SUS for the treatment of cancer, rheumatoid 
arthritis and other chronic diseases. Almost all are in the process of tech-
nology transfer to the national public companies. 
 In the specific case of cancer, the ability to introduce biopharmaceu-
ticals for treatment has proven to be important in reducing inequality 
in access to this type of treatment. The Aragão et al. (2012) study 
demonstrated that biopharmaceuticals not incorporated into SUS were 
usually accessed via legal proceedings and that their implementation 
was restricted to such demands, prioritizing users of the private health 
system. In 2010, the federal government spent US$3.4 million on 
responding to judicial demands related to the supply of biological thera-
pies to treat cancer; since 2012, some of these have been incorporated 
into SUS. This signifies per capita spending of up to US$183,300 in 2009 
and 2010. 
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 The public health system is responsible for the treatment of approxi-
mately 80% of cancer cases in Brazil. From 1999 to 2010, federal expend-
iture on chemotherapy alone rose in real terms from R$780 million to 
more than R$1 billion. In 2010, total expenditure, including spending on 
radiotherapy, surgery and radioiodine therapy, passed a landmark R$1.5 
billion, or US$852 million (Aragão et al., 2014; MS, 2011). Spending 
on oncology medication represented more than 10% of total spending 
on medicines, with the largest burden coming from the acquisition of 
biological medication. With the exception of immunobiologicals (serum 
and vaccines) and one group of high-cost medicines aimed at a broad 
range of rare pathologies, oncology drugs accounted for the largest share 
of total Ministry of Health spending on medicines. Biopharmaceuticals, 
which will be produced through PDPs, currently represent R$1.8 billion 
per year of Ministry of Health public procurement expenditure (MS/
DECIIS, 2015). 
 In the case of cancer, considered here as an example, one needs to 
remember that treatment based on biological medicines is very costly, 
given that this is a high-complexity production category and, there-
fore, one with higher costs. Furthermore, it is more difficult to copy 
biological medicines once their patents have expired. Unlike chemicals, 
which may be copied as a whole, proteins are not amenable to identical 
copying; such copies are therefore biosimilar and require specific regula-
tion. Moreover, companies in this sector have extremely high powers 
of negotiation, given the market concentration in a very small set of 
businesses. 
 Making use of public purchasing power and establishing policies to 
promote the domestic pharmaceutical industry, including public labo-
ratories, are strategies to protect against the monopolistic practices 
exercised by the large pharmaceutical companies. These practices are 
made possible by a regime of intellectual protection highly favourable to 
economies in developed countries. In a sector in which the substitution 
of goods is highly limited, the persistence of such practices will certainly 
deepen social inequalities at both international and national level. From 
this perspective, policies that take into account the degree of market 
concentration may ensure the introduction of innovative technologies, 
while at the same time reducing inequalities in access to medicine. 
 Concluding reflections 
 Since the promulgation of Brazil’s 1988 Constitution, significant 
progress has been made in improving the population’s access to health 
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services, including to pharmaceutical health care. A series of legal and 
regulatory frameworks have been established in order to guarantee the 
free or subsidized provision of medicine to the population. To guarantee 
the domestic production of essential products, the Ministry of Health 
has become the country’s central pivot in ensuring the local develop-
ment of production capacity in order to develop technologies to meet 
SUS needs. 
 The Ministry of Health has managed to use its purchasing power to 
guide public and private investment in the interests of the SUS. This has 
reduced the main risk of technological innovation, which is the absence 
of a market. Product Development Partnerships have had huge success in 
transferring technology from the private sector (particularly the sector’s 
large company leaders) to the public sector, which receives the tech-
nology and jointly develops the ingredients. Thus, even if production is 
shared with the private sector, the technology domain has moved to the 
public sector, as the regulatory framework indicates. However, the final 
results of the new model of partnerships established from 2012 should 
also be evaluated in the future, in relation to the ability to internalize 
the skills for production of APIs. Previous partnerships between private 
and public companies, as in the case of anti-retroviral drugs, allowed 
domestic production, but the country continued to depend on imports 
of the APIs. 
 What we observe is the construction of public policies to guide a 
range of health industry actors towards a social need, in this case the 
demand for medicine. To achieve this, the Ministry of Health has begun 
to coordinate policies traditionally regarded in Brazil as belonging to the 
economic sphere. Such orientation shifts the production logic of capi-
talist reproduction guided by the market, directing public and private 
investment towards the production of goods aimed at meeting SUS’s 
priority health needs. 
 Such initiatives have led to successful actions, such as improved access 
to treatment for HIV/AIDS, cancer, diabetes, hypertension and a series of 
other diseases prevalent in the country, either through direct SUS provi-
sion or mediated through the PFPB in the form of free or low-cost distri-
bution through the country’s network of pharmacies. These initiatives in 
turn have contributed to the development of a domestic generic medicine 
industry capable of producing technologies to meet public and private 
health demands at competitive prices, as well as developing production 
capacity in more innovative areas, such as biopharmaceuticals. 
 The use of procurement powers and the policies to incentivize the 
domestic pharmaceutical industry, including public pharmaceutical 
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companies, are forms of protection from the monopolistic practices exer-
cised by the large pharmaceutical corporations. Such practices are made 
possible through an intellectual protection regime which is extremely 
favourable to the economies of high-income countries. In a sector in 
which the substitution of goods is extremely limited, the persistence of 
such practices clearly deepens social inequalities at both national and 
international level. 
 However, huge challenges remain. The country remains a large-scale 
importer of pharmaceuticals and medicine. The construction of internal 
production capacity to reduce external dependency is a long-term 
process, involving heavy investment. 
 The production of generic medicines is extremely important in 
meeting domestic health needs, but it does not help to reduce the deficit 
because it is based on the import of active ingredients and, in certain 
cases, of formulations which are then combined. There is now a need 
for a policy that enables Brazilian companies to grow and acquire know-
how in the development of generic medicines so they can make the leap 
towards the production of a more intensive local technology synthesis 
and broaden their portfolio of similar and innovative medicines for the 
market. 
 Notes 
 1 .  The research project that was the basis for this chapter received finan-
cial support from the National Council for Technological and Scientific 
Development (CNPq) through a grant to the Instituto Nacional de Ciência 
e Tecnologia em Saúde (CITECS) – National Institute of Science and Health 
Technology. The authors would like to thank Cressida Evans for the transla-
tion into English from the Portuguese version of this paper. 
 2 .  Federal Constitution law: Article 194: Social security encompasses a set of 
integrated actions by the public power and the civil society geared to assure 
the rights related to health, social security and social assistance. Article 196. 
Health is a right assured to all citizens and a state duty warranted through 
social and economic policies with the objective of reducing the risk of disease 
and other health impairment, and universal and egalitarian access to health 
actions for prevention, protection and recovery care (Brasil, 1988). 
 3 .  Law 12349/2010 and regulated by Decree 7546/2011. 
 4 .  Redrafted in Law no 12349, 2010. 
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 Introduction 
 The Indian health industry, with substantial pharmaceuticals and biop-
harmaceuticals capability, has been called ‘Supplier to the World’. This 
industry has had three defining policy environments running from 1950 
to 2000, the last of which is arguably still ongoing. These three environ-
ments are distinct  market environments, in which the range of market 
instruments used has been notable and the public gains to which they 
have been put have been noteworthy (Srinivas, 2004; 2012). 
 In earlier work (Srinivas, 2012) I have provided an explanatory frame-
work for addressing the long timeline this history represents in the polit-
ical economy of health plans in a late industrial push. In the process of 
analyzing 50 years of capability building, that study demonstrated that 
India had accomplished a great deal on the supply of medicines, espe-
cially generics, vaccines, and diagnostic kits, but was far less impressive 
in its health outcomes. This chapter builds further on the analysis in 
that work, but specifically turns its attention to  problem-solving : the type 
of state capacity required to reconcile industrial and health goals as an 
essential part of development plans (Srinivas, 2014a). In examining the 
experience of the First Market Environment, this chapter argues that no 
explanation of its history is complete, indeed at all relevant, unless we 
attend to why a state so capable along one dimension can be so wanting 
in another (Srinivas, 2004; 2012). 1 
 The importance of India’s ‘First Market Environment’ 
 The First Market Environment (FME) had two distinct market phases: 
Phase I, from 1950 through the 1960s, and then Phase II running still 
 10 
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powerfully until the late 1970s. Phase I was the  public sector produc-
tion effort under immense state regulation. This period included 
the Industries Development and Regulation Act (IDRA) of the 1950s 
that had been designed to boost indigenous production, diversifica-
tion and investment, followed by the Industrial Policy Resolution of 
1956, the Monopoly and Restrictive Trade Practices Act of 1969 and 
the Drugs (Display of Prices) Order promulgated in 1962 which was 
then adapted many times over in both the First and Second Market 
Environments. 
 In contrast to Phase I of the FME during which the public sector led 
in most respects, Phase II of the FME was marked by a focus on Indian 
 private firms . Again, the state was busy. Its actions included the with-
drawal of permissions for industrial diversification to foreign-owned 
firms in 1970, the Drug Price Control Order (DPCO) in 1970 and two 
changes to the Indian Patent Act in 1970 and 1972. Then, in 1978, the 
New Drug Policy (NDP) of the Government of India followed. The NDP 
provided explicit goals (although some in conflict) and three powerful 
categories of its own for drugs and their production licenses: 17 essential 
drugs preferentially and solely allocated to the public sector, 27 drugs for 
production only by Indian firms and 64 drugs open to production by 
anyone (for details, see Srinivas, 2012: chapter 3). 
 The Second Market Environment (SME) overlaps slightly with Phase II 
of the FME in the continuing focus on essential medicines. It runs from 
the 1980s and into the 1990s. However, the SME is distinct in the receding 
power of the state and the visibility instead of three powerful interna-
tional effects on Indian firms especially in the 1980s. These included the 
three ‘Ws’: the Waxman-Hatch Act of the US (1984), which provided 
strong incentives for foreign companies that manufactured generics; the 
WTO’s new pressures (1985) on the Trade in Intellectual Property Rights 
(TRIPs) harmonization and patent reforms; and the WHO and other 
multilateral agencies’ procurement efforts for vaccines and other drugs 
which disproportionately influenced the technical standards of produc-
tion (Srinivas, 2004; 2012). 
 In summary, Phase I of the FME built a political rhetoric of universal 
access while using strong state controls of the market and privileges of 
the public sector; Phase II of the FME showed a strong push to domestic, 
private sector capabilities while using public health drugs such as anti-
biotics to channel both policy design and private sector behaviour. 
Indigenous supply capabilities were therefore built over the two Phases, 
first in the public, then in the private sector, of deep investments, slow 
technological learning and directed technology transfer. By the end 
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of the FME in the early 1980s, India had emerged as a redoubtable 
contender amongst developing nations with pharmaceutical capability, 
and was challenging even some industrialized economies. 
 The industrial capabilities of the FME were built with clearer plans for 
public health – such as the supply of essential medicines – than in any 
subsequent period (Srinivas, 2004; 2012). Unlike the FME, which was 
inward-looking in order to build indigenous capabilities, the state in the 
SME especially from the early 1980s used a variety of market and non-
market instruments to induce firms to export. Because of the consid-
erable capabilities built in the FME, private indigenous firms stood to 
make lucrative gains from export markets. Unlike the FME, the SME 
through the overseas buying instruments of the 1980s was determinedly 
focussed on upgrading for export markets and on what I have argued 
elsewhere is the welfare-state priorities of other nations, not necessarily 
those of India (Srinivas, 2011; 2012). 
 The SME acted as an important culling zone for firms that were inter-
nationally uncompetitive. It also heralded international influences on 
Indian firms that could not be carefully scripted and regulated by the 
state. With growing vaccine capability alongside generics, the SME 
also signalled the growing attraction of large-scale procurement from 
multilateral agency buyers such as UNICEF and the WHO. The state was 
undoubtedly less able to control export markets. 
 Finally, what followed and arguably still exists is a less distinct Third 
Market Environment (TME) associated with technological shifts in biop-
harmaceuticals begun in the 1980s and into the 2000s. In important 
respects these capabilities grew alongside and converged with vaccines 
in the SME, and with a range of other products and processes in the 
TME. The state in the TME was far less visible relative to the FME, but 
more decisive than in the SME. Yet, because of shifting technological 
considerations, the state’s control of domestically owned indigenous 
private firms far was less than in even the SME. 
 This Third Market Environment provides an uncertain regulatory envi-
ronment for new technological frontiers, where the national ownership 
and national priorities are more ambiguous. Substantial mergers and 
acquisitions have occurred, new technology capabilities are emerging 
and new regulatory zones in science and engineering are being explored. 
Furthermore, manufacturing capabilities have taken something of a 
backseat to the build-out of private sector opportunities in insurance, 
logistics, clinics, hospitals and so forth. Technological advances have 
created the need for a fundamental new balancing between production 
capabilities and the certainty of access to medicines. 
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 Problem-solving versus state capacity 
 The three market environments exemplify different tensions arising 
from growing supply capabilities. How then can industrial and health 
goals be reconciled as an essential element of development planning? 
The argument here is that to address this question it is insufficient to 
focus on the diffuse notion of state capacity. Rather, much more can be 
induced from a focus on problem-solving, to see how industrial capa-
bilities can inch closer to health outcomes. Should the health industry 
be an economic engine or a means to healthier populations? If it is a 
means, then the outcomes should be measured in terms of healthier 
populations. If it is an end, then some troubling developmental tensions 
remain. 
 What, then, is missing in the explanations to date? The two-decade 
period of the FME requires dissection because it is tempting to see the 
technological supply-side gains from start to finish in the relatively 
straightforward terms of a move from less to more capable state and 
firms. Without the detailed analysis of subsequent environments and of 
the state’s struggle to align industry and health, the FME is itself difficult 
to bookend and resolve. What becomes hidden is substantial variation 
in the health climate within which the industry was steeped, and the 
obscure logics by which certain industrial policies were prioritized over 
health needs. 
 For late industrial economies such as India, the means rhetoric is far 
more visible in the FME, contrasting with the ends rhetoric in the SME 
and TME. The FME offers the first environment in which the nation-state 
appears explicitly and self-consciously to foster industrial and health 
policies moving closer together. It was the first and only environment 
(Srinivas, 2012) where the range of instruments for policy and planning 
were so wide across both industry and healthcare; they are far less visible 
in later phases (see also Chaudhuri, 1986; Sahu, 1998; Srinivas, 2004). 
 These national politics of the FME include autonomous nation-
building faced with immense hurdles of technology transfer and the 
realpolitik of picking international partner nations. The crucial point is 
that the FME was an important industrial development ‘First’, as well as 
a ‘Market’ first. It was the epitome of a nationally structured and regu-
lated set of market environments across two phases (public and private 
sector industrial capabilities) aimed at building health successes. 
 The lion’s share of attention has focussed on the technical details 
of the FME. Indeed, there is much to extol on the industry side. In 
comparison with Brazil, for instance, the sheer volume of Indian firms, 
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and the concerted set of national industrial policies to keep out foreign 
firms, boost inward technology transfer and develop close state-business 
compacts, points to a redoubtable Indian advance. The broader notion 
of state capacity helps us less in explaining why the state was much 
less successful in ensuring better health delivery in later years, precisely 
when industrial capabilities were growing stronger. It is clear that simple 
causal explanations from industry to health or vice versa offer an incom-
plete analysis. 
 Sahu (1998), for example, clearly demonstrates how tenuous was the 
link to the technology frontier, and how contested in many respects 
(although ultimately collaborative) the relationship between firms and 
the government became in the effort to research, develop and manu-
facture at home. Indeed, some of the contention between domestic 
firms and the government was ultimately resolved precisely because the 
needs of the nation rose to the top, and this was accomplished both 
rhetorically as well as pragmatically (Chaudhuri, 1986; Sahu, 1998). This 
pragmatism at least at national policy levels allowed a series of joint 
initiatives for technology transfer to be put into place between Indian 
and foreign firms and research institutes. It is clear that some types of 
problem-solving – such as those focussed on technological learning – 
were privileged over others. 
 The FME can be understood as a concerted national policy effort to 
synchronize the production of essential items to address several subsec-
tors of health care needs and ensuring access for the population. This 
entailed an effort across multiple geographic territories, institutional 
navigation in India’s complex quasi-federal system of central and state 
governments, and of different urban and rural development planning 
and governance contexts (Srinivas, 2012). Evidence of this diversity 
is seen today, where adjacent subnational states may vary noticeably 
in strategies and instruments to regulate their health industry and its 
firms. 2 Indeed, we could argue that state capacity not only varies but 
that the need to problem-solve becomes more acute, not less, as techno-
logical capabilities advance. Waiting for industrial capabilities to evolve 
fully before systematically addressing health outcomes appears to be a 
dubious recipe. 
 Problem-solving capacity can therefore be termed the ability to 
frame, formulate and attempt to solve complex development challenges 
(see also Srinivas, 2014a). Problem-solving is arguably like exercising 
a muscle. The emphasis therefore is on the attempt to solve complex 
problems, not necessarily on solving them. The more one exercises 
the muscle (the attempt to solve), the stronger the muscle (ability to 
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problem-solve) becomes. The big difference, however, is that the meta-
phor of exercising a muscle refers to single individuals, whereas the 
attempt to problem-solve complex problems requires institutional and 
organizational muscle. In other words, even if an individual might be 
able to think ahead to solutions, a truly complex social problem requires 
institutional and organizational mechanisms to experiment and seed 
the solution. This is what we might term ‘the institutionalization’ of the 
solution. 
 The tradition of using a grounded problem-solving approach is hardly 
new in development. Proponents such as Albert Hirschman (1967) used 
such thinking to probe public performance in development projects and 
to understand how political and economic reform occurred. Despite 
such a history of use, however, the more general idea of governance 
has risen to define and to shape concepts of state capacity, and the 
more specific problem-solving capacity has been obscured. One might 
even suggest that such problem-solving muscle should be the core of 
the state’s capacity in development and health, especially for late indus-
trial economies where such substantial technological capabilities are 
being fostered (Srinivas, 2014a). The FME is an inspirational story when 
analyzed as state capacity directed towards building technological capa-
bilities. It provides a more cautionary tale when seen through the lens of 
state efforts in problem-solving for healthier populations. 
 Problem-solving heuristics as a dynamic element 
of state capacity 
 The rhetorical ‘states versus markets’ development debate is not very 
helpful in the dilemma of effective policy design. The institutional triad 
(Figure 10.1) is a heuristic developed in Srinivas (2012) to show a way to 
understand the evolution of the industry as a whole, and the timeline 
of the Indian case in comparison with others. It offers a first means of 
comparative analysis in problem-solving, and a long timeline to under-
stand the difficult process of planning on three particular institutional 
fronts: (1) production, (2) consumption/demand and (3) delivery. The 
health industry, after all, has several complex relationships to consider 
and is not easily divided under traditional ministries and agencies. The 
Health Ministry, for example, may sometimes control the moral high 
ground, but the Industries Ministry drives the dynamics of investment 
and the returns of firms. The triad therefore makes the policy levers and 
their institutional environment more evident. It reminds us that there 
is no single good or bad option in absolute terms, but there always exist 
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several, continual problem-solving choices to make in development 
terms. 
 The triad’s three vertices refer to (1) production, (2) individual or 
collective consumption or demand and (3) delivery. States not only have 
to juggle any two; they have to juggle all three. As the Indian nation-
state focussed in the FME on (1), the pressure to problem-solve arose in 
deepening capabilities in (1). For a problem-solving agency, the chal-
lenge is that every vertex is connected to every other, and outcomes are 
rarely causal. With the heuristic, I argued then that very few nations 
have successfully juggled all three vertices of the triad for any substan-
tial length of time. We can say that developmental success is more likely 
 as long as state agencies constantly attempt to exercise their  problem-solving 
muscle . 
 Inevitably, if somewhere along the way the outcomes of development 
remain unprioritized, agencies are likely to be solving problems on which 
they have no agreement, which results in conflict. Yet we know that 
even in India there have been attempts to address more than one vertex. 
For example, states such as Karnataka in the south have been experi-
menting with boosting health insurance programs – often co-operative 
health insurance models – to build up consumption/demand (2) and 
improve delivery of hospitalization and certain outpatient services (3). 
Similarly, private hospital chains such as Apollo have been problem-
solving in a more directed way with state health officials and national 
Industrial Production
(1)
Provision/delivery
(clinics and hospitals)
(2)
Consumption (through
individual or collective
buying instruments) (3)
 Figure 10.1  Institutional triad of health care 
 Source : Srinivas (2012: 8; CCBY permission granted) 
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satellite agencies to boost telemedicine, a technology-driven service 
(long-distance consultation and diagnostics) which connects (1) and 
(3). Telemedicine is a way to solve specific types of problems and is not 
a panacea for all emergency, curative and primary care segments, but 
it can provide an important solution in many rural areas where access 
to medicines produced (1), demand (2) and delivery (3), can all face 
challenges. 
 Developmental problem-solving is surely context- and place-specific 
in strategy. Consider a competing, powerful, developmental view: that 
problem-solving has universal qualities; that what works in Gambia 
should work in India; or that one problem to be solved is very much 
like another. Older writing on development long recognized that prob-
lems were context-driven, did not require ‘big-push’ approaches, but 
had to grapple with the complexity and disequilibria of real-world and 
situated processes. Albert Hirschman, for instance, recognized that the 
aphorism of ‘One thing at a time’ is not always helpful in development, 
since context-specificity required relational strategies unique to places, 
so that one-at-a-time sequencing may not move the developmental dial 
(Hirschman, 1990, and his earlier 1967 work). Later, the idea of ‘good 
enough governance’ (Grindle, 2007) signalled relative solutions and rela-
tive performance of states, governments and bureaucracies. UNCTAD 
(2009, IV), for example, connects ‘problem-solving energies’ to democ-
racy, but while democracy may be helpful to force frequent exercise, it 
is no guarantee either of setting development priorities or of the state’s 
commitment to continue to exercise its problem-solving muscle. 
 When one acknowledges that the three vertices in Figure 10.1 are 
always changing with respect to the other and in response to more 
systemic factors, a focus on problem-solving can point to  development 
plans that are patient. In such plans, long-term and short-term goals are 
set and process and outcomes can be measured. No state can attend to 
all three vertices at once, and technological learning, although it has 
crucial aspects in all dimensions of (1), (2) and (3), is nevertheless not 
sufficient alone. Therefore, development planning that is patient requires 
acknowledging that problem-solving is essential, with clear priorities 
and value-judgements that must be communicated, with measureable 
outcomes. It requires institutional design that constantly exercises and 
rewards this problem-solving muscle. For example, vaccine procurement 
can directly connect production (1) to demand (2) through ambitious 
buying and clear market signals, but unless the public health system is 
energized, delivery (3) may be problematic (see comparable arguments 
for Indian vaccines in Srinivas, 2006; Puliyel and Madhavi, 2008). 
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 Putting patents in their place 
 Once the emphasis is on problem-solving within the state, the design 
of realistic industrial policies can also take credible shape. New indus-
trial policies can thus take on this problem-solving character, offering 
institutional mechanisms through which both productive capabilities 
and beneficial social indicators can be achieved (Srinivas, 2011; 2012). 
Technological advance and learning in these industrializing contexts is a 
specific type of problem-solving capability, but it offers no panacea. 
 Therefore, policies that are too narrow in terms of technolog-
ical advance are unlikely to solve end problems. One example is the 
constant debate on patents. The Indian Patent Act 1970 was a crucial 
catalyst not just to reform the sector’s production and access concerns 
but of the planning and reform process required to set new health goals. 
The Indian Patent Act 1970 was a mechanism to protect processes, not 
products, and was somewhat unexceptional relative to other countries. 
However, with the rise of Indian public and private sector successes and 
the use of the Patent Act as a protectionist tool, the Act became more 
internationally contentious and most visible in the context of the WTO 
TRIPS negotiations. The 1970 Act represented contested terrain: it was 
widely praised by those who wished to boost the learning capabilities 
of Indian firms on the one hand; praised also by those whose goal was 
more affordable access to medicines; and criticized by others who argued 
that the fillip it provided to learning was skewed towards ‘imitation’ and 
‘reverse engineering’ rather than ‘real’ innovation. Finally, it was criti-
cized for creating protectionist and regressive policies. 
 However, the First Market Environment shows that such unilinear 
explanations rely too heavily on patents to explain developmental 
outcomes; much wider problem-solving gaps existed. The carrots offered 
to firms were more extensive than just patents, and were ultimately 
defined by the state’s priorities whatever the economic arguments 
might have been (see also Jacob, 2010: 83). In both the first and second 
phases of the FME, intellectual property rights (IPR) acted in concert 
with a range of other industrial instruments for competition, invest-
ment, infrastructure and a range of health institutional design issues 
(many of which remained unsuccessful). Process patents along with the 
Drug Price Control Order and these other policies forced lowered costs 
through competition (Abrol and Guha, 1986). 
 In the Second Market Environment, Indian firms and policy makers 
faced substantial new pressures to harmonize towards a product patent 
regime. Conflicting views of reform from bureaucrats and politicians 
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underscored that problem-solving with regard to affordable access had 
no single narrative or political rhetoric during the trade harmonization 
negotiations (Jacob, 2010). The elites of the senior Indian Administrative 
Service (IAS) bureaucracy, for example, possessed considerable discretion 
and strategic flexibility in shaping policy design and its reform. 
 Patents offer monopoly protections but are second-best solutions. 
Acting alone, they rarely solve developmental challenges, although 
they may resolve trade pressures. Especially in the FME, patents required 
complementary industrial and social policies including clear foreign 
direct investment (FDI) guidelines, restrictions on monopolies, price 
controls, canalization of bulk drugs, rules for pharmacy procurement 
and use, assumptions about the capacity of clinics and hospitals and 
so on (Basant, 2010; Rai, 2009; Sahu, 1998; Srinivas, 2011, 2012). Some 
actively contend that the more one set of capabilities has advanced, the 
more firms have sought monopoly status and protections of all kinds. 
Madhavi (2013) states definitely that market guarantees and supports 
for public-private partnerships have worked to create the public sector’s 
demise in vaccines. 
 Getting better 
 The FME’s emphasis on universal access pointed policies towards essen-
tial medicines, especially public health priorities such as antibiotics. 
Combined with process patents and price controls, it induced compe-
tition and Indian production capabilities in both public and private 
sectors. The SME saw the introduction of the strongly worded New Drug 
Policy (NDP) (Government of India, 1978). However, the NDP presumed 
that item (5) below was necessarily at the right position and compatible 
with the other goals set out as:
 1.  To develop self-reliance in drug technology; 
 2.  To provide a leadership role to the public sector; 
 3.  To aim at a quick self-sufficiency in the output of drugs with a view 
to reduce the quantum of imports; 
 4.  To foster and encourage the growth of the Indian sector; 
 5.  To ensure that the drugs are available in abundance in the country to 
meet the health needs of our people; 
 6.  To make drugs available at reasonable prices; 
 7.  To keep a careful watch on the quality of production and prevent 
adulteration and malpractices; 
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 8.  To offer special incentives to firms which are engaged in Research and 
Development; and 
 9.  To provide other parameters to control, regulate and rejuvenate this 
industry as a whole, with particular reference to containing and chan-
nelizing the activity of foreign companies in accord with national 
objectives and priorities. 
 The aspirations on the list were noteworthy, but the NDP reflected many 
unresolved triad questions about value ordering of the vertices and 
phasing of priorities. They assumed, for example, that cheap and reli-
able production would solve access to medicines problems. It assumed 
that domestic production was a necessity, but also that such production 
combined with other items on the list was sufficient. Only the fifth item 
in the above list questions this concern most directly. 3 The rest of the 
points notably address industrial production priorities and incentives. 4 
 As Chaudhuri (1986) points out, foreign firms had to be forced into 
certain roles in the industry. Some of them had been established in India 
as early as 1923, began the domestic production of formulations only 
in 1955 and, despite a range of inducements through national pharma-
ceutical policies, had not begun producing bulk drugs even by 1978. 
In contrast, several Indian firms had seized the opportunities to do so 
provided by the state. As I have argued about the FME (Srinivas, 2012: 67), 
‘India’s unique gains in this period were due in part to a multi-pronged 
policy approach with politically defensible market entry points through 
“essential” drugs and protectionist restrictions. But politics would have 
been insufficient without systematic and demonstrable technology 
outcomes and the development agenda focused on the twin goals of 
process technology gains and affordable medicines’. By challenging 
multinational companies in the courts, through national government 
supports and through a range of bureaucratic interventions, through 
the use of monopoly restrictions, production allocation licenses, price 
controls and process patents, Indian problem-solving was already agile 
on the industrial front. With clearer priorities in health outcomes and 
deliberate problem-solving rewards, such problem-solving might have 
reached its highest point yet. 
 I recently argued that we should consider an evolving spectrum of 
need and demand (Srinivas, 2014b): Need that is not recognized as need; 
Need that is recognized as need but not as demand; to Recognized, but 
unfulfilled demand; and finally, Effective demand (what is tradition-
ally ‘demand’) and labelled as (2) above. Indeed, part of the toolbox for 
problem-solving is to identify that which is invisible or for which market 
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signals are inappropriate. Indian examples include the Jaipur Foot pros-
thetic and the Oral Polio Vaccine cases, both of which required a rich 
set of actors and organizations that painstakingly problem-solved. In 
the Jaipur foot prosthetic case, actors progressed from identifying needs 
to ensuring that those in need had artificial limbs that worked, were 
caringly customized or could be easily repaired. These were especially 
rewarding outcomes because while road accidents in India had seen 
staggering rises, the state responded pitiably. The Jaipur Foot required 
a strong charitable organization in India to take need to demand in 
various forms, while all the while improving both the technology of 
prosthetics appropriate to the country and attempting to meet both 
domestic and export needs. Ensuring both production and then delivery 
of Oral Polio Vaccines (introduced in 1978, the same year the NDP came 
into force) required non-market instruments. This was because although 
vaccines were free through government programs, they were not easily 
available or, where available, not taken up. Here, too, an immense effort 
was state-led but richly enhanced by non-state partnerships. 
 Two successes further exemplify the potential of well-honed problem-
solving led by, but not limited to, the state. One is India’s sustained and 
unsurpassed success in block-level planning and wide administrative 
and spatial spread for polio immunizations. Private, non-profit organ-
izations, religious groups, labour unions, and many others have thus 
played vital roles in identifying the needs-demand spectrum for policy 
makers and health administrators. 
 The second is emerging urban evidence of success and learning from 
Surat City. Surat, in dealing with plague and then floods, developed 
systematic improvements in disease surveillance. In India’s polio success 
and in Surat’s ambitious disease surveillance, industrial capabilities for 
polio vaccines or diagnostic kits and antibiotics were necessary but 
not sufficient. Challenges after all still remain for Surat in its current 
response to swine flu and its citywide integration of differentiated and 
localized community-level surveillance systems. Both polio and Surat 
have also brought to the fore India’s continued administrative challenges 
in solving last-mile access issues, and the importance of partnerships – 
local and international – in building experimentation and learning. 
 Problem-solving in the realm of vertex (2) therefore requires admin-
istrators to anticipate how (1) and (3) may be speaking to the effec-
tive demand of (3) but not solving the deeper developmental ‘hidden’ 
needs (see also Mitra, 1986). At the end of a good problem-solving 
process, in other words, one should be able to see beyond the obvious. 
The muscle should begin carrying more problem-solving weight and be 
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more flexible. Problem-solving skills can therefore be collective, both 
within and outside the state. Both polio and disease surveillance cases 
exemplify persistent problem-solving exercises through a wider set of 
governance networks which included the state, firms, NGOs and other 
community partners. They also exemplify a clear need for connecting 
market and other instruments to a territorial agenda: national but oper-
ating through block-level strategies in the polio case, and citywide and 
neighbourhood strategies for Surat. 
 An illustrative case of less successful problem-solving demonstrates 
the difference between access in principle versus access in practice. 
Bengaluru (Bangalore) City in Karnataka state is possibly one of India’s 
best sites for medical innovation, and for quality and range of health 
facilities, yet suffers from an unfortunately common lack of attention 
to sustained problem-solving. 5 In the 2012 H1N1 outbreak and in the 
2015 outbreak of swine flu, Bengaluru faced an unchanged situation: 
doctors struggled in government research institutes and treatment 
centres to obtain antibiotics and diagnostic kits. International procure-
ment of diagnostic kits was successful and had ironically steered both 
state and manufacturer away from production to address the domestic 
crises (see also Srinivas, 2006). 6 By 2015, little sustained problem-solving 
had occurred in the state health system in the intervening three years 
since H1N1, and the city’s doctors and patients experienced an alarming 
sense of  deja vu . 7 
 Yet, problem-solving has to be patient. Oral polio vaccines were intro-
duced in 1978. By 2011, India had become polio-free and by 2014 the 
three-year cautionary timeline had passed. State problem-solving is 
never apolitical in this timeline. It may engender bitter debates about 
the need for privatization or allegations of fraud. For instance, there has 
been debate about whether national government policies, which in the 
FME were seen as progenitors of public health, have since deliberately 
undermined public sector production capabilities in vaccines; further-
more, that such policies exaggerated demand data to justify a growing 
role for the private sector’s profits (Madhavi, 2003; Puliyel and Madhavi, 
2008). Worse still is the claim that epidemiological evidence was delib-
erately sidelined and a ‘techno-centrism’ adopted in designing vaccine 
policy (Bajpai and Saraya, 2012), where advance market commitments 
to new technologies have outstripped ‘evidence-based vaccine poli-
cies’ (Madhavi, 2013). The FME and SME strengthened vaccine produc-
tion capabilities and created important procurement spaces for priority 
medicines and vaccines. Multilateral and international vaccine procure-
ment played a much weightier role in the SME in boosting the private 
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sector and creating some tensions between state regulation of exports 
and domestic uptake. 
 Therefore, rather than reaching far too wide by seeing state capacity 
as a normative function across the entire period of productive capa-
bilities, and rather than depending too heavily on the diffuse notion 
of growing ‘good governance’, a focus on problem-solving requires 
policy and planning on the ground to become directed and value-
explicit: for example ‘Everyone – no matter what their economic or 
social status – should have real, measurable access to affordable medi-
cines, vaccines, or diagnostic kits. This priority policy will be enforce-
able by 2020 and will carry explicit penalties for non-performance 
of government agencies or for those seeking windfall private profits 
but not delivering better access’. 8 Problem-solving, in other words, is 
a core state capacity. When done well, problem-solving in the state’s 
line agencies forces dilemmas and discussions about value-proposi-
tions that have then to be designed by networks of actors into policy 
and last-mile planning. 
 Conclusion: strong production, weak problem-solving 
in health 
 The FME was perhaps the most ambitious market environment in the 
convergence it sought between industry and health goals, and the most 
overt in these ambitions. These ambitions were seen in decisions by 
the bureaucracy, through judicial judgements and legal battles against 
multinational firms, through recognition of personnel and delivery 
needs. Yet, was this ambition manifested in sustained problem-solving 
at multiple scales of governance? No. 
 Indian drug policies, wittingly or not, delinked industrial growth from 
health needs, even while the state made several market restructuring 
attempts in order to build capabilities. With the exception of priority 
national health programs, centralized planning targets were focussed on 
production capacity and far less on incentives for demand uptake of 
this capacity and delivery. Despite the rhetoric of grassroots mobiliza-
tion and rural devolution, there were weak decentralized health plans. 
The industrial priorities of the pharmaceutical industry were resolved 
conservatively within the institutional contours of the Ministry of 
Chemicals and Fertilisers rather than those provided by the Ministry of 
Health. 
 While the national government offered carrots and sticks for private 
domestic firms, these focussed mainly on technological advances and 
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market concentration. These incentives encouraged diversification, 
dominance in bulk drugs, process patents and price controls that placed 
caps on health spending and boosted competition. Abrol and Guha 
(1986), for instance, argue that while the country successfully moved 
from formulations capability into more challenging bulk drugs, quality 
consistency suffered. Madhavi (2003) and others have argued that over 
time and with growing technological capabilities, private suppliers 
became emboldened in dictating policy design to the state, favouring 
their own profits over people’s health. Technological advance makes 
domestic resolution of the health industry’s priorities more, not less, 
complex in late industrial economies (Srinivas, 2012). 
 Yet Indian health and industrial goals were quite decisive and conver-
gent in Phase I of the FME when the public sector was involved. After 
all, national priorities and institutionalized problem-solving were 
largely equivalent to the priorities and problem-solving in nationally 
owned public sector firms. However, the problems and the multitude of 
actors grew as the FME progressed, and the problem-solving capabilities, 
although in principle greater, were diffused through the private sector 
and became more difficult for the state to regulate. At no time during 
the FME could quality, safety or guaranteed redress be assured. The value 
priorities related to needs became ironically more obscured by growing 
technological capabilities and by the attractions of the foreign markets 
and growing export earnings. 
 Some nations thus begin problem-solving by creating domestic health 
delivery as the priority even if they import, while other nations do as 
India did, developing and deepening their industrial supply. India 
triumphed in the latter dimension. Yet, there is no ‘best’ starting point 
for any problem-solving; its value-basis, systemic linkages and context 
make it so – points recognized also by Hirschman (1967; 1990). The 
triad is a perpetually co-evolving system in which states make continual 
improvements and build institutional ties (Srinivas, 2014a). Problem-
solving requires institutions that are agile, staff and rules that are both 
flexible but oriented towards timely outcomes, and outcome meas-
ures that are clear, transparent and can be monitored and enforced. 
Without these credible commitments to problem-solving towards 
health outcomes, more generalized state capacities become irrelevant 
and illegitimate. 
 Two market environments have now passed, and a third arguably 
is still under way with biotechnologies changing how we contend 
with all aspects of health care. The decades since 1950 have demon-
strated that Indian production of generic medicines, diagnostic kits, 
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biopharmaceuticals and vaccines has grown stronger and ever more 
sophisticated. In the absence of regular exercise to connect its vertices, 
however, the triad remains slack and the state’s problem-solving muscles 
weakened. Rather than resembling a dynamic, co-evolving triad, the 
result is then an ossified triangle with its base vertices unable to dictate 
terms to its apex. 
 Notes 
  Acknowledgements: My thanks to Maureen Mackintosh and Geoff Banda for the 
invitation to participate in this book; to them and to Watu Wamae for insightful 
comments on the draft; and to Radha Ray and the Open University IKD team for 
making the London stays so pleasurable. This has been an intellectually generous 
and well-managed research effort. It is my good fortune to have had this oppor-
tunity to extend my research, exchange ideas with a great workshop team and 
receive comments from strong editors. 
 1 .  See Sahu’s (1998) slightly different periodization but whose emphasis is also 
on production capabilities. 
 2 .  For example, Karnataka state in South India has experimented quite substan-
tially with health care insurance systems (demand) and new pharmaceutical 
stocking and distribution practices (delivery). Although quite progressive in 
this regard, it has no deliberate state or urban administrative mechanisms to 
test the integration regularly. 
 3 .  See also Stoker and Jeffery (1988: 565). 
 4 .  For the range of specific cases, and contentions and ambiguities, see Sahu 
(1998) and Srinivas (2006, 2012). Stoker and Jeffrey (1988) discuss the New 
Drug Policy and foreign firms. The Astra-IDL case emphasized that foreign 
firms benefitted from the state’s unresolved priorities. Most of its arguments 
about producing a drug already available in India were to emphasize the novel-
ties in production process and the foreign exchange savings to the country. 
Most questions from bureaucrats to Astra in turn focussed on manufacturing 
details, employment and local industry effects, and financial priorities such as 
royalties, branding, export priorities and shares (Ibid: 565). 
 5 .  In the Hindu newspaper story, the same leading Head of Department of 
Neuro-Virology in Bangalore NIMHANS admits to shortages of A(H1N1) 
testing kits, and although orders had been placed, they had to stop testing 
because of the unfulfilled orders;  http://www.thehindu.com/news/national/
karnataka/shortage-of-ah1n1-testing-kits-worries-patients/article3359557.
ece , last accessed 27 December 2014. 
 6 .  http://www.deccanherald.com/content/459453/state-facing-shortage-swine-
flu.html , last accessed 29 March 2015. Srinivas (2006) makes a similar point 
that international vaccine procurement programs had offered important 
benefits to Indian firms. However, Indian regulators and health administra-
tors would have to redesign Indian vaccine policies and plans in order to 
attend to domestic health priorities. Madhavi (2003, 2013) emphasizes the 
undue influence exerted by private firms on state priorities. 
 7 .  See also Kotwani et al. (2007) on uneven availability of common drugs. 
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 8 .  Although former Prime Minister Indira Gandhi made her famous Alma Ata 
speech at the WHO on not allowing profiteering from life or death, she did 
not unfortunately vow to boost problem-solving alongside. 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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 Part III 
 Industrial Policies and 
Health Needs 
 The last chapter of Part II framed the development policy challenge 
of aligning industrial and health goals as ‘problem-solving’. This last 
section of the book draws on case studies and experience to address 
some of these major policy challenges. 
 The section starts with a problem health policy makers grapple with 
across the world: how to control prices of medicines. While most high-
income countries closely manage medicines pricing in the context of 
universalist health systems, most developing countries have low levels 
of control. Chapter 11 describes an important effort to change this situa-
tion in South Africa, a country grappling with the legacy of an inherited 
and profoundly inegalitarian two-tier health system. The author draws 
lessons for both policy and process in other African contexts. 
 A second major industrial policy issue with huge health consequences 
is the definition and enforcement of quality standards in pharmaceu-
tical manufacturing. Manufacturers and health care providers alike have 
a shared interest in ensuring the industry grows without compromising 
public health safety. Standards are both a key technical issue and an 
arena for international debate on procurement and regulatory strate-
gies. Chapter 12 argues for stronger local African initiative in defining, 
regulating and harmonizing quality standards. 
 Procurement of medicines operates as implicit industrial policy, and 
Part II argued that it is understudied. Chapter 13 investigates innova-
tive approaches, drawing on high-income country initiatives in valuing 
and pricing innovator medicines for lessons applicable in lower-resource 
contexts. The chapter picks up from Chapter 11 the issue of price nego-
tiation and its discussion links to Chapter 14, which addresses more 
broadly the interaction between industry and government through 
biopharmaceutical business associations. 
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 Chapter 13 also opens up the key issue of business finance for indus-
trial development, a theme addressed further in Chapter 15. Chapter 15 
brings together a number of different threads in the book by discussing 
finance and incentives to support the development of national phar-
maceutical industries. The chapter identifies a convergence of thought 
and initiative recently generated across the African continent for the 
development of policy incentives for industrial development for health 
benefit. 
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 Introduction 
 Despite the heightened interest in the African pharmaceutical market, 
there are constraints and challenges that continue to affect access to 
medicines. One of the key constraints is the high prices of medicines. 
In the private sector, wholesale and retail mark-ups have been found to 
range from 2% to 380% and from 10% to 552%, respectively (Cameron 
et al., 2011). A later study found wholesaler mark-ups between 25% and 
50% (IMS Health, 2014a; 2014b), and retail mark-ups between 25% and 
500% (Rosen and Rickwood, 2014). Local manufacturers and importers 
alike have expressed concern over the high mark-ups in the distribution 
chain, as the exorbitant prices are believed to limit patients’ access and 
sales. 
 African governments are all grappling with the issue of high medi-
cine prices. Coupled with the increasing momentum for developing 
local pharmaceutical industries, the issue of medicine prices and how 
to contain them will come into sharp focus for policy makers. African 
policy makers are also acutely aware of measures employed by other 
countries around the world to contain runaway health care costs, and 
specifically pharmaceutical expenditure. Although price controls are 
important policy instruments, they are very controversial. The South 
African experience with pharmaceutical price controls may therefore be 
a useful case study to inform other African countries’ interventions. 
 11 
 Policies to Control Prices of 
Medicines: Does the South African 
Experience Have Lessons for Other 
African Countries? 
 Skhumbuzo  Ngozwana 
OPEN
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 This chapter presents the South African experience with the single 
exit price (SEP) regulations which were enacted to deal with these distor-
tions and to replace the mark-up-based retail pricing systems with fixed 
professional fees in order ultimately to reduce the price to patient. 
 Pharmaceutical price control options 
 Governments have moved to control prices, first, because the innovative 
pharmaceutical industry has historically been dominated by monopo-
lies, creating the tendency to price products at a premium. Medicines 
are also different from any other consumer goods in that patient is often 
price-insensitive, given that the doctor prescribes and a third party pays 
for the drugs. Furthermore, many consumers and health care profes-
sionals equate a higher-priced product with quality, and conversely see 
a lower-priced product as inferior, resulting in the ready acceptance to 
prescribe, dispense or ask for high-priced products. The challenge for 
governments therefore is how to institute proper controls to ensure that 
medicines are priced fairly and that access is not constrained by high 
prices. 
 The literature on pharmaceutical price controls identifies three 
distinct ways in which expenditure can be controlled: direct controls on 
the prices of medicines across various levels in the distribution chain; 
through demand-side measures including financial and reimbursement 
systems; and finally by influencing demand through the implementa-
tion of demand-side measures. 
 Price controls at the level of the manufacturer 
 The most difficult step in price controls is arriving at a reasonable or 
fair price for a medicine. The literature on price controls and the tools 
employed are mostly from high-income countries. These include the 
cost-plus method, profit caps, comparative pricing, direct price negotia-
tions and pharmaco-economic evaluations, or a combination of these 
tools. The cost-plus pricing model is difficult to employ in a country 
where most suppliers are subsidiaries of international companies or 
importers of products from other markets. In this scenario, experience 
shows that it is very difficult to obtain accurate and reliable data to 
arrive at a determination of real costs and profits. 
 The second method of price controls, using profit caps, is employed 
in, for example, the United Kingdom through the Pharmaceutical Price 
Regulation Scheme (PPRS), whereby the government negotiates a reason-
able profit with companies for products sold to the National Health 
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Service. This method too faces difficulties with arriving at accurate costs 
and profits when dealing especially with subsidiaries of international 
companies and importers. 
 The third method is comparative pricing, comparing prices of prod-
ucts in other markets with local market prices. Complexities include 
varying dosage forms, strengths and trade names, and the fact that the 
margins and mark-ups allowed to players in the chain differ across terri-
tories. The Netherlands, for example, sets maximum permissible prices 
using the average wholesale price of similar products in a basket of coun-
tries including Belgium, Germany, France and the United Kingdom. It 
is reported that upon its introduction in 1996, Dutch pharmaceutical 
prices dropped by an average 20% (Rietveld and Haaijer-Ruskamp, 
2002). 
 The fourth commonly used tool involves direct price negotiations 
between buyers and pharmaceutical companies. In France, the govern-
ment directly controls prices through negotiations before a product is 
launched. Finally, pharmaco-economic evaluations are used by regula-
tors to attempt to arrive at a fair price, taking into consideration the 
societal costs of the disease and the costs of other treatments. Through 
economic modelling, the direct and indirect benefits of the drug are 
calculated and compared with alternative therapies. Pharmaco-economic 
evaluations are used extensively in the UK, Netherlands, Canada and 
Australia, among other markets (see also Chapter 13). 
 Price controls at the wholesale and pharmacy level 
 Wholesaler margins are controlled through setting either a maximum 
margin or a maximum price at which wholesalers can sell on to retail 
pharmacy. Margins in retail pharmacy can be controlled by setting a fixed 
percentage mark-up to the wholesale price of each medicine, by setting 
a maximum over all mark-up, or finally by tiered mark-ups where the 
percentage mark-up reduces as the price of the product increases. The 
fixed-margin system is widely used in Europe, with margins for prescrip-
tion drugs normally around 30%, whilst over-the-counter products are 
freed from price controls. Although margins are fixed, wholesalers may 
still be able to negotiate discounts and thus increase their profits. The 
tiered structure is intended to create disincentives for dispensing more 
expensive products. 
 Some countries, including China, have a system of price controls that 
differentiates between imported and locally produced products (Bao, 
2000). The Chinese system also differentiates based on drug classes: 
basic therapeutic and preventive drugs acquired in large volumes, class 1 
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anti-psychotics, anaesthetic agents, contraceptives and other special 
classes. 
 Other measures to influence prices 
 There are other demand-side measures that can influence prices and 
expenditure. These include positive and negative lists, reference prices, 
co-payments, parallel importation, and generic substitution, as well as 
education of health care professionals and the public. A negative list 
of products that are not reimbursed forces companies to lower prices 
in order to gain a listing on the positive list. Similarly, reference prices, 
which are used to benchmark products in the same therapeutic category 
that are assigned a certain price cap, and related demand-side measures 
such as co-payments, are meant to force patients to opt for the cheaper 
medicines. Generic substitution and closely related educational meas-
ures to educate health care professionals and patients about the quality 
and benefits of generic medicine are other demand-side measures that 
have been employed to lower medicine expenditure. 
 The basis of the South African price control regime 
 Implications of the two-tier South African health care system 
 When the first democratic government in South Africa came into power 
in April 1994, it inherited a two-tier health care system (private and 
public) reflective of the country’s divided history. These two tiers have 
widely differing resources and access medicines via different channels. 
The private health care tier is a well-resourced private insurance-based 
world-class platform which serves an estimated 15% of the popula-
tion (Council for Medical Schemes, 2014). The private pharmaceutical 
market is valued at $4.1 billion (IMS Health, 2014b) and is supplied with 
medicines by about 130 manufacturers and importers supplying 5,000 
product lines. 
 The second tier, the public sector health care system, serves the 
remaining 85% of the population. It is under-resourced, with chronic 
staff shortages, a quadruple burden of disease and systemic lack of 
funding. Public sector supplies are obtained through tenders adminis-
tered by the Central Procurement Unit of the Department of Health. It is 
supplied with 2,400 product lines by an estimated 90 manufacturers and 
importers, at an estimated value of $1 billion a year in 2014. 1 
 Besides these deep divisions, the democratic government faced spiral-
ling health care costs and an increasingly exclusionary health care 
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system, in which those who served the poor and marginalized were 
paying more for medicines than those in the affluent areas who were 
more likely to benefit from price and volume discounts, rebates, bonuses 
and other incentives. The pricing of medicines had historically been 
left to market forces, so companies were free to price their products as 
they wished, to offer bonuses and deals, discounts and rebates, and to 
discriminate among clients on the basis of volume of purchases and 
other considerations. The government therefore decided to intervene to 
correct the distortions. 
 Despite the large literature on pharmaceutical price controls in highly 
developed markets with well-developed health insurance schemes and 
universal coverage (Rietveld and Haaijer-Ruskamp, 2002), there was 
little from the developing world with similar health care systems to 
South Africa with a significant portion of patients without health care 
insurance and with considerable out-of-pocket expenditure on health 
care and medicines. 
 The government was also aware of developments internationally, 
where high medicines prices were receiving global attention from 
governments and consumers alike. Further, they were acutely aware that 
price controls have to be enacted in such a way that they still create 
headroom for market forces to work to exert further downward pressure 
on pricing. In trying to come up with mechanisms to control prices, 
the government looked to emulate countries that had successfully intro-
duced controls and managed to reduce, contain and sustain medicine 
expenditure. 
 A further challenge faced by South Africa was the huge fragmenta-
tion of the distribution channel, unlike the Western world where there 
are a few distributors and wholesalers controlling the entire distribution 
chain, and hence enjoying economies of scale. So the choice of policy 
options to contain drug costs would have to take into consideration the 
country’s unique health care structure. 
 The South African rationale for price controls 
 The government believed that medicines were public utility goods, and 
not mere commodities, and that it could no longer allow a situation 
where companies priced their products as they pleased. This was rein-
forced by their view that the prevailing drug prices in South Africa were 
inflated artificially through the elaborate system of bonuses, discounts, 
rebates and other perverse incentives systems that led to the dispensing 
of more expensive drugs, and irrational use of drugs. These perverse 
incentives, the state alleged, added an additional 50% to the final cost 
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of the drug. The Department of Health claimed that South Africa was 
among the world’s top five most expensive medicine markets. 
 The Department of Health’s position was strongly challenged by the 
Pharmaceutical Manufacturers Association (PMA) of South Africa, who 
held the claims were devoid of truth and based on an unfair comparison. 
The PMA held that the Department of Health was trying to influence 
the public and create the impression that the pharmaceutical industry 
was responsible for the high medicine costs, in order to introduce meas-
ures to control the industry. To circumvent this, the PMA approached 
the office of the Public Protector to make a determination whether the 
statements made by the Department of Health, perceived as laying the 
groundwork for price controls, were factual. 
 A key contention was that the Department had compared prices of 
products sold in the South African retail sector with prices of multi-source 
products sold by a prominent global NGO, the International Dispensary 
Association, which supplies developing countries with generics bought 
internationally in bulk. The PMA’s position was that the department was 
using an untenable comparison to justify the introduction of medicine 
registration and pricing reform in South Africa, whilst ignoring the fact 
that patient prices were often double the ex-manufacturer prices, and 
that various studies had indicated that South African prices were on par 
with international prices. 
 Despite the PMA’s efforts to block the reforms, the government made 
clear that they would immediately take measures to correct the disparities 
and distortions. In this regard, a number of key government policies – 
legislative and regulatory provisions – were enacted. The next section 
reviews the constitutional mandate that led to the interventions. 
 Constitutional enablers of the National Drug Policy 
 On 8 May 1996, the democratically elected parliament adopted the new 
Constitution of the Republic of South Africa. 2 This enshrined a Bill of 
Rights. Section 27 underpinned the legislative and regulatory processes 
that would follow in reforming the health sector; it read: 
 Section 27 (1) (a); everyone has the right to have access to healthcare 
services, including reproductive health. 
 Section 27 (2): the state must take all reasonable legislative and other 
measures within its available resources, to achieve the progressive 
realisation of each of these rights. 
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 Informed by this provision in the constitution, and acutely aware of 
the urgency to address the imbalances of the past, to create a new and 
equitable health care system with universal access to affordable quality 
health care for all, and ensure the progressive realization of Section 27, 
the government introduced a number of policy papers which would 
drive far-reaching regulatory and legislative reforms. The most impor-
tant was the National Drug Policy (NDP) of 1996. The NDP had far-
reaching implications, laying the basis for the Single Exit Price (SEP) 
regulations discussed below. 
 National Drug Policy 
 The NDP (Department of Health, 1996) was aimed broadly at increasing 
access to safe, affordable quality medicines for all South Africans, and 
laid the foundation for all the subsequent legislative and regulative 
revisions and amendments. Specifically, the NDP’s objective was ‘[t]o 
promote the availability of safe and effective drugs at the lowest possible 
cost’. The NDP intended to rationalize the pricing structure of drugs and 
included the following to realize that aim:
 the appointment of a Pricing Committee;  ●
 introducing total transparency in the pricing structure of pharmaceu- ●
tical manufacturers, wholesalers and dispensers of drugs; 
 introducing a non-discriminatory pricing system;  ●
 replacing the wholesale and retail percentage-based mark-up system  ●
with a fixed professional fee; 
 regulating price increases.  ●
 The far-reaching aims of the NDP found expression in the amendment 
to the Medicines and Related Substances Control Act 101 of 1965. The 
new Act 90 of 1997 introduced, among others, sections dealing with 
bonuses and samples (18 A and B), the ethical marketing of pharmaceu-
ticals (18C), generic substitution (22F) and the creation of the Pricing 
Committee and enactment of the single exit price regulations (22G). 
 The Medicines and Related Substances Act 
 Before the introduction of the SEP regulations, the South African phar-
maceutical market was dominated by innovator brands, with very little 
generic penetration. Medicines were promoted directly to doctors and 
pharmacists, who often received samples, bonuses and many other 
incentives to drive the prescription or dispensing of particular drugs. 
These practices led to doctors often prescribing more expensive drugs. 
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 The amended Medicines Act made provisions for the parallel impor-
tation of medicines into South Africa by others other than the patent 
holder (15C), the prohibition of bonusing, rebates and any other incen-
tive scheme (18A), prohibition of sampling of medicines (18B), manda-
tory generic substitution (22F) and the formation of a Pricing Committee 
and the clauses governing its mandate 3 (22G), namely that:
 (1) The Minister shall appoint such persons as he or she may deem fit to 
be members of a committee to be known as the pricing committee. 
 (2) The minister may, on the recommendation of the Pricing Committee 
make regulations 
 (a) on the introduction of a transparent pricing system for all medi-
cines and scheduled substances sold in the republic 
 (b) on an appropriate dispensing fee to be charged by a pharmacists 
or person licensed in terms of Section 22 C (1) (a). 
 (3) The transparent pricing system contemplated in sub-section (2) (a) 
shall include a single exit price which shall be the only price at which 
manufacturers shall sell medicines and scheduled substances to any 
person other than the state. 
 The provisions contained in the amendment to the Medicines and 
Related Substances Control Act 101 of 1965 were immediately chal-
lenged in court by the Pharmaceutical Manufacturers Association of 
South Africa (PMA), who felt that the Department had overreached itself 
in drafting the act. Although the PMA withdrew its court challenge in 
2001 following an international outcry and mounting international and 
civil society pressure, the regulations pertaining to a Transparent Pricing 
System for Medicines and Scheduled Substances 4 only came into effect 
on 2 May 2004. 
 The Single Exit Price regulations 
 South Africa’s attempt to control prices at wholesale level has elements 
of a fixed professional fee but with a fixed maximum, based on a tiered 
scale that considers the price of the product. At retail pharmacy level, 
the professional fees are also fixed, on a tiered system that endeavours 
to promote the dispensing of cheaper products. Over-the-counter prod-
ucts are exempted from controls, but pharmacists cannot benefit from 
discounts as they do in Europe. 
 The SEP was defined by the regulations as a composite of the manu-
facturer’s exit price, plus the distribution or logistics fee and a 14% value 
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added tax (VAT). The SEP thereby derived would be the one and only 
price at which wholesalers, pharmacies and other people allowed to 
dispense in terms of Section 22C (1) (a) could sell the medicine in South 
Africa, irrespective of the volumes purchased. The SEP would control 
pricing throughout the pharmaceutical value chain, setting dispensing 
fees for pharmacists and logistics fees for wholesalers and distributors. 
 The final price to the end user would include the SEP and the profes-
sional (dispensing fee) for the service rendered. Whilst companies would 
have the freedom to set initial prices, the pricing committee would 
decide on an annual price increase in accordance with a methodology 
in the SEP regulations. 
 Whilst the introduction of the SEP was widely criticized and seen as an 
anti-private-sector move by the new democratic government, the high 
prices of medicines had received attention previously from government 
commissions under the National Party. The three previous commis-
sions – the Snyman Commission (1962), the Steenkamp Commission 
(1978) and the Browne Commission (1985) – had also made recom-
mendations including curbing excessive medicine promotions, generic 
substitution, issuing of compulsory licences, calling for the state to 
participate in the supply of medicines through a tender system and for 
the state to investigate the introduction of price controls. 
 Setting the regulations 
 The Minister of Health appointed a pricing committee with representa-
tion from the Departments of Trade and Industry and Finance and the 
Competition Commission. The committee had pharmacists, lawyers, 
health economists, pharmaco-economists, academics and consumer 
representatives, but no industry representation. Their mandate was to 
establish a new regime of total transparency in the pricing structure of all 
prescription medicines and over-the-counter products. The committee 
would also set up regulations for logistics and dispensing fees, inter-
national benchmarking of pharmaceuticals and pharmaco-economic 
evaluation of medicines. 
 The government stated that, when fully implemented, it expected the 
SEP regulations to reduce the prices of medicines by 40–70%. In line 
with the regulations, effective 2 August 2004 and for a year thereafter, 
the price of medicines would not be higher than 50% of the ‘Blue Book’ 
manufacturer net price. 5 The Blue Book was a well-known industry 
publication that supplied the pharmaceutical industry and health care 
sector with independent and accurate price lists. The government held 
that the manufacturer net price listed in the Blue Book was inflated to 
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cater for the complex systems of bonuses, rebates and other incentives 
at play in the industry, in order to allow the retail chains to acquire 
drugs at below 50% of the listed Blue Book price. 
 The SEP regulation 8 allowed for a manufacturer to set their single exit 
price, which could only be raised once on an annual basis, whilst tempo-
rary price reductions were allowed as often as the manufacturer wanted 
to make them for competitive reasons. The SEP could be increased 
only once a year based on a predetermined formula 6 that incorporated, 
among others, the Consumer Price Index (CPI) and Producer Price Index 
(PPI) for the preceding year; changes in the rates of foreign exchange 
and purchasing power parity; and the need to ensure the availability, 
affordability and quality of medicines. The currencies considered are the 
US Dollar and the Euro, as most South African pharmaceutical compa-
nies purchase products and inputs of production from abroad with these 
two currencies. 
 The final increase as per formula is calculated as follows:
 API Formula  =  70% CPI (historical) + 15% (Rand/Dollar variance) 
+ 15% (Rand/Euro variance) 
 The exchange rate split of 15% US$ and 15% Euro was based on data 
provided by the Department of Trade and Industry and data on pharma-
ceutical imports. 
 Although this formula has been applied from the beginning, the 
actual price increases granted by the MoH have displayed a degree of 
discretion, and the timing has often been delayed, in some cases by up 
to five months. 
 Manufacturers can also apply for increases above the formula-based 
increases, to assist manufacturers and importers to compensate for 
exchange-rate-related increases in the prices of production inputs or 
finished products imported from principals overseas. The exceptional 
circumstances under which the minister would authorize such an 
increase were adverse financial, operational and other consequences 
for the manufacturer; adverse effects on the availability of the medi-
cine in South Africa should the increase not be granted; the nature of 
the disease the medicine was registered for; resultant adverse effects on 
public health; and lastly, to ensure that the constitutional obligations 
were not abrogated. 
 Finally, the Director General of the Department of Health could 
inform the public if she or he felt that the single exit price of a medicine 
was unreasonable. Manufacturers and importers were required to inform 
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the Director General six months before the registration of a medicine 
the intended SEP, the countries where the product was sold and how 
much it was selling for, the costs of manufacturing, and the marketing 
and selling costs of the product. 
 At inception, the regulations stipulated the maximum professional 
fees that could be added to the single exit price by various players in the 
distribution chain. 
 Controversies and challenges 
 The SEP regulations were immediately challenged in court by various 
organizations. The pharmacy groups contended that the fees were not 
sufficient for them to survive, and that the stipulated professional fees 
threatened the survival of many independent pharmacies. Further, the 
Pharmaceutical Society of South Africa (PSSA), a large retail pharmacy 
chain, New Click (Pty) Ltd, and others argued that the Department 
had overreached itself in promulgating the regulations. The Cape High 
Court found in favour of the state and dismissed the case, although the 
dissenting judgment 7 held that it was difficult to understand how the 
SEP was arrived at; that the logistics fee regulations were contradictory 
and at odds with other legislation; and that the dispensing fee had been 
based ‘on no more than a thumb suck’ and a simplistic ‘one size fits all’ 
approach. The PSSA, New Clicks and others appealed the Cape High 
Court ruling, and the case went to the Supreme Court of Appeal where 
the Cape High Court decision was overturned. 
 The Supreme Court of Appeal, in overturning the decision of the Cape 
High Court, made this finding 8 :
 The order of the court below is set aside and replaced with the 
following order in each application: 
 (a)  The ‘Regulations relating to a Transparent Pricing System for 
Medicines and Scheduled Substances’ as published in GN R553 on 
30 April 2004 are declared invalid and of no force and effect. 
 The state in turn appealed, and the case went all the way to the 
Constitutional Court, which ruled that the Department had indeed 
acted within the law, but ordered the Department to go back to the 
drawing board and review the professional fees. 
 The Department of Health adjusted the proposed dispensing fee 
to 26% of SEP to a maximum of R26. This proposal was immediately 
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rejected by the Pharmaceutical Society of South Africa, once again on 
the grounds that it was insufficient and would cause unnecessary hard-
ship to their members and eventual closure of pharmacies. The PSSA 
proposed a tiered dispensing fee system with average fees of R37, a 
proposal that found no favour with the Department of Health. 
 Following these court challenges and negotiations between the various 
parties, the dispensing fee and the logistic fees have gone through 
various iterations, and have now been finalized. The June dispensing 
fee was first published in March 2006, and was immediately rejected by 
pharmacists. This was then replaced with a new proposal of June 2009. 
More discussions and consultations followed, and the last iteration was 
published in June 2014 (Table 11.1). The table shows the complex calcu-
lations of the permitted fee for each band of the SEP, at the various revi-
sion dates. 
 The proposed dispensing fees were revised upwards over time as 
pharmacists complained that their business would be unsustainable 
(Table 11.1). The lowest tier has stayed below R100 (US$8.50) and the 
fixed fee was reduced, but the dispensing fee has been revised upwards 
with the adjustment of the percentage of the total medicine price. In 
the top tier of products above R799.85 (US$67.80), the fee has also been 
adjusted upwards through a revision of both the fixed component and 
the percentage of the medicine price 
 Logistics fee 
 Prior to publication of the logistics fee regulation, wholesalers and 
manufacturers negotiated the logistics fee independently, and there 
were reports of widely varying logistics fees, with some companies 
paying in the high double digits. Innovator companies with patent-
protected products that wholesalers were desperate to stock would often 
pay in the low single digits, whilst some did not pay any logistics fees at 
all. This position put the generic pharmaceutical industry at a distinct 
disadvantage, as wholesalers would often squeeze generic companies 
for bigger logistics fees to make up for the loss with innovator compa-
nies. The government finally moved to regulate the logistics fee, and 
in March 2011 published the first draft regulations for Logistics Fees 
(LF). The second iteration was published in September 2012 following 
negotiations and discussions with providers of logistical services. The 
fee involves four tiers, with a LF of 8% of the ex-manufacturer price 
excluding VAT + R3 ($0.25) for items less that R100 (US$ 8.50), and a LF 
of R54 (US$4.58) for items exceeding R1,000.00 (US$84) 
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 Table 11.1  Pharmacy dispensing fee: fee in rands (R) plus permitted mark-up (%), by band of SEP in rands (R) and date of publication of schedule 
 Date of publication of fee schedule 
 03/2006  06/2009  12/2010  09/2013  06/2014 
 SEP < R77.00 
R7.00 + 28% of SEP
 SEP < R100.00 
R6.00 + 36% of SEP
 SEP < R75.00 
R6.00 + 46% of SEP
 SEP < R81.00 
R6.30 + 46% of SEP
 SEP not > R 85.70 
R 6.95 + 46% of SEP
 SEP = R75.00 < R 150.00 
 R 23 + 7% of SEP 
 SEP = R100.00 < R 250.00 
 R 32 + 10% of SEP 
 SEP = R75.00 < R 200.00 
 R 15.75 + 33% of SEP 
 SEP = R81.00 < R 216.00 
 R 16 + 33% of SEP 
 SEP R 85.70 < R228.53 
 R18.55 + 33% of SEP 
 SEP > R150.00 < R250.00 
 R 26 + 5% of SEP 
 SEP > R150.00 < R1000.00 
 R 45 + 5% of SEP 
 SEP > R200.00 < R700.00 
 R 51 + 15% of SEP 
 SEP > R216.00 < R756.00 
 R 55 + 15% of SEP 
 SEP > 228.53 < R799.85 
 R59.00 + 15% of SEP 
 SEP > R 250.00 
 R 31 + 3% of SEP 
 SEP > R 1000.00 
 R 65 + 3% of SEP 
 SEP > R 700.00 
 R 121 + 5% of SEP 
 SEP > R 756.00 
 R 131 + 5% of SEP 
 SEP > R799.85 
 R 140 + 5% of sep 
 Source : Government Gazettes, various years, extracted by author. 
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 Despite representations from wholesalers and support from the 
generics industry for the logistics fee to include a minimum fee and a 
fixed cap, the department rejected that application on the grounds that 
having a fixed minimum would be anti-competitive. It published the 
final logistics fee with only a fixed cap. Manufacturers and importers 
would be free to negotiate a fee up to the capped level with whole-
salers. The regulations also stipulated that where the current logistics 
fee exceeds the current caps, manufactures and providers of logistical 
services must negotiate to reduce the fee within 60 days of publication 
of final logistics fees. The regulations, however, allowed the minister 
to authorize a manufacturer or importer to increase the logistics fee in 
exceptional circumstances. 
 Experience with the Single Exit Price regulations to date 
 Price increases under the regulations 
 Table 11.2 below captures the experience with the SEP to date. It shows 
the quantum as determined by the SEP methodology and the eventual 
increase granted by the Minister. 
 It is clear from the table that the minister has not always adhered to 
the formula, and has exercised discretion in granting increases – a sore 
point for the industry. 
 Although the industry has complained about the low increases from 
inception, experience shows that since the introduction of the SEP, 
they have not always taken the full increase granted. In fact, temporary 
price reductions have been taken frequently within the period of an 
 Table 11.2  SEP increases since the implementation of the SEP (%) 
 Year 
 SEP calculation as per 
methodology (%) 
 SEP granted by 
the Minister (%)  Variance 
 2004/05 & 
 2006/07 
 2.60 
 2.60 
5.20 N/A
2008 8.40 6.50 –1.90
2009 12.12 13.2 +1.08
2010 9.90 7.40 –2.50
2011 –2.10 0.00 N/A
2012 6.90 2.14 –4.76
2013 8.20 5.80 –2.40
2014 8.90 5.80 –3.10
 Source : National Department of Health, Pharmaceutical Task Group, author analysis. 
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SEP increase. This has largely been for competitive reasons, and at times 
motivated by the need to sell short dated stock before it expires. 
 A further justifiable complaint is that the Department of Health delays 
the increases, so companies lose out. For example, in 2010, there was 
a five-month delay between the increase and the time that companies 
could take the increase. These delays occurred as a consequence of 
the ‘application’ process introduced, and decisions to accept applica-
tions only from 1 April. Given the 30-day approval process, the earliest 
companies can take an increase is 1 May, which leaves companies with 
just seven months to enjoy the price increase. Besides these delays, there 
were also frequent rejections due to such matters as formatting issues on 
the SEP increase application template, Department of Health database 
discrepancies and missing documentation. 
 SEP impact on prices 
 The experience of South Africa with price controls demonstrates that, 
contrary to popular opinion, the Department of Health conceptualized 
a regime based on global practice and tried to blend a number of instru-
ments with a good historical record of effectiveness in other countries. 
 In terms of controls at the manufacturer level, in attempting to arrive 
at a fair ex-manufacturer price, and considering the complexities of 
setting a fair price in a predominantly import based industry, the govern-
ment settled arbitrarily on 50% of the Blue Book price on the basis that 
prices were inflated by the same figure to make up for the incentives, 
bonuses, sampling and other perversities in the system. The price nego-
tiation component between companies and government has only been 
recently employed for state procurement, where besides published refer-
ence prices, the Central Procurement Unit can and does directly nego-
tiate prices with manufactures, especially if they are not too far from the 
reference prices listed. At the same time, elements of comparative pricing 
were built into the regulations through the International Benchmarking 
provisions wherein South African prices would be compared to a basket 
of prices in five countries including Canada, Australia, New Zealand 
and Spain. Similarly, pharmaco-economic evaluations were also built 
into the regulations, although these and comparative pricing through 
benchmarking have yet to be finalized. 
 When it comes to other measures to control prices, South Africa has 
not adopted positive and negative lists, whilst experience with demand-
side measures such as reference prices, co-payments, and generic substi-
tution and education of health care professionals and the public is 
mixed. Private health care insurance schemes all have reference pricing 
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systems in place, and accompanying co-payments if patients elect to 
use more expensive products outside the formulary and reference prices. 
Government enacted provisions for mandatory generic substitution, 
and although this and other measures have seen generic usage increase 
from the mid-20% in 2002 to around 60% by volume (IMS Health, 
2014a), there is still scope for more growth. To this extent, the govern-
ment can do more to educate patients about the safety, quality and effi-
cacy of generic medicines, as well as the benefits for patients and health 
systems. This is an area that still requires much work. 
 There is general acceptance that the introduction of the SEP regime has 
resulted in a downward impact on the prices of medicines. The graph in 
Figure 11.1 is drawn from data from the Council of Medical Schemes, 
which publishes an annual report detailing, among other things, total 
health care expenditure in the private sector, and looks at the contribu-
tion of the various players. 
 The Department of Health reported savings of 19%, made up of 
25–50% for generic medicine prices and 12% for originator medi-
cines. 9 IMS Health reported an average drop in medicine prices of 24% 
between June 2003 and June 2006 (Vokes, 2007) since the introduc-
tion of the SEP. Similarly, Emsley and Booysen (2004) reported that the 
introduction of the SEP had resulted in a reduction of 36.7% in the 
prices of quetiapine and 13% for haloperidol. Admittedly, that paper 
was published a few months after the introduction of the SEP, so it is 
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 Figure 11.1  Medicine contribution to total private health care costs 
 Source : Drawn by the author from data from Council for Medical Schemes (2014). 
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not clear if the reductions have been sustained. Further evidence of the 
impact of SEP on prices was reported by Steyn et al. (2007), who demon-
strated that the SEP regime had reduced the average cost of anti-diabetic 
medicines by around 29.6%. Finally, the biggest private health insur-
ance company, Discovery Medical Aid, reported: ‘Because of the single 
exit price legislation, these drug price reductions benefit all users in the 
private healthcare system. Conservative estimates suggest total annual 
savings of about R 319 million per year are achieved for the scheme in 
medicine expenditure’ (DHMS, 2012). 
 The media and other parties have also reported extensively on the 
impact of these price regulations. For example, the  Mail and Guardian , 
South Africa’s leading weekly newspaper, reported on 26 February 
2008: ‘The introduction of medicine pricing regulations a few years ago 
resulted in a 20% drop in prices, and savings of over R 2.3 billion on 
medicines’. 
 Other reports and theses, especially looking at the impact of the SEP on 
the pharmacy profession, and occasionally on the patient, do however 
offer a different view of the impact. They describe a profession decimated 
by the regulations, with multiple closures of pharmacies, especially in 
rural areas. Although critically important and requiring further critical 
academic enquiry, they are outside the scope of this chapter. There is 
also anecdotal evidence that the early gains made may be slowly eroding 
as the contribution of medicines to overall health care costs continues 
to creep up, albeit slowly. Whether this is purely a factor of the SEP poli-
cies starting to fall short, or because of increased medicines usage, or the 
impact of pseudo-generics which tend to crowd out true generics and 
inflate prices, or other factors, requires further study. 
 SEP impact on manufacturers and access to medicines 
 It is accepted internationally that the entry of generics significantly 
widens access to medicines, and the size (volume) of the market often 
expands after patent expiry. The impact of the SEP regime on access to 
medicines is an area that still requires further investigation. 
 The reference prices are normally set with the first generic entrants 
and often undergo revisions with further entry. In certain instances, the 
revisions have been quite dramatic, leading to wholesale price decreases, 
further lowering the price of the drug and indirectly promoting access. 
The case of simvastatin is instructive. Simvastatin is highly genericized, 
with the first generic product launched in 2002 by Adcock Ingram. 
Adcock remained the clear market leader despite other generic alterna-
tives. In 2009, Michol, a new simvastatin generic entrant, came in at a 
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very low SEP, and as a consequence the prices of a pack of 30 simvastatin 
tablets dropped from over R120 to around R25. Arguably, the effect of 
this would have been to increase access by patients, especially those 
who pay out of pocket for package deals that include consultation fees 
and medicines from family practitioners. 
 The impact of the SEP has also come through in capping prices through 
private medical schemes’ reference pricing systems. All the private 
medical insurance schemes have their own reference pricing systems 
to set the maximum price a scheme will pay for a generic drug. The 
effect has been to force newly launched generics to price below the refer-
ence price, and in some instances to compel the innovator to drop their 
prices or face the risk of their products facing co-payments. Similarly, if, 
for competitive reasons, a generic manufacturer drops prices drastically 
and sets a new reference price, other companies are forced to follow suit 
or face the prospect of co-payments, which will deter patients. 
 Impact on manufacturers 
 Manufacturers have complained that the SEP regime has put the sector 
under pressure, as the SEP increases are insufficient to offset the effect of 
the weaker Rand, coupled with wage and utilities inflation. This leads to 
reduced earnings and threatens the commercial viability of some product 
lines. Given that most companies import both the active pharmaceutical 
ingredients and other raw materials from overseas, the weakening of the 
Rand in a price-controlled environment leads to significantly higher cost 
of goods sold, without the recourse to increase prices to offset that. This 
is particularly so because although the regulations have a mechanism 
for extraordinary prices increases, companies complain that the process 
is onerous, hugely bureaucratic and difficult to access. These pressures 
have led to some manufacturers discussing discontinuation of some 
products. Recently, it was reported that Fresenius Kabi had withdrawn 
one product, Voluven, from the market, although the company stated 
that the withdrawal was not related to cost pressures (Bateman, 2014). 
 Delays are also a major problem for manufacturers. When a company 
applies for an SEP for a new product, or informs the Department of 
an SEP price adjustment, the Department ‘approves’ and then notifies 
price vendors such as Medikredit. The product is then allocated a NAPPI 
(billing) code, after which it can be sold on the South African market. 
Companies complain that delays in assessing the SEP applications and 
informing vendors delays market access for new products, and in the 
case especially of first-to-market generics, restricts and denies patients 
access to cheaper products. Although the regulations envisaged that the 
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SEP would be agreed within 48 hours of notifying the Department of 
Health, the process has evolved to one of ‘approval’, and delays of up to 
a month are not uncommon. 
 The potential closure of independent community pharmacies in rural 
and remote areas, mentioned above, may clearly reduce access. The 
Pharmaceutical Society of South Africa opposed the SEP regulations and 
the dispensing fees on the basis that they threatened the viability of 
independent community pharmacy. Since the early court challenges, 
there have been widespread reports that some community pharmacies 
did go into bankruptcy. The Pharmaceutical Society of South Africa 
reports that many small town and rural pharmacies have closed (PSSA, 
2014) negatively affecting access. Dodd (2007) demonstrated that inde-
pendent pharmacies saw net profits fall, that the price controls could 
push some pharmacies into bankruptcy and that closure of pharmacies 
in remote and rural areas would render the distribution of medicines 
economically unviable and thus affect access. 
 Some contend, furthermore, that the SEP regime has the unintended 
consequence of keeping prices higher than they would otherwise have 
been. They argue that late entrants often find it impossible to offer 
discounts on the prevailing prices, given that medical schemes will still 
reimburse up to the level of the reference price, so there is no incentive 
for pharmacists to offer the lower-priced product. This is compounded 
by the fact that the dispensing fee is calculated as a percentage of the 
price of the drug, inadvertently incentivizing pharmacists to dispense 
the highest-priced generic as long as it is within the reference price 
band. 
 Finally, it is argued that the SEP regime creates a disincentive for new 
entrants to offer lower entry prices. Some experts believe that because 
companies know that they will struggle to get price increases (Medical 
Chronical, 2012) sufficient to offset inflationary pressures and Rand 
weakness, among other challenges, they deliberately set high prices 
from the outset, possibly reducing access. The proponents of this view 
note that medicine prices in South Africa are artificially inflated, and 
higher in comparison to the same products in other countries. 
 Conclusion: are there lessons for other African countries? 
 South Africa embarked on the SEP path exactly a decade ago, informed 
by the realization that, as public utility goods, medicine prices could not 
be left to the vagaries of the market. In that time, there has been much 
acrimony, public disagreements in the media and other public spaces 
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between the main protagonists. Throughout all of this, the Department 
of Health, backed by the government and the ruling party, as well as 
public health and patient advocates, held firm. There have been threats 
of court cases, and many actual court cases, which have invariably led 
to iterations of the dispensing and logistics fees. What has emerged, 
though, is that through proper consultation and a willingness to open 
up and present the evidence base for positions held on various issues, it 
is possible to move towards negotiated positions. The first critical lesson 
for those who would want to embark on the price regulation route, 
therefore, is the absolute necessity of having clear and unambiguous 
political support for reform. Without this, there is no hope for success. 
 The second key lesson from South Africa’s journey with price 
regulations is the necessity of involving all key stakeholders in the 
process very early on. Governments and policy makers must take the 
private sector into their confidence and clearly and firmly explain 
the rationale for their decisions, ensuring that all views and all aspects 
are taken into consideration beforehand. Arguably, if the South African 
Department of Health had embarked on an exercise with the pharmacy 
profession, escorted by reputable independent and honest brokers, to 
arrive at a reasonable and evidence-based dispensing fee, there would 
have been no need for court cases, nor for the time spent in the last 
couple of years on endless consultations and the various iterations of 
the dispensing fee. 
 Third, it is imperative to collect the evidence base to guide policy 
decisions to be taken before embarking on a price reform process. This 
means making a full and thorough assessment of the entire distribu-
tion chain and finding the factors at play with each of the stakeholders. 
In the South African example, the R26/26% dispensing regime was no 
danger to the big retail chains, but threatened the survival of the small 
community pharmacy. 
 Fourth, it is imperative to make both the interpretation and implemen-
tation of any regulatory processes as simple as possible. The complexity 
that crept into the South African SEP regime and the bureaucratization 
of the process only served to make the pricing regime more unpopular. 
A measure of predictability and certainty around the application and 
approval process, the time periods for taking the increases and so forth 
would have lessened the tension between industry and the regulators. 
 Finally, although the SEP regime seems to have had a positive impact 
on prices, it is clear that supply-side measures on their own have only 
limited impact. It is thus critical for those governments that intend to 
regulate prices to devote equal attention to the demand side. This can be 
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done, among other methods, through massive patient education about 
the benefits of generic medicines, the incentivization of health care 
professionals to prescribe or dispense the cheapest products – above and 
beyond the dispensing fee – and the need to adopt generic prescribing 
across the board. 
 Notes 
 1 .  National Department of Health, South Africa – Tender analysis by author, 
from data accessed in December 2014 at  http://www.doh.gov.za/mpc3.php . 
 2 .  The Constitution of the Republic of South African – ‘Everyone has the right 
to have access to – a) health care services, including reproductive health care’. 
Section 27 (1) (b) of the Constitution further mandates the state to, ‘take 
reasonable legislative and other measures, within its available resources to 
achieve the progressive realisation of the right’. 
 3 .  The Medicines and Related Substances Control Act 101 of 1965 as amended. 
 4 .  Department of Health. Regulations Relating to a Transparent Pricing System 
for Medicines and Scheduled Substances. GG No R 553 30 April 2004. 
 5 .  Department of Health. Regulations Relating to a Transparent Pricing System 
for Medicines and Scheduled Substances. GG No R 553 30 April 2004. 
 6 .  National Department of Health – Regulations relating to a transparent pricing 
system for medicines and scheduled substances made in terms of Section 22G 
of the Medicines and Related Substances Act, 1965 (Act No 101 of 1965). 
 7 .  New Clicks South Africa (Pty) Ltd  v Tshabalala-Msimang and Another NNO ; 
Pharmaceutical Society of South Africa and Others  v Tshabalala-Msimang and 
Another . 
 8 .  The Supreme Court of Appeal of South Africa – In the matter between The 
Pharmaceutical Society of South Africa AND Others and the Minister of Health 
and ANOTHER, New Clicks South Africa (Pty) Ltd and Dr Manto Tshabalala-
Msimang and ANOTHER, Case No 542/04 & 543/04. 
 9 .  A presentation by the Department of Health on Medicine price regulation – 
the South African experience (2009). 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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 Introduction 
 This chapter discusses standards, an elusive term and concept. For the 
African pharmaceutical sector especially, the term is used by the manu-
facturing sector, regulators, technical experts, procurement agencies, 
health system actors and policy makers to mean different things. There 
is a dearth of systematic studies that address what standards are, their 
classification and the logic behind their set-up and operation, and this 
has contributed to a huge asymmetry in understanding. The socio-
economic, technical and political issues and how they have an impact 
on local production and industry development, including their effects 
on access to markets, have also not been systematically explored. 
 A common understanding of standards, their classifications and devel-
opment, is important as the continent implements the African Union’s 
Pharmaceutical Manufacturing Plan of Action (see also Chapter 15). 
Even more important is the need for African technical experts, regula-
tors and policy makers to realize that standards and their development 
in the pharmaceutical sector is a process under their control. They can 
drive agenda setting and design realistic and context-sensitive road maps 
which align local industry development without compromising public 
health safety. The ability of policy makers to take a critical approach to 
the meaning and use of standards in the African pharmaceutical sector 
is an important enabler for designing road maps. 
 12 
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 In this chapter we set up some of the issues that need further debate. 
We deconstruct standards and classify them into two groups; technically 
based standards and organizational or institutionally based standards. 
Technically based standards cover product, process, plant and envi-
ronmental aspects. Organizational or institutionally based standards 
are those which are important for creating market confidence in firms’ 
output through assuring the credibility and legitimacy of products, 
quality, production, distribution and recall processes. This credibility 
and legitimacy arises from physical inspections of production and distri-
bution facilities, and the availability and examination of documenta-
tion and data management processes – administrative activities essential 
for endorsement, certification and accreditation. 
 We argue that this perspective helps to build an understanding of 
which types of standards are ‘mutable’ 1 – that is, judgement-based 
standards such as inspection, certification and accreditation for which 
capability building and improvement is a gradual process. By contrast, 
standards which cannot be compromised are those which deal directly 
with patient and public health safety concerns, namely quality, safety 
and efficacy of medicines. Such distinctions aid technical and policy 
people in designing and implementing appropriate interventions and 
road maps for technological capability and standards upgrading which 
do not compromise locally manufactured medicines’ quality, safety and 
efficacy. These distinctions also help in crafting responsive, context-
sensitive standards and compliance development processes that do not 
impose unnecessarily high costs or regulatory barriers on existing local 
industry. Our discussion of standards is informed by extensive literature 
searches, fieldwork in India, Kenya, Zimbabwe and South Africa where 
we interviewed technical experts in 2014, and interaction with regula-
tory and compliance experts in the UK. 
 A brief historical perspective 
 The history of standards in the pharmaceutical industry is traceable 
to adverse events in patient safety, and one of the notable failures was 
the 1950–60s thalidomide disaster (Grabowski et al., 1978), in which 
a morning sickness pill containing thalidomide taken by pregnant 
mothers resulted in newborns with severe birth defects. The disaster 
catalysed stringent drug approval and monitoring processes, necessi-
tating the passing of the Kefauver-Harris Drug Amendments Act in 1962 
which called for proof of safety and efficacy in the approval process, 
approvals that now use animal testing and clinical trials that can take 
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up to 12 years. The logic for the development of stringent regulation 
was that there was a need for an independent government regulatory 
agency to ensure public health whose goals were not compromised by 
commercial interests of pharmaceutical companies (Abraham, 2002). All 
stages of the drug life cycle are regulated from drug discovery to release 
of the drug on the market (Harper et al., 2007). Table 12.1 summarizes 
five key stages in the life cycle of a pharmaceutical drug, and the regula-
tory requirements or standards pertinent for each stage. 
 For drug discovery, the key guideline is good laboratory practice 
(GLP), and for phase 1 to 3 clinical trials the guideline is good clinical 
practice (GCP). When the drug moves to the production phase, good 
manufacturing practice (GMP) becomes the guiding regulatory require-
ment, followed by good distribution practice guideline for distribution 
covering traceability of medicines (systematic identification of products) 
to aid in organized defective product recall from the market. For post-
market surveillance, pharmacovigilance is the regulatory requirement. 
In addition, there is a wide range of other regulatory requirements at 
 Table 12.1  Drug life cycle stages and regulatory requirements 
 Drug life cycle stage  Regulatory requirements/Guidelines 
Drug discovery Good laboratory practice (GLP): these guidelines 
focus on toxicological safety and protection of 
the test subject
Clinical trials (phases 1, 2, 3) Good clinical practice (GCP): these guidelines 
consider product efficacy and safety evaluation, 
as well as individual protection and safety 
during testing
Manufacturing Good manufacturing practice (GMP): these 
guidelines are concerned with assuring a 
manufactured product’s quality, safety and 
efficacy, for both the product and the patient. 
The process aims to build in quality and ensure 
quality standards.
Distribution Good distribution practice: these guidelines deal 
with storage, transportation and traceability for 
product recall.
Post-market surveillance Pharmacovigilance: Sometimes called phase 4, 
this is monitoring of the product after market 
authorisation to check for any adverse events or 
product failure in all respects.
 Source : Adapted from Harper et al. (2007) and Muller et al. (1996). 
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supranational and national levels, inspired by public health concerns 
and safeguards against drug disasters, to address trade and market entry 
obligations (Immel, 2001). 
 The situation is less complex and expensive for generic medicines, 
which are modelled on branded drugs, since proof of safety and efficacy 
has already been demonstrated for the branded drug. The generic drug 
producer needs at the minimum to demonstrate the equivalence of the 
drug for approval and it does not go through rigorous clinical trials. The 
bulk of medicines produced in Africa are generics, and consequently the 
standards that we will discuss in this chapter focus on generics manufac-
ture. We do not cover standards in drug discovery and clinical trials. 
 While the first set of GMP guidelines for manufacturing, processing, 
packing or holding finished pharmaceuticals was introduced by the US 
Food and Drug Administration (FDA) in 1963 (Immel, 2000), the WHO 
has spearheaded the standards-setting process since the late 1960s, 
coming up with several amendments and extensions to the guidelines. 
In this chapter we focus on good manufacturing practice (GMP), defined 
by the WHO (2004) as the part of quality assurance that ensures that 
products are consistently produced and controlled to the quality stand-
ards appropriate to their intended use and as required by market author-
ization. Many countries, including India, Kenya and South Africa, have 
developed their own GMP guidelines based on the WHO guidelines. The 
WHO is thus a global technical agency responsible for setting stand-
ards and normative guidance and for establishing best practice, all of 
which are implemented through national drug regulatory authorities 
(DRAs) and other relevant institutions. There is criticism, however, that 
the WHO sets standards for all its member states regardless of the level 
of development. There is also some questioning of the way in which 
the WHO has shifted from a solely advisory body (technical assistance 
included) towards acting as a regulatory body after it began pre-qualifi-
cations of pharmaceutical products for developing countries. WHO pre-
qualification has acted as a catalyst for upgrading facilities in developing 
countries, but its stringent requirements have also been an impediment 
to market access to global donor-funded medicines purchase, in particu-
larly for HIV/AIDS, TB and anti-malarial drugs. 
 Standards, their establishment and assurance 
 A standard can be viewed broadly as a consensus between different agents 
to do certain key activities according to agreed-upon rules (Nickerson 
and Muehlen, 2006). This is a definition of standards as a process: a 
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common and agreed understanding of the rules of the game and how 
it is played, which resonates with the definition of institutions. These 
standards, therefore, operate on the back of strong institutional and 
organizational arrangements empowered to certify compliance with set 
rules through proclamations or a tightly controlled allocation of insignia 
or certification. Independent validation from a third party is critical for 
building confidence of other stakeholders who lack inside information 
or the means to gather credible information to make informed deci-
sions. Standards therefore provide consumers with a basis for making 
informed consumption decisions and manufacturers with a benchmark 
of best practice (Nadvi, 1999) and hence a competitive tool. 
 A technology standard, on the other hand, is defined as ‘a set of 
specifications to which all elements of products, processes, formats or 
procedures under its jurisdiction must conform’ (Tassey, 2000: 58). This 
form of standards has been credited with the standardization that has 
significantly reduced manufacturing costs through economies of scale 
achieved by mass-production of similar or ‘standard’ components (Katz 
and Shapiro, 1985; Farrell and Saloner, 1986). It is argued that the pres-
ence of standards reduces uncertainty by providing actors with a frame-
work that enables widespread diffusion of a technology (Rosenberg, 
1976), as well as a modular approach to the production process where 
components can be manufactured by different producers. 
 Organizational or institutionally based standards interact with tech-
nology standards through the processes of data or process interrogation 
against set norms, validation, acceptance and certification. Thus certi-
fication and/or accreditation of products or firms affirm that accepted 
best practice (norms), ‘standardized’ and imbued with accountability, 
has been used at various stages in a product’s design, development, 
manufacture, distribution and disposal. Specifically for the pharmaceu-
tical sector, inspection, validation, certification, accreditation and regu-
lation provide a system of traceability and accountability. This is done 
through detailed verification of quality-dependent procedures through 
internal and independent audits, quality training of personnel and 
constant monitoring of quality performance measures (Nadvi, 1999), as 
well as market performance and rectification in cases of failure. 
 Government departments, regulatory agencies, pharmaceutical 
companies’ industry associations and other stakeholders play key roles 
in the design, implementation and refinement of policies and stand-
ards governing the sector. The credibility of a standard setting and 
monitoring process depends on the representativeness of the political 
process, how well it exploits existing technical knowledge, matches 
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context of application, and how committed participants are to the issue 
at hand (Fischhoff, 1984). These processes inherently reflect different 
interests, power structures and the resources of different stakeholders. 
Consequently and at the heart of this discussion, low-income countries 
tend to typically be ‘standard takers’ rather than ‘standard makers’, with 
the responsibility for implementation, monitoring and enforcement of 
the standards resting with the national governments (Stephenson, 1997), 
which in many African settings are resource-constrained. It is with this 
background to technical and organizational/institutional standards that 
we argue that African technical and policy organs need to gain a confi-
dent understanding that designing and implementing a road map to 
improving standards in the pharmaceutical value chain is something 
that is and should be under their control. 
 Standards as tools for competition and pressure to improve 
 The significance of standards has grown over time and they have come to 
represent an important locus of collective strategy (Astley and Fombrun, 
1983) within which the ‘rules of the game’ are set (Jain, 2012). For many 
producers and service providers in both the global North and South, 
compliance with international standards can add a competitive edge 
and form a necessary condition to access niche markets (Nadvi, 1999). 
More recent research emphasizes that standards provide opportunities 
and incentives for low-income countries to modernize local industry and 
strengthen supply of quality products (Jaffe and Henson, 2004; World 
Bank, 2005). This growing evidence base suggests that in low-income 
countries standards can link upgrading local industrial capabilities with 
supply of medicines and hence better local health service quality and 
inclusiveness (Nadvi and Waltring, 2002). 
 It has been argued that good-quality and affordable pharmaceutical 
products, whether imported or locally produced, depend largely on 
the outcome of standards-based competition (Narayanan and Chen, 
2012). In the international trade literature, research suggests stand-
ards can be non-tariff barriers to trade (Stephenson, 1997; Wilson and 
Abiola, 2003), with regards to labour (Maskus et al., 2004; Maskus and 
Wilson, 2001) and environmental standards (Anderson, 1996; Anders 
and Caswell, 2009). These barriers emanate from inadequate provi-
sion of finance, local governance and regulatory structures. Kaplinsky 
et al. (2011) considered how standards such as hazard analysis critical 
control points (HACCP) and International Standards Organisation 
(ISO) are used as non-tariff barriers, especially for resource-constrained 
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countries. Supporting this assertion, a growing body of literature shows 
that without financial and technological support for domestic manufac-
turers, standards create significant cost and international market entry 
barriers (EC, 1997; Nadvi, 1999; Stephenson 1997). 
 International procurement practices and requirements of donors 
often enforce higher pharmaceutical quality standards than stipulated 
by national regulatory authorities. Implementation of these higher 
standards by local firms and achieving certification requires investment 
in people, equipment and changes in production organization as well as 
management practices – a costly exercise. Multiple accreditation caused 
by the need for local, regional and international certification such as 
WHO pre-qualification has direct negative bottom-line impact. One 
African firm reported during fieldwork that a WHO pre-qualification 
inspection can cost as much as US$100,000, a large financial burden 
especially if accreditation and certification is not supported by success 
with global health and international medicine supply tenders. As a result, 
some local industrialists have questioned the logic of solving national-
level institutional failure at supranational level. They argue that it is 
better to strengthen local regulatory authorities or take the harmoniza-
tion route by solving the institutional challenges at national or regional 
level. These criticisms inform our critical discussion of standards, what 
they are and how road maps for improving standards and industry capa-
bilities can be crafted. 
 The need to deconstruct standards 
 A respondent from Kenya on being asked what standards were, remarked 
as follows: ‘this is where we have a problem ... the word “standard” is 
misused both at global and national levels’. Such a remark underscores 
the need to deconstruct standards and classify them. He went on to 
describe what he considered to be standards, such as the guideline 
that describes good manufacturing practice (GMP) (which he termed a 
standard in itself), facility standards and personnel standards, as some 
of the key issues to be considered. In this section we discuss consecu-
tively the two types of standards identified above: technical standards 
and institutional or organizational-based standards 
 Technical and process standards 
 GMP guidelines are intended to be a set of minimum standards, covering 
recommendations on quality management, personnel, production 
facilities and equipment, documentation and records, production and 
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in-process controls, packaging and identification labelling, storage and 
distribution, laboratory controls, validation, complaints and recalls, and 
contract manufacturers (WHO, 2004). The diverse range of issues covered 
by GMP guidelines not only makes them a key and central lens for our 
discussion of pharmaceutical standards but also highlights why these 
guidelines are one of the most contested yet key drivers of the pharma-
ceutical industry. Under GMP we have chosen to focus on four standards 
that emerged as key in our research. Two of these standards (product 
and process) were classified as those which should not be compromised 
because of their direct relationship with patient and public health safety. 
The GMP process is critical for ensuring product quality, safety and effi-
cacy. As noted in Chapter 3, GMP standards constitute a ‘production 
culture’ interwoven with professional judgement as regulators decide on 
what is deemed adequate especially for processes and facility standards. 
 Product and process standards 
 There was consensus among the multinational and local pharmaceu-
tical manufacturers interviewed on the fact that product and process 
standards cannot be compromised. These they argued, should be the 
same wherever medicines are produced in the world. These standards 
are engineered in such a way that quality is built in and checked for at 
various stages and the evidence meticulously documented. The suppliers 
of raw materials have their facilities, processes and products vetted, and 
on receipt, raw materials are sampled and subjected to specific physical, 
chemical and biological tests. Raw materials are carefully stored ensuring 
avoidance of cross-contamination. There is a clear and documented chain 
of custody, traceability and accountability that is established along the 
whole process. In many African countries the production pharmacist 
is ultimately responsible and accountable for the release of batches of 
products after compliance with product and process standards as well as 
quality control tests. The quality control tests cover chemical, physical 
and biological characteristics of the product and avoiding contamina-
tion in the same three areas. Some of the tests, for example for tablets, 
include microbial tests, hardness and how well the tablet dissolves. 
 The drivers of product and quality standards are people, the produc-
tion equipment and laboratory equipment. Improving standards there-
fore requires in many instances equipment and skills upgrading. For 
example, a Zimbabwean firm improved ingredient drying in the wet 
granulation tablet-making process by investing in a high-capacity fluid 
bed dryer. They also invested in automatic capsule-filling machines 
to improve standards and productivity. On the question of whether 
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technical standards change there were diverse opinions in the inter-
views. Some respondents argued that technical standards do not change, 
whereas some regulators reported that technical standards have become 
more stringent with time. One interesting perspective came from a 
technical expert who when asked by researchers in Tanzania whether 
very stringent GMP is necessary, argued that for infusions and injecta-
bles (parenterals), it was essential that they have to be sterile because 
they go straight into the bloodstream. However, he said, for tablets, 
the minimum safe requirements are different because they go into the 
stomach. Yet, he argued, current requirements are that they should be 
‘almost sterile’, a standard hard to attain for manufacturers in Tanzania, 
and more stringent than essential good hygienic standards using good 
SOPs (standard operating procedures). 
 It is insights or perspectives such as these that need to be debated by 
those responsible for designing the road maps for upgrading standards 
in all their forms for the pharmaceutical sector. Our discussion, however, 
does not delve into the technicalities of GMP and the specific tests and 
indicators of quality. Our intention is to spark debate. In separate conver-
sations, UK compliance experts acknowledge that there are different 
interpretations of GMP. What the US FDA means by GMP compliant is 
not necessarily what Europe’s EMA means by GMP compliant and by 
extension what different African countries mean by GMP compliance. 
This argument resonates with the standards of the regulators as referred 
to by a Kenyan technical expert. It therefore becomes difficult according 
to the Kenyan expert to bring into one country a product produced in 
another, hence the African regulatory harmonization efforts described 
later in this chapter. 
 Facility and personnel standards 
 Another set of standards that technical experts in Kenya identified are 
facility and personnel standards. These encompass environmental and 
structural standards for buildings and health, educational and tech-
nical standards for personnel (which are often assumed). One Kenyan 
respondent remarked that ‘[facility standards] – that’s where the problem 
of Africa lies’. He reported that facility standards are assumed but not 
clearly enunciated by regulators, and are especially problematic for old 
production facilities that have to be refurbished. A Kenyan respondent 
said, for example, that the WHO talks of ‘competent people and suitable 
premises’ in its requirements for pre-qualification – which, however, 
leaves a lot of room for different interpretations. Facility standards 
are linked to environmental standards and determine air quality and 
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freedom from contamination through physical separation. Personnel 
standards include technical know-how, hygiene standards (medical 
check-ups included) and administrative skills as discussed later. Thus 
personnel standards cover diverse skills sets depending on functions, 
which might include but are not limited to analytical and organic 
chemistry, microbiology, plant engineering, production, pharmacovig-
ilance, quality assurance and research and development. Facility and 
personnel standards formed the class of standards for which improve-
ment, according to the technical experts we interviewed, should be 
approached in a gradual and cumulative manner. In Tanzania, regula-
tors reported that they know that the firms are growing and they give 
them ‘timelines’ for improvement. These are the classes of standards 
that we classify as being mutable. 
 Organizational/institutional aspects of standards 
 The supply of medicines and other medical products into the health 
delivery systems is intensively regulated and governed by strict product, 
process, marketing and institutional standards. The need for regulation 
comes from information asymmetry between the producers on one side 
and patients and clinicians on the other side. Patients cannot assess 
safety or observe quality and efficacy of medicines on their own, and 
neither can the medical practitioners who decide on their behalf (Harper, 
2007). This is where regulatory bodies come in, by seeking evidence of 
compliance with guidelines, rules and regulations to give credibility and 
legitimacy to organizations inspected. Accreditation and certification 
are an institutionally based regime of standards that are built on and 
meant to validate the technical, process, facility and personnel stand-
ards as reflected in the various guidelines such as GLP, GCP, GMP, Good 
Distribution Practice and pharmacovigilance. 
 The challenge for Africa rests in skills shortages at the regulator and 
among compliance managers at firms. As the firm operates, it records 
data which must be managed and produced as evidence to the regulators 
(inspectors). This process requires someone with a technical background 
who also is conversant with data management and documentation. The 
regulators in addition to the physical inspections also analyse docu-
ments and check against the set norms. As discussed earlier, this is where 
the judgement of the assessor (regulator) comes into play. These stand-
ards are of an organizational and institutional nature and are dominated 
by soft issues of training and retaining human capital. 
 These institutional/organizational standards tend to be resource-
driven and path dependent. Their evolution depends in part on historical 
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legacies of national institutions, industrial capabilities and tertiary 
training that included practice-based polytechnic training. South Africa 
and Zimbabwe as a result have relatively well-developed medicines regu-
latory systems. For South Africa the main piece of legislation shaping 
pharmaceutical standards is the Medicines and Related Substances 
Control Act (1965) and its various amendments. The Medicines Control 
Council (MCC), a public sector body tasked with regulating pharmaceu-
tical products in South Africa has eleven expert committees, which eval-
uate the safety and efficacy of a drug submitted for approval and they 
inform the decisions of the MCC. Apart from the Registrar of Medicines, 
all members of the MCC committees are engaged on a part-time basis, 
including the evaluators, who are often in full-time employment else-
where. There is, however, concern on such a heavy reliance on external 
expertise. 
 The Medicines Control Council (MCC) comprises four units, inspec-
torate and law enforcement, operations and administration, clinical 
and medicines registration. These units perform an administrative and 
coordinating role, facilitating the work of the expert committees. The 
MCC works within, and is influenced by, the public sector institutional 
context, as well as serving as the local competent authority for moni-
toring implementation of requirements from agencies such as the WHO, 
FDA and ICH in pharmaceutical manufacturers operating in South 
Africa. In terms of skills, respondents in South Africa also identified loss 
of regulatory skills especially at regulatory bodies as a key challenge. 
They reported that it took a long time to train a competent regulatory 
person, especially those with industrial experience, and as a result they 
are perpetually in training mode. The firms also reported that they face 
the same skills training and retention problems. 
 Harmonization to upgrade regulatory standards 
 An interesting issue identified by experts in the Kenyan pharmaceutical 
industry was the issue of the ‘standard’ of the regulatory bodies them-
selves. Different countries have different regulatory capacities and capa-
bilities. Highly resource-limited countries do not have the same capacity 
and capabilities as resource-rich countries. As a result, manufacturers fear 
that accreditation by one country does not equate to the same level of 
stringency as accreditation by another. Interviewees reported that some 
countries in the East African region had few regulatory pharmacists who 
looked at dossiers and at the same time had to do factory inspections – 
an impossible task. 
 These realities are some of the catalysts for regional medicines 
harmonization initiatives such as the African Medicines Regulatory 
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Harmonisation (AMRH) initiative led by the New Partnership for 
Africa’s Development (NEPAD). In recognition of regulatory capacity 
limitations for some countries and its consequent socio-economic 
impact, NEPAD Agency undertook, in collaboration with partners 2 
to initiate the African Medicines Regulatory Harmonization (AMRH) 
Programme since 2009. The AMRH initiative is part and parcel of the 
implementation of the African Union Pharmaceutical Manufacturing 
Plan for Africa (PMPA) (see Chapter 15) and aims to facilitate access to 
quality, safe and efficacious medicines to the African people by working 
through the existing political structures, and the regional economic 
communities (RECs). 
 In particular, the initiative aims to catalyse the establishment of effec-
tive national, regional and continental medicines regulatory agencies, 
and has made significant progress since 2009 in Eastern, Western and 
Southern Africa towards transparent, efficient and effective regulatory 
systems that provide assurance of faster approval of medical products and 
technologies that meet internationally acceptable standards of quality, 
safety and efficacy. Some of the key aspects focussed on are harmonized 
guidelines for registration of medicines, good manufacturing practice 
(GMP) inspection guidelines, quality management systems (QMS) and 
information management system (IMS). 
 Through NEPAD Agency’s coordination, the East African Community 
(EAC) successfully launched the Medicines Regulatory Harmonization 
(MRH) programme in March 2012, and is now at implementation stage 
with substantial progress made in the endorsement of the harmonized 
guidelines for registration of medicines, good manufacturing practice 
(GMP) inspection guidelines, quality management systems (QMS) and 
information management systems (IMS). The NEPAD Agency has under-
taken to expand the AMRH programme to other RECs beginning with 
the Economic Community of West African States (ECOWAS) through its 
health agency, the West African Health Agency (WAHO) in collabora-
tion with the West African Economic and Monetary Union (UEMOA). 
The MRH Programme for West Africa was launched on 2 February 2015. 
Progress has also been made on implementation of the programme in 
the Southern African Development Community and central African 
regions. 
 Cost implications of standards 
 Regulation raises numerous questions concerning compliance costs in 
relation to benefits obtained, transaction costs associated with regula-
tory administration and enforcement, and unanticipated or unwanted 
responses on the part of the regulated industry. Regulations may have 
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high individual compliance costs, which are compounded by the fact 
that organizations are simultaneously attempting to comply with other, 
possibly conflicting regulations. When regulatory standards or mecha-
nisms conflict, they may prevent one another from achieving their 
intended benefit. Increasing legislative controls in highly complex, 
and heavily regulated arenas such as health care can lead to ‘regula-
tory inflation’ rather than enhanced compliance. Moreover, the risks of 
compliance failures and regulatory inflation are heightened in the field 
of healthcare because jurisdiction is often fragmented and operates at 
multiple layers from global to local levels (Mugwagwa et al., 2015). 
 The consensus from South African respondents with respect to stand-
ards was that innovation, technological capability upgrading and health 
delivery were cost-sensitive processes, and that while adopting and 
keeping standards came at a cost, higher costs were being incurred from 
policy and regulatory uncertainties on the one hand and inefficient 
quality assurance systems on the other. Trying to curb costs today by 
compromising on standards would lead to ‘fewer drugs to treat current 
and future generations’, but taming the policy and regulatory jungle to 
ensure cost-effective and sustainable compliance with standards would 
be good for companies, regulators and patients in the short and long 
runs. Multiple accreditation has direct bottom-line impact. 
 The Kenyan standards and upgrading road map 
 Respondents in Kenya were in general agreement that product and 
process standards are necessary and that they should be seen as ‘minimum 
regulatory expectations’ required to manufacture a product that meets 
specific needs, that is, fits the purpose for which it is made. Kenya has 
developed a road map for upgrading standards. They acknowledge that it 
is a gradual process requiring multi-sectoral coordination and concerted 
efforts. In an interview, an industry expert involved in designing and 
developing the road map for the country said:
 So we came up and said you must solve the problem, but it’s not a 
small one ... we looked at the whole scenario and came up with seven 
key areas 
 which are detailed below as direct quotes:
 1.  You must have a road map for the local industry to improve because 
you cannot shut down any one of them because they have been 
producing. 
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 2.  You must have a system where you check the quality of the product 
on the market and remove the ones which are not performing and 
remain with those which are performing well. 
 3.  You must have someone overseeing the market and industry and 
that is the regulator, you must incentivize the capacity and improve 
its capacity. 
 4.  Whereas the industry is trying to achieve the standards, it’s going 
to cost money, so you should look for a way where they can get the 
money. 
 5.  You must provide the incentives for the time the industry is 
improving, they must not improve and lose their market, so you 
must protect it and come up with incentives that will help them. 
 6.  You must come up with a strategy for capacity building of human 
[skills], their capacity to undertake this both in the regulatory and in 
the private sector 
 7.  There are those items which are essential for the industry to place 
their products on the market, but not one single company can do 
it alone, so you must put them together and see how they can be 
shared, and this is what you call the support services or shared 
platform. 
 Recognizing that they could not do all seven activities at once, they 
prioritized the first initiative. They developed the road map, and by 
mid-2014 the technical aspect had been completed and they were waiting 
for the narrative part of the document, endorsements and final launch. 
A concerted effort to involve industry, regulators and the Ministry of 
Industrialization was made during the process of developing the road 
map (Technical Expert, Kenya, 2014). The technical expert through his 
networks brought together the ministers for health and industrialization 
in a joint meeting to discuss the road map. 
 Money for upgrading processes and standards 
 Kenya realized that the process of upgrading production facilities and 
machinery would impose financing constraints on affected firms. The 
fourth point in the strategy above deals with the need to facilitate funds 
availability. To that end they engaged the Kenyan Bankers Association, 
who informed them of their fears about funding pharmaceuticals 
production. According to the pharmaceutical industry respondent, the 
bankers said: ‘We are risk-based institutions, we go only where there 
is less risk, but in pharmaceuticals the risks are so high that we dare 
not’. This statement points to issues of finance capability on the part of 
banks (see Chapter 15). Reinforcing the challenge of finance capability, 
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one respondent cited an example of a Development Bank which refused 
to fund a quality control laboratory because they said they could not 
demonstrate what would come out of the laboratory. The pharmaceu-
tical technical expert argued that the bank failed to see the overall picture 
and how the quality control laboratory would result in better produc-
tion processes and products. The bankers themselves acknowledged that 
they lack a deep appreciation of the industry dynamics:
 We have never got an expert who we can trust to go there [pharma-
ceutical industry] and do an evaluation; and I said to them then I 
should become a banker. (Technical expert, Kenyan pharmaceutical 
sector, 2014) 
 Efforts are under way to bring industrialists and bankers together to try 
and bridge the gap in knowledge about the sector and hence improve 
risk analysis. Kenya’s road map, however, evidences a purposive and 
integrated approach to improving standards and upgrading facilities. 
In interviews the technical experts acknowledged that this would be a 
long process the success of which depends on availability of resources 
for investment in equipment and people. The programme in Kenya is 
being supported by UNIDO, supplementing limited national resources 
allocated to this important initiative. Kenya appears to be taking control 
of the issue of standards, and although they are still at the initial steps 
of implementing the programme, there are lessons that other African 
technical and policy people can learn. 
 Initiatives focusing on building capacity and capabilities on standards 
in local manufactures require coherence/harmony between different 
approaches. Some global institutions working with African countries, 
such as the WHO, take a product-by-product approach to standards 
(WHO pre-qualification), whereas UNIDO and GIZ take a systemic 
technological approach. This helps to explain different approaches to 
improving standards in African countries. UNIDO and GIZ prefer to 
build local technical skills by training local industry. In the next section 
we look at the Indian standards upgrading to extract lessons that Africa 
can use. 
 What lessons can Africa learn from the Indian GMP 
upgrading road map? 
 Over the last three decades the Indian pharmaceutical industry has 
emerged as a major supplier of cheap generic drugs across the world. 
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The Indian government was credited for infusing life into the Indian 
pharmaceutical industry through industrial and regulatory policy inter-
vention, and the success of the Indian firms made these interventions 
a recipe for pharmaceutical industrial development in other emerging 
countries (see also Chapter 10). 
 Pharmaceutical production in India is governed by the Drugs and 
Cosmetic Act of 1940 and the much amended Drug and Cosmetics Rules of 
1945. The Act and Rules regulate drugs imported, manufactured, distrib-
uted and sold. No pharmaceutical products can be imported, manufac-
tured, stocked, distributed or sold unless they meet the quality standards 
laid down in the Act. An Indian Pharmacopoeia was published in 1955, 
and over the years problems in controlling spurious or counterfeit medi-
cines have dominated Indian policy agendas. The Indian government 
initially aimed to enforce GMP standards in all pharmaceutical manu-
facturing firms via the Drug Policy of 1986. This laid down requirements 
for GMP adherence in Schedule M of the Rules, which came into force in 
1987. Schedule M was strengthened to require WHO-GMP standards, by 
amendment in 2001, with the aims of ensuring that firms upgraded and 
of eradicating counterfeit and substandard drugs. Those pharmaceutical 
firms that did not comply with these regulations have been refused 
manufacturing licenses from each State Drug Control Administration 
office. In the case of manufacturing plants approved before December 
2001, non-compliance led to their licenses being revoked, forcing closure 
of these manufacturing facilities. 
 The financial cost involved in complying with GMP has proved a 
significant barrier for small companies in India to upgrade manufac-
turing facilities. Upgrading of manufacturing plants by small scale 
firms would result in those firms graduating to become medium-scale 
firms, thereby losing the tax benefits and other concessions available to 
small scale enterprises. The Indian government responded to this issue 
by providing some concessions for the Indian firms, increasing invest-
ment limits and turnover thresholds for eligibility as a small-scale firm. 
On the other hand, several large-scale companies upgraded their plants 
to access high-income country markets, and their significant financial 
resources made this transition feasible. The deadline for implementation 
of GMP was postponed from 31 December 2003 to 31 December 2004, 
and then postponed again until 30 June 2005. Each State Drug Control 
Administration office also had the authority to extend the deadline of 
compliance within its area of jurisdiction. 
 In spite of these concessions, this mandatory application of GMP had 
a significant impact on the Indian pharmaceutical firms. According to 
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official estimates, in 2001, 327 pharmaceutical manufacturing plants 
closed, had their licenses suspended, or were forced to shift to some other 
state. A total of 370 plants were not in a position to comply with GMP 
and have closed since 2005 (Planning Commission, 2002, par. 7.1.192). 
In addition to an increase in competitive pressure, GMP compliance has 
been another force that has induced the exit of small firms from the 
market. However, the introduction of GMP has also contributed to the 
enhancement of trust in Indian products in the global market. In addi-
tion, complying with GMP standards of the US and Europe has increased 
exports to Western countries and expanded the opportunity for contract 
manufacturing. 
 Since 2000, the strong presence of the Indian firms in the markets 
of advanced countries, and specifically in the US, has brought severe 
scrutiny from regulatory agencies around the world. More numerous 
FDA inspections led to an increase in the number of warning letters 
and import bans for the Indian firms (see also Chapter 6). The FDA has 
identified a number of Indian pharmaceutical manufacturers who have 
had problems with data integrity and GMP at their respective facilities. 
Gaffney (2015) notes that since GMP data are intended to ensure that 
products meet pre-established specifications, absence of credible data 
management creates concern that these products cannot be trusted. 
 The case of Ranbaxy provides a prime example of the FDA atti-
tude towards implementation of GMP in the Indian firms. The FDA 
has repeatedly issued warning letters and import bans to two of the 
company’s manufacturing plants because of data integrity issues. The 
warning letters note that the FDA has concerns about non-compliance 
with US current Good Manufacturing Practices requirements, although 
‘FDA has no evidence of harm to any patients who have taken drugs 
made in these two facilities’ (Jeffrey et al., 2001; US Food and Drug 
Administration, 2008). Elaborating on their concerns at one of the 
manufacturing plants, the FDA warning letter focuses on concern that 
‘written records of major equipment cleaning and use are inaccurate’ 
(USFDA, 2008) and notes that their investigative team uncovered 14 
instances ‘where ... records for equipment used in manufacturing opera-
tions ... included initials or signatures of employees who reportedly veri-
fied cleaning of equipment but were not shown as present by security 
log records’ (USFDA, 2008). 
 Jeffrey (2001) argues that this experience highlights the way in which 
international regulatory authorities play a crucial and detailed role 
in setting production and data management standards at the Indian 
manufacturing sites, using the set of regulations and rules developed to 
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protect high-income countries’ consumers. The cost of implementing 
and complying with these regulations is incurred by the Indian manu-
facturers and government and in most cases passed on to the Indian 
consumers. Further, these regulatory troubles have caused the Indian 
firms significant revenue losses and reduced competition in generic 
markets, contributing to profit margins of multinational pharmaceu-
tical companies. This experience raises issues about the authority of 
developing country governments in setting standards, and about the 
appropriateness of international standards to the local context in the 
developing countries. 
 Concluding discussion 
 Pharmaceutical standards and regulations are necessary yet complex 
institutions which change over time, operate at various vertical and 
horizontal scales, are subject to different interpretations and applica-
tions and have potential to assist the manufacturing of, and access to, 
safe efficacious medicines. However, they can also act as undesirable 
market entry barriers. African pharmaceutical industry players accept 
that standards are important, but they contend that the other regions of 
the world which are more advanced now ‘did not themselves improve 
their standards overnight’. Rather, it was a gradual and long drawn-out 
process as countries learned best practice from the first movers. African 
technical experts argue that Africa should not be pressured to catch up 
‘overnight’. When African and other developing countries look broadly 
at pharmaceutical standards, they need to view them as a process, and 
there is therefore a need to introduce clear road maps for a gradual 
strengthening of the requirements for standards, driven by local or 
regional regulatory institutions. 
 We conclude that in order to improve standards and upgrade techno-
logical capabilities, first, standards need to be deconstructed and under-
stood based on risk management principles. Second, institutional or 
organizational standards that are based on judgement and can be grad-
ually improved should be recognized as mutable in that sense. Third, 
technically based standards should also be viewed from a risk manage-
ment perspective. Once this has been done, African technical and policy 
actors need to take control of the issue of pharmaceutical standards and 
to design and manage context-sensitive regulatory frameworks and road 
maps backed by an evidence base that draws from a clear understanding 
of standards, attendant risk profiles and their role in industry develop-
ment and access to medicines. 
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 1 .  We acknowledge Dr Farah Huzair for proposing the terms ‘mutable and immu-
table’ standards at an Innogen Knowledge Exchange workshop on African 
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World Health Organization (WHO), the World Bank (WB), the Bill and 
Melinda Gates Foundation (BMGF), the UK Department for International 
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Joint United Nations Programme on HIV/AIDS (UNAIDS) 
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 Introduction 
 Procurement is then an integral part of health policy. However, it 
is of course also a part of industrial policy. This is because the way 
in which purchasing decisions are structured and regulated impact 
profoundly on the way in which production happens. Thus, consid-
eration of the pros and cons associated with procurement regimes 
needs to be in terms, not only of whether immediate health policy 
priorities are achieved, but also in light of longer term sustainability 
of supply of innovative health products. Thus, price, value and inno-
vation are closely interwoven. (Srinivas, 2012: 126) 
 Part II of this book has demonstrated that building synergies between 
health systems and industrial development is a complex process of 
reshaping the politics and political economy of the two systems. A 
key tool for building and sustaining health-industry relationships, as 
Smita Srinivas observes above and as some Part I chapters also empha-
sized, is procurement. Yet procurement remains under-researched and 
over-simplified as a technical, linear, ordering and delivery process (see 
Chapter 8), rather than an exercise in deepening and strengthening 
the domestic economy through market and non-market relationships 
building. 
 This chapter aims to shift the literature on health sector procure-
ment into a more developmental mould. It is an innovative procure-
ment chapter in the conceptual sense, addressing the question of how 
health sector procurement can be developmental both by addressing 
health sector needs and values and by sustaining industrial suppliers. It 
also puts forward innovative arguments, exploring in some detail how 
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procurement can constitute a business asset, and using the example of 
value-based pricing (VBP) in medicines procurement to explore how 
procurement can better address health sector needs in marketized and 
fragmented lower-income health systems. 
 The chapter is divided into two sections. The first section focuses on 
procurement as an industrial policy in African pharmaceutical markets. 
It takes a detailed microeconomic look at procurement design from the 
perspective of local pharmaceutical firms, for whom access to working 
capital is a major developmental constraint. Using illustrative data from 
Zimbabwe, the chapter shows that procurement can be either a source 
of finance or a serious drain on the finances of firms that operate in the 
context of high bank charges and interest rates, and in highly competi-
tive markets. Careful procurement redesign can have a substantial 
impact on firms’ cash flow and investment prospects. 
 The second section turns to innovative procurement strategies that 
stitch industrial production and innovation into the values and needs 
of health sector users in African countries. It explains and examines the 
emergent practice of value-based pricing (VBP) as a tool to link medicines 
prices to health needs. So far applied mainly in high-income countries, 
VBP nevertheless falls within a category of global and local procurement 
initiatives that try to foreground need in the design of public procure-
ment. The discussion recognizes that public procurement, because of 
its scale and the values it embodies, is not simply a process of market 
purchase. Medicines markets and other related institutions are co-created 
by public and private sectors in complex and diverse ways. Integral to 
this pattern of interaction and articulation is the way in which medi-
cines are purchased and the way in which prices are determined. These 
decisions are political as well as economic, as reflected in the Srinivas 
quote above. 
 Public procurement as an industrial policy tool 
 In the economic development literature, and in the debates on public 
policies such as defence procurement, there is a long-standing recog-
nition that public procurement can operate as industrial policy. ‘Buy 
local’ campaigns and local preferences often formed part of import 
substitution policies of the type discussed in Part I. The liberalization 
policies of the 1980s, in both lower-income and higher-income coun-
tries, generally removed local procurement preferences and employed 
international competitive tendering to open up domestic markets to 
external competition. The development economist Sanjaya Lall, whose 
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conceptual framework of industrial capabilities is used throughout this 
book, was a persistent proponent of the continuing need for indus-
trial development policy in these ‘globalized’ and fast-moving market 
contexts. In the early 2000s he posed the question: ‘What can poor 
countries do to strengthen their industrial competitiveness in the 
international economic setting?’ (Lall 2003). His argument that in 
developing countries, industrial capabilities (technological, financial, 
organizational and dynamic) develop slowly, and are cumulative and 
‘path dependent’ as industries and institutions build on existing skills 
(Chapter 2), implied the need for local policy interventions such as 
local content rules for firms’ procurement. Lall (2003) identified firms’ 
procurement capabilities, as well as those of governments, as elements 
of cumulative industrial improvement, and recognized the importance 
of developing larger groups of firms in one sector so that they generate 
‘spill-over’ benefits (Chapter 2). 
 Much writing on procurement focuses on its role in providing a 
market for locally supplied goods and services, and hence sustaining 
business development (Ogot et al., 2009; Uyarra and Flanagan, 2009; see 
also Chapter 3). The market impact of public procurement is very large. 
Among OECD (high-income) countries in 2011, 13% of GDP on average 
was spent by government on procurement of goods and services (OECD 
nd). In some African countries, outsourcing has rapidly increased the 
size of public procurement. In Kenya for example, public procurement 
as a percentage of GDP rose from about 6% in 2002 to 27% in 2008 
(Ogot et al., 2009). 
 Lall’s framework indicates, however, that public procurement as a 
developmental tool should go beyond providing a market, to support 
local industrial innovation. Public health procurement can act as a 
financing and incentive mechanism to improve technological capabili-
ties, a key element of pharmaceutical industry development as discussed 
throughout this book. Increasingly, public procurement is promoted 
as an industrial and innovation policy tool (Kattel and Lember, 2010; 
Uyarra and Flanagan, 2009). Public procurement creates and enhances 
markets for new and existing technologies by shaping the demand 
environment. It can promote sustainable consumption and production 
patterns: for example, the US government in 1993 issued an Executive 
Order for all federal agencies to procure energy-efficient computers, 
resulting in market transformation for Energy Star computer equipment 
(Kjöllerström, 2008). Procurement can target purchase of goods and 
services that are new to the country, or new to the world. This chapter 
explores innovative ways to strengthen the role of procurement in 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
246 Chataway, Banda, Cochrane and Manville
relation to pharmaceutical industry development and the needs of the 
health sector in Sub-Saharan African countries. 
 Trade credit and working capital: the view from the firms 
 To understand how the financial aspects of procurement design 
can influence industrial development, it helps to start by analysing 
how pharmaceutical firms in Africa can use trade credit to reduce 
borrowing and keep down manufacturing costs. Firms can use their 
input suppliers as an in-kind financing mechanism, via trade credit, 
in order to reduce their call on their own funds or expensive bank 
finance. Firms’ private sector procurement mechanisms therefore play 
a critical role in managing working capital financing requirements 
and cash flows. 
 By negotiating for generous trade credit terms, firms can fund varying 
proportions of raw material procurement, production and logistics proc-
esses, and sometimes influence the debtors’ collection period. Astute 
use of these options turns the firms’ own procurement process into 
a generator of in-kind finance. Failure to use them causes the firm to 
haemorrhage cash if it pays suppliers in advance or opts not to stretch 
its suppliers by paying their invoices early, before reaching the limit of 
their credit terms. 
 We describe here how trade credit can aid small to medium enterprises 
in accessing in-kind finance through contractual relationships with 
larger and more established firms and organizations with better access 
to finance. Suppliers endowed with market power and reputation can 
access formal credit (usually cheaply) from banks and then extend trade 
credit (an in-kind loan) to buyers with less access to bank or own finance 
(Nilsen, 2002; Petersen and Rajan, 1997). Because suppliers choose to 
whom to advance trade credit, trade credit serves as a screening and 
monitoring device for suppliers (Berlin, 2003). The fact that there are 
more suppliers, who are better at evaluating credit risk, than there 
are financial intermediaries makes trade credit an important source of 
finance in an economy. When suppliers extend credit to buyers, they 
reduce transactional costs, making business transactions cheaper and 
easier (Gianetti et al., 2011). 
 Trade credit is therefore a cheap source of short-term, external, in-kind 
finance, advanced not as money but goods on credit. If firms under-
stand how to handle finance (if they have good finance capabilities, see 
Chapter 15), they can use trade credit to reduce cautionary cash hold-
ings thereby alleviating cash flow problems. 
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 Thus for firms in poorly developed markets, trade credit assumes great 
importance: there is evidence that industries have an elevated depend-
ence on trade credit in countries with poorly developed financial markets 
(Fisman and Love, 2003). For Zimbabwe, Fafchamps (1997), using 
evidence from the 1993 Regional Program for Enterprise Development 
(RPED) panel survey of 200 Zimbabwean companies, found that trade 
credit indeed played a significant role in financing enterprises. Trade 
credit as a percentage of outstanding balances constituted 27% for micro 
enterprises, 26% for small enterprises, 30% for medium enterprises and 
30% for large enterprises. 
 However the economic deterioration of the 2000s decade in Zimbabwe 
caused a high level of uncertainty, shortage of foreign currency and 
increased country risk. Consequently, local firms found it difficult to 
access trade credit from suppliers for APIs and excipients. The dearth of 
trade credit and reliance on expensive bank finance throttled financial 
breathing space for the companies. 
 In those circumstances, firms can find themselves in a perverse situa-
tion, whereby local pharmaceutical firms are funding suppliers instead 
of vice versa. Local companies had low bargaining power because they 
purchased small quantities of raw materials, and their suppliers were not 
worried if they lost them as customers. Local firms procured raw mate-
rials from merchants and brokers with critical mass to move 15 to 30 
tonnes of products, and the brokers then sold smaller quantities at higher 
margins to local firms. APIs and excipients were paid for in advance 
because suppliers feared country political risk and foreign currency risk, 
a legacy from the times when Zimbabwe had serious foreign currency 
shortages despite the country’s subsequent shift to using a basket of 
foreign currencies. Zimbabwean firms, because they paid in advance, 
were therefore financing economically stronger suppliers in India and 
China. 
 Where international suppliers sold to local firms, they also reduced 
their perceived risk by demanding a letter of credit (LC). The LC costs 
2.5% of value, plus charges for establishing the LC and transaction 
charges. Local firms sought to reduce these high financing costs by nego-
tiating for in-country bonded warehouses to hold goods for purchase, 
reducing delays due to shipping and customs clearance and hence the 
period when the firm would be out of pocket while awaiting the raw 
materials. Broadly, the trade financing pattern became another example 
of a perverse subsidy from weaker African economies to stronger trade 
partners, which one can find reflected also in other markets. 
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 Public procurement terms as a financial asset for businesses 
 The discussion above demonstrates just how strongly a pattern of 
trade financing can influence the cash flow and business development 
of local firms. It follows that the design of the payment and credit 
systems used in public sector procurement can strongly affect the busi-
nesses from which the government purchases goods and services. The 
payment mechanisms in public procurement constitute implicit busi-
ness financing mechanisms – or a drain on the business. 
 Public drug procurement payments can be made in at least in three 
ways; advance payment, cash on delivery or credit terms. Each of these 
payment modes affects the manufacturers’ cash flows, cost of finance 
and eventually the cost of manufacturing pharmaceuticals. The payment 
terms can be a source of finance for the firm to use in the production 
process, or they can cause the producer to seek external expensive 
finance whilst awaiting payment for goods produced and delivered for 
periods ranging up to six months. 
 Advance payment provides direct business funding, as payment is made 
in advance of goods and services delivery. Advance payment reduces the 
need for manufacturing firms to borrow expensive bank finance when it 
does not have sufficient cash holdings. With advance payment, the firm 
uses these funds to purchase raw material, fund the production process 
and pay labour. While advance payment, in accounting terms, becomes 
a short-term liability on the balance sheet of the firm, nevertheless the 
funds obtained for the pharmaceutical products to be supplied constitute 
an asset (cash holding) that the firm uses for production and logistics. 
 With the cash-on-delivery payment method, the buyer pays on receipt 
of goods and services. The manufacturing firm therefore funds raw mate-
rial acquisition, production and logistics with either own or borrowed 
(expensive) funds. Compared to the advance payment method, cash 
on delivery therefore imposes varying degrees of financing costs on the 
firm. If the firm uses its own funds, the financing costs are lower than 
bank borrowing, though accountants will argue that using internally 
generated funds has important opportunity costs for the business. 
 The third payment method involves credit terms. The manufacturing 
firm delivers goods to the procurement agency, which pays after a 
certain pre-agreed period of time from the date they receive the invoice. 
The period can generally range from 30 to 90 days and in some instances 
as much as 180 days. This is the most strenuous payment method of 
the three described for the manufacturing firm’s cash flows. The firm 
must fund raw materials acquisition, production and logistics processes 
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through the period up to payment. The firm must also have skills in 
chasing on-time payment by the buyer. This chasing process is espe-
cially difficult in many instances when the government or state agencies 
are the buyer, and they need to wait for disbursement of funds from 
central treasury (see, e.g. Chapter 3). Onerous credit terms of this kind 
have constrained many African pharmaceutical manufacturing firms to 
resort to very expensive bank financing prior to receiving payment. 
 In effect, many local pharmaceutical firms have no option but to 
provide the government with credit terms: they are effectively helping 
to finance the local health system. This generates recurrent cash flow 
problems as they try to fund successive operating cycles. The process of 
waiting for payment, especially on an order which is large relative to the 
firm’s capacity, can undermine the firm’s ability to procure raw materials 
and pay labour and associated production costs for the next production 
cycle, as well as constraining effective sales and distribution. 
 In these constrained situations, there are ways in which a confirmed 
order or an invoice can be used by a firm to fund production cycles. Two 
possibilities are a supply chain structured-credit finance approach, and 
invoice discounting or factoring. 
 In the first, supply chain structured-credit approach, the firm can use 
the strength of the procurement agency’s own high credit standing. Once 
the firm has a confirmed order, it can go to a bank to approve a credit 
facility with conditions. One of the conditions could be the firm assigns 
the amount payable after fulfilment of the order to the bank. By assigning 
the firm’s (creditworthy) debtors to the bank, it gives the bank control 
over the funds to be paid. Because funds are disbursed before products 
have been produced, the firm needs to procure raw material and produce 
and deliver products before the buyer pays. Consequently, this type of 
financing carries production, performance and payment risk, hence the 
need for the firm to have an acceptable production reputation and for the 
buyer to have good payment reputation. What is key is that the firm can 
access funds based on a confirmed order from a reputable buyer: an effi-
cient public procurement body that pays reliably can fulfil this role. 
 The second approach of invoice discounting and factoring requires 
a much broader and deeper financial institution architecture in the 
country, including banks and factoring and discounting institutions. 
This financing method involves a financial institution paying a propor-
tion (up to 85%) of invoice value to a firm in advance, against invoices 
billed to the firm’s buyers. Factoring and invoice discounting are prepay-
ment methods against a sales ledger for a firm – in other words, it offers 
advance or early payment to the firm that sold its goods. Instead of the 
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firm waiting for payment by the buyer after, say, 180 days, the firm is 
able to access working capital finance to fund its production cycles. In 
this instance, instead of getting advance payment from the customer, 
the firm gets the advance payment (a proportion) from the financial 
institution. 
 Essentially invoice discounting and factoring work in the same way, 
the difference residing in who has credit control over collection of the 
debt (amount payable to the supplier). With discounting, the firm has 
control on debt collection, while in factoring, the firm hands over the 
collection of the debt to the financial institution, writing formally to its 
customers to pay the bank directly; the bank then carries the responsi-
bility of collecting the debt. 
 It follows that if the public procurement agency for the health sector 
has a good track record for paying on time, it opens up an avenue for 
firms to access funds based on invoices. This financing approach is 
attractive because production risk is no longer an issue as the products 
have already been manufactured. The greatest risk is payment risk by the 
procurement agency, since many agencies procuring medicines using 
African government funds may find it hard to pay consistently on time, 
since their own funding may be erratic (see Chapter 8). 
 Procurement as an asset: a Zimbabwean example 
 Where there is political will and substantial financing, public – including 
donor-backed –procurement can become a substantial asset for local 
manufacturing firms and the health systems they supply. An example is 
the support generated for manufacturing anti-retroviral (ARV) drugs in 
Zimbabwe. The Zimbabwean government initially created and assured 
the market for locally produced ARVs by providing a funding mecha-
nism, in a context where there were strong local manufacturing capabil-
ities. As a result, Zimbabwe became one of the first African countries to 
manufacture ARVs locally, in 2003. We explore how this came to pass. 
 During the economic challenges of the late 1980s and 1990s, Zimbabwe 
faced a huge social and health challenge emanating from the HIV/AIDS 
pandemic. HIV/AIDS was placing a huge strain on an overburdened and 
underfunded health system. In response, the government converted 
an existing drought levy into the AIDS levy to finance the HIV/AIDS 
programme. The government set up the National Aids Council and the 
National Aids Trust to collect and administers the AIDS levy, set at 3% 
of salaries for formally employed people. Fifty per cent of the AIDS levy 
is reserved for medicines procurement, with the balance allocated to 
prevention, awareness and administration costs. 
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 The government issued a compulsory license to manufacture ARVs 
and promised to purchase 75% of the locally manufactured medicines 
(Osewe et al., 2008). It is important to recognize that the government 
could only issue a compulsory license because Zimbabwe had built the 
infrastructure and capabilities to locally manufacture pharmaceutical 
drugs from the 1950s (Chapter 1). Transferring the technology in order 
to manufacture ARVs locally was thus possible because of this industrial 
background. 
 However, in spite of government’s intentions, the hyperinflationary 
environment of the 2000s constrained public health financing capacity, 
culminating in the collapse of the public health system (2003 to 2009). 
The result was a shift to high donor dependence for financing the 
public health system and medicines procurement. This shift incapaci-
tated public procurement as an industrial policy tool (NECF, 2010), and 
was the greatest cause of decline in local industry capacity utilization. 
Reliance on donor funding that fragments public procurement policies 
continues to pose a demand-side constraint for local pharmaceutical 
manufacturing. 
 However, there are exceptions: one donor-funded programme in 
Zimbabwe provides an unusual example of support from donors for local 
pharmaceutical production. Ordinarily, in many African health settings, 
donor-funded health programmes tend to import medicines from 
India or China independently of public procurement mechanisms. For 
example, in Zimbabwe the principal purchaser of anti-retroviral drugs 
for The Global Fund is the United Nations Development Programme 
(UNDP), which procures the drugs through their pooled procurement 
base in Copenhagen. 1 This removes public procurement as an indus-
trial policy tool from the available policy arsenal for stimulating and 
supporting innovation and industrial development in the African 
context. In such situations, the market becomes unreachable for local 
manufacturers. 
 However in this case, purposive support for local manufacturing was 
provided. The Extended Support Programme funded by the European 
Union and DFID (the UK Department For International Development) 
supported local manufacturers CAPS Pharmaceuticals and Varichem in 
Zimbabwe to manufacture and supply medicines to the local health 
system during the era of economic collapse (Table 13.1). This example 
shows that donor-funded programmes can support local industry and 
operate as an effective industrial policy tool. Table 13.1 shows that 
CAPS and Varichem were contracted to supply more than US$4 million 
worth of drugs to the programme. The contract value shows the values 
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of medicines that were supposed to be delivered, and value delivered 
shows what the companies had actually delivered by the time the report 
was compiled (EU, 2010). Table 13.1 also shows that locally based phar-
maceutical wholesalers, including PCD, GHC, Mission Pharma and SJV, 
were allocated quotas that they filled through imports. 
 A key issue raised by this example is the political scope for governments 
to incentivize or compel large donors to purchase locally manufactured 
pharmaceutical products. Such a move can increase governments’ space 
for policy manoeuvre. The South African government, for example, 
insists on local suppliers in many circumstances: when foreign compa-
nies win tenders, they must go into an agency arrangement with a local 
South African firm, as exemplified by a case where a Zimbabwean firm 
won a tender to supply ARVs to the South African public health system 
and had to partner with a South African firm. Other African govern-
ments have been less energetic or effective in imposing local partner 
requirements on overseas suppliers. 
 Public industrial procurement to serve health needs and values 
 The previous section has centred on the scope for aligning demand for 
health commodities with industrial development needs. This section 
 Table 13.1  Donor support for local industry through contracting for local health 
supplies: Zimbabwe 
 Contracts for drug supply by some pharmaceutical manufacturing firms 
and importers 
 Supplier 
 Contract Value 
(Euro) 
 Value Delivered 
(Euro) 
 % Completion 
of Supply 
Varichem Lot 2 1,788,800 1,522,404 85.11
Varichem Lot 4 198,500 198,500 100
CAPS Lot 1 2,289,784 961,139 41.98
PCD Lot 2 433,967 433,967 100
PCD Lot 3 570,235 570,235 100
PCD Lot 4 198,500 198,500 100
GHC 1,585,464 1,585,379 99.99
Mission Pharma Lot 1 986,615 981,044 99.44
Mission Pharma Lot 2 63,000 63,000 100
SJV 253,280 253,280 100
 Total  8,368,145  6,767,488  80.87 
 Source : EU, 2010. 
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reverses the view, to ask: To what extent can medicines procurement be 
shaped to ensure that local industrial development increasingly serves 
the health needs of the populations dependent on the local health 
system? This is a question raised and addressed for the Brazilian health-
industrial complex and its policy development in Chapter 9. Here, we 
examine schemes that link reimbursement and assessment of a product’s 
value to the impact that products have in real-world contexts. These 
efforts can be seen as reflecting a desire to link the introduction of new 
products to competent health care, which allow for maximum access 
and benefit. The objective is to bring local industrial production and 
innovation closer to the health needs it should serve 
 Our focus is on a particular innovative procurement mechanism: 
value-based pricing of medicines. While this is to date a mechanism 
largely experimented with in high-income countries, we think it is 
important because it shifts the attention of procurement policy from 
a market (often monopoly) price for an already developed drug to 
an assessment of how a drug will actually work in particular country 
contexts and for identified needs. Its attractiveness is in indicating 
ways forward in adapting procurement to a focus on population health 
benefit and patient needs. 
 The broader lessons are particularly pertinent for developing country 
contexts, where fragmented and marketized health systems may generate 
wide gaps between population needs and market demand. Public and 
donor procurement mechanism then need to specify as well as address 
population health needs. An early and widespread example of such an 
innovative procurement mechanism was the essential medicines lists, 
developed by the WHO and by health activists, that specify priorities for 
procurement of essential medicines, by generic names, to support access 
to drugs that are deemed essential for particular populations (Laing 
et al., 2003). The parallel to the discussion of VBP here is that the essen-
tial medicines lists also aimed to shift the design of public procurement 
towards better serving needs. 
 Public procurement and industrial innovation for unmet need 
 The use of VBP has focussed to date on the role it can play in relation 
to innovator drugs targeted for currently unmet or poorly met health 
needs. The dominant framework of thought on incentives for industrial 
innovation identifies an imbalance between investment risk in innova-
tion and reward for the innovation. This ‘market failure’ is then put 
forward as the rationale for public sector investment in basic science: 
there is insufficient incentive for the private sector to invest in basic and 
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long-term research, so the public sector should underpin drug discovery 
with support for early-stage research. 
 However, this conceptual apparatus does little to explain the actual 
way in which the public and private sectors invest in drug discovery, 
development and procurement. At all stages, public and private sectors 
inform each other in influencing the rate and direction of innovation. 
As argued in the introduction, markets and other institutions are co-cre-
ated by public and private sectors. The discussion of VBP locates it as one 
example of this changing pattern of political and economic interaction 
and articulation, in this case in the way in which drugs are purchased 
and prices are determined. 
 One observation from recent patterns of public and private interac-
tion is that market and institutional failures clearly occur not only at the 
research stage but also at the other end of value chain – at the market 
access end. This is especially the case in developing country contexts, 
and a growing international focus on policy, charitable and public sector 
initiatives has emerged over the past two decades using procurement 
to address the problems. The institutional vehicles include The Global 
Alliance for Vaccines and Immunization (GAVI), set up in 2000, which 
brings together public and private actors to address the challenge of 
equal access for new and underused vaccines programmes in the world’s 
poorest countries. As of 2013, GAVI stakeholders have committed US$8.2 
billion to achieving their mission and have supported the immuniza-
tion of an estimated 440 million children (GAVI, 2013). 
 The Global Fund and access initiatives that are disease specific include 
other examples of efforts to raise the financial endowment needed 
to generate innovation, product uptake and access to markets for 
producers, as well as access to medicines for the patients. Their procure-
ment initiatives are designed to support the skills, finance and techno-
logical resource endowment required for innovation. In Europe, there 
has also been renewed policy thinking about how to construct public 
and private interaction so that appropriate products get to patients 
(Chataway et al., 2012). Initiatives such as the European Commission’s 
Innovative Medicines Initiatives support basic and applied research 
(Morgan Jones et al., 2013). 
 Other high-income country initiatives such as the Innovate UK stem 
cell programme support policy thinking and address regulatory, business 
development, funding and access to market issues. At the same time, new 
approaches to health technology assessment constitute what has been 
colloquially termed ‘the fourth hurdle’. Going beyond efficacy, effec-
tiveness and product approval, they cover value assessments and relate 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
Innovative Procurement 255
to pricing and procurement. Procurement and the technology assess-
ment that goes along with it should be seen as a form of regulation. 
 Previous work has suggested that well-targeted systems of regu-
lation and standard setting result in better outcomes than broad-
brush approaches in terms of overall outcomes, including innovation 
(Chataway et al., 2006). For instance, broad regulatory judgment across 
Europe that banned all products that left chemical residue in water 
had the unintended consequence of encouraging use of products that 
were environmentally damaging in a number of other respects than the 
products that had been banned. The message this regulation sent out to 
innovators who had worked on creating more environmentally friendly 
products was negative. It may well be the case similarly that regulation 
that bans all use of medicines that have undesirable consequences for 
a very limited number of patients can result in treatments that are less 
beneficial for the majority. New regulatory science as conceived of by the 
US Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) hopes to target regulation ever more carefully to those 
who are at risk. 
 Value-based pricing 
 This hope that targeted policy and intervention will deliver better results 
also underpins value-based pricing. The central idea of VBP is that the 
price of a drug may differ according to the impact that it has on different 
groups of patients, and maybe also across different health system 
contexts (Claxton et al., 2008). The desire to become more targeted and 
specific is common to both traditional rule-based regulation and inno-
vative procurement-based regulation. 
 Lying behind VBP is a concept of health benefits and costs. Pricing of 
new innovator drugs is a question not of how much they cost, but of 
how much the firm can take out of a health system through the price 
it manages to charge. Where there is a highly competitive market for a 
medicine, competitive tendering can drive down prices. Where there 
is a monopoly supplier, the price is a matter for negotiation if procure-
ment agencies have the competence and methodologies. A recent MSF 
report reported from contacts with nine pharmaceutical companies that 
value-based and differential pricing strategies were used predominantly 
in non-competitive markets for vaccines (e.g. for new products) where 
manufacturers do not have to compete on price (MSF, 2015). 
 Since resources in all health systems are limited, health economists 
use tools for technology assessment to feed into assessments of whether 
a certain therapy should be reimbursed. The concept of the incremental 
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cost effectiveness ratio (ICER) has become one driver of reimburse-
ment for new drugs. Along with measures of Quality Adjusted Life Years 
(QALYs), ICER calculations are used to measure health benefit and cost 
to health care provider, and these metrics are used to compare the attrac-
tiveness of different therapies. VBP provides a different approach to the 
logic of reimbursement. The UK is one of the countries that has been 
debating the introduction of a new way of determining the price for 
new drugs. The new UK regime has been partly driven by fiscal austerity 
in the country, in which funds for the purchase of new drugs may well 
depend on savings in other aspects of health spending. VBP seems to 
offer a broader approach to pricing decisions, which looks at the impact 
of drugs on overall health and social care systems. 
 The UK Department of Health has traditionally used a pharmaceu-
tical price regulation scheme to control expenditure on branded drugs. 2 
Recently, however, it has been considering a move to a more outcomes- 
or value-based approach (Persson et al., 2010). Like the calculations of 
quality-adjusted life years (QALYs) gained from using the new drug, VBP 
would also assess the benefits of a drug to individuals. The difference is 
that VBP signals a move to determining the price to be paid for the drug 
on the basis of assessment of a drug’s impact in terms of health benefits 
 and its contributions to the overall health system. The value-based price 
is in theory the price that ensures that health benefits for patients and 
the wider society exceed the health benefits displaced elsewhere in the 
health system and in the society due to the medicines’ additional costs 
(Camps-Walsh et al., 2009; Claxton et al., 2008). The move is also to a 
more targeted and perhaps more adaptive system, with ongoing assess-
ments of a drug’s value potentially influencing its price. Again in theory, 
the calculation would take into account the importance of incentives 
for innovation. 
 The move has a number of implications, and Verhoef and Morris 
(2015) provide a summary of what value criteria other than QALYs (or 
similar measure of patient-level health gains) have been advanced in the 
literature as possible components of VBP. These include:
 Wider patient- or disease-related value criteria such as severity of  ●
disease (e.g. whether it is an acute, chronic, rare or terminal disease); 
unmet need; size of relevant population; age groups particularly 
suffering an impact of the disease (e.g. children); socially disadvan-
taged patients; number of other treatment options. 
 Health care-related value criteria: being treated at a convenient time  ●
and location and after only a short wait; being treated in a way that 
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patients consider less unpleasant (e.g. taking a medicine once a 
week as opposed to three times a day); and the degree of risk of the 
treatment. 
 Wider societal value criteria such as ability of patients (and carers)  ●
to resume work or to work more productively; cost savings to other 
publicly funded services (e.g. social care), patients or carers; and how 
innovative the medicine is. 
 Some versions of VBP schemes might also involve differential pricing 
for different patient cohorts. For example, a group of patients with one 
genetic makeup may benefit more than another group, and therefore 
the price paid for the drug being taken by the group that benefits more 
would be higher. 
 Value attributes will need to be collected, measured, aggregated and 
converted to evaluate a ‘value metric’ (Deloitte, 2012). 3 The data that 
will feed into this assessment will need to go beyond purely clinical trial 
data. Real-world data – that is, data relevant to the drug in use, not just 
in trials – would apply both before the market launch (e.g. up-to-date 
cost of illness data) and post-launch: comparative real-world data, infor-
mation on side effects and changes in effectiveness over time (Greiner, 
2011). The sources of such data could transcend patients, clinicians, 
hospitals and social networks. The quality of the data and its format, 
governance and ethical considerations are likely to influence the feasi-
bility and extent to which VBP can reflect real-world values. There may 
well be a need for the development of new methods which can assess 
value in different contexts and under different conditions, and which 
can incorporate trade-offs. 
 A move towards VBP is certainly not without its complexities and 
dangers, and it is important to note that only a limited number of coun-
tries have attempted to implement VBP schemes. However, it is also the 
case that those countries do appear to be experiencing benefits as a result 
of the schemes they have implemented. Sweden is the most widely cited 
example of a country that has implemented a workable and successful 
scheme. Evidence from Sweden summarized in Persson (2012) suggests 
that a VBP scheme may be well placed to encourage the adoption of 
innovative medicines, especially those that address unmet needs. This 
is particularly important in the case of orphan drugs designed to treat 
rare diseases and which due to their high cost-per-QALY often fail to 
obtain reimbursement. The Swedish Dental and Pharmaceutical Benefits 
Agency (TLV), from June 2003 to April 2010, received 30 requests for 
orphan drugs reimbursements and awarded 29 (Cochrane et al., 2015). 
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 Nevertheless, there is limited evidence about how the approach can 
work in practice, and the evidence available comes from international 
examples applying only a few elements of the VBP approach. The situ-
ation is made additionally complex because VBP metrics are often used 
on conjunction with other schemes. Sweden combines VBP with other 
approaches such as coverage with evidence development (CED) schemes 
(Cochrane et al., 2015), and this in turn makes gathering evidence on 
the effectiveness of VBP approaches challenging (Persson, 2012). 
 Additionally, it is difficult to judge what impact funder silos, which 
mean that costs and benefits from health and social care, for example, 
are calculated without reference to each other, will have on the way 
that treatments are rewarded. How will methodologies be developed to 
assess the full costs and benefits in the health, social care and domestic 
settings? Can multiple budgets be brought together and analysed coher-
ently? These and other unresolved issues seem to have led to delays 
in the introduction of VBP-based schemes, although thinking about 
how VBP might be introduced on a large scale is beginning to influence 
approaches to determining price. 
 So why focus on VBP? Earlier we argued that the classic image of 
publicly supported fundamental science and private support for more 
applied work is not useful. Innovation emerges from a more diverse and 
complicated patterns of interactions between private and public sectors 
that work across the R&D and product development processes to create 
new medicines and make them accessible to patients. The public sector 
has to intervene in multiple ways to ensure that incentives offered for 
drug development are balanced with broad public interest agendas in 
ensuring access to medicines in response to need. 
 Value-based pricing is thus not about the drug; it is about the impact 
of the drug in the context of the health system and unmet health needs. 
In this respect, VBP could act as an incentive for innovation that is more 
focussed on delivery of and access to products that are designed to meet 
the most pressing needs in particular contexts. Perhaps VBP could be 
thought alongside other mechanisms to try and address local health 
needs in developing countries. For example, it could be used in conjunc-
tion with product development partnerships (PDP) or market guarantees 
focussed on particular health challenges. 
 A shift to pricing mechanisms for procurement that use local health 
needs assessment is challenging for developing countries. Nguyen et al. 
(2014) emphasize the difficulties more broadly with pharmaco-eco-
nomic evaluation in developing countries, citing a lack of capacity due 
to a shortage of qualified researchers and health care data. Fragmented 
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health systems generate poor data on health needs. However, African 
and other low- and middle-income public procurement bodies face the 
challenge of procuring innovator medicines as well as generics, and 
need to develop assessment skills for price negotiations. More generally, 
a procurement process that seeks to identify population health needs 
and then encourage local supply development has to build up tools over 
time to assess the benefits of local innovations. 
 Conclusion: procurement as development policy 
and process 
 Public procurement is an important development tool, and in medicines 
it needs to be designed to interlock industrial innovation and develop-
ment with the huge scale of African unmet health need. Given the scale 
of medicines procurement, and its life-or-death importance, its institu-
tional design and operation therefore require much more policy and 
research attention. Medicines procurement is at the same time highly 
technical – requiring capabilities identified in this chapter in financing 
and health benefit assessment – and also highly political. It involves sets 
of rules, but it is also a complex set of social and institutional relation-
ships. When it goes wrong, both health and industry suffers. 
 We have suggested two innovative aspects of procurement that will 
occupy much more attention of African policy makers. The first is the 
procurement payment systems and the ways in which they can be 
designed to act as assets and incentives for local industrial development. 
The other is the assessment processes that can underpin pricing systems 
that go beyond competitive tendering to generate negotiated prices for 
innovative suppliers. Finally, we have argued that value-based pricing is 
just one example of potential innovative procurement mechanisms that 
can be designed to have at their heart the objective of both incentivizing 
industrial suppliers and directing their efforts to address unmet health 
need. Public procurement may be underfunded by national budgets, but 
collaboration with donors and private firms can, if purposively designed, 
promote local production, innovation and access to medicines. 
 Notes 
 The authors would like to thank Sonja Marjanovic from RAND Europe for helpful 
conversations about this chapter. 
1. The Global Fund to Fight AIDS, Tuberculosis and Malaria,  http://www.theglo-
balfund.org/en/ (accessed 25 April 2015). 
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 2 .  The NHS spends about £11 billion annually on drugs of which £8 billion is 
on branded drugs. This represents about 13% and 10% of available resources, 
respectively (Claxton et al., 2008). 
 3 .  Figure 6 in this report has some case vignettes of VBP agreements. 
 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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 Introduction 
 The making and delivery of new medicines is not only a process of 
science and technology, of production and marketing, but also a process 
that is inherently political. As such, the relational and political interac-
tions between industry and government are key to shaping regulatory 
environments that either promote or constrain an industry’s ability to 
collectively learn, innovate and grow (Malerba, 2002). Often critical 
to the governing of these relations over time are intermediary actors 
such as industry associations and various advocacy groups that through 
processes of conflict, negotiation and collaboration promote knowl-
edge exchange and institutional capacity building. In developing and 
emerging countries, such intermediaries are likely to play a particularly 
prominent role in filling institutional knowledge gaps towards shaping 
regulation and subsequent industry development (Kshetri and Dholakia, 
2009). Moreover, these interactions between industry and government 
can be particularly complex and often contentious when government 
views an industry as potentially contributing to the public good, as 
in the case of the pharmaceutical industry and its role in the provi-
sion of health care. In such cases, it can be suggested that the strategies 
employed by industry associations over time will need to address the 
needs of the government and the civil society it negotiates with in order 
to effectively advance the interests of the industry it represents. 
 This chapter builds on these notions by analysing the changing role 
of biopharmaceutical industry associations and related umbrella organi-
zations in South Africa since the 1960s when the sector’s first industry 
 14 
 Industry Associations and the 
Changing Politics of Making 
Medicines in South Africa  
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association was formed. More specifically, we examine the ways in which 
the changing political context and institutional interplay have shaped a 
South African industry-government relational trajectory that is histori-
cally uneven and reactively contentious. In this case, respective pharma-
ceutical associations have shifted gradually away from pure, narrowly 
aimed lobbying tactics to greater cooperation with government and 
civil society on a host of policy-related issues, from health innovation to 
national goals of development. 
 Our analysis considers developments during three main periods 
through which the South African biopharmaceutical industry has 
evolved: (1) a period of pre-liberalization; (2) a period of expanding 
pluralism; and (3) a period characterized by increasing partnership. 
While the activities of industry associations reside primarily in the 
second and third periods, a discussion of the first period is deemed 
essential in understanding the unfolding of industry-government rela-
tions in subsequent and more recent periods. Findings indicate that 
two decades of both increasing pluralism and globalization have created 
tensions amidst regulatory uncertainties between government and the 
pharmaceutical industry regarding access to medicines on the one hand 
and strong intellectual property rights (IPRs) on the other. We suggest 
that such uncertainties can be reduced through improving interaction 
between biopharmaceutical industry associations, government and 
civil society organizations (CSOs). This can result in more legitimate 
and cumulative platforms for partnering on a number of regulatory 
issues and broader, more holistic developmental aims. 
 We begin this chapter by positioning industry associations as interme-
diaries within a broader policy subsystem and clarifying their importance 
in the developing and emerging country context. We then consider the 
activities of industry associations within wider government-industry 
growth and development coalitions, presenting both the challenges and 
opportunities towards potentially collaborative yet inherently political 
relations. We follow this with a brief overview of the South African case 
and the approach and methodology employed in our analysis. Next, we 
consider the importance of historically embedded relational dynamics 
between government and the pharmaceutical industry in South Africa 
that are punctuated by periods of regulatory uncertainty, mostly 
involving intellectual property regimes that either reinforce or alter 
existing relational trajectories. We underpin our analysis with evidence 
from case studies on four industry associations engaged in the South 
African pharmaceutical industry. 1 These case studies include interviews 
with senior managers, biopharmaceutical and other industry association 
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presidents and government policy makers in relevant departments. 
These findings, along with data collected through various secondary 
sources, lend insights into the current political strategies of biophar-
maceutical industry associations and the possibilities of more develop-
ment-oriented government-industry coalitions going forward. 
 Industry associations and the policy subsystem 
 We define industry associations as industry specific member-based organ-
izations that actively lobby and negotiate with government on their 
members’ behalf to shape government policy and regulation. Included 
in this are business umbrella groups such as chambers of commerce who 
represent the interests of a number of industries and sectors, and are 
engaged in broad industry coalition building. These organizations are 
part of what Sabatier (1991) describes as the ‘policy subsystem’ comprised 
of intermediary bodies regularly involved – through a variety of aggrega-
tion processes – in the shaping of policy within their specific domain 
of interest (Jenkins-Smith and Sabatier, 1994). For developing and 
emerging countries, this subsystem is bound to be particularly impor-
tant where given institutional capacities for innovation and industry 
growth will often be lacking (Frankel, 2006), and where their potential 
development will be the result of politically contested relations between 
government, industry and civil society. Furthermore, these are likely 
to involve considerable negotiation between local and global interests 
(e.g. international bodies and multinational companies [MNCs]). In this 
context, industry associations will likely play a leading role in bridging 
institutional knowledge gaps between government and industry, and 
between the local and the global (Kshetri and Dholakia, 2009). 
 To advocate their members’ interests successfully, industry associations 
will generally need to engage in and perform the following activities and 
functions. First, industry associations will employ far-reaching knowl-
edge and information gathering and dissemination activities that target 
government, the broader industry community and the public. Second, 
industry associations will develop and maintain working relations 
with key individuals and ministries in government, often using ‘elite’ 
members and officials to lead outreach and lobbying efforts (Kshetri 
and Dholakia, 2009). Third, industry associations must be capable of 
building widespread industry coalitions for engaging with government. 
Otherwise, industry fragmentation can result in an ineffective industry 
voice; this can lead to government-industry tensions during times of 
regulatory uncertainty and less-than-optimal policy outcomes. Finally, 
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industry associations will need to function as ‘veto players’ which influ-
ence politics of development and therefore governing structures of 
innovation capabilities (Tsebelis, 2002). In the context of developing 
countries, it is increasingly acknowledged that the political creation of 
successful institutions of innovation happens under significant pressure 
from industry associations (Doner and Sheneider, 2000). 
 Despite their potential contribution to development, negative conno-
tations are often ascribed to industry associations and their activities, as 
they have been viewed as controversial actors of innovation and devel-
opment. For instance, as early as the 18th century, Adam Smith, in his 
 The Wealth of Nations , accused industry associations of playing a nega-
tive role in the economy, conspiring against the public or raising the 
prices of goods. More recently, industry associations have been viewed 
as special interest groups and/or elitist organizations that pursue narrow 
rents for a limited number of members at the expense of the wider 
sector and economy, discouraging competition and thus curtailing 
collective innovation within an industry (see Olson, 1982; Schmitter 
and Streeck, 1999). This aligns with ideas concerning corporatism where 
national economic policy is formed through closely coordinated collab-
oration between government, industry and labour, either imposed by 
the government (state corporatism) or formed voluntarily (neo-corpo-
ratism) (see Schmitter, 1974; Cawson, 1986). Examples of these might 
be apartheid-era South Africa and contemporary Sweden, respectively 
(Thomas, 2004). Schmitter (1974) was concerned with what he coined 
‘societal corporatism’, where a small number of interest organizations 
are able to monopolize the policy subsystem, competitively eliminating 
other interest groups and essentially forcing the government to enter 
into collaborative relations with industry due to political necessity 
(Maree, 1993). In some cases, some form of societal corporatism may 
be beneficial, allowing for more rapid development of national capaci-
ties during times of necessity or crisis. The obvious downside of societal 
corporatism is that the state can become beholden to a few key interest 
groups, for example a small group of domestic conglomerates or a select 
number of foreign companies. In this way it is thought that industry 
associations, in certain political contexts, can even threaten democracy 
(Cawson, 1982). 
 State-industry relations and coalitions towards development 
 While industry associations may influence the shaping of government-
industry relations, the strategies they employ and the subsequent extent 
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to which government and industry work together may be determined 
more by long-standing and embedded relational dynamics between 
the two. Relations between government and industry are often referred 
to as coalitions, in that some degree of co-dependence and thus coop-
eration between government and industry is not only inevitable but 
necessary. In the context of developing countries, relations between 
government and industry may be characterized as ‘growth coalitions’, 
ranging from ‘weak growth coalitions’ where there is at least a minimal 
recognition that ‘business needs the support of government to make 
profits; governments need to share in these profits to finance govern-
ment and politics’ (Moore and Schmitz, 2008: 1), to ‘strong growth 
coalitions’ where government and industry engage in active coopera-
tion towards the goal of policies that both parties expect to foster invest-
ment and increase in productivity (Brautigam et al., 2002). According to 
Schneider and Maxfield (1997), strong growth coalitions require govern-
ment and industry to share information and to have a high degree of 
‘reciprocity, trust, and credibility’ towards one another. However, this 
does not change the fact that growth coalitions presuppose bargaining 
or compromises between industrial and political elites and CSOs. Khan 
(1995, 2000) refers to such coalitions as forms of political settlements – 
the balance-of-power among contending elites, CSOs and social groups. 
Political settlements are based on a common understanding of how 
narrow elitist interests can be served through policies of innovation and 
development. 
 Since the 1980s, a main focus of political-industrial settlements or 
government-industry relations for many developing countries, including 
South Africa, has been the implementation of neo-liberal economic poli-
cies. Cornerstones of this policy approach include currency stabilization, 
denationalization of industry, trade liberalization through the lowering 
of trade barriers, providing incentives for exporters and reducing favour-
able treatment of domestic firms, as well as the cutting of deficits for 
decreasing inflation and lowering interest rates – all aimed at spurring 
domestic innovation and growth in conjunction with increased foreign 
direct investment. Results of such neo-liberal-focussed growth coali-
tions have been mixed, with many developing countries experiencing 
sharp yet isolated increases in growth and wealth production amidst 
continued widespread poverty. For developing countries, therefore, it 
has been argued that government-industry growth coalitions need to 
evolve to a more development-oriented model that focuses on poverty 
alleviation over an extended period of time (Brautigam, 1997, 2009; 
Handley, 2008). Seekings and Nattrass (2011: 339) argue, however, that 
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development coalitions necessitate ‘much deeper deliberation and nego-
tiation than a growth coalition: the objective is not only to agree on the 
mix of public sticks and carrots that serve to promote economic growth, 
but to agree on a mix that promotes a particular pattern of growth’, one 
that is focussed on the needs and welfare of the poor. For industry and 
the associations that negotiate with government on industry’s behalf, 
such a move would require a considerable shift away from pure lobbying 
to greater partnering with government. 
 The global pharmaceutical industry and 
the case of South Africa 
 The global biopharmaceutical industry is comprised of a relatively small 
number of large research-oriented MNCs based mainly in the developed 
North and a large number of both small and large companies that manu-
facture generic medicines both in the developed North but most promi-
nently and increasingly so in the developing South (see Chapter 6). 
Most generics manufacturers operate as independent companies while 
others are subsidiaries of large MNCs. The research-based MNCs make 
generally large profits through the global sale of patented blockbuster 
drugs which are more expensive than generics and are at times priced 
out of the reach of poor patients. The research-based MNCs insist that 
the high prices for the medicines they sell and the profits they garner 
are necessary for covering the costs of marketing and continued R&D 
activities. But the inability of many to pay these prices, including the 
governments of developing countries, and the increasing expiration of 
many patented medicines have facilitated the tremendous growth of the 
generics industry which has substantially lowered the price for a number 
of essential medicines, including anti-malarial, and anti-retroviral drugs, 
among many others, some experiencing a 50–90% reduction in price, 
thus considerably increasing access to these medicines. The growth of 
the generic medicines industry and its impact on research-based MNCs 
have created considerable fragmentation and conflict within the phar-
maceutical industry and between the pharmaceutical industry and the 
governments of emerging countries such as South Africa. 
 South Africa’s economic growth for the last few years has averaged 
2–3% and it slowed down to 2.0% in 2014. However, as the second-
largest African economy after Nigeria the country exerts strong economic 
and political influence on the African continent. The country made the 
transition from an apartheid state to a constitutional democratic state in 
1994. Since then, South Africa has experienced considerable economic 
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growth, but also increased inequality and extreme poverty in certain 
sections of the population. In the area of biopharmaceuticals, the 
country has emerged as the industry forerunner in Africa with a signifi-
cant presence of both domestic manufacturers and MNCs, although the 
domestic manufacturing industry is relatively small, with up to 65% 
of the country’s pharmaceuticals still being imported (IPASA, 2013). 
Furthermore, its private market, worth US$2.8 billion in 2012, is rela-
tively small and constitutes less than 1% of the market globally. In 2011, 
two leading pharmaceutical companies in South Africa were domesti-
cally based MNCs, Aspen Pharmacare and Adcock Ingram; domestic 
companies import up to 90% of active pharmaceutical ingredients from 
other countries, including India and China. Meanwhile, historically, 
and presently, the country has had a number of active biopharmaceu-
tical industry associations, making it an important case study for inves-
tigating the realities of pharmaceutical production in Africa and the role 
of industry associations in it. 
 With respect to industry associations, companies in this sector are 
members of different associations depending on the segment of the 
market that they occupy. Most foreign MNCs are members of the newly 
formed Innovative Pharmaceutical Association South Africa (IPASA), 
which emerged from a merger between two former associations, 
Innovative Medicines South Africa (IMSA), for research-based/inno-
vator MNCs; and Pharmaceutical Industry Association of South Africa 
(PIASA), whose membership included both innovator and generics 
companies. The new association, IPASA currently represents 24 inno-
vative pharma companies dedicated to producing or importing inno-
vative medicines in South Africa. According to IPASA, only companies 
that conduct their own R&D qualify for membership. This means that 
domestic companies with no intellectual property (IP) are excluded from 
the new association. Only IP holders, for example MNCs with inno-
vator products, can become members of IPASA. In addition to IPASA, 
there is also the National Association of Pharmaceutical Manufacturers 
(NAPM), Pharmaceuticals Made in South Africa (PHARMISA), Self-
Medication Manufacturers Association of South Africa (SMASA) and 
National Association of Pharmaceutical Wholesalers (NAPW), among 
others. They also all belong to the Pharmaceutical Task Group (PTG), 
a broad coalition involving IPASA, NAPM, PHARMISA and SMASA. The 
PTG deals with the government on issues of mutual concern such as 
pricing, regulation and national health insurance. For example, the PTG 
has retained an advocate to represent the pharmaceutical industry in 
the Competition Commission enquiry into high health care prices. That 
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being said, many of these associations and member companies are also 
members of the leading chambers of commerce, CHAMSA and SACCI, 
and connect with one another through these platforms. This current 
status of industry has evolved through two main periods: pre-liberaliza-
tion and the post-apartheid. 
 Pre-liberalization era 
 While disagreements over the past two decades on particular regula-
tory issues have at times stymied relations between the South African 
pharmaceutical industry and the South African government, tensions 
between the two are very much rooted in a long history of tense and 
generally non-negotiable relations between the South African govern-
ment and the South African business elites, which have carried over into 
more recent periods from the apartheid era. As Seekings and Nattrass 
(2011: 343–44) explain, 
 Indeed, relations between state and business in South Africa 
throughout the 20th century were framed by the coexistence of a 
strong state and powerful corporate capital. The state enjoyed consid-
erable political autonomy from capital, but remained dependent on 
capital for continued economic growth. The outcome was often tense 
relationships, as the state sought to push and bully capital into subor-
dinate co-operation, whilst avoiding genuine deliberation, and being 
careful not to undermine white prosperity. 
 As such, during the apartheid era, the South African government was 
intent on maintaining and enriching the white minority through ever 
increasing control and exploitation of the black majority. This neces-
sitated a command-oriented state, the brutal subjugation of blacks and 
the complicity of white-owned industry which was dominated by a 
small number of large state-supported conglomerates all linked in some 
manner to the South African gold-mining industry. Offering consid-
erable trade protection (much of this induced through international 
boycott) and ensuring low-wage black labour, the South African govern-
ment expected industry to operate within certain constraints and to be 
‘subservient, as long as it was dependent on state patronage’ (Seekings 
and Nattrass, 2011: 344); this resulted in a state-industry relationship 
that was generally reactive yet ultimately accommodating in terms of 
industry response, and largely devoid of negotiated compromise. 
 With an economy centred on mining and energy extraction, and stag-
nated by the apartheid system and resulting sanctions and boycotts, the 
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South African government lacked the ability and capacity to either invest 
in a broad-based science and technology infrastructure (e.g. weak univer-
sity R&D) or facilitate the growth of technology-based industries (the 
exception being defence). A strong domestic pharmaceutical industry 
was never really established in South Africa during this period. The need 
for medicines, however, meant that large research-based pharmaceutical 
MNCs continued to sell and distribute medicines in South Africa, with 
some operating manufacturing facilities in the country. That being said, 
two pharmaceutical companies, Sterling Winthrop and Merck, divested 
their interests in South Africa and left the country due to the boycott. 
A few domestic generics-based pharmaceutical companies such as 
Adcock Ingram were able to successfully operate under the constraints 
of apartheid, but their growth and proliferation would not really occur 
until after apartheid’s end. During this period, two main biopharma-
ceutical industry associations were established. The first was the South 
African Pharmaceutical Manufacturers Association (PMA), established in 
1967, and the second was the National Association of Pharmaceutical 
Manufactures (NAPM), established in 1977. The membership of the 
PMA was a mix of domestic and foreign-owned pharmaceutical compa-
nies, but the MNCs were more dominant given their market strength; 
members of NAPM, by contrast, were almost solely domestic manufac-
turers of generics. Both associations used to work closely with govern-
ment and/or play advisory roles in policy areas such as health and drug 
manufacturing. This was consistent with the corporatist state-industry 
relations of the apartheid era. 
 Post-apartheid South Africa 
 South Africa’s transition to democracy in 1994 led to weakening of 
the corporatist hold of the state and strengthening of the civil society 
(Lehman, 2008). This does not imply that a pluralist approach to state-
industry relationships prevailed. Rather, pluralism and corporatism seem 
to coexist in post-apartheid South Africa. The relationships between 
industry associations and state appear to be co-operative; govern-
ments tend to view the business elites as a key player in pro-market 
liberal reforms. Indeed, as Seeking and Nattrass (2011: 339) point out, 
‘Capitalism not only survived the transition from apartheid to democ-
racy, but high profit rates suggest that capitalism continues to flourish 
in the post-apartheid environment’. This is precisely the reason why 
South Africa, despite its exceptional economic performance, experi-
ences increased inequality and extreme poverty in certain sections of 
population, namely the black majority. The co-operative state-industry 
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relations in the post-apartheid era failed to form a strong ‘growth 
coalition’ that could also deliver development. Therefore, within the 
governing party – the African National Congress (ANC) – the new 
political elite(s) developed distrust against the business elite(s). The 
ANC adopted pro-market policies with respect to the global economy 
without necessarily having a pro-business or pro-industry attitude. 
According to Seeking and Nattrass (2011: 344), ‘In the early 1990s, 
two views of businesses coexisted within the ANC. On the one hand, 
business was seen to have been one of the pillars of apartheid, exploita-
tive of workers and abusive of consumers. On the other, there was a 
growing appreciation of the overall weakness of South African capi-
talism, in particular its inefficiencies stemming from chronic protec-
tion against foreign competition and over-concentration’. The first 
view clearly supported regulation of employment relations and protec-
tion of black businesses. The second view supported trade liberaliza-
tion and industrial policy. As Seeking and Nattrass (2011) observe, 
both views entailed a commandist approach to business and industry 
without so much negotiation. 
 In this post-apartheid mix of corporatism and pluralism, large phar-
maceutical companies began to re-establish themselves in South Africa, 
insisting on strong protection of patented drugs through TRIPS. On the 
other hand, CSOs such as non-governmental organizations (NGOs) and 
advocacy groups began to formally participate in the policy-making 
process (Lehman, 2008). In 1994 there were more than 50,000 NGOs in 
South Africa, most of them pursuing development objectives (Fioramonti, 
2005). In the post-apartheid era, the state inherited a strong regulatory 
capacity (ibid) and relied on it to protect public health from the spread 
of diseases such as HIV/AIDS through the poorest sections of popula-
tion. According to Seekings and Nattrass (2011: 353), ‘Its interventions 
in the private sector were programmatic rather than targeted in that the 
state legislated frameworks for change ... and then endeavoured – with 
mixed success – to ensure that private sector complied with the statutory 
requirement’. 
 One well-known intervention was the government’s 1997 Medicines 
and Related Substances Control Act that would allow South Africa to 
import and manufacture cheaper generic HIV drugs. This Act prompted 
39 big pharmaceutical companies (mainly MNCs) to file through PMA 
a patent right lawsuit against the South African government – the 
so-called Big Pharma v Nelson Mandela case. In response, CSOs and 
activists accused PMA of violations of the human right to health by 
making essential medicines unaffordable and called the international 
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community to protect developing countries against big pharmaceutical 
companies (Wolff, 2012). Although in 2001 PMA agreed to drop the 
lawsuit as a result of the growing opposition, it was too late. The PMA 
suffered an international public relations disaster with three MNCs, 
GlaxoSmithKline, Merck and Bristol-Meyers Squibb, breaking ranks with 
36 other companies and pushing hard for a settlement that would stave 
off increasing damage ( The Guardian , 2001). Eventually, these 36 compa-
nies agreed to go along with the lawsuit withdrawal, but PMA dissolved, 
splitting into two new associations: the Pharmaceutical Industry 
Association of South Africa (PIASA) and the Innovative Medicines South 
Africa (IMSA). 
 PIASA was established as an association of companies involved in the 
manufacturing and marketing of medicines in South Africa. Its members 
were research-based MNCs and local manufacturers of pharmaceuticals. 
PIASA had about 90 members, consisting of both large and small compa-
nies. Other organizations, such as the South Africa Medical Device 
Industry Association (SAMED), were members of PIASA, testifying to the 
diversity of the association. The objective of PIASA was to shape stra-
tegic regulatory issues relating to clinical trials, registration of medicines 
and IPRs. In addition to this, the association tried to tackle regulatory 
hurdles that discourage investment in South Africa’s biopharmaceu-
tical sector. PIASA was also engaged in activities to influence the quality 
and cost of medicines, access to treatment, health insurance, drug laws 
and pharmaco-economic evaluation. Among such activities advocacy, 
networking and innovation diffusion appear to be the most crucial ones. 
PIASA interacted with government but also with other associations, 
including IMSA in the health policy and regulation arenas. For instance, 
it had substantial involvement in the formulation of the South African 
Health Charter and Private Health Care Reform programmes. This close 
interaction of PIASA with government was often seen as uneven, given 
the conflict of public and private interests. Another important activity 
of PIASA was diffusion of knowledge through hiring consultants and 
providing members with expert advice on pertinent issues in the health 
innovation and regulation terrains. Such issues included standards for 
manufacturing facilities, drug registration fees and regulatory harmo-
nization. This range of activities in the institutional context of South 
Africa indicates that PIASA played a crucial role in influencing the coun-
try’s innovation system. 
 By contrast, IMSA was established as an industry association for 
research-based companies, even though some of its members also used 
to produce generics. This is not surprising; generics are crucial for the 
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public health service in the country. Among IMSA’s members there were 
12 MNCs who captured about 53% of the MNC market share in South 
Africa. Generally speaking, this biopharmaceutical association engaged 
in R&D policy, innovation regulation and lobbying. IMSA did not always 
perform such activities alone but in collaboration with other associa-
tions. Thus, for instance, in the PTG initiative IMSA played an active 
role in national health insurance issues, working jointly with PIASA 
and other public actors of South Africa. Another key focus of IMSA 
was on IPRs, especially access to drugs and marketing. The association 
worked with and through its members to exert influence on these issues. 
IMSA’s key contacts in government were the Department of Health, the 
Department of Science and Technology and the Department of Trade 
and Industry. It also made policy contributions to parliament’s port-
folio committee on health. However, IMSA also functioned as a govern-
ment tool for industrial policy implementation. That is to say, it worked 
closely with government for the implementation of broader national 
policies by their members, for example requirements under the Black 
Economic Empowerment (BEE) programme. 
 The split of PMA into PIASA and IMSA was not the most negative 
consequence of the ‘Big Pharma v Nelson Mandela’ case. After all, 
in April 2013 these associations came together again, forming the 
Innovative Pharmaceutical Association South Africa (IPASA). It might be 
argued that the most negative consequence of the ‘Big Pharma v Nelson 
Mandela’ case was the damage to trust between government and biop-
harmaceutical associations. As one interview respondent pointed out, 
 [P]re-1994 I think the industry was more in an advisory role, although 
perhaps not with lobbying focus, access to government ministries 
was quite possible. What changed it completely for the industry was 
the court case of 1998 to 2004 which was all about weakening intel-
lectual property and so created a sense that we [the industry] were 
against the government. So from that time onward, whenever you 
went into the halls of government, they [the government] would see 
you as ‘you are that industry that took us to court’; so that created 
such animosity between the Department of Health, the relationship 
has never really been constructive. (Interview extract: 23) 
 This statement confirms that, in South Africa, state-business relations 
(SBR) in the area of biopharmaceuticals remain fragile and therefore 
lack essential characteristics of effectiveness. According to Cali and Sen 
(2011: 1543), such characteristics include:
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 (i) transparency: whether there is a flow of accurate and reliable infor-
mation, both ways, between business and government, and from 
representatives of business to their own members; (ii) reciprocity: 
whether there is capacity and autonomy of state actions to secure 
improved performance in return for subsidies; (iii) credibility: whether 
the state command credibility of the private sector, and whether capi-
talists are able to believe what state actors say; and (iv) whether there 
is mutual trust between the state and the business sector. 
 Clearly, South African SBR in the area of biopharmaceuticals are neither 
transparent and reciprocal nor credible and mutually trusting. Rather, 
due to the long-term impact of the ‘Big Pharma v Nelson Mandela’ case, 
these relations are based on mutual suspicion and distrust. 
 Analysis and discussion: resetting the state-industry 
relationships 
 Since its formation in 2013, IPASA has been engaged in a highly 
uneven relationship with government over the latter’s policy plan to 
change the patent rules for medicines. That plan incorporates patent 
flexibilities after the Doha Declaration (WTO, 2001) and recommends 
elimination of weak patents, promoting the production of generics 
(DTI, 2013). In response, IPASA embarked on a campaign against the 
full implementation of the government plan, lobbying the govern-
ment and other national and international actors for a stronger IPR 
regime. Its main objection is that by using TRIPS flexibilities and by 
promoting generics, the South African government’s plan on IP policy 
will reduce innovation and fail to attract investment, particularly 
FDI, into knowledge-based firms such as those in biopharmaceuticals 
(IPASA, 2013). The South African government insists that the issue is 
not about weakening the TRIPS regime and the country’s biopharma-
ceutical innovation system, but about implementing TRIPS with all 
the necessary flexibilities for the sake of public good ( The Economist , 
2014). The tension between government and IPASA (the majority 
of research-based pharma MNCs) heightened substantially when it 
was made known that IPASA was participating (perhaps leading) a 
campaign in collaboration with a Washington, DC-based public rela-
tions firm that aimed to promote the supposed adverse consequences 
of a weak IPR regime as proposed by the government, to target the 
South African public, business community and academic institutions. 
This bypassing of the government by IPASA in its attempts to thwart 
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government policy, and doing so during an election year, fuelled 
already high levels of distrust between the South African government 
and the research-based, primarily foreign-owned pharmaceutical 
companies. 
 The above episode is an apparent setback to relations that, while 
recently punctuated with conflict, have been defined more by 
increasing collaboration both within industry on key regulatory issues, 
particularly taxation and medicine registration procedures, and with 
government on broader health care policy. For example, a number 
of these biopharmaceutical industry associations have been involved 
more recently in wider policy discussions with government regarding 
science and technology workforce development, industry-university 
collaboration and the role of research-based pharmaceutical companies 
in the development and implementation of a South African National 
Health Insurance scheme. Resetting relations will require reengaging 
government on such issues, but huge differences on IPR will need to be 
addressed, if not wholly overcome. Even though stronger IPR laws are 
supported by much of South Africa’s business community (e.g. SACCI 
supports a stronger IPR regime), the research-based pharmaceutical 
industry, due to its status as an important yet ‘reluctant’ and untrust-
worthy medicines provider, will need to go further. It needs to shed the 
perception that its interests in South Africa do not go beyond clinical 
trials and the profit-driven motive of protecting of its patented medi-
cines and future therapies for sale not only in South Africa but the 
entire African continent. 
 For its part, the South African government needs to decide what type 
of role it sees the pharmaceutical industry playing in a relatively poor 
yet modern South Africa. On one hand, the South African government’s 
approach to access to affordable medicines has indeed increased access, 
but has also resulted in a growing reliance on foreign generics (e.g. from 
India) rather than the development of a domestic generics industry. On 
the other hand, it has recently put forward public-private partnership 
(PPP) initiatives towards developing indigenous high-tech industries 
such as biotech, yet has not sufficiently articulated, at least in public, 
the role of IPR or the pharmaceutical industry in this new policy vision. 
This seeming contradiction is played out between government minis-
tries, particularly long-standing divisions between the Department of 
Health, which supports weak IPR laws for ensuring access to affordable 
medicines, and Science and Technology (DST), which favours stronger 
IPR laws as a means of fostering innovation more generally and realizing 
the positive externalities that a robust research-based pharmaceutical 
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industry might provide South Africa. However, DoH and the Department 
of Trade and Industry (DTI) are aligned in the area of access to health. 
Such intra-government divisions, while justified, do complicate negotia-
tions with industry and likely reinforce industry fragmentation between 
research-based MNCs and generics manufacturers. Current fragmenta-
tion on both sides of the negotiating table are contributing to tense 
relations between the South African government and the pharmaceu-
tical industry and probably resulting in policy inertia and far less-than-
optimal regulation. 
 Conclusion 
 In this chapter, we have considered the neglected role of industry 
associations in Africa as key intermediaries in innovation that, 
through evolutionary processes of conflict, negotiation and knowl-
edge diffusion, facilitate institutional capacity building while shaping 
regulation and subsequent industry development. To do so, we have 
analysed the shifting strategies over time of biopharmaceutical 
industry associations and related organizations in South Africa. We 
have considered the importance of historically embedded relational 
dynamics between government and the pharmaceutical industry in 
South Africa involving critical junctures of regulatory uncertainty, 
mostly involving highly contested intellectual property regimes. 
Tracing developments during three main periods within different 
national context, our findings support previous research that suggests 
industry associations are more effective in lobbying and negotiating 
with government when industry is relatively cohesive and able to 
speak with one voice. This chapter, however, also suggests that in 
the case of the pharmaceutical industry, the extent to which industry 
associations can effectively engage with government is determined, 
in large part, by the willingness of government over time to neither 
demand nor capitulate, but to compromise with industry in ways 
that meet its own requirement for accessible medicines while recog-
nizing the positive externalities of a robust domestic pharmaceutical 
industry. When such willingness is limited, either long-standing or 
temporarily, biopharmaceutical industry associations in South Africa 
are increasingly asserting themselves as ‘partners’ with government 
in attempts to correct these long-held tensions with the aim towards 
negotiating better policy outcomes. 
 In the case of South Africa, decades of tension between government 
and industry in general, which carried over from the apartheid era, have 
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exacerbated long-standing pharmaceutical industry fragmentation on 
key policy issues such as IPR, particularly those between MNCs and 
domestic generics companies. In turn, this has inhibited constructive 
policy dialogue and reinforced industry-government distrust, particularly 
regarding the pervasive assumption that the growth of an innovation-led 
biopharmaceutical industry in South Africa is incompatible with wide-
spread access to effective and affordable medicines. Subsequent policy 
divisions between the DOH and DST both mirror the overall divisions 
and mistrust between industry and government and may contribute to 
regulatory inefficiencies. This has placed South Africa’s biopharmaceu-
tical industry associations, particularly those representing MNCs, often 
in direct and open conflict with government. 
 Finally, the historical trajectory and the shift to greater partnering 
strategies captured here provide insight into the conditions and proc-
esses through which ‘growth coalitions’ in developing countries such as 
South Africa either remain weak and ineffective in terms of developing a 
domestic industry or grow strong in that they effectively promote both 
the growth of domestic industry and the subsequent realization of posi-
tive externalities and spill-overs. In doing so, the challenges of moving 
government-industry relations to a more effective ‘development coali-
tion’ model that is focussed on growth and poverty alleviation are laid 
bare. In the case of South Africa, the government and the pharma-
ceutical industry seem to be locked, based on decades of tension and 
mistrust, in a rather weak ‘growth coalition’ that, while promoting the 
interest of a few key industry players and keeping prices of medicines 
low, has kept the domestic South African pharmaceutical industry rela-
tively small, dependent on foreign generic suppliers, with few positive 
externalities or spill-overs gained. For moving towards a stronger growth 
coalition, the biopharmaceutical industry associations of South African 
will need to build trust with government and to reconcile industry divi-
sions among themselves. 
 Notes 
  Acknowledgements: This chapter draws on a research project, ‘Unpacking the 
Role of Industry Associations in Diffusion and Governance of Health Innovations 
in Developing Countries’, funded by The Leverhulme Trust UK, during 2013–
15, reference number RPG-2013–013. The authors would like to thank Maureen 
Mackintosh and participants of the  Making Medicines in Africa Workshop (15–16 
December 2014) for reading earlier drafts and providing useful comments and 
suggestions. 
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 1 .  In total, 19 interviews were conducted, involving 4 industry associations: 
Innovative Pharmaceutical Industry Association (IPASA), National Association 
of Pharmaceutical Manufacturers (NAPM), South African Chambers of 
Commerce (SACCI) and South African Medical Device Industry Association 
(SAMED). 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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 Introduction 
 There is a now a growing international consensus that development of 
the pharmaceutical industry in Africa can contribute to both economic 
development and improved public health. This final chapter begins by 
identifying the striking convergence of thought and initiative that has 
recently been generated across continental African representative bodies, 
international agencies and national governments. We outline this emer-
gent consensus and then examine challenges it faces by focusing on the 
core interconnected policy issues of financing and incentives for indus-
trial development in pharmaceuticals. A sustainable and expanding 
pharmaceutical industry must reach essential quality standards and also 
constantly upgrade, moving up the technology ladder while improving 
cost efficiency. This requires a cocktail of incentives in which finance 
is key (Chataway et al., 2009). These incentives, in turn, rely on the 
building up of appropriate financial capabilities within firms and finan-
cial institutions as well as within governments. This chapter innovatively 
traces the interconnections between micro-level financial capabilities 
and national government policy competences in the design and effec-
tive implementation of financial incentives and associated policies to 
facilitate industrial development in pharmaceuticals in Africa. 
 The emerging commitment: transforming pharmaceutical 
manufacturing in Africa 
 At the African continental level, the African Union Commission (AUC) 
identified the imperative of pharmaceutical industry development in 
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their  Pharmaceutical Manufacturing Plan for Africa (PMPA) (AU, 2007), 
endorsed at the African Union Heads of State and Government Summit 
in 2007. Progress on realizing the ambition espoused in this document 
was initially slow to materialize, prompting the Conference of African 
Ministers of Health (CAMH) to call at their fifth meeting in 2011 for 
a ‘Business Plan’ for the accelerated implementation of the PMPA. A 
partnership was formed later that year between the AUC and the United 
Nations Industrial Development Organization (UNIDO) to develop the 
business plan, and in May 2012 the resulting document (AU, 2012a) was 
approved by a special session of the CAMH in Geneva. In July 2012 the 
Business Plan was endorsed by AU Heads of State and Government at 
their summit in Addis Ababa. 
 Regionally and institutionally, collaborative work on local pharma-
ceutical development has snowballed. The African Ministers of Industry 
have also now recognized the pharmaceutical industry as a priority, in 
the Accelerated Industrial Development of Africa (AIDA) framework 
endorsed at their 19th meeting in Algiers in 2011. African Regional 
Economic Communities have also developed plans. The East African 
Community Regional Pharmaceutical Manufacturing Plan of Action 
2012–16 was launched in 2011 (EACRPMPA, 2011). The West African 
Health Organization (WAHO) has been developing the Economic 
Community of West African States (ECOWAS)  Regional Pharmaceutical 
Plan (ERPP) and its implementation. The ERPP explicitly aligns with the 
principles and objectives of the Business Plan for the PMPA, and WAHO 
has rapidly developed a comprehensive approach, despite wrestling with 
the unprecedented crisis of the Ebola outbreak in the region. 
 The public health commitment 
 International organizations concerned with public health are also now 
indicating growing support for this agenda. The Joint United Nations 
Programme on HIV/AIDS (UNAIDS) under the leadership of Michel 
Sidibé has long been an advocate of the importance of strengthening 
local production, in particular to address the sustainability of HIV/AIDS 
treatment, as well as access to medicines for tuberculosis and malaria. 
It is a central component of Pillar Two of the African Union’s  Shared 
Responsibility and Global Solidarity Roadmap for HIV, TB and Malaria 
Response in Africa , developed with support from UNAIDS (AU, 2012b). 
 In 2008 the World Health Assembly adopted the  Global Plan of Action 
and Strategy on Public Health , a broad document that identifies the role that 
local production of essential medicines could play in improving public 
health. As part of its implementation, the World Health Organization 
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(WHO) has run an EU Commission-funded project to assess this role. 
Phase 1 of the study concludes that the development of the local phar-
maceutical industry does not inevitably lead to improved public health, 
and hence that promoting the public health impact should be central 
to efforts to strengthen the industry. These initiatives have helped to 
ensure that public health considerations are central to the Business 
Plans that are being developed. They plot a practical path whereby the 
industry can contribute to both public health and economic develop-
ment agendas that were previously considered by some to be mutually 
exclusive (Kaplan and Laing, 2005). 
 The strong current consensus amongst the international community, 
that the development of the pharmaceutical sector in Africa is an imper-
ative, was notably underlined by the Joint WHO Bulletin Editorial by 
Mr Sidibé, Mr Li (Director General of UNIDO) and Dr Chan (Director 
General of WHO) (Sidibé et al., 2014). The authors strongly supported 
the development of the industry in Africa through the implementation 
of the PMPA Business Plan. 
 The challenge of implementation 
 Practical bilateral and multilateral support for the industry is growing. 
The German government has a long track record of supporting the 
pharmaceutical industry in Africa. Since 2006 it has funded a UNIDO 
project on strengthening the local production of essential medicines 
in developing and least-developed countries, a project initiated by the 
previous UNIDO Director General Dr Kandeh Yumkella. Bilaterally 
through its aid agency Deutsche Gesellschaft für Internationale 
Zusammenarbeit (GIZ), Germany has supported the EAC pharmaceu-
tical plan and many other initiatives such the bioequivalence centre in 
Addis Ababa (see Chapter 5) and initial feasibility studies for a similar 
centre in Ghana. 
 Other international support includes the United States Pharmacopeial 
Convention (USP) which, with funding from the United States Agency 
for International Development (USAID), has been running a programme 
on Promoting the Quality of Medicines (PQM), including capacity 
building for manufacturers and regulators. In 2013 it opened the Centre 
for Advanced Pharmaceutical Training (CePAT) in Ghana, to train regu-
lators and the industry in quality assurance and quality control. The 
St. Lukes Foundation in Tanzania has similarly been training industry 
professionals on international standards of production through its 
Industrial Pharmacy Advanced Training Programme, taught by US 
academics from Purdue and Howard universities, supported by UNIDO. 
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The need to exploit opportunities under the exemptions and flexibili-
ties offered by the Trade Related Aspects of Intellectual Property Rights 
(TRIPS)  agreement 1 has led the United Nations Development Programme 
(UNDP), the United Nations Conference on Trade and Development 
(UNCTAD) and the African Regional Intellectual Property Organization 
(ARIPO), amongst others, to establish relevant programmes. 
 The PMPA  Business Plan identifies the problem of a piecemeal 
approach that has not delivered rapid development of the industry, 
and proposes that coordination across different initiatives is required. 
The international organizations need to invest in supporting emerging 
national and regional processes to enable development of the industry. 
Coordinated technical assistance is required to support relatively weak 
skills availability in the short term and to engage in capacity develop-
ment across public and private sectors for the long-term sustainability of 
the industry. National governments too need to invest to support their 
industries: this point was underscored during a high-level side event 
at the Ministers of Finance and Economic Planning meeting co-hosted 
by the African Union Commission and the United Nations Economic 
Commission for Africa (UNECA) in Abuja in March 2014. 
 Ghana is an example of a country where a coordinated agenda is 
progressing. In October 2013 early implementation of the AUC’s PMPA 
 Business Plan began in Ghana, following an invitation from President 
Mahama to the Chairperson of the AUC, Dr Nkosazana Dlamini Zuma. 
A technical assistance work plan was agreed by the national stakeholders 
and a consortium of partners including UNIDO, WHO, UNAIDS, UNDP, 
UNFPA, the New Partnership for Africa’s Development (NEPAD), the 
African Network for Drug and Diagnostic Innovation (ANDI) and the 
Federation of African Pharmaceutical Manufacturer’s Associations 
(FAPMA). The work plan recognizes both the critical need to build 
capacity within public sector institutions and the private sector and the 
need within the industry for time and support to invest in upgrading. 
 The need for complex cross-institution coordination to implement the 
work plan is illustrated by the collaboration with the Ghanaian Food and 
Drug Authority (FDA) to develop and implement a good manufacturing 
practices (GMP) road map; the development of training modules for 
industry on developing capital investment plans and managing capital 
project life cycles; the creation of a business linkages platform to enable 
companies to access the know-how that they require in the short term 
whilst internal technical capacity is developed; and a market data initia-
tive to provide market transparency to inform policy makers, industry 
and investors in their decision making. Technical assistance has also 
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been provided to assist government in assessing investment proposals 
made by pharmaceutical companies under the Export Development 
and Agriculture Investment Fund (EDAIF) stimulus package, described 
below. 
 Upgrading, market consolidation and the challenge 
of finance 
 Central to all this work is the recognition that the pharmaceutical sector 
in Africa needs to upgrade standards in order to be able to provide safe, 
efficacious, quality-assured essential medicines. Achieving this objec-
tive is a highly complex undertaking requiring coordinated action of 
many parties at national, regional, continental and international levels 
(Chapter 12). Africa-based companies are able to compete at interna-
tional standards, contrary to some earlier expressed views (see Chapter 6; 
Chaudhuri and West, 2014). The most technically advanced compa-
nies such as Universal in Kenya (WHO-prequalified for its Lamivudine 
Zidovudine FDC), Quality Chemicals International Limited in Uganda 
(with additional site licence for Cipla’s pre-qualified products) and four 
companies in Nigeria that have recently received WHO-GMP certifica-
tion (including May and Baker and Evans Pharmaceuticals) have attained 
high international standards. 
 However, the industry’s contribution to economic development and 
improved public health requires a broader swathe of companies to 
upgrade to international quality standards, not just for products to treat 
the major pandemics but for all medicines that have a critical role to play 
in treating communicable and non-communicable diseases. As earlier 
chapters have shown, companies across Africa are striving to upgrade 
their facilities and their manufacturing processes and procedures. 
However, whilst there have been no published systematic studies on 
the range of quality standards to which manufacturers on the continent 
adhere, it is clear that many companies licensed to manufacture phar-
maceuticals in Africa currently operate in premises and/or have quality 
management systems that fall below what should be acceptable. 
 The concept of the GMP ‘road map’ establishes rising quality targets 
over a defined period of time. During transition to meet these milestones, 
those companies that are operating below them should be restricted to 
manufacturing products where the risk to health is minimized. Such a 
stepwise approach creates a transition process for the industry whilst 
protecting public health. So long as the requirements are enforced by 
credible sanctions, the framework can discourage unproductive use of 
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subsidies by manufacturers not in practice investing in upgrading. It 
also provides some market protection for leading companies that have 
made significant investment, since they can sell a broader range of prod-
ucts during the transition phase. 
 The PMPA Business Plan focuses initially on generic small-molecule 
non-sterile production of final formulations in Africa. Even with this 
subset of essential medicines, the complexity of the system within which 
manufacturing takes place is significant (see Chapter 2). The industry has 
multiple stakeholders, operates in widely varying contexts across coun-
tries and regions, and includes manufacturers at significantly different 
levels of industrial development. 
 Nevertheless, some general requirements for industry development 
can be identified, and of these the central requirement is finance. 
Companies need to access capital to invest in retrofitting facilities or 
building new plants to meet international standards. The magnitude 
of investment required will depend on many variables including the 
specific pharmaceutical forms that a manufacturer wishes to produce, 
the scale of the plant and the starting point of the organization, but most 
companies will require at least US$10 million (see also Chapter 5 for the 
financial requirements for a start-up). The efficient use of this invest-
ment requires that companies in this knowledge-intensive industry can 
access the capabilities to design and build GMP-compliant plants and 
develop or acquire the capabilities to run them. Companies need assist-
ance to access know-how, time to develop plans and implement them, 
and more time to develop the capabilities first to operate efficiently and 
then to adapt and innovate. 
 Upgrading is done by companies, not governments. But policy makers 
and international development organizations need to understand the 
challenges faced by manufacturers, and to work with them and with 
national and regional entities to enable effective upgrading whilst 
avoiding wasteful use of scarce resources. The AUC has recognized 
this need for close collaboration, convening a consortium of conti-
nental and international partners, including the Federation of African 
Pharmaceutical Manufacturers Associations (FAPMA), to implement the 
PMPA Business Plan. The consortium will work with African trade asso-
ciations, regions and sovereign states on strategies for upgrading the 
industry. 
 Regulatory market shaping 
 In order to invest sustainably, pharmaceutical companies also need 
access to a large and effectively regulated market in which returns can be 
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made. Further strengthening of regulatory authorities is needed to ensure 
that legitimate manufacturers do not face competition from spurious, 
substandard and counterfeit products. Pharmaceutical manufacturers 
also need to utilize capacity efficiently in order to be competitive, and 
market scale is an important contributor to achieving cost efficiency. 
Since many African countries’ populations are relatively small, current 
efforts to defragment African regional markets, and confidence in their 
likely success, are vital prerequisites to mobilizing investment for many 
pharmaceutical manufacturers. While for a few firms international 
donor-funded markets may offer larger-scale market opportunities, the 
sustainability of an exclusive focus on these markets in the long term is 
questionable. 
 Important progress has been made in the direction of regional market 
consolidation, through the African Medicines Regulatory Harmonization 
initiative (AMRH), particularly in the EAC and ECOWAS Regional 
Economic Communities. The documentation for regulatory approval 
across member states will at least be standardized, removing significant 
transaction costs from manufacturers, and boding well for increasingly 
harmonized regulatory requirements in the future (see Chapter 12). 
 Finally, as earlier chapters have documented, local manufacturers are 
frequently at an inherent disadvantage in competition with imported 
medicines, and corrections to the tax and tariff frameworks are required 
at regional level. The ECOWAS Regional Pharmaceutical Plan (ERPP) 
advocates for zero tariffs on raw materials, machinery and equipment 
for pharmaceutical manufacturing within the Regional Economic 
Community and exemption of inputs from VAT. It also recognizes the 
need for an appropriate regional framework to support the stepwise 
approach to upgrading. 
 Such initiatives can help investors to assess potential returns. However, 
the quantification of the market opportunities remains elusive, given 
the paucity of market data for most African countries and regions. This 
market opacity increases the perceived risk for investors, leading in turn 
to higher interest payments through an increased risk coupon required 
for debt providers, or to a higher internal rate of return required by 
equity investors. The cost of investment capital for African pharmaceu-
tical investors remains a barrier for many companies in countries where 
interest rates on bank loans may exceed 25%. The next two sections 
tackle the funding challenge in more detail, first from the point of view 
of the manufacturers and private financing institutions, and then from 
the point of view of governments seeking to enable investment for 
industrial growth. 
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 Building financial capabilities in manufacturers and 
financial institutions 
 The African local pharmaceutical industry is playing technological 
catch-up based on building technological capabilities (Chapter 2). 
These technological capabilities are sometimes summarized as know-
what, know-how, know-why and know-who (Ernst and Lundvall, 1997). 
They include the skills needed for investment, production and creating 
market and non-market linkages (Lall, 1992): using technology effec-
tively for expansion; handling key production systems from quality 
control and operation and maintenance to adaptation and improve-
ment; and dealing effectively with suppliers and customers. While it is 
accepted that finance plays a strategic role in funding working capital 
requirements and capital investment, it is however less well documented 
that many Africa-based firms lack essential capabilities in raising and 
managing finance effectively (Banda, 2013). 
 The essential finance capabilities include the ability to understand 
a project life cycle and phase finance and to structure the most rele-
vant type of financial product. It also encompasses lending technology, 
pricing and an overall financial approach that does not choke the finan-
cial health of the borrowing firm, but rather enhances its productive 
capacity. Financial capability involves knowing where to get the most 
appropriately structured financial products, from whom, and when to 
use them. These firm-level financial capabilities are particularly impor-
tant for developing-country contexts, where financial systems are not 
well developed and growth of capital-intensive enterprises depends on 
capital investment financing (long-term foreign loans), in most cases 
from offshore sources. 
 In this section we explore finance capability in the firm and finan-
cial institution. This discussion is grounded in empirical work carried 
out on Zimbabwean pharmaceutical companies and financial institu-
tions, and additional interviews with pharmaceutical sector players in 
Uganda, Kenya, Tanzania and Ethiopia up to 2013. We analyse how 
firms use finance expertise and competencies, to identify and manage 
short-, medium- and long-term funding cycles. We focus on financial 
institutions at a micro-level and attempt to tease out the technical 
knowledge and capabilities needed to competently assess, classify, 
monitor and manage risks. The classes of risk may include credit, 
management, performance, regulatory, foreign exchange, payment 
and market risk which in various combinations manifest during a 
project lifecycle. 
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 The financing context for pharmaceutical firms in Africa 
 Economic, social and financial history shows sources of finance for 
setting up enterprises globally have been predominantly internal or 
own finance, made up of savings, wealth and loans from family and 
friends (Lazonick and O’Sullivan, 1997a, 1997b), in the industrialization 
era. Enterprise growth was funded internally by retained earnings, and 
externally banks were the most prevalent source of finance historically 
(Lazonick and O’Sullivan, 1997a, 1997b), specifically for the period from 
1970 to 1989 (Corbett and Jenkinson, 1996). Other sources of external 
finance were venture capitalists and capital markets. The key determi-
nants of financing source were the enterprise’s management experience, 
skills and credit reputation. 
 Growing companies with experienced management, poor to good 
future prospects, medium to high risk and established credit reputa-
tions are likely to use banks as sources of external funds (Corbett and 
Jenkinson, 1996). African enterprise financing studies similarly find that 
of all external funding sources, bank finance has been the most preva-
lent (Fafchamps et al., 1995.) 
 For established companies, with established credit records, low credit 
risk and run by experienced management, capital markets are the most 
likely source of external finance. However, capital markets did not play 
a major role in raising capital for industrialization, except to a certain 
extent in the US (Lazonick and O’Sullivan, 1997a, 1997b). Capital 
markets were used particularly to transfer ownership of corporate entities 
from family-run or close-knit ownership structures to publicly quoted 
companies, rather than to raise finance for industrialization. 
 Capital markets, however, are of little significance in Sub-Saharan 
African markets because of their small scale and low capitalization, with 
the possible exceptions of South Africa, Nigeria and Kenya. Venture 
capital and capital markets are more the exception than the norm in 
Africa. A more important source of external finance is foreign direct 
investment (FDI), which can embody technology flows (Portelli and 
Narula, 2004). FDI allows the developing country to import tech-
nology without payment, since the investor brings in knowledge and 
skills required to operate the technology. Ensuring effective technology 
transfer is a challenge. However, data on financing manufacturing 
industry in seven countries in Sub-Saharan Africa indicate that FDI 
and external/offshore financing were the main sources of capital, rein-
forcing Ndlela’s (2007) and Riddell’s (1990) accounts of FDI as being 
critical for the emergence of the manufacturing industry in countries 
such as Zimbabwe. 
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 How then do firms select internal or external avenues for financing 
investment? Internal funds include retained earnings, depreciation 
or fresh equity injection from existing shareholders. External funds 
include bank debt, hybrid bonds or issuing of new equity to new share-
holders. When internal funds are limited, management seeks external 
funds. A ‘pecking order’ theory (Myers, 1984) argues that in the face 
of limited information, firms will prefer to use own financial resources 
such as retained earnings or profits; only if self-financing is insufficient 
will management use external debt instruments: first bank debt, then 
hybrid bonds, and the last option will be new equity. The order of pref-
erence is determined by the objective of retaining management control. 
Hybrid securities such as convertible bonds dilute management control 
less, and carry fewer external accountability (discipline and reporting) 
requirements compared to stock exchange equity. Equity is a last resort 
because of onerous reporting standards and controls when dealing with 
broad shareholding structures and professional managers as agents of 
shareholders (Myers and Majluf, 1984). 
 Finance capability gaps in pharmaceutical firms 
 Faced with these financing constraints and choices, a firm with limited 
internal funds needs to develop capabilities to scan for potential funders 
and financial products nationally, regionally and internationally. The 
firm needs to articulate its organizational, dynamic and technological 
capabilities in a robust well-argued project finance document with 
supporting data. In building the project finance document and data, 
the firm needs to use its external networks to assess economic, industry 
and business environments and attendant risks, as well as stress-testing 
project data. The finance department as the key operating contact point 
with external financiers articulates the firm’s competencies and capabili-
ties in procurement (trade credit included), research and development, 
production and engineering, as well as sales and marketing capabilities. 
Table 15.1 Column 1 summarizes the financial capabilities the firms 
require. 
 The firm then needs to negotiate with financial institutions on appro-
priate finance products by competently structuring the debt or equity 
relevant to business needs. If this is not managed properly, financial insti-
tutions can push their preferred high-yielding products. The firm may 
then be burdened with finance products characterized by high charges, 
onerous covenants, triggers and security (collateral) requirements. Firms 
thus have a great deal to gain from finance capability to identify and 
structure appropriate borrowing products and negotiate on pricing. 
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Our interview data show, however, that these finance capabilities are 
lacking in many firms. One respondent in Zimbabwe remarked that the 
firms ‘were afraid to approach international banks because they are not 
able to produce a robust project proposal and are afraid of being asked 
questions’. Crafting a project proposal requires knowledge of the firms’ 
 Table 15.1  Finance capabilities at the firm and financial institution levels 
 Pharmaceutical firms’ required 
competencies 
 Funder’s (financial institutions’) 
required competencies 
 Identify the businesses’ financial needs:
Working capital and capital investment 
requirements 
Understand the industry, business, 
economic, political, and regulatory 
environment.
Ascertain the best available financing 
structure; a mix of short, medium and 
long term finance through debt, equity 
or hybrid instruments to structure the 
funding model for the firm
Sector-specific knowledge to 
competently identify, analyse 
and manage risks in business, 
industry, management, markets 
and regulation. Some funders have 
a central set of industry and sector 
specific skills that assists all business 
units.
Structuring the funding model requires 
development of knowledge of lending 
technologies and funding instruments 
on the market and outside national 
borders
Alignment of internal capabilities 
in prospecting, screening, analysis, 
structuring financial products/
funding schemes, document 
perfection, disbursement of funds, 
monitoring and control and eventual 
repayment of principal and interest.
Crafting a competent project finance 
proposal that identifies project risks 
and how they are managed through 
the management, organisational and 
technological capabilities of the firm.
Whilst managing projects identify 
opportunities and the exhibit 
flexibility to change within and after 
the life of the funded project.
Competency to apply financial resources 
to originally identified funding needs, 
and through financial management 
capability run successive asset 
conversion cycles to generate profit and 
maintain commercial viability.
Through learning-by-doing transfer 
skills and capabilities developed to 
other industrial sectors and within 
departments in the institution.
Competence to repay interest and 
principal on time, and meet challenges 
in restructuring debt after negotiation 
with the funders.
 Source : Compiled by author from fieldwork in Zimbabwe, 2010–13. 
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capabilities, what the money is needed for, and how revenue will be 
generated to repay debt. Based on the dynamics of the proposed project 
business cycles, the firm needs to be able to know which financing tool 
would be most advantageous to it instead of waiting for the bank to 
always propose the mode of financing. 
 Building finance capabilities in banks 
 Finance capability in financial institutions refers to their ability to source 
projects to invest in (investment capability); analyse the risks; structure 
the finance instrument, price the debt instrument and loan duration; 
followed by monitoring and control and eventually repayment of the 
debt by the borrower. Various players within the financial institution 
interact in the process of financing a project. The internal staff identify 
and analyse risks that include but are not limited to business, industry, 
management, country, political and foreign currency risks. The risk 
management process is closely tied to loan structuring, documentation, 
disbursement and monitoring and control procedures. 
 These processes depend on in-depth knowledge of the sector being 
assessed (Table 15.1). In practice, information is opaque and hard to 
assess. Our research evidence from Zimbabwe and secondary data 
evidence from East and West Africa suggests lack of in-depth and relevant 
pharmaceutical sector knowledge by financial institutions. A repeated 
claim by pharmaceutical executives is that financial institutions do not 
understand the business of African pharmaceutical drug manufacture. 
Evidence from Zimbabwe suggests that financiers also need to develop 
an in-depth knowledge of the economy, industry and health sector for 
preliminary analysis of projects. They need to greatly improve their 
networking within the financial sector and the national economy to 
acquire relevant information for prospecting and analysing projects. 
 Table 15.2 maps, using Lall’s (1992) concept of firm-level technolo-
gies, the capabilities needed by these financial institutions. The table 
maps prospecting, risk analysis, facility structuring and documenta-
tion, loan approval, loan disbursement, monitoring and control and 
ultimately loan repayment. Under prospecting capabilities, relationship 
managers use investment and networking capabilities to scout different 
industrial sectors for potential deals. They need intimate knowledge 
of the economy, industry, various business sectors, credit policy and 
underwriting standards. Interview respondents pointed to the use of 
both codified and tacit knowledge at this early stage. They empha-
sized the importance of experienced ‘old-timers’ for connections and 
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 Table 15.2  Finance capabilities required by financial institutions, mapped using Lall’s (1992) firm-level technological capability framework 
 Commercial 
Bank Activity  Processes Carried Out  Equivalent Technological Capability 
Deal 
Prospecting
Based on local knowledge and economic set-up, the market 
development and sales team prospect for lending candidates that fall 
within credit policy and underwriting standards. They use networked 
capabilities for introductions and access to potential borrowers.
The bank uses  linkage capabilities and 
 investment capabilities in accessing borrowers 
and internal project finance appraisal systems.
Credit Risk 
Function
Using the following lending technologies: financial statement lending, 
leasing/asset backed, small business credit scoring or relationship 
lending in various combinations risk experts analyse for various forms 
of risks.
The banks use  investment capabilities to ascertain 
their appetite for lending to the borrower . Linkage 
capabilities are used to collect information that 
informs risk analysis and management.
Approval 
Process
Internal credit processes are followed to independently assess the 
project documents produced within the institution. The approvers 
use their knowledge and networks to make informed decisions in the 
approval process.
 Investment capability and  linkage capabilities 
are used to assess the project for funding.
Accessing 
Funds by The 
Borrower
Internal loan administration departments ensure compliance 
with internal processes, all conditions precedent, and regulatory 
requirements.
This is mainly  process engineering capability. 
Ensuring 
Repayment 
of Borrowed 
Funds
Based on conditions laid out in the loan agreement, internal experts in 
sales, credit and credit administration control and monitor the project 
loan. They use proprietary data and processes as well as external sources 
of information such as trade and press reports for adverse or positive 
information. This can also serve as a source of further deal prospecting.
The main capabilities used are  investment, 
linkage, product and process engineering 
capabilities .
 Source: Compiled by author from experience and fieldwork between 2011 and 2013. 
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networks evidencing the need for linkage capabilities. Risk analysis, loan 
structuring and approval use codified and tacit knowledge for decision 
making by way of agreed financial ratios and internal metrics. Chief 
Risk Officers also acknowledged the inherent use of ‘gut feel’, implying 
relevance of tacit knowledge. 
 Capabilities that need to be built thus include loan disbursement, 
monitoring and control and finally repayment of the loan (Table 15.2). 
The process involves agreement of terms and conditions between the 
borrower and financier through a loan agreement document (commonly 
called the loan facility). On fulfilment of the conditions precedent, the 
loan administration department processes the security for the loan 
facility and disburses the funds. Monitoring and control is based on 
the conditions set out in the loan facility. The capabilities at this stage 
include those of product and process engineering and also linkage capa-
bilities. Our evidence from empirical work in Zimbabwe and interviews 
with pharmaceutical executives from East Africa shows a clear perception 
of financial institutions’ deficit of in-depth knowledge of pharmaceu-
tical manufacturing business dynamics and attendant risks and oppor-
tunities. These challenges were acknowledged by financial institution 
executives who agreed that they did not understand the pharmaceutical 
industry. This information asymmetry and opacity leads to classification 
of the African pharmaceutical manufacturing sector as high-risk, nega-
tively influencing loan pricing. 
 The financiers and pharmaceutical executives interviewed proposed 
to tackle these failings through training and exposure to the pharma-
ceutical industry. Finance capability cannot be taken for granted and 
requires purposive and strategic investment to build these competences. 
An illustration of what can be done is drawn from an innovative mid-
career recruitment programme of one international bank in Zimbabwe; 
Standard Chartered Bank. This programme allowed the bank to build 
skills and a broader knowledge base by recruiting non-traditional bank 
trained professionals (Table 15.3). This formed part of an Africa-wide 
initiative by Standard Chartered Bank Africa. 
 A senior manager who has since left the bank said this programme 
was a short-term strategic move to fill an identified skills gap. This 
seems paradoxical; an innovative and strategic approach which could 
have contributed a longer term strategy to generate risk analysis skills 
for project management and build capabilities was relegated to a short 
term measure. The senior manager argued that once the identified skills 
gap had been filled, they could revert to the usual graduate trainee 
programme and train in-house. He argued that the mid-career entrants 
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came in at middle-management level, were more expensive to the bank 
and so reverting to the cheaper junior level graduate trainees helped 
contain costs. However it is clear that these ‘non-traditional bankers’ 
had added value to credit risk analysis, management and monitoring, 
with their specialist skills and in-depth technical knowledge. They 
served as a knowledge bank that junior and senior management tapped 
into to understand once-opaque industrial operations. As Table 15.3 
shows, many of these recruits’ skills were used to build a deeper tech-
nical knowledge of industries that the bank funded. The short lived 
innovative programme (a flash of strategic brilliance) demonstrates the 
lost opportunity for long term skills and finance capability building. 
 Government interventions to assist companies to access 
investment capital 
 There is therefore a need for micro-level financial skills to be developed 
within the industry and within the financial community. However, it is 
also recognized that governments need to intervene to enable compa-
nies to access affordable investment capital. What types of interventions 
can governments employ to help resolve this critical issue? A govern-
ment can provide soft loans, or it can use direct intervention to reduce 
 Table 15.3  Recruitment of non-traditional banking skills to build finance capa-
bility by one Zimbabwean international bank in 1998–2000 
 Intake  Skills Sets  Roles in the Bank 
1 Engineers, Economists Credit Risk Analysis, Monitoring 
and Management; Relationship 
Management; Processing; Global 
Markets; Retail Banking
2 Engineers (electrical, 
mechanical and civil), 
Scientist, Agriculture and 
Geo-Sensing, Computing 
Technology and 
Programming,
Credit Risk Analysis, Monitoring 
and Management; Relationship 
Management; Processing; Marketing; 
Treasury (Global Markets); Retail 
Banking; Direct Banking; Branch 
Management; Credit Operations; 
Interest Recalculation; Structured 
Trade Finance; Transactional Banking; 
Syndicated Lending
3 Accountant, Scientist Credit Risk Analysis, Monitoring and 
Management; Finance; Treasury Back 
Office Operations
 Source : Compiled by author from fieldwork in Zimbabwe (2010–13) and experience. 
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the cost of financing (e.g. interest subsidies). As well as such specific 
initiatives, it can intervene to create a conducive industry context that 
makes investment in the sector attractive to various providers of capital, 
thereby reducing perception of risk and theoretically increasing the 
availability of and reducing the cost of capital. Finally, a government 
can employ time-limited incentives to support industry investment. 
 Direct capital provision 
 Many industry actors and a number of trade associations have called for 
their governments to set up designated funds for low-cost investment in 
the pharmaceutical sector. One example is in Ghana, where in 2014 the 
President announced that Cedis 50 million would be set aside from the 
Export Development and Agriculture Investment Fund (EDAIF) for soft 
loans to the pharmaceutical sector (with recent currency depreciation 
this is now equivalent to less than USD$20 million). The government of 
Nigeria proposed a Naira 200 billion (roughly USD$100 million) fund to 
support the sector, but this has yet to materialize. 
 These limited examples to date suggest that for most countries, direct 
capital provision may not be viable or of sufficient impact to enable the 
transformation of the industry. Where countries (such as Ghana) have 
more than a handful of manufacturers, it is unlikely that governments 
have resources to create a fund of sufficient magnitude to tackle the 
capital funding gap for a meaningful number of companies. Furthermore, 
a government making direct capital provision must be equipped to 
make informed decisions, to ensure these scarce public resources are not 
wasted through poor investment. Public funding of investment capital 
for the pharmaceutical sector therefore demands the development of 
financial capabilities of the type just outlined within governments as 
well as private institutions. 
 However, where limited resources can be brought to bear, there is the 
potential for leveraging these public funds to assist a number of compa-
nies to achieve an affordable cost of capital. For example the propor-
tion of individual investments that a fund supports could be limited 
to a certain percentage of capital required. A blended cost of capital 
combining public with commercial investment can be more afford-
able than pure commercial capital. Such leverage could be enhanced 
if governments consider taking a junior debt position, thereby perhaps 
reducing the risk coupon required by private sector investors. 
 Assuming that an investment fund can be regularly recapitalized, 
through a sustainable funding mechanism such as a levy on pharma-
ceutical imports for example, public resources could be allocated in 
tranches. In this way the capital requirements of an organization at one 
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particular time during a project lifecycle can be addressed without tying 
up resources required for total overall capital requirements, and there-
fore a greater number of companies can be supported simultaneously 
over a number of years. 
 Direct government expenditure to reduce the cost of financing 
 Governments can also facilitate access to affordable investment capital 
through subsidizing interest payments. Interest subsidies were made 
available to Indian pharmaceutical manufacturers to support their 
development. Using public resources to support the servicing of debt 
rather than providing the capital itself can be a more efficient use of 
public resources. However, limitations on the political acceptability of 
direct transfer of public funds to the private sector, given other pressing 
demands on public expenditure, may make such a model untenable for 
many countries. At the least, mechanisms are essential to control waste 
of resources and limit government financial liabilities. 
 Can criteria be established for companies to be eligible for such subsi-
dies? There is widespread anxiety about governments trying to ‘pick 
winners’, or rather failing to spot losers, thereby backing unsustainable 
manufacturers and losing scarce funds to unintended uses. All industrial 
policy interventions require the development of industrial skills and 
capabilities within government. 
 Another concern may be that an interest subsidy approach can rein-
force a debt-financing model, shifting the industry away from equity 
financing. Equity financing should form an element of the capital struc-
ture of firm in which the return on investment is necessarily long term. 
Hence, parallel mechanisms may be needed to encourage companies to 
seek some equity financing to cover some of the capital requirements 
for upgrading. These mechanisms could include facilitating repatriation 
of profits, to stimulate interest from foreign investors, or levelling the 
playing field between debt and equity financing through limiting the 
tax shields that debt conveys. 
 Interest subsidies provide an investment incentive, but have the 
advantage that they do not have a direct impact on revenues and oper-
ating profitability, unlike preferential pricing or other forms of market 
protection. They may therefore be a constructive means of support in 
that they do not encourage uncompetitive practices. 
 Creating an industry context that attracts capital 
 Creating a conducive context for pharmaceutical manufacturing 
involves the combination of multiple interventions, not all of which 
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are necessarily within the purview of individual governments. The 
importance of a regional market has already been highlighted. However, 
individual governments can tackle dimensions such as the overall busi-
ness environment (corporate tax rates and special economic zones, 
for example), as well as sector-specific aspects such as strengthening 
regulatory oversight and developing human resources. While credible 
forward-looking statements from governments help, genuine impact 
does require observable developments and interventions. 
 The role of time-limited incentives 
 The PMPA Business Plan, regional plans and national strategies all call 
for time-limited incentives. Given the specific nature of the pharma-
ceutical industry, what is the purpose of these incentives, what are 
the tools available to governments and how do these vary by country 
context? 
 First, there is a clear distinction to be made between time-limited 
incentives and policies to induce structural change whether on the 
demand or supply side. For instance, resolving the widespread unequal 
tax and duty regimes applied to imports versus inputs for local produc-
tion (Chapters 2–6) is a long-term structural approach that needs to be 
embedded. However, it is also possible to decide to adjust tax regimes for 
a limited period of time, to convey a temporary competitive advantage 
to local producers in competition with imports. 
 Examples of time-limited incentives that could be utilized can be 
drawn from the policy actions already implemented within Africa, on 
other continents, and for other industries. A major concern for manu-
facturers is funding their working capital requirements. For African 
companies this is a particularly profound problem, since they need to 
import the vast majority of inputs from abroad. Often, credit terms 
are used up before raw materials can even begin to be converted into 
final formulations. Such concerns can be addressed through provision 
of working capital credits, an approach that was used successfully in 
India, or through underwriting letters of credit enabling manufacturers 
to secure improved credit terms from their suppliers. 
 Other government incentives can focus on reducing the tax burden 
for which companies are liable, as a means to free up resources to 
fund investment. Effectively, this provides an additional margin that 
can make local products more competitive in the transition period, as 
companies learn to operate facilities more efficiently. Examples of incen-
tives to achieve these intents are tax holidays and special depreciation 
provisions. The latter were once again used in India where companies 
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were able to include depreciation over time on the profit and loss state-
ments up to 150% of the capital cost for plants and equipment. 
 Previous chapters have covered the use of procurement preferences 
and restricted lists and highlighted the potential for such approaches to 
give a boost to local manufacturers. There are acknowledged downsides 
associated with market protection, particularly if done at a national 
rather than a regional level, since it can, for example, reduce competi-
tion. Introducing preferential import tariffs on inputs for local produc-
tion is another mechanism to provide a degree of protection for nascent 
industries. Again, a regional approach that consolidates markets can 
help to implement this while sustaining local competition. 
 This discussion is far from exhaustive in covering the range of indus-
trial policy incentives available. The relative merits of the different tools 
depend strongly on context, but their fundamental purpose is to support 
the industry during a transition phase so that companies can build 
capabilities, develop plans for upgrading facilities and execute them, 
whilst continuing to compete viably during the transition. This transi-
tion period also provides time for policy makers to put in place longer 
term initiatives to sustain the economic and technical viability of high-
quality manufacturing, including defragmenting markets and building 
the institutional capacities and skills within government and industry 
actors. Initiatives are under way to address these structural realities, but 
a much stronger push is still required, with the support of international 
technical assistance programmes to build government skills and accel-
erate industrial knowledge accumulation. 
 The importance of country context 
 Each country considering development of its pharmaceutical industry 
faces a unique context which determines what policies and initiatives 
are required and feasible. With a large domestic market, a government 
could employ protective measures to support industry growth, using 
import substitution as Ethiopia has done (Chapter 4). For smaller coun-
tries, however, regional exports are likely to be a critical part of the busi-
ness mix for a sustainable industry. Botswana has an expressed desire to 
establish a pharmaceutical industry, but with a population of 2 million, 
its strategic positioning objective is to become a regional centre for phar-
maceutical production. 
 Another key variable is the state of the public finances. All countries 
face choices as to where they invest public resources, and where such 
resources are severely constrained, the Ministry of Finance and the 
National Revenue Authority are likely to resist policy initiatives that will 
10.1057/9781137546470 - Making Medicines in Africa, Edited by Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage and Watu
Wamae
D
ow
n
lo
ad
ed
 fr
o
m
 w
w
w
.
pa
lg
ra
v
ec
o
n
n
ec
t.c
om
 - 
lic
en
se
d 
to
 n
pg
 - 
Pa
lg
ra
v
eC
on
ne
ct
 - 
20
15
-1
2-
15
Finance and Incentives for National Industries 297
reduce the contribution of current taxes levied on the sector to govern-
ment income, or that increase expenditure through for example procure-
ment preferences or industry subsidies. For example, at present, Ghana 
and Kenya face difficult public finance situations, making budget-neutral 
support mechanism such as domestic market protection an attractive 
option. While the options open to governments and their relative power 
vary according to the specific context, complementary regional initia-
tives such as tariff harmonization, regulatory harmonization and general 
collaboration between countries can increase the leverage that national 
government interventions have to stimulate upgrading and develop-
ment of the sector. 
 Conclusion 
 We began by highlighting recent developments at regional, continental 
and international levels that have generated a new convergence of high-
level political will to support the development of the pharmaceutical 
manufacturing industry in Africa. The chapter has sought to shift the 
understanding of the key challenge of investment finance within those 
strategies, from a focus on access to capital to a framework of collabo-
rative financial capability building in firms, financial institutions and 
governments. The chapter outlines the shared political recognition of 
the need for time, protection and incentives to build the industrial base 
through upgrading and transition to higher skills and quality stand-
ards. Development of new skills within interconnected institutions, 
evolution of regional markets and firms making the requisite invest-
ments and learning to operate competitively at international standards 
cannot happen overnight. This final chapter, framed by the intensive 
international and regional collaborations that are now under way, also 
frames the detailed studies in this book as a timely contribution to those 
endeavours. 
 Note 
 1 .  See the World Trade Organisation website at  https://www.wto.org/english/
tratop_e/trips_e/trips_e.htm for more information on TRIPS. 
 
Except where otherwise noted, this work is licensed under a 
Creative Commons Attribution 4.0 Unported License. To view 
a copy of this license, visit https://creativecommons.org/version4
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comparative pricing, 205, 217
competitive tendering, 119
compulsory licensing, 41–2
Conference of African Ministers of 
Health, 279
Cosmos, 36, 42
cost efficiency, in Kenya, 37
cost-plus pricing model, 204
costs
APIs, 127–8, 131
ARVs, 127–9
distribution, 35
overheads and labour, 126
shipping, 130
standards, 235–6
country-level capabilities, 33
coverage with evidence development 
(CED), 258
credit risk function, 290
credit terms, 160, 248–9
Datlabs, 14
Dawa, 27, 42
deindustrialization, 11, 15
depreciation provisions, 295–6
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exports
Brazilian pharmaceuticals, 178
Kenyan pharmaceuticals, 17, 19, 28, 
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external funds, 287
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FDIs, see foreign direct investments 
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investment, 57, 58, 289
in manufacturers and financial 
institutions, 285–9
financial institutions, 287, 288, 
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internal and external, 287
see also donor funding
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growth, 266
Indian in Africa, 109–14
generic medicines, 11
manufactured in Kenya, 18
manufactured in Zimbabwe, 16
market in Brazil, 172–3
MNCs and, 106, 108–9
in South Africa, 218, 219–20
standards, 227
Generic Medicines Law, 170, 171
Germany, 11, 280
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Indian imports, 109, 110
industrial policy, 115–20
retail prices of formulations, 118
GIZ, 82, 238
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Global Alliance for Vaccines and 
Immunization, 254
Global Fund, 52, 251, 254
global pharmaceutical industry, 104–5
anticipated trends, 107
and South Africa, 266–73
see also multinational corporations 
(MNCs)
globalization, 163
good clinical practice (GCP), 226
good laboratory practice (GLP), 226
good manufacturing practice (GMP), 
226, 227, 230–2, 235
APIs and FPPs, 132–3
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in Ghana, 116
in India, 238–41
‘road map’, 81, 238–41, 282
in Tanzania, 51–2, 57
government of Brazil (GoB), 87, 88, 91
government of Mozambique (GoM), 
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government policy
in Brazil, 169–70
and collaborative capabilities, 163–4
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in Ghana, 115
and industry associations, 261–3
investment capiital accession, 292–7
leverage over funding, 154–7
licensing and joint ventures, 41–3
subsystem, 263–4
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see also industrial policies; public 
sector; state-industry relations
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Manufacturing, 131
green chemistry, 131
Growth and Transformation Plan 
(GTP), 71, 80, 82
growth coalitions, 265–6
GSK, 34, 53, 108
harmonization initiatives, 234–5
hazard analysis critical control points, 
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institutional triad of, 188, 189
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non-profit wholesaling, 157–9
organization, 147–9
private sector procurement and 
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H1N1 outbreak, 195
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human resources
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imports/importers, 160–1
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industrial policies
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